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Abstract
In the pre-clinical development stages of most drug design campaigns, the equilibrium binding
affinity of a prospective lead candidate, in the form of an IC50, Kd or DG° value, is the most
commonly employed benchmark parameter for its effectiveness as a putative drug. Hydrogen
bonding, van der Waals and electrostatic interactions, as well as hydrophobic effects are among
the most prominent factors that contribute to binding. In structure based design approaches,
these interactions can routinely be linked to a structural motif of a drug molecule, which can
greatly assist in the construction of compounds with a desired set of properties. Equilibrium
binding affinity can also be expressed in terms of kinetics, were the steady-state constant Kd is
defined as the ratio of the rate constants of dissociation (kd) and association (ka). The
thermodynamic expression DG° can be subdivided into an enthalpic (DH°) and an entropic (–
TDS°) term. In either case, the molecular mechanisms that define the kinetics of binding or the
compensation of enthalpic and entropic contributions are not fully understood. The goal of
this dissertation is the in-depth investigation of the molecular processes that drive protein–
ligand interactions. A special focus is set on the partitioning of thermodynamic and kinetic
parameters into their respective microscopic elements. For this, the metalloprotease
thermolysin (TLN) is used as a model system. This protein is well characterized and represents
a robust system with excellent crystallographic properties and a thoroughly documented
inhibitor class.
The first publication (Chapter 2) presents an improved strategy for the synthesis and
purification of phosphonamidate peptides that are known as potent inhibitors of TLN. Due to
the inherent instability of the phosphorous–nitrogen bond, the introduction of polar
functional groups into the inhibitor scaffold is quite challenging. Here, a synthetic strategy is
presented that minimizes the amount of hydrolysis during peptide coupling, deprotection and
purification through the use of an allyl-based protection system and a solid-phase extraction
(SPE) protocol for the final purification step. This allows the synthesis of highly pure TLN
inhibitors incorporating a variety of functional groups for use in biophysical experiments.
In the second publication (Chapter 3), a strategy for the design of inhibitors is highlighted,
which relies on the targeted design of water networks that are formed around a protein–ligand
complex. Based on information from a previous study, the shape of a hydrophobic portion of
a TLN ligand is altered in a way that allows a beneficial stabilization of water molecules in the
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first solvation layer of the complex. Supported by molecular dynamics simulations, a series of
diastereomeric inhibitors is synthesized and the binding process is characterized by X-ray
crystallography, isothermal titration calorimetry (ITC) and surface plasmon resonance
spectroscopy (SPR). The optimization of the hydrophobic P2’ moiety results in a 50-fold
affinity enhancement compared to the original methyl substituted ligand. This improvement
is mainly driven by a favorable enthalpic term that originates from the stabilization of water
polygons in the solvation shell.
In the follow-up study in Chapter 4, the binding signature of a series of inhibitors that place a
charged and polar moiety in the solvent exposed S2’ pocket of TLN is investigated. Here, a
partially hydrated ammonium group is gradually retracted deeper into the hydrophobic
protein environment. From the crystal structures it is evident that the polar ligands do not
recruit an increased amount of water molecules into their solvation layer when compared to
related analogues that feature a purely aliphatic residue at the solvent interface. The penalty for
the partial desolvation of the charged functional group, in combination with the lack of a
strongly ordered water network, results in a severe affinity decrease that is driven by an
unfavorable enthalpic term.
The deep, hydrophobic S1’ pocket of TLN determines the substrate specificity of the protease
and is commonly addressed by high affinity inhibitors. Experimental evidence from previous
studies suggests, however, that this apolar crevice is only poorly solvated in the absence of an
interaction partner. With the study in Chapter 5, an attempt for the experimental analysis of
the hydration state of the S1’ pocket is presented. For this, a special inhibitor is designed that
transforms the protein pocket into a cavity, while simultaneously providing enough empty
space for the accommodation of several water molecules. A detailed analysis of an
experimentally phased electron density map reveals that the cavity remains completely
unsolvated and thus, vacuous. As an intriguing prospect for the exploitation of such poorly
hydrated protein pockets in drug design, the placement of an iso-pentyl moiety in the ligand’s
P1’ position results in a dramatic, enthalpically driven gain in affinity by a factor of 41 000.
With a detailed structural analysis of a series of chemically diverse TLN inhibitors, the kinetics
of the protein–ligand binding process are investigated in Chapter 6. From the SPR derived
kinetic information, it becomes apparent that the nature of the functional group in the P2’
position of a thermolysin inhibitor has a significant impact on its dissociation kinetics. This
property can be linked to the interaction between the respective functionality of a ligand and
Asn112, a residue that lines the active site of the protease and is commonly believed to align a
substrate for proteolytic cleavage. This residue undergoes a significant conformational change
when the protein transitions from its closed state to its open form, from which a ligand is
released. Interference with this retrograde induced-fit mechanism through strong hydrogen-
bonding interactions to an inhibitor results in a pronounced deceleration of the dissociation
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process. The case of the known inhibitor ZFPLA demonstrates that a further restriction of the
rotation of Asn112 by a steric barrier in the P1 position of a ligand, can reduce the rate constant
of dissociation by a factor of 74 000.
Fragment-based lead discovery has become a popular method for the generation of prospective
drug molecules. The weak affinity of fragments and the necessity for high concentrations,
however, can result in false-positive signals from the initial binding assays that routinely plague
fragment-based screening. The pursuit of such a “red herring” can lead to a significant loss of
time and resources. In Chapter 7, a molecule that emerged as one of the most potent binders
from an elaborate fragment screen against the aspartic protease endothiapepsin is identified as
a false-positive. Detailed crystallographic, HPLC and MS experiments reveal that the affinity
detected in multiple assays can in fact be attributed to another compound. This entity is formed
from the initially employed molecule in a reaction cascade that results in a major
rearrangement of its heterocyclic core structure. Supported by quantum chemical calculations
and NMR experiments, a mechanism for the formation of the elusive compound is proposed
and its binding mode analyzed by X-ray crystallography.
Zusammenfassung
In der präklinischen Phase einer Wirkstoffentwicklung wird häufig die Affinität einer
Verbindung im thermodynamischen Gleichgewicht in Form eines IC50, Kd oder DG° Wertes
als Referenzparameter für ihre Effektivität als möglicher Wirkstoffkandidat verwendet. Einige
der Faktoren, die auf molekularer Ebene zur Affinität einer Verbindung beitragen sind
Wasserstoffbrückenbindungen, van der Waals Interaktionen, elektrostatische
Wechselwirkungen, sowie hydrophobe Effekte. Mit Hilfe Struktur-basierter Methoden können
diese Wechselwirkungen häufig den strukturellen Motiven eines Wirkstoffkandidaten
zugeordnet werden. Dadurch kann die gezielte Konstruktion von Molekülen mit gewünschten
Eigenschaften ermöglicht werden. Bindungsaffinität kann mithilfe des kinetischen Terms Kd
als Quotient der Geschwindigkeitskonstanten von Dissoziation (kd) und Assoziation (ka)
ausgedrückt werden. Der thermodynamische Ausdruck DG° lässt sich in einen enthalpischen
(DH°) und einen entropischen Beitrag (–TDS°) aufteilen. In beiden Fällen sind die molekularen
Mechanismen, die die Bindungskinetik definieren oder zur Kompensation von Enthalpie und
Entropie beitragen, nur unvollständig verstanden. Das Ziel der vorliegenden Arbeit ist eine
detaillierte Untersuchung der molekularen Prozesse, die die Interaktion von Proteinen und
ihren Liganden ausmachen. Ein besonderes Augenmerk liegt dabei auf der Aufspaltung
thermodynamischer und kinetischer Größen in ihre jeweiligen mikroskopischen Elemente.
Hierfür wird die Metalloprotease Thermolysin (TLN) als Modellsystem verwendet. Dieses
Protein ist gut charakterisiert und zeichnet sich daher als ein robustes Testsystem mit
exzellenten kristallografischen Eigenschaften und einer bekannten Klasse von Inhibitoren aus.
In der ersten Publikation (Kapitel 2) wird eine verbesserte Strategie für die Synthese und
Aufreinigung von peptidischen Phosphonamidaten vorgestellt, die als potente Inhibitoren von
TLN bekannt sind. Die inhärente Labilität der Phosphor–Stickstoff Bindung dieser
Substanzklasse erschwert die Einführung polarer funktioneller Gruppen in das Inhibitor-
Grundgerüst. Mit Hilfe einer neuen synthetischen Methode kann die Hydrolyse der
Verbindungen während der Peptidkupplung, Entschützung und Aufreinigung durch die
Verwendung einer Allyl-basierten Schutzgruppenstrategie und einer
Festphasenextraktionsmethode auf ein Minimum reduziert werden. Dadurch wird die
Darstellung von TLN-Inhibitoren mit einer Vielzahl funktioneller Gruppen in hoher Reinheit
ermöglicht.
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Die zweite Publikation (Kapitel 3) befasst sich mit einer Methode für den Entwurf neuer
Inhibitoren, die auf dem gezielten Design des einen Protein–Ligand Komplex umhüllenden
Wassernetzwerks basiert. Basierend auf den Ergebnissen einer vorangegangenen Studie wird
die Form eines hydrophoben Teils des TLN-Liganden solcherart verändert, dass eine
begünstigte Stabilisierung von Wassermolekülen in der Hydrathülle des Komplexes
ermöglicht wird. Unterstützt durch Molekulardynamiksimulationen wird eine Serie
diastereomerer Inhibitoren synthetisiert und deren Bindungseigenschaften mittels
Röntgenkristallstrukturanalyse, isothermaler Titrationskalorimetrie (ITC) und
Oberflächenplasmonresonanzspektroskopie (SPR) untersucht. Die Optimierung der apolaren
P2‘-Gruppe des Inhibitors resultiert in einer 50-fachen Verbesserung der Affinität im Vergleich
mit dem ursprünglichen Methyl-substituierten Liganden. Dieser Gewinn wird hauptsächlich
durch einen vorteilhaften enthalpischen Term bedingt, der aus einer Stabilisierung
polygonaler Wasserstrukturen in der ersten Hydratationsschicht entstammt.
In der Folgestudie in Kapitel 4 wird die Binding einer Serie von Inhibitoren untersucht, die
eine polare und geladene Gruppe in die Lösungsmittel-exponierte S2‘ Tasche von TLN
platzieren. Eine terminale Ammonium-Funktionalität wird hierbei kontinuierlich tiefer in die
hydrophobe Umgebung des Proteins gezogen. Die Untersuchung der Kristallstrukturen zeigt,
dass die polaren Liganden, im Vergleich mit unpolaren Analoga, keine verstärkte Nahordnung
in der umgebenden Wasserstruktur bewirken. Der Beitrag für die partielle Desolvatation der
geladenen Gruppe in Kombination mit der Abwesenheit eines starken Wassernetzwerks hat
einen empfindlichen Verlust an Bindungsaffinität, hauptsächlich bedingt durch einen
ungünstigen enthalpischen Term, zufolge.
Die tiefe, hydrophobe S1‘ Tasche von TLN bedingt die Substratspezifität der Protease und wird
häufig von potenten Inhibitoren adressiert. Vorangegangene Experimente legen nahe, dass
diese Bindetasche in Abwesenheit eines Interaktionspartners jedoch nur unvollständig
hydratisiert ist. Die Studie in Kapitel 5 stellt eine experimentelle Untersuchung des
Solvatationszustandes der S1‘ Tasche vor. Hierfür wird ein spezieller Inhibitor entwickelt, der
die Proteintasche abdeckt. Die so entstandene Kavität bietet weiterhin genug Platz um die
Bindung mehrerer Wassermoleküle zu ermöglichen. Die Analyse einer experimentell
phasierten Elektronendichtekarte zeigt jedoch, dass die Kavität nicht solvatisiert, und somit
vollständig leer ist. Vielversprechend für die Ausnutzung solch unvollständig hydratisierter
Taschen für die Entwicklung neuer Arzneistoffe ist die Beobachtung, dass die Platzierung einer
iso-Pentyl Gruppe in der P1‘ Position des Liganden eine dramatische, enthalpiegetriebene
Erhöhung der Affinität um den Faktor 41.000 zur Folge hat.
Eine detaillierte Analyse der Kristallstrukturen einer Serie von chemisch unterschiedlichen
TLN-Inhibitoren ermöglicht die Untersuchung der Kinetik des Protein–Ligand
Bindungsprozesses in Kapitel 6. Anhand der kinetischen Daten aus SPR Experimenten wird
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ersichtlich, dass die Art der funktionellen Gruppe in der P2‘-Position des Liganden einen
erheblichen Einfluss auf die Dissoziationskinetik aufweist. Diese Eigenschaft kann auf die
Interaktion der jeweiligen Funktionalität des Inhibitors mit Asn112, einer Aminosäure, die
dafür bekannt ist, ein Substrat für die Peptidspaltung in der Bindetasche auszurichten,
zurückgeführt werden. Die Seitenkette dieser Gruppe erfährt eine signifikante
Konformationsänderung wenn das Protein aus seiner geschlossenen Form in die offene
Konformation übergeht, aus der ein Ligand dissoziieren kann. Eine Beeinflussung dieses
Mechanismus durch starke Wasserstoffbrückenwechselwirkungen zu einem Inhibitor führen
zu einer Verlangsamung des Dissoziationsprozesses. Aus dem Fall des bekannten Inhibitors
ZFPLA wird ersichtlich, dass eine zusätzliche Behinderung der Bewegung von Asn112 durch
eine sterische Barriere in der P1-Position des Liganden die Geschwindigkeitskonstante der
Dissoziation um einen Faktor von 74.000 verringern kann.
Die Fragment-basierte Suche nach neuen Leitstrukturen hat sich als eine potente Strategie für
die Entwicklung neuer Wirkstoffe erwiesen. Die niedrige Affinität der Fragmente und die in
den initialen Assays häufig verwendeten hohen Konzentrationen begünstigen jedoch das
Auftreten falsch positiver Ergebnisse. Die Verfolgung einer solchen „falschen Fährte“ kann mit
einem erheblichen Verlust von Zeit und Ressourcen verbunden sein. In Kapitel 7 wird die
Affinität eines Moleküls, das in einem Fragment-basierten Screening gegen die
Aspartylprotease Endothiapepsin als hochpotenter Binder aufgefallen war, als falsch-positives
Ergebnis identifiziert. Umfangreiche Kristallografie-, HPLC- und MS-Experimente zeigen,
dass die Bindungseigenschaften, die in mehreren unabhängigen Methoden detektiert wurden,
tatsächlich einer anderen Verbindung zugeordnet werden können. Dieses Molekül wird aus
der initial eingesetzten Substanz in einer Reaktionskaskade gebildet, die mit einer massiven
Umlagerung des heterozyklischen Grundgerüsts einhergeht. Unterstützt durch
quantenmechanische Berechnungen und NMR-Experimente wird ein Mechanismus für die
Bildung der Verbindung postuliert und deren Bindungsmodus mittels Röntgenkristallografie
aufgeklärt.

Chapter 1
General Introduction
and Thesis Outline
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1.1 The Study of Molecular Recognition in Rational Drug Design
The Paradox of Modern Drug Development
Modern pre-clinical drug development programs are often based on the screening of large
compound libraries, comprising thousands or even millions of entries. The binding affinity of
compounds in such libraries to a target protein of interest can routinely be determined in
highly automated biochemical or biophysical experiments. In combination with a method that
provides information about the binding mode of a ligand, these affinity parameters are then
used to guide the optimization process. Here, techniques that give three dimensional structural
information, such as X-ray crystallography, are particularly helpful to identify possible
interaction vectors. While the determination of a protein structure by crystallography or NMR
techniques historically represented a significant experimental challenge, modern methods
have dramatically simplified this process. In many cases, improvements like powerful
recombinant expression systems, as well as automated pipetting and plate monitoring devices
for crystallography allow the determination of a protein structure with a manageable
experimental effort. Owed to the broad availability of modern synchrotron radiation facilities
for academic and industrial research, the quality of the collected crystallographic data is higher
than ever. In addition, the advent of computer-based methods in drug design yielded
algorithms that are able to predict the binding pose of a ligand or even its binding affinity and
guide the development of a drug candidate.
Yet, despite the rapid progress of experimental and computational tools in rational drug
design, the number of new molecular entities that enter the market is in steady decline. In many
cases, lead compounds that perform well in pre-clinical settings fail to achieve a relevant
pharmacological effect when applied to a patient population in clinical trials. Molecules that
prove useful in in vitro assays are abandoned, because of toxicity or unfavorable
pharmacokinetic properties. Compounds that are scored high by computer algorithms
ultimately fail to show activity when they are tested in an experimental setting.
From these drawbacks it is evident that our understanding of the molecular processes that drive
the interaction of proteins and ligands in biological recognition processes is still incomplete.
Additional basic research is required to elucidate the molecular mechanisms that contribute to
the effectiveness of successful drugs and identify reasons for the failure of promising lead
compounds in clinical settings.
Dissection of Common Affinity Metrics
Most optimization programs in medicinal chemistry rely on a measure of equilibrium binding
affinity for the evaluation of a prospective lead compound. Commonly employed equilibrium
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binding metrics, such as Kd or DG° values, can be subdivided into microscopic elements. The
kinetic term Kd is defined as the quotient of the rate constants of dissociation (kd) and
association (ka). The thermodynamic expression DG° can be divided into an enthalpic (DH°)
and an entropic (–TDS°) contribution. These relationships are of particular interest for drug
design, since some of the parameters have been linked to beneficial properties of drug
molecules. A slow dissociation rate, for example, is believed to improve the efficacy of a
compound in an in vivo setting and inhibitors with a predominantly enthalpic contribution to
binding affinity have may have the potential to show a higher selectivity against off-target
effects, as well as a higher tolerance to resistance mechanisms[1,2].
However, while medicinal chemistry programs are routinely able to improve the equilibrium
binding affinity of a lead molecule, a prediction of the distribution of affinity values into their
constituents has been proven to be difficult. It is apparent that the molecular determinants that
define biological recognition are still poorly understood. To further our understanding of the
underlying processes, it is necessary to investigate protein–ligand interaction with thoroughly
characterized test systems under well-defined experimental conditions. Only when individual
parameters can be carefully singled out, a reliable evaluation of the intricate processes, which
are often superimposed by a plethora of other effects, is possible within the complex setting of
biological system.
1.2 Thermodynamics in Drug Development
The Binding Thermodynamics of Drug Molecules
The determination of thermodynamic values adds another layer of complexity to the data
evaluation in the context of a drug design effort. Apart from the overall affinity of a prospective
lead compound, thermodynamic data give information about the molecular processes that
drive the binding of a respective ligand [2]. Electrostatic and dipolar interactions, hydrogen
bonding and van der Waals interactions are factors that contribute to the enthalpic term,
whereas the entropic term is influenced by the gain or loss of rotational or translational degrees
of freedom and the displacement of conformationally restricted water molecules into the bulk
solvent. However, it is important to note that the data derived from experiments such as
isothermal titration calorimetry (ITC) comprise contributions of the whole binding event,
starting from the separately solvated interaction partners until the system is at equilibrium.
Any process that gives rise to a heat signal during the course of that reaction contributes to the
resulting shape of the binding isotherm. These include effects like desolvation, conformational
transitions, changes in protonation state or the residual water solvation pattern surrounding
any of the participating entities. In addition, a frequently observed compensation of enthalpic
and entropic contributions, resulting in a similar free energy of binding, further complicates
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data analysis [3,4]. A meaningful correlation of distinct structural features of a ligand to
thermodynamic properties requires a careful analysis of a congeneric series of similar
compounds in combination with high quality crystallographic information [5].
Solvent Effects on the Thermodynamics of Molecular Recognition
The solvation shell of the interaction partners in a biological system plays an active role in any
binding process. Before two species can directly interact with one another, water molecules
that form the hydration layer around either binding partner have to be expelled from the
solute–solvent complex. The displacement of water from a hydrophobic surface patch into the
bulk water phase is commonly associated with an entropic advantage (see 1.2.3). In contrast to
that, hydrophilic groups engage in strong polar interactions to surrounding water molecules.
If solute–solvent hydrogen bonds have to be broken to allow an interaction of a ligand with a
target protein, the resulting enthalpic penalty has to be compensated by equally favorable
contacts between the two solutes. The desolvation penalty for any hydrogen bond that is not
saturated in the ligand’s binding pose represents a severe loss in affinity. These findings
underline why solvation effects have to be considered in the development of a prospective drug
molecule. Especially if polar functional groups are introduced into a ligand scaffold to improve
its solubility or pharmacokinetic properties without engaging in meaningful interactions to a
protein, an increased desolvation penalty can easily result in a significant loss of affinity.
Hydrophobic Effects in Molecular Recognition
A dominant role in molecular recognition in water has been attributed to the so called
“hydrophobic effect”. This expression describes the entropic benefit that arises from a
displacement of orientationally constrained water molecules at a hydrophobic interface into
the bulk solvent [6,7]. This effect is not only cited as the reason for the phase separation of an
oil–water system, it has also been implicated as the main driving force behind protein folding,
aggregation, and protein–ligand interaction [8]. However, detailed analyses of the
thermodynamics of hydrophobic hydration have also shown that this simplified model does
not hold true in every case. In multiple instances, the displacement of water molecules from an
apolar surface has been reported to give rise to an enthalpically favorable change in free energy
[9–11]. These “non-classical hydrophobic effects” have been attributed to the displacement of
highly mobile, disordered water molecules in hydrophobic environments, whose entropy
content does not differ significantly from bulk. The energetic benefit upon their release is
consequently driven by enthalpically beneficial solvent–solvent interactions, as well as newly
formed van der Waals contacts between the hydrophobic solutes. The hypothesis that water
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molecules that are located at hydrophobic interfaces generally assume a more ordered,
entropically unfavorable state, could not be proven experimentally[12,13]. This highlights the
fact that the energetic details of solvation are not uniform, but instead are very much
dependent on the local features, especially the shape, of a given binding site and the resulting
structure of water molecules in its solvation layer [14–16]. Therefore, the common usage of the
term “hydrophobic effect” is often misleading. Instead, it has to be considered that favorable
hydrophobic effects can originate for diverse thermodynamic reasons to a very different extent.
Figure 1.1. Typical setup of an ITC instrument. A) The ITC apparatus determines the heat content
that is generated by a binding event in the sample cell in comparison with a reference cell. The
power that is necessary to maintain the isothermal condition over time is recorded. B) Thermogram
recorded during the course of a titration. C) Binding isotherm extracted from a typical ITC
experiment. The enthalpy of binding is represented by the distance between the plateaus of the
sigmoidal curve. The association constant Ka can be derived from slope at the inflection point. The
position of the inflection point on the molar ratio axis gives information about the site number n.
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Determination of Binding Thermodynamics by ITC
In experiments with biological systems, thermodynamic parameters are most commonly
determined by ITC (Figure 1.1). This method allows the simultaneous assessment of Ka, DG°,DH° and –TDS°, as well as the “site number” n, a descriptor of the interaction mechanism or
the stoichiometry of the reaction [17]. An ITC instrument records the differential power that
is necessary to maintain a constant temperature between a reference cell and a sample cell, after
a defined amount of an interaction partner has been titrated into the sample cell, which
contains an analyte of interest. In this way, the heat signal from the interaction between the
two species is determined, which allows the calculation of the parameters n, Ka and DH° during
the course of a complete titration. The terms DG° and –TDS° are in turn derived from the
experimentally determined values.
1.3 Binding Kinetics in Drug Development
Drug–Target Residence Time
Most biochemical and cellular assays that are used to investigate the interaction of a
prospective drug with its target protein are based on the determination of the binding affinity
under thermodynamic equilibrium conditions. Most commonly, in vitro experiments for the
determination of IC50, Kd or DG° values operate under “closed system” conditions with fixed
concentrations of the interaction partners. In stark contrast to that, in vivo pharmacology is
characterized by non-equilibrium conditions. In this “open system”, the concentration of an
applied drug is constantly affected by pharmacokinetic processes like absorption, metabolism
and excretion. For this reason, the predictive properties of equilibrium binding metrics for in
vivo efficacy have been questioned [18,19]. The fixation on these, arguably inappropriate,
descriptors in preclinical development has been deemed a probable cause for the high rate of
attrition in the later stages of clinical trials. As an alternative predictor for the effectiveness of
a prospective drug, the lifetime of the protein–ligand complex has been suggested [18,20–24].
The rationalization behind this hypothesis is the assumption that the pharmacological effect of
a drug can only persist as long as the molecule is bound to its target. Only when the ligand
dissociates from its binding site, the addressed protein is able to execute its pathophysiological
function.
The lifetime of a protein–ligand complex is determined by the rate of association and the rate
of dissociation. Since the rate constant of association is subjected to several physicochemical
and pharmacological limitations in an in vivo setting, complex lifetime can typically be
described with the rate constant of dissociation (kd) or related parameters like the half life of
dissociation (ݐ½ௗ௜௦௦ = ln2 kd–1) or, more commonly, residence time (t = kd–1). These parameters
can easily be determined by SPR or another suitable method in a preclinical setting.
While this approach is not without debate, multiple studies have been reported that support a
correlation between drug–target residence time and in vivo efficacy [25–27].
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The molecular determinants that define the binding affinity of a molecule have been studied
for decades. By optimizing the relevant interactions of a ligand, it is typically possible to achieve
a significant gain in affinity during the course of a lead optimization program. In contrast to
that, a profound understanding of how these parameters split up into association and
dissociation kinetics is still lacking. While the focus on long residence time inhibitors
represents a promising strategy for drug design, a targeted optimization has proven to be
difficult, because the mechanisms that contribute to the lifetime of a protein–ligand complex
are not fully understood in most cases.
Figure 1.2. Typical setup of an SPR instrument. A) A solution of an analyte is passed over the gold
surface of a sensor chip. The binding event to a protein, which is immobilized on the surface,
changes the local refractive index. The resulting variation in the resonance angle of the surface
plasmon is detected by an optical setup. B) A shift of the angle of total reflection indicates a binding
event. C) The plot of SPR response against time can be fit to a kinetic model, from which the rate
constants can be calculated.
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Determination of Binding Kientics by SPR
In theory, the kinetics of a protein–ligand interaction can be determined by any method that
is able to monitor and differentiate the concentrations of the bound and unbound state of a
protein in a time resolved manner. However, the use of a technique that relies on the optical
phenomenon of surface plasmon resonance (SPR, Figure 1.2) has constantly gained in
popularity for this application [28–30]. This method is able to detect changes in the refractive
index that occur when molecules adsorb to or desorb from a solid–liquid interface. When a
protein of interest is immobilized on that surface, the association and dissociation of a binding
partner can be monitored in very high temporal resolution. The shape of the resulting
sensogram can be fit to a kinetic model of the interaction, which provides information about
the rate constants of association (ka) and dissociation (kd), as well as the steady-state
dissociation constant Kd.
1.4 The Metalloprotease Thermolysin as a Model System for
Medicinal Chemistry
Thermolysin (TLN) is a zinc-dependent metalloprotease from B. thermoproteolyticus that
belongs to the M4 family of proteases. The protein consists of 316 amino acid residues and
commonly binds four calcium ions that are responsible for its profound thermostability [31].
The tertiary structure of the enzyme can be divided into a mostly helical domain at its C-
terminus and an N-terminal domain that features a distinct b-sheet motif (Figure 1.3). The
active site is located on a central a-helix in between the two domains. The characteristic
HEXXH-motif, which commonly binds the catalytic zink ion within the M4 family and related
metalloproteases, is formed by His142, Glu 143, and His146 [32].
The substrate specificity of TLN is mainly determined by its well defined hydrophobic S1’
cavity. Here, apolar residues of moderate and large size are accommodated, which results in a
preference for substrates with Val, Leu, or Phe residues in the P1’ position. The non-primed S1
and S2 sites, as well as the less defined S2’ pocket, are mostly apolar and solvent-exposed. None
of these binding sites contribute significantly to the affinity against a substrate or inhibitor [33].
The first crystal structure of TLN has been reported in 1972 [34]. From this point on, the
enzyme has been utilized as a model system for the development of inhibitors against
pharmaceutically relevant targets such as angiotensin-converting enzyme or neutral
endopeptidase [35–37]. Its chemical robustness, excellent crystallographic properties and
ready access in large quantities also disclose TLN as an ideal test system to study the details of
protein–ligand interactions.
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1.5 Phosphonamidate Peptides as Inhibitors of Thermolysin
Phosphorous Containing Inhibitors of Thermolysin
The phosphorous containing natural product phosphoramidon (1) from S. tanashiensis has
been described as a potent inhibitor of TLN and related proteases (Figure 1.4) [38]. This
compound features a central tetraedric phosphoramidate moiety that is able to coordinate to
the catalytic zink ion and mimic the transition state of peptide cleavage. Based on the same
mechanism of action, the related group of phosphonamidate peptides (2) have been
introduced. These compounds have been proven to be potent inhibitors of proteases such as
TLN [39], Carboxypeptidase A [40], angiotensin-converting enzyme [41], or endothelin-
converting enzyme [42], and have been successfully used as valuable tools for the investigation
of protein–ligand interactions.
Figure 1.3. Cartoon representation of TLN in the closed state (PDB 5MNR). The central helix (green)
is connected to the helical C-terminal domain (yellow) and the N-terminal domain (red) that is
characterized by a distinct b-sheet motif. The catalytic zink ion (blue sphere) is coordinated by
His142, His146 and Glu166. Glu143 is retracted into the S1 pocket in the closed state of the enzyme.
Four calcium ions (green spheres) in the peripheral loop regions contribute to the remarkable
stability of TLN. The small image section shows an inhibitor bound to the active site of TLN (PDB
5JS3). The interaction is driven by the accommodation of a hydrophobic residue to the S1’ specificity
pocket. An interaction with the shallow and solvent exposed S1, S2, and S2’ pockets has a weaker
contribution to binding affinity.
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Physicochemical Properties of Phosphonamidates
Despite the obvious relation to carboxamides, the physicochemical properties of
phosphonamidates differ significantly from those of their carbon-analogs. The defining feature
of carboxamides is the partial delocalization of the nitrogen lone-pair. Quantum-chemical
calulations revealed that the carboximidic acid tautomer of acetamide contributes with 28% to
the resonance hybrid of the molecule [43]. This property of carboxamides results in a rotational
barrier of 60–80 kJ mol–1 around the carbon–nitrogen bond. In addition, a pKa value of 15–24
is determined for the N-H protons of primary and secondary carboxamides [44,45]. With a
pKa value of –1, these compounds are preferably protonated at the carbonyl oxygen. In contrast
to that, entirely different properties have been reported for phosphonamidates. A pKa value of
5 is commonly determined for a free phosphonamidic acid [46]. This value is about three
orders of magnitude higher than the expected Ka of a typical phosphonic acid. Supported by
crystallographic experiments and NMR data, this observation endorse the assumption that
phosphonamidates are preferably protonated at the phosphonamidate nitrogen and
commonly exist in a zwitterionic state [46].
This property has major implications for the stability of phosphonamidates, especially in
aqueous solution. The charged ammonium group of an N-protonated phosphonamidate can
act as a leaving group in a nucleophilic substitution reaction. This explains the fact that a half
life of several minutes to hours in aqueous acidic solution has been found for some compounds
of this class [40,46–48].
Figure 1.4. Phosphorous containing inhibitors of TLN.
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Synthesis of Phosphonamidates
The most commonly employed strategy for the synthesis of phosphonamidates is the activation
of a phosphonic acid as a phosphonochloridate. These intermediates can either be prepared
from phosphonic acid diesters by treatment with PCl5 [49] or from a reaction of phosphonic
acid monoesters with thionyl or oxalyl chloride [50,51]. Another synthetic access to
phosphonochloridates is the Atherton-Todd reaction, an oxidative chlorination of phosphinic
acid esters with CCl4 [52]. The use of modern peptide coupling reagents has also been explored
for the formation of the P–N bond in phosphonamidates [49,53–56]. While compounds like
carbodiimides or uronium reagents routinely give excellent results for the synthesis of
carboxamides, their performance as coupling reagents for phosphonamidates has been
notoriously mediocre. The best results have been achieved with the phosphonium reagents
BOP and PyBOP (Scheme 1.1).
The reason for the sluggish reaction rates of phosphonamidate coupling is the formation of
several inactive species during the complex reaction mechanism. Especially pyrophosphonate
intermediates represent a dead end for the infamously slow reaction of phosphonic acid
derivatives with amines [50,54]. However, it has been shown that a profound knowledge of this
mechanism and an adaption of the experimental procedure to the specific requirements of the
reaction does in fact allow the use of most coupling reagents for the formation of
phosphonamidates [56].
Scheme 1.1. Commonly employed strategies for the activation of phosphonic acids in
phosphonamidate coupling reactions.
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1.6 Fragment-based Lead Discovery
General Methods
Fueled by impressive reports of success, fragment-based lead discovery (FBLD) methods have
massively gained in popularity since their emergence in the 1990s [57,58]. These methods rely
on the screening of so called fragments, typically molecular entities with a formula weight of
less than 300 g mol–1, for affinity against a target protein. The entries of a fragment library have
to be diligently selected, so that a broad spectrum of interaction capabilities, three dimensional
shape, and complexity are covered. In addition to that, the library should provide diverse
synthetic vectors for later elaboration of a fragment into a lead molecule [59,60]. Following the
famous concept of Lipinski’s “rule of five” for drug design, a similar “rule of three” has been
proposed as a guidance for fragment sized libraries [61]. When these considerations are
adequately addressed, a fragment library is able to cover a significantly larger portion of the
available chemical space compared to a full sized compound library for high throughput
screening.
The methods that are commonly used for affinity screening consist of classical biochemical
assays that utilize the detection of fluorescence or radioligand binding, as well as modern
Figure 1.5. Typical Workflow of fragment-based lead discovery. A library of fragment-sized
compounds is screened for its affinity against a protein of interest. The binding mode of the
resulting hits is determined by X-ray crystallography. The original fragment hit is evolved into a full
sized lead compound by a combination with other screening hits (fragment merging, fragment
linking) or a structure-based drug design approach (fragment growing).
General Introduction | 33
C
h
a
p
te
r 
1
biophysical techniques, such as thermophoresis, thermal shift assay, NMR, SPR, and ITC. In
combination with a method that gives information about the binding mode of a prospective
hit, a comprehensive map of the interaction capabilities within the binding site of a target
protein can be constructed.
Taking advantage of this information, the fragment-sized screening hits can then be elaborated
into full sized lead compounds. This can be achieved by merging or linking several fragments
together, or by applying structure-based techniques to grow a molecule to drug-like
proportions. In either case, the binding properties of the resulting lead compounds usually
exceed the affinity of the initial hits by several orders of magnitude (Figure 1.5).
Evaluating the Performance of Pre-Screening Assays
The initial selection of molecules from a compound library is most commonly based on the
results from a biochemical or biophysical assay that gives information about the binding
affinity of a fragment. Sometimes, a screening cascade is employed that utilizes an initial, fast
and crude method for the primary selection of a library subset, followed by a more elaborate
technique [62,63]. The goal of these pre-screening efforts is the selection of a set of compounds
that are subsequently analyzed by putatively low-throughput methods like protein X-ray
crystallography or three-dimensional NMR techniques, in order to obtain information about
their binding mode and viable interaction vectors within the protein binding pocket.
Employing the aspartic protease endothiapepsin (EP) from the fungus C. parasitica, an
elaborate study was set up to investigate differences in the yield of a variety of modern
screening techniques that are routinely used for the evaluation of fragment libraries [64,65].
Surprisingly, the overlap between different pre-screening assays proved to be alarmingly low,
which undermines the confidence that an exhaustive set of binders can be reliably extracted
from a library by employing a single affinity assay, instead of a cascade of several subsequent
assay determinations. Alternatively, a high-throughput crystallographic pipeline was set up
that proved to be most efficient for the identification of compounds as a starting point for
fragment elaboration [66–68].
False Positives and Pan Assay Interference Compounds
Library screening campaigns have been a fundamental part of drug design efforts in
pharmaceutical companies for the last decades. However, data interpretation of high
throughput screening results has been notoriously plagued by the occurrence of false positive
hits from the initial assays [69]. In many cases, the originally detected binder shows no affinity
in subsequent experiments or proves to bind through a non-specific mechanism to the protein
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of interest. Metal chelation [70], redox activity [71], chemical reactivity [72,73], aggregation
[74], compound impurity [75–77], promiscuous binding [70,78,79], as well as an inherent
compound fluorescence or other means of interference with the assay detection method [80]
have been identified as reasons for the emergence of false positives. Molecules and
functionalities that are infamous for their properties to give false positive readouts in
commonly employed assays have been dubbed “PAINS”, short for “Pan Assay Interference
Compounds” [81]. The pursuit of false positive hits from a library screen can represent a
significant loss of time and resources. Therefore, the prevention or early detection of such
events has become a major concern in screening campaigns.
1.7 Thesis Outline
The work presented in this thesis tries to answer fundamental questions about the molecular
processes that drive the interaction of proteins and their binding partners in biological
recognition. For this research effort, the metalloprotease thermolysin serves as a reliable and
well documented model system. The main objective was the dissection of thermodynamic and
kinetic affinity descriptors into their respective elements and a correlation of these values to
structural observations. For each specific question, a defined, congeneric series of inhibitors
was analyzed with an experimental setup that was tailored to the needs of the respective
research objective.
The results presented in Chapter 2 serve as the basis for the following experiments. Here, a
reliable synthetic method for the preparation of phosphonopeptidic inhibitors for TLN is
detailed. The high polarity and instability of deprotected phosphonamidates complicates their
preparation, especially during the final deprotection step. Traditional protocols, such as a
purification by preparative reversed phase HPLC, can lead to a decomposition of the target
compounds in the aqueous mobile phase. This is particularly prevalent when polar and basic
functional groups are included in the inhibitor scaffold. The protocol presented in this section
describes a methodology that is based on an alloc/allyl ester protection strategy in combination
with a solid phase extraction procedure. This workflow gives the deprotected inhibitors in good
yields and excellent purity.
The research described in Chapters 3, 4, and 5 is concerned with the influence of water
molecules on the interaction of TLN with its inhibitors. As a solvent that is ubiquitously
present in biological systems, water takes an active role in biological recognition processes.
Using the TLN system as a case study, the experiments conducted here try to elucidate the
nature and extent of solvent effects on the thermodynamics and kinetics of binding. In Chapter
3, the influence of hydrophobic hydration around a solvent-exposed portion of an inhibitor on
the thermodynamic signature of binding is investigated. Based on a previously conducted
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study, a design concept is evaluated that aims to optimize the structure of water networks in
the hydration shell of the ligand. In contrast to this, the experiments presented in Chapter 4
study the effects that charged and polar groups can have on the binding thermodynamics when
they are placed in a solvent-exposed region at the surface of the protein–ligand complex. Here,
the interactions of a charged group to surrounding water molecules seem to be of a more
transient nature, so that the penalty for the partial desolvation of the polar group dominates
the binding profile. In Chapter 5, it is attempted to experimentally validate the hypothesis that
the deep and well defined hydrophobic S1’ pocket of TLN remains unsolvated when no ligand
is bound to the protein. Using a tool compound, which was specifically designed to generate
an empty cavity in the binding pocket, in combination with a careful analysis of an
experimentally phased electron density map, it is concluded that the S1’ pocket in TLN is
indeed empty. The dramatic gain of affinity by a factor of 41 000 for compounds that address
this void with an iso-pentyl moiety can be attributed to a reduction of the empty space in the
cavity.
The focus of the study in Chapter 6 laid on the molecular mechanisms that are responsible for
long residence time binding of inhibitors of TLN. Here, binding kinetic data of a series of TLN
inhibitors is analyzed by SPR and the information gathered from these experiments is
correlated to the crystal structures of the complexes. It is concluded that the rate-determining
step of ligand dissociation is correlated to the movement of Asn112, a residue that lines the
active site of the protease and is believed to orientate a substrate for peptide cleavage. By
interfering with this retro-induced fit mechanism, the residence time of an inhibitor can be
dramatically prolonged.
Chapter 7 outlines a side project that is not strictly connected to the questions raised in the
previous chapters. In this section, the intrinsic reactivity of a compound is investigated that
stood out in a fragment library screening for affinity to the aspartic protease endothiapepsin.
The molecule that is found within the active site of the protein in the crystal structure is
generated from the originally employed fragment in a reaction cascade that involves an
extensive rearrangement of its heterocyclic core structure. The newly generated species binds
to the protein by pronounced electrostatic interactions that perfectly complement the topology
of the binding pocket. This, potentially highly potent, binder presumably accounts for the high
affinity that was detected in initial binding assays.
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2.1 Abstract
For modern biophysical methods such as isothermal titration calorimetry, high purity of the
inhibitor of interest is indispensable. Herein, we describe a procedure for the synthesis and
purification of functionalized phosphonamidate peptides that is able to generate inhibitors for
the metalloprotease thermolysin for use in biophysical experiments. The method utilizes an
allyl ester/alloc protection strategy and takes advantage of a fast and effective solid phase
extraction (SPE) purification step. Applying this strategy, we were able to synthesize a series of
highly polar inhibitors featuring amino- and hydroxy-functionalized side chains in excellent
purity.
Keywords
thermolysin, metalloprotease, inhibitor synthesis, phosphon-amidate, solid phase extraction,
allyl/alloc protection
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2.2 Main Text
The introduction of phosphonamidate moieties in peptidic structures has repeatedly yielded
highly potent transition state analogous inhibitors for a broad range of proteases such as
thermolysin (TLN) [39], HIV protease [82], carboxypeptidase A [40], angiotensin-converting
enzyme [41], leucine aminopeptidase [83], endothelin converting enzyme [42] and human
collagenase [84]. In form of phosphonamidate ester conjugates, the phosphonamidate group
has also been incorporated in haptens designed for the generation of catalytic antibodies [85]
and utilized for the bio-orthogonal modification of proteins [86]. This scope of applications
highlights the applicability of phosphonamidates in biochemical and biomedical research.
While phosphonamidate esters are sufficiently stable under physiological conditions [86–88],
the inherent instability of free phosphonamidates has been deemed as major disadvantage and
prevented a broad application of these compounds [89–91].
In our group, P(V)-based  peptidomimetic inhibitors of thermolysin have proven to be
valuable tool compounds to study the formation of contiguously connected water networks on
the surface of the protein-ligand complex and their influence on binding thermodynamics
[15,92–95]. In this context, a high purity of the inhibitors used for the measurements is of vital
importance. In isothermal titration calorimetry experiments, the enthalpic term is strongly
dependent on the applied inhibitor concentration. Inaccuracies in the latter property can easily
lead to false data interpretation when studied samples are not sufficiently pure [96,97].
Herein we report a modified strategy for the synthesis and purification of Cbz-protected
phosphonamidates (Figure 2.1), utilizing allyl ester/alloc protection and an efficient solid-
phase extraction (SPE) protocol that allows the facile introduction of a variety of functional
groups in the P1’- and P2’-position of a peptidomimetic inhibitor. For a prospective
biophysical study, we envisaged to introduce polar functional groups to the basic scaffold of
thermolysin inhibitors, while simultaneously adhering to the N-terminal Cbz-protecting
group, which has to be seen as an integral part of the inhibitor scaffold. The most commonly
employed strategy in the synthesis of phosphonamidate peptides utilizes alkyl or benzyl esters
as protecting group for the phosphonamidate and C-terminal carboxylic acid functions. The
Figure 2.1. Basic scaffold of phosphonamidate type inhibitors of thermolysin.
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deprotection is consequently accomplished by hydrolytic cleavage [15], treatment with TMSBr
[98], NaI [89] or hydrogenolysis [41], respectively (Scheme 2.1). These strategies combine the
advantage of mild reaction conditions with easily removable reagents, thus avoiding the
formation of major side products. For the solid-phase synthesis of aryl phosphonamidate
peptides by a Staudinger reaction, the necessity of protecting groups can even be eliminated
[99]. The purification of the delicate deprotected phosphonamidates is usually achieved by
employing ion exchange chromatography or preparative RP-HPLC. However, in various cases,
the samples are subsequently used in biochemical assays without any final purification step
[83].
Due to the incompatibility of the desired carboxybenzyl phosphonopeptides to hydrogenolytic
side chain deprotection and the unsatisfactory range of hydrolytically labile protecting groups
for functional groups such as amines, we investigated different strategies as alternative to
established protocols. Under consideration of orthogonality and ease of purification after
Scheme 2.1. Synthetic strategies for the deprotection of phosphonamidate protease inhibitors.
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deprotection, an allyl ester/alloc-strategy was chosen for side-chain and backbone protection.
Through usage of diethylamine as nucleophilic scavenger in the palladium-catalyzed
deallylation reaction, all reagents and side products, except for the catalyst, are volatile and can
be easily removed under reduced pressure. The considerable difference in polarity between the
palladium catalyst and the deprotected phosphonopeptides allows for facile separation of the
two species by liquid-liquid extraction or reversed phase chromatography.
The synthesis of phosphonic acid diallylester 2 as precursor of the basic building block for the
TLN inhibitor series was accomplished by a one-pot reaction of benzylcarbamate and
paraformaldehyde in glacial acetic acid followed by an Arbuzov reaction with triallylphosphite.
The resulting diallylester 2 was then selectively transferred to the monoallylester 3 by
hydrolysis with aqueous NaOH (Scheme 2.2).  Phosphonamidate coupling was achieved by
reacting the corresponding phosphonochloridate with the free amino group of a peptidic
building block (Scheme 2.3). The required phosphonochloridate was generated from 3 by
activation with SOCl2. As suggested by Hirschmann et al., the phosphonochloridate was treated
with DIPEA prior to the addition of the coupling partner to generate an intermediate
phosphonylammonium species with an increased reactivity towards nucleophiles [50].
Deallylation of the protected phosphonamidates was achieved by a palladium-catalyzed allyl
transfer reaction using diethylamine as nucleophile. This method generated the fully
deprotected inhibitor as a diethylammonium salt. After removal of the volatile side products,
most hydrophobic contaminants were separated by a liquid-liquid extraction step. Analysis of
the raw reaction products by qNMR indicated high conversion along with a purity of 70–80%,
with excess diethylamine and catalyst residue as the major contaminants.
For compounds containing a primary amino group, the above procedure lead to the formation
of non-stoichiometric mixtures of the inherently zwitterionic substances with diethylamine.
Due to the rather close similarity of the pKa values of diethylamine and the primary amino
group, no consistent salt formation could be achieved. Additionally, the diethylammonium
salts proved to be highly hygroscopic. Incubation of the raw reaction product with aqueous
LiOH solution prior to liquid-liquid extraction lead to the formation of uniform lithium salts
Scheme 2.2. Reagents and conditions: (a) (CHO)n, AcOH, 50 °C, 4 h; (b) P(OAll)3, neat, 110 °C,
overnight (64%, two steps); (c) NaOH, H2O, 1 h, 81%.
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with greatly reduced hygroscopicity. By using a semi-preparative HPLC setup for the
purification of functionalized phosphonopeptides, we frequently failed to achieve sufficient
separation efficiencies, had trouble with detection and overall poor sample recovery. This
might be attributed to the fact that the lability of the reaction product does not allow for the
Scheme 2.3. Reagents and conditions: (a) SOCl2, DCM, 0 °C to rt, 3 h; (b) 4 M HCl in dioxane, rt, 1 h;
(c) DIPEA, DCM, 40 °C, overnight.
 An Improved Strategy for the Synthesis of Phosphonamidate Peptides | 43
C
h
a
p
te
r 
2
addition of an acidic modifier such as TFA to the mobile phase, which, in consequence,
severely deteriorates the peak shape. Additionally, there are reports that some
phosphonamidates seem to show a tendency for decomposition during chromatographic
purification, even without the addition of acidic modifiers [100]. Regularly, we also observed
hydrolysis in preparative HPLC runs. As an alternative purification method, we investigated
the use of solid-phase extraction (SPE). While predominantly used as a technique for sample
preparation in analytical setups [101], SPE can be seen as a small-scale chromatography system
that retains high sample concentration (narrow bands) and reduces exposure of the analyte to
mobile and stationary phases to a minimum. While the separation efficiency is comparatively
low, this technique has been successfully used for preparative purification of synthetic peptides,
modified sugars and anthocyanidin-glucosides from plant material [102–104].
SPE cartridges with various phases and surface modifications are readily available from
commercial suppliers, a number of which were tested for the purification of phosphonamidate
peptides. The eluted fractions were analyzed by HPLC. Amino and cyano-modified silica gel
phases and polymeric DPA-6S resin, however, did not show any retention of the desired
compounds or contaminants in reversed phase mode. The use of a zwitterionic ammonium–
sulfonic acid phase in HILIC mode was also investigated. This technique enabled the efficient
separation of the desired products from apolar reaction side products. Unfortunately, direct
application of alkaline samples to the column lead to hydrolysis of the surface modification.
When the sample pH was adjusted, separation of the ionic product from buffer substances
proved impossible. Efficient purification could be achieved with a C18-modified silica gel phase.
Here, the contaminants showed a strong retention, while the desired phosphonopeptides could
be easily eluted with water or water/acetonitrile mixtures. By using these SPE phases, we were
able to obtain the desired inhibitors with high purity. Table 2.1 shows a variety of
phosphonopeptides prepared following the reported protocol. The scope of the procedure
includes inhibitors featuring polar and basic functional groups. Additionally, the use of a
palladium-catalyzed deprotection reaction grants access to compounds featuring a
hydrolytically labile ester group, which have been challenging to prepare by traditional
methods [105]. The novel SPE protocol enables a fast and efficient purification of the inhibitors
while simultaneously reducing the amount of compound degradation in aqueous solvents. The
purity of the isolated products is excellent and allows their use in biophysical assays such as
isothermal titration calorimetry, a method that heavily relies on the accurate knowledge of
ligand concentrations.
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Table 2.1. Synthesis of peptidic phosphonamidate inhibitors.
Entry Reactant Product Yield
Purity
(qNMR)
1
18 = 73%
19 = 63%
20 = 66%
18 = 95%
19 = 97%
20 = 99%
2
21 = 78%
22 = 72%
23 = 72%
24 = 75%
21 = 99%
22 = 99%
23 = 96%
24 = 96%
3 66% 97%
4 59% 97%
5 75% 97%
6 72% 96%
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Table 2.1. Continued.
Entry Reactant Product Yield
Purity
(qNMR)
7 79% 96%
8 77% 97%
9 77% 97%
2.3 Experimental Section
1H, 13C and 31P NMR spectra were recorded on a JEOL ECX-400 or JEOL ECA-500 instrument.
All chemical shift values are reported in ppm relative to the non-deuterated solvent signal. An
external standard was used for 31P NMR spectra (85% H3PO4) and 13C NMR spectra in D2O
(Trimethylsilyl propanoic acid). Quantitative NMR spectra were recorded using
recommended instrument parameters for quantitative analysis (see Supporting Information).
Relaxation delay was set to 50–60 s to ensure complete relaxation between pulses. Dimethyl
terephthalate (Sigma-Aldrich, TraceCERT 99.99%) was used as an internal standard for
quantification. All qNMR spectra were recorded in deuterated methanol. ESI-MS spectra were
recorded on a Q-Trap 2000 system by Applied Biosystems. For high resolution ESI-MS, a LTQ-
FT Ultra mass spectrometer (Thermo Fischer Scientific) was used. For HPLC chromatography,
a Shimadzu LC-20 system equipped with a diode array detector was used. Analytic separations
were carried out with a MN Nucleodur 100-5 C18 ec 4.6 × 250 mm column using a water-
acetonitrile gradient with the addition of 0.1% TFA. While these conditions lead to hydrolysis
of the analyte, the purity of the sample, regarding other contaminants, can be determined
nevertheless. The absence of hydrolytic cleavage products in the sample was assured by 1H and
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31P NMR. For SPE purification, Thermoscientific HyperSep C18 500 mg 3 mL cartridges were
used. Melting points were determined with a Krüss KSP1N melting point meter.
2.4 Procedures
Benzyl ((bis(allyloxy)phosphoryl)methyl)carbamate (2): Benzyl-carbamate (756 mg, 5.00
mmol, 1.0 eq) and paraformaldehyde (180 mg, 6.00 mmol, 1.2 eq) were suspended in acetic
acid and heated to 50 °C for 5 h. The solvent was removed under reduced pressure and triallyl
phosphite (2.02 g, 10.00 mmol, 2.0 eq) was added to the residue. The mixture was heated to
110 °C for 14 h. All volatile components were removed under reduced pressure and the crude
product was purified by silica gel chromatography (cyclohexane/EtOAc 1:1). The product was
obtained as a colorless oil (1.042 g, 3.20 mmol, 64%). 1H NMR (CDCl3, 400 MHz): d = 3.66
(dd, J = 11.2, 6.0 Hz, 2H), 4.55 (dd, J = 7.6, 6.5 Hz, 4H), 5.05 (s, 1H), 5.11 (s, 2H), 5.24 (dd, J =
10.4, 1.1 Hz, 2H), 5.34 (dd, J = 17.1, 1.2 Hz, 2H), 5.84 – 5.99 (m, 2H), 7.28 – 7.41 (m, 5H). 13C
NMR (CDCl3, 101 MHz): d = 36.2, 37.8, 67.0, 67.1, 67.4, 118.7, 118.7, 128.3, 128.4, 128.7, 132.6,
132.6, 136.2, 156.2. 31P NMR (CDCl3, 162 MHz): d = 24.0. MS (ESI): m/z [M + H]+ calcd for
C15H21NO5P: 326.31; found: 326.08.
Benzyl (((allyloxy)(hydroxy)phosphoryl)methyl)carbamate (3): An aqueous solution of
NaOH (80 mg, 2.00 mmol, 3.5 eq) was added to 2 (189 mg, 0.58 mmol, 1.0 eq) and the mixture
was shaken vigorously until the solution cleared. After stirring for 1 h at rt, the mixture was
washed with EtOAc (3 × 15 mL) and the organic phase was discarded. The aqueous phase was
acidified to pH 1 and extracted with EtOAc (3 × 15 mL). The combined organic phases were
washed with a saturated NaCl solution and dried over MgSO4. The crude product was washed
with hot TBME to give the product as a colorless solid (135 mg, 0.47 mmol, 81%); mp 91–92
°C. 1H NMR (CDCl3, 400 MHz): d = 3.50 – 3.70 (m, 2H), 4.45 – 4.57 (m, 2H), 5.10 (s, 2H), 5.22
(dd, J = 10.4, 0.9 Hz, 1H), 5.28 – 5.37 (m, 1H), 5.82 – 5.96 (m, 1H), 6.85 (bs, 1H), 7.27 – 7.38
(m, 5H). 13C NMR (CDCl3, 101 MHz): d = 66.9, 67.0, 67.5, 118.7, 128.3, 128.4, 128.7, 132.5,
132.5, 136.2, 156.5. 31P NMR (CDCl3, 162 MHz): d = 25.2. MS (ESI-): m/z [M - H]- calcd for
C12H15NO5P: 284.23; found: 284.10.
General procedure for phosphonamidate coupling: SOCl2 (4.0 eq) was dissolved in dry DCM
under argon atmosphere and cooled to 0 °C. A solution of benzyl
((hydroxy(allyloxy)phosphoryl)methyl) carbamate (3, 2.0 eq) was added to the solution over
30 minutes. The cooling bath was removed and the reaction was stirred at rt for 4 h. All volatile
components were removed under reduced pressure. In a second flask, the Boc-protected
peptidic building block (1.0 eq, syntheses detailed in the Supporting Information) was treated
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with HCl (4 M in dioxane, 4.0 eq) for 1 h and all volatile components were subsequently
removed under reduced pressure. The activated phosphonic acid was dissolved in dry DCM.
DIPEA (3.0 eq) and the deprotected peptide were consecutively added to the solution, after
which the mixture was heated to 40 °C and stirred overnight. The solution was diluted with
EtOAc and washed with 5% citric acid (3 × 10 mL), 1 M HCl (1 × 10 mL) and 1 M NaOH (3 ×
10 mL). The separated organic phase was washed with brine and dried over MgSO4. The
product was obtained as a mixture of diastereomers and used in the next step without further
purification.
Compound 4: Peptide S3 (178 mg, 0.39 mmol), HCl (4 M solution in dioxane, 0.5 mL, 2.00
mmol), 3 (222 mg, 0.78 mmol), SOCl2 (186 mg, 1.56 mmol), DIPEA (151 mg, 1.17 mmol). The
product was obtained as a yellow oil (158 mg, 0.25 mmol, 65%). 1H NMR (CDCl3, 400 MHz):d = 0.84 – 1.03 (m, 6H), 1.41 – 1.54 (m, 1H), 1.57 – 1.92 (m, 3H), 1.99 – 2.22 (m, 1H), 2.99 –
3.16 (m, 1H), 3.32 – 3.48 (m, 1H), 3.51 – 3.99 (m, 4H), 4.41 – 4.76 (m, 6H), 5.03 – 5.42 (m, 8H),
5.75 – 5.99 (m, 3H), 7.25 – 7.40 (m, 5H). 13C NMR (CDCl3, 101 MHz): d = 21.8, 22.0, 23.0, 23.1,
24.61, 24.64, 32.2, 37.1, 44.0, 50.0, 53.9, 65.6, 65.68, 65.73, 65.8, 66.36, 66.43, 67.37, 67.41,
117.78, 117.83, 118.1, 118.4, 119.3, 119.4, 128.2, 128.32, 128.34, 128.37, 128.65, 128.67, 131.46,
131.52, 132.95, 133.00, 136.3, 136.4, 156.6, 156.7, 171.9, 172.1, 174.28, 174.32. 31P NMR (CDCl3,
162 MHz): d = 27.6, 28.2. MS (ESI+): m/z [M + H]+ calcd for C29H44N4O9P: 623.66; found:
623.26.
Compound 5: Peptide S8 (235 mg, 0.50 mmol), HCl (4 M solution in dioxane, 0.5 mL, 2.00
mmol), 3 (285 mg, 1.00 mmol), SOCl2 (238 mg, 2.00 mmol), DIPEA (194 mg, 1.50 mmol). The
product was obtained as a yellow oil (283 mg, 0.44 mmol, 89%). 1H NMR (CDCl3, 400 MHz):d = 0.81 – 1.02 (m, 6H), 1.38 – 1.95 (m, 7H), 3.02 – 3.29 (m, 2H), 3.41 – 4.00 (m, 4H), 4.36 –
4.68 (m, 6H), 5.00 – 5.43 (m, 8H), 5.79 – 6.04 (m, 3H), 7.25 – 7.43 (m, 6H). 13C NMR (CDCl3,
101 MHz): d = 21.9, 22.0, 23.0, 23.0, 24.56, 24.59, 25.9, 26.1, 29.0, 38.0, 40.4, 43.88, 43.94, 52.2,
53.8, 65.6, 66.1, 66.2, 67.3, 67.4, 117.8, 118.1, 118.3, 119.1, 119.2, 128.2, 128.3, 128.6, 131.55,
131.58, 132.87, 132.94, 133.0, 133.1, 136.3, 156.7, 156.8, 171.8, 172.1, 173.9, 174.0. 31P NMR
(CDCl3, 162 MHz): d = 27.5, 28.4. MS (ESI+): m/z [M + H]+ calcd for C30H46N4O9P: 637.69;
found: 637.51.
Compound 6: Peptide S9 (242 mg, 0.50 mmol), HCl (4 M solution in dioxane, 0.5 mL, 2.00
mmol), 3 (285 mg, 1.00 mmol), SOCl2 (238 mg, 2.00 mmol), DIPEA (194 mg, 1.50 mmol). The
product was obtained as a yellow oil (262 mg, 0.40 mmol, 81%). 1H NMR (CDCl3, 400 MHz):d = 0.83 – 1.06 (m, 6H), 1.28 – 2.11 (m, 9H), 3.02 – 3.25 (m, 2H), 3.40 – 3.96 (m, 4H), 4.40 –
4.76 (m, 6H), 5.02 – 5.45 (m, 8H), 5.76 – 6.03 (m, 3H), 6.91 – 7.04 (m, 1H), 7.26 – 7.49 (m, 5H).
13C NMR (CDCl3, 101 MHz): d = 21.8, 22.0, 22.3, 23.0, 23.1, 24.5, 29.3, 31.3, 38.0, 38.2, 39.4,
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39.6, 40.2, 40.3, 43.7, 52.2, 52.4, 53.8, 65.6, 66.08, 66.13, 67.3, 117.7, 118.1, 118.4, 119.08, 119.12,
128.2, 128.3, 128.6, 131.6, 132.9, 133.0, 133.1, 136.3, 156.7, 172.0, 174.0. 31P NMR (CDCl3, 162
MHz): d = 27.6, 28.3. MS (ESI+): m/z [M + H]+ calcd for C31H48N4O9P: 651.72; found: 651.42.
Compound 7: Peptide S11 (197 mg, 0.57 mmol), HCl (4 M solution in dioxane, 0.5 mL, 2.00
mmol), 3 (328 mg, 1.15 mmol), SOCl2 (271 mg, 2.28 mmol), DIPEA (221 mg, 1.71 mmol). The
product was obtained as a brown solid (185 mg, 0.36 mmol, 72%); mp 118–119 °C. 1H NMR
(CDCl3, 400 MHz): d = 0.61 – 1.01 (m, 6H), 1.33 – 1.86 (m, 3H), 3.40 – 3.77 (m, 2H), 3.73 –
3.98 (m, 1H), 4.25 – 4.68 (m, 6H), 4.94 – 5.46 (m, 6H), 5.67 – 5.95 (m, 2H), 7.19 – 7.47 (m, 5H).
13C NMR (CDCl3, 101 MHz): d = 22.0, 22.1, 22.95, 23.01, 24.6, 24.7, 43.7, 46.4, 53.1, 53.4, 65.2,
65.9, 67.3, 117.9, 118.0, 128.26, 128.33, 128.6, 132.6, 132.9, 133.0, 136.36, 136.41, 156.8, 175.2,
175.4. 31P NMR (CDCl3, 162 MHz): d = 27.6, 28.1. MS (ESI+): m/z [M + H]+ calcd for
C23H36N4O7P: 511.54; found: 511.48.
Compound 8: Peptide S15 (179 mg, 0.50 mmol), HCl (4 M solution in dioxane, 0.5 mL, 2.00
mmol), 3 (285 mg, 1.00 mmol), SOCl2 (238 mg, 2.00 mmol), DIPEA (194 mg, 1.50 mmol). The
product was obtained as a colorless solid (146 mg, 0.28 mmol, 56%); mp 148–149 °C. 1H NMR
(CDCl3, 400 MHz): d = 0.82 – 0.98 (m, 6H), 1.37 – 1.51 (m, 1H), 1.56 – 1.95 (m, 2H), 3.22 –
3.88 (m, 7H), 4.40 – 4.60 (m, 4H), 5.03 – 5.42 (m, 6H), 5.64 – 6.00 (m, 4H), 6.98 – 7.11 (m, 1H),
7.27 – 7.44 (m, 5H). 13C NMR (CDCl3, 101 MHz): d = 21.8, 22.1, 23.0, 23.1, 24.7, 38.0, 38.1,
39.86, 39.92, 40.7, 40.9, 43.7, 53.6, 53.8, 65.6, 65.8, 67.4, 67.5, 118.0, 118.3, 118.4, 128.3, 128.4,
128.7, 132.8, 133.0, 136.2, 156.9, 174.6. 31P NMR (CDCl3, 162 MHz): d = 27.8, 28.4. MS (ESI):
m/z [M + H]+ calcd for C24H38N4O7P: 525.56; found: 525.26.
Compound 9: Peptide S16 (334 mg, 0.90 mmol), HCl (4 M solution in dioxane, 1.0 mL, 4.00
mmol), 3 (513 mg, 1.80 mmol), SOCl2 (428 mg, 3.60 mmol), DIPEA (349 mg, 2.70 mmol). The
product was obtained as a yellow solid (446 mg, 0.83 mmol, 92%); mp 100–101 °C. 1H NMR
(CDCl3, 400 MHz): d = 0.80 – 1.03 (m, 6H), 1.39 – 2.00 (m, 5H), 3.07 – 3.32 (m, 4H), 3.37 –
3.92 (m, 2H), 4.39 – 4.64 (m, 4H), 5.03 – 5.46 (m, 6H), 5.77 – 5.98 (m, 2H), 7.28 – 7.42 (m, 5H).
13C NMR (CDCl3, 101 MHz): d = 21.8, 22.0, 23.0, 23.1, 24.7, 29.7, 36.2, 36.3, 37.7, 37.8, 39.4,
39.6, 43.8, 53.4, 53.6, 65.5, 65.7, 67.3, 117.8, 118.1, 118.3, 128.3, 128.4, 128.7, 132.8, 133.0, 136.3,
156.9, 174.2, 174.5. 31P NMR (CDCl3, 162 MHz): d = 27.9, 28.2. MS (ESI): m/z [M + H]+ calcd
for C25H40N4O7P: 539.59; found: 539.51.
Compound 10: Peptide S17 (272 mg, 0.70 mmol), HCl (4 M solution in dioxane, 1.0 mL, 4.00
mmol), 3 (399 mg, 1.40 mmol), SOCl2 (333 mg, 2.80 mmol), DIPEA (271 mg, 2.10 mmol). The
product was obtained as a brown solid (258 mg, 0.47 mmol, 67%); mp 112–113 °C. 1H NMR
(CDCl3, 400 MHz): d = 0.85 – 1.05 (m, 6H), 1.41 – 1.79 (m, 7H), 3.11 – 3.29 (m, 4H), 3.50 –
3.93 (m, 3H), 4.39 – 4.64 (m, 4H), 5.01 – 5.43 (m, 7H), 5.81 – 6.05 (m, 2H), 7.10 – 7.19 (m, 1H),
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7.29 – 7.49 (m, 5H). 13C NMR (CDCl3, 101 MHz): d = 21.9, 22.1, 23.0, 23.1, 24.7, 26.5, 26.6,
27.3, 38.0, 38.2, 39.1, 40.6, 43.7, 53.3, 53.6, 65.4, 65.6, 67.3, 117.8, 118.1, 118.3, 128.3, 128.4,
128.7, 132.9, 133.1, 136.3, 156.6, 156.8, 173.8, 174.2. 31P NMR (CDCl3, 162 MHz): d = 27.8, 28.2.
MS (ESI): m/z [M + NH4]+ calcd for C26H45N5O7P: 570.31; found: 570.44.
Compound 11: Peptide S19 (192 mg, 0.50 mmol), HCl (4 M solution in dioxane, 0.5 mL, 2.00
mmol), 3 (285 mg, 1.00 mmol), SOCl2 (238 mg, 2.00 mmol), DIPEA (194 mg, 1.50 mmol). The
product was obtained as a brown oil (264 mg, 0.48 mmol, 96%). 1H NMR (CDCl3, 400 MHz):d = 0.79 – 1.04 (m, 6H), 1.22 – 1.56 (m, 2H), 1.72 – 1.95 (m, 1H), 3.22 – 3.81 (m, 10H), 4.23 –
4.37 (m, 1H), 4.40 – 4.68 (m, 4H), 5.00 – 5.42 (m, 6H), 5.78 – 6.05 (m, 2H), 7.19 – 7.44 (m, 5H).
13C NMR (CDCl3, 101 MHz): d = 21.4, 21.7, 23.4, 23.5, 24.4, 24.6, 38.3, 39.3, 42.1, 42.2, 43.6,
43.9, 45.3, 49.1, 49.6, 53.5, 65.0, 65.2, 66.5, 67.2, 67.3, 117.9, 118.0, 128.2, 128.3, 128.59, 128.64,
132.7, 132.9, 133.0, 136.4, 154.9, 155.0, 156.4, 172.6, 173.2. 31P NMR (CDCl3, 162 MHz): d =
27.4, 28.0. MS (ESI+): m/z [M + NH4]+ calcd for C26H43N5O7P: 568.63; found: 568.44.
Compound 12: Peptide S21 (164 mg, 0.50 mmol), HCl (4 M solution in dioxane, 0.5 mL, 2.00
mmol), 3 (285 mg, 1.00 mmol), SOCl2 (238 mg, 2.00 mmol), DIPEA (194 mg, 1.50 mmol). The
product was obtained as a brown oil (240 mg, 0.48 mmol, 97%). 1H NMR (CDCl3, 400 MHz):d = 0.78 – 0.98 (m, 6H), 1.54 – 1.75 (m, 3H), 3.32 – 3.52 (m, 2H), 3.70 – 3.97 (m, 2H), 4.29 –
4.43 (m, 2H), 4.47 – 4.71 (m, 3H), 4.98 – 5.45 (m, 6H), 5.75 – 6.03 (m, 2H), 7.23 – 7.46 (m, 5H).
13C NMR (CDCl3, 101 MHz): d = 21.8, 22.8, 24.8, 37.0, 38.4, 40.6, 51.4, 66.1, 66.8, 116.8, 118.8,
128.0, 128.1, 128.5, 131.7, 134.4, 134.5, 136.8, 156.8, 156.9, 166.9, 172.9. 31P NMR (CDCl3, 162
MHz): d = 19.3. MS (ESI+): m/z [M + NH4]+ calcd for C23H38N4O7P: 513.55; found: 513.41.
Compound 13: Peptide S22 (171 mg, 0.50 mmol), HCl (4 M solution in dioxane, 0.5 mL, 2.00
mmol), 3 (285 mg, 1.00 mmol), SOCl2 (238 mg, 2.00 mmol), DIPEA (194 mg, 1.50 mmol). The
product was obtained as a brown oil (239 mg, 0.47 mmol, 94%). 1H NMR (CDCl3, 400 MHz):d = 0.86 – 1.04 (m, 6H), 1.23 – 1.49 (m, 3H), 1.53 – 1.82 (m, 3H), 3.45 – 3.81 (m, 2H), 3.84 –
4.05 (m, 1H), 4.44 – 4.73 (m, 5H), 5.09 (d, J = 10.8 Hz, 2H), 5.19 – 5.47 (m, 4H), 5.71 (dd, J =
28.8, 23.4 Hz, 1H), 5.80 – 6.01 (m, 2H), 7.28 – 7.44 (m, 5H). 13C NMR (CDCl3, 101 MHz): d =
21.4, 21.6, 21.9, 23.0, 25.0, 37.7, 38.1, 39.1, 39.5, 41.09, 41.13, 50.6, 50.9, 51.0, 51.1, 65.25, 65.31,
65.37, 65.43, 66.0, 67.3, 118.2, 118.3, 118.9, 128.2, 128.26, 128.31, 128.6, 131.7, 132.80, 132.85,
132.90, 136.4, 156.7, 156.8, 172.7, 173.0, 173.7, 173.9. 31P NMR (CDCl3, 162 MHz): d = 27.4,
27.6. MS (ESI+): m/z [M + NH4]+ calcd for C24H40N4O7P: 527.58; found: 527.43.
Compound 14: Peptide S23 (185 mg, 0.50 mmol), HCl (4 M solution in dioxane, 0.5 mL, 2.00
mmol), 3 (285 mg, 1.00 mmol), SOCl2 (238 mg, 2.00 mmol), DIPEA (194 mg, 1.50 mmol). The
product was obtained as a brown oil (231 mg, 0.43 mmol, 86%). 1H NMR (CDCl3, 400 MHz):d = 0.82 – 1.01 (m, 9H), 1.01 – 1.15 (m, 3H), 1.59 – 1.83 (m, 3H), 2.04 – 2.43 (m, 1H), 3.48 –
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3.84 (m, 4H), 4.43 – 4.69 (m, 4H), 5.05 – 5.15 (m, 2H), 5.17 – 5.39 (m, 4H), 5.79 – 6.01 (m, 2H),
7.27 – 7.42 (m, 5H). 13C NMR (CDCl3, 101 MHz): d = 17.5, 17.6, 19.3, 19.4, 21.6, 21.7, 22.9,
23.0, 24.9, 24.9, 32.1, 32.2, 37.8, 38.1, 39.3, 39.5, 40.9, 41.0, 50.9, 51.1, 60.0, 60.6, 65.2, 65.3, 65.4,
65.97, 66.01, 67.17, 67.23, 117.9, 118.0, 118.85, 118.88, 128.1, 128.2, 128.55, 128.57, 131.7,
132.80, 132.87, 132.90, 133.0, 136.4, 156.55, 156.60, 156.7, 156.8, 172.6, 172.9, 173.0, 173.1. 31P
NMR (CDCl3, 162 MHz): d = 27.9, 28.3. MS (ESI+): m/z [M + NH4]+ calcd for C26H44N4O7P:
555.63; found: 555.37.
Compound 15: Peptide S24 (221 mg, 0.50 mmol), HCl (4 M solution in dioxane, 0.5 mL, 2.00
mmol), 3 (285 mg, 1.00 mmol), SOCl2 (238 mg, 2.00 mmol), DIPEA (194 mg, 1.50 mmol). The
product was obtained as a brown oil (280 mg, 0.46 mmol, 92%). 1H NMR (CDCl3, 400 MHz):d = 0.83 – 1.01 (m, 6H), 1.58 – 1.77 (m, 3H), 3.37 – 3.74 (m, 3H), 4.10 (m, 2H), 4.37 – 4.70 (m,
7H), 5.02 – 5.37 (m, 8H), 5.81 – 5.98 (m, 3H), 7.27 – 7.41 (m, 5H). 13C NMR (CDCl3, 101 MHz):d = 21.6, 23.0, 24.9, 38.1, 39.6, 40.4, 45.2, 45.4, 51.3, 51.3, 54.8, 55.4, 65.2, 65.3, 65.5, 65.5, 65.97,
66.03, 66.1, 67.2, 67.3, 117.8, 118.2, 118.3, 118.9, 128.16, 128.18, 128.3, 128.55, 128.58, 131.7,
132.8, 136.3, 136.4, 156.7, 157.5, 171.3, 171.5, 172.6, 172.7. 31P NMR (CDCl3, 162 MHz): d =
27.6. MS (ESI+): m/z [M + NH4]+ calcd for C28H45N5O9P: 626.67; found: 626.38.
Compound 16: Peptide S26 (221 mg, 0.50 mmol), HCl (4 M solution in dioxane, 0.5 mL, 2.00
mmol), 3 (285 mg, 1.00 mmol), SOCl2 (238 mg, 2.00 mmol), DIPEA (194 mg, 1.50 mmol). The
product was obtained as a brown oil (199 mg, 0.33 mmol, 65%). 1H NMR (CDCl3, 500 MHz):d = 0.85 – 1.03 (m, 6H), 1.57 – 1.80 (m, 3H), 3.58 – 3.79 (m, 2H), 4.11 – 4.46 (m, 3H), 4.49 –
4.70 (m, 7H), 5.04 – 5.18 (m, 2H), 5.18 – 5.40 (m, 6H), 5.81 – 5.97 (m, 3H), 7.28 – 7.41 (m, 5H).
13C NMR (CDCl3, 101 MHz): d = 21.8, 23.0, 24.9, 40.9, 41.1, 51.2, 51.3, 54.2, 54.2, 65.6, 66.1,
66.2, 67.5, 67.5, 69.0, 118.5, 118.9, 119.0, 119.4, 119.4, 128.3, 128.4, 128.7, 131.4, 131.7, 132.7,
132.7, 136.3, 154.6, 156.8, 169.6, 172.5. 31P NMR (CDCl3, 162 MHz): d = 27.1, 27.7. MS (ESI+):
m/z [M + NH4]+ calcd for C28H44N4O10P: 627.65; found: 627.33.
Compound 17: Peptide S28 (172 mg, 0.50 mmol), HCl (4 M solution in dioxane, 0.5 mL, 2.00
mmol), 3 (285 mg, 1.00 mmol), SOCl2 (238 mg, 2.00 mmol), DIPEA (194 mg, 1.50 mmol). The
product was obtained as a yellow oil (189 mg, 0.37 mmol, 74%). 1H NMR (CDCl3, 400 MHz):d = 0.86 – 1.04 (m, 6H), 1.42 – 1.64 (m, 4H), 1.65 – 1.91 (m, 2H), 2.92 – 3.17 (m, 1H), 3.38 –
3.85 (m, 2H), 3.98 – 4.17 (m, 1H), 4.39 – 4.73 (m, 4H), 5.01 – 5.39 (m, 7H), 5.76 – 6.02 (m, 2H),
7.28 – 7.44 (m, 5H). 13C NMR (CDCl3, 101 MHz): d = 16.87, 16.90, 21.3, 21.5, 23.0, 23.1, 24.5,
24.6, 37.9, 38.1, 39.3, 39.6, 43.17, 43.23, 43.58, 43.64, 52.2, 52.3, 65.0, 65.1, 65.2, 65.3, 66.0, 66.1,
67.20, 67.24, 69.3, 69.4, 117.8, 118.0, 119.03, 119.06, 128.1, 128.2, 128.3, 128.57, 128.59, 131.38,
131.42, 132.9, 133.0, 136.3, 136.4, 156.4, 170.2, 174.0, 174.5. 31P NMR (CDCl3, 162 MHz): d =
26.6, 27.5. MS (ESI+): m/z [M + Na]+ calcd for C24H35N2NaO8P: 533.51; found: 533.34.
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General procedure for phosphonamidate deprotection: The protected phosphonamidate
(1.0 eq) was dissolved in DCM and diethylamine (20.0 eq) and Pd(PPh3)4 (10 mol%) were
consecutively added to the solution. After stirring at rt for 3 h, all volatile components were
removed under reduced pressure. The residue was taken up in DCM and the solution was
extracted with water containing 2.2 eq LiOH (3 × 2 mL). The combined aqueous phases were
washed with DCM and lyophilized. The crude product was purified using a reversed phase SPE
cartridge (500 mg, C18). The SPE column was conditioned with 1 mL MeCN followed by 5 mL
H2O. The sample was dissolved in 1 mL H2O, slowly passed through the column and eluted
using H2O or H2O/MeCN mixtures. The eluted fractions were analyzed by HPLC. All fractions
containing the desired product in sufficiently pure form were combined and lyophilized. The
purity of the products was analyzed by quantitative NMR spectroscopy.
Compound 18: Compound 4 (93 mg, 0.15 mmol), Pd(PPh3)4 (17 mg, 0.02 mmol), HNEt2 (219
mg, 3.00 mmol), LiOH (14 mg, 0.33 mmol). The product was obtained as a colorless solid (57
mg, 95% purity by qNMR, 0.11 mmol, 73%); decomposition above 200 °C. 1H NMR (D2O, 400
MHz): d = 0.82 – 0.94 (m, 6H), 1.35 – 1.50 (m, 2H), 1.56 – 1.68 (m, 1H), 1.85 – 1.94 (m, 1H),
1.99 – 2.07 (m, 1H), 2.78 – 2.89 (m, 2H), 3.21 – 3.35 (m, 2H), 3.62 – 3.67 (m, 1H), 4.16 (dd, J =
8.4, 5.0 Hz, 1H), 5.05 – 5.19 (m, 2H), 7.34 – 7.43 (m, 5H). 13C NMR (D2O, 101 MHz): d = 21.2,
22.2, 24.0, 36.8, 39.7 (d, JCP = 135.7 Hz), 43.21, 43.27, 52.5, 54.0, 67.1, 127.8, 128.4, 128.8, 136.4,
158.2, 177.4, 177.7. 31P NMR (D2O, 162 MHz): d = 18.2. HRMS (ESI): m/z [M + H]+ calcd for
C19H32N4O7P: 459.2003; found: 459.2003.
Compound 19: Compound 5 (96 mg, 0.15 mmol), Pd(PPh3)4 (17 mg, 0.02 mmol), HNEt2 (219
mg, 3.00 mmol), LiOH (14 mg, 0.33 mmol). The product was obtained as a colorless solid (51
mg, 97% purity by qNMR, 0.10 mmol, 63%); decomposition above 200 °C. 1H NMR (D2O, 400
MHz): d = 0.80 – 1.09 (m, 6H), 1.44 – 1.98 (m, 7H), 2.73 – 3.00 (m, 2H), 3.19 – 3.57 (m, 2H),
3.67 – 3.87 (m, 1H), 4.15 – 4.33 (m, 1H), 5.06 – 5.42 (m, 2H), 7.38 – 7.75 (m, 5H). 13C NMR
(D2O, 101 MHz): d = 21.2, 22.2, 24.0, 25.0, 28.8, 39.5, 39.7 (d, JCP = 136.1 Hz), 43.2, 54.0, 54.4,
67.1, 127.8, 128.4, 128.8, 138.0, 158.3, 177.4, 178.3. 31P NMR (D2O, 202 MHz): d = 18.2. HRMS
(ESI): m/z [M + H]+ calcd for C20H34N4O7P: 473.2160; found: 473.2161.
Compound 20: Compound 6 (100 mg, 0.15 mmol), Pd(PPh3)4 (17 mg, 0.02 mmol), HNEt2
(219 mg, 3.00 mmol), LiOH (14 mg, 0.33 mmol). The product was obtained as a colorless solid
(50 mg, 99% purity by qNMR, 0.10 mmol, 66%); decomposition above 200 °C. 1H NMR (D2O,
500 MHz): d = 0.91 – 1.02 (m, 6H), 1.33 – 1.53 (m, 5H), 1.73 – 1.84 (m, 4H), 2.72 – 2.81 (m,
2H), 3.30 – 3.38 (m, 2H), 3.74 – 3.76 (m, 1H), 4.22 (dd, J = 7.2, 5.3 Hz, 1H), 5.17 – 5.23 (m,
2H), 7.47 – 7.54 (m, 5H). 13C NMR (D2O, 101 MHz): d = 21.3, 21.8, 22.2, 24.0, 26.4, 31.1, 39.2,
39.7 (d, JCP = 136.0 Hz), 43.2, 54.0, 54.6, 67.1, 127.7, 128.3, 128.8, 136.5, 158.3, 177.2, 178.5. 31P
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NMR (D2O, 202 MHz): d = 18.2. HRMS (ESI): m/z [M + H]+ calcd for C21H36N4O7P: 487.2316;
found: 487.2315.
Compound 21: Compound 7 (77 mg, 0.15 mmol), Pd(PPh3)4 (17 mg, 0.02 mmol), HNEt2 (219
mg, 3.00 mmol), LiOH (14 mg, 0.33 mmol). The product was obtained as a colorless solid (39
mg, 99% purity by qNMR, 0.12 mmol, 78%); decomposition above 200 °C. 1H NMR (D2O, 400
MHz): d = 0.75 – 0.90 (m, 6H), 1.31 – 1.47 (m, 2H), 1.55 – 1.68 (m, 1H), 3.17 – 3.34 (m, 2H),
3.51 – 3.61 (m, 1H), 3.92 (s, 2H), 5.01 – 5.16 (m, 2H), 7.29 – 7.49 (m, 5H). 13C NMR (D2O, 101
MHz): d = 21.0, 22.3, 24.0, 39.7 (d, JCP = 137.0 Hz), 43.0, 47.9, 54.1, 67.1, 127.7, 128.4, 128.8,
136.4, 158.3, 178.5. 31P NMR (D2O, 162 MHz): d = 17.9. HRMS (ESI): m/z [M + Na]+ calcd for
C16H27N4O5PNa: 409.1611; found: 409.1614.
Compound 22: Compound 8 (146 mg, 0.28 mmol), Pd(PPh3)4 (32 mg, 0.03 mmol), HNEt2
(404 mg, 5.60 mmol), LiOH (26 mg, 0.62 mmol). The product was obtained as a colorless solid
(82 mg, 99% purity by qNMR, 0.09 mmol, 72%); decomposition above 200 °C. 1H NMR (D2O,
400 MHz): d = 0.74 – 0.94 (m, 6H), 1.33 – 1.50 (m, 2H), 1.52 – 1.71 (m, 1H), 2.69 – 2.90 (m,
2H), 3.12 – 3.43 (m, 4H), 3.53 – 3.73 (m, 1H), 4.98 – 5.27 (m, 2H), 7.29 – 7.55 (m, 5H). 13C
NMR (D2O, 101 MHz): d = 21.1, 22.3, 24.1, 38.8, 39.42 (d, JCP = 137.9 Hz), 39.46, 42.9, 54.4,
67.1, 127.8, 128.4, 128.8, 136.4, 158.2, 179.0. 31P NMR (D2O, 162 MHz): d = 18.4. HRMS (ESI):
m/z [M + Na]+ calcd for C17H29N4O5PNa: 423.1768; found: 423.1766.
Compound 23: Compound 9 (54 mg, 0.10 mmol), Pd(PPh3)4 (12 mg, 0.01 mmol), HNEt2 (146
mg, 2.00 mmol), LiOH (9 mg, 0.22 mmol). The product was obtained as a colorless solid (28
mg, 92% purity by qNMR, 0.05 mmol, 55%); decomposition above 200 °C. 1H NMR (D2O, 400
MHz): d = 0.65 – 0.98 (m, 6H), 1.29 – 1.52 (m, 2H), 1.51 – 1.73 (m, 3H), 2.55 – 2.76 (m, 2H),
3.01 – 3.38 (m, 4H), 3.46 – 3.67 (m, 1H), 4.98 – 5.22 (m, 2H), 7.24 – 7.53 (m, 5H). 13C NMR
(D2O, 101 MHz): d = 21.1, 22.2, 24.0, 29.3, 36.4, 37.5, 40.0 (d, JCP = 136.2 Hz), 43.2, 54.2, 67.1,
127.8, 128.4, 128.8, 136.4, 158.3, 178.4. 31P NMR (D2O, 162 MHz): d = 18.1. HRMS (ESI): m/z
[M + Na]+ calcd for C18H31N4O5PNa: 437.1924; found: 437.1923.
Compound 24: Compound 10 (50 mg, 0.09 mmol), Pd(PPh3)4 (10 mg, 0.01 mmol), HNEt2
(132 mg, 1.80 mmol), LiOH (8 mg, 0.18 mmol). The product was obtained as a colorless solid
(30 mg, 96% purity by qNMR, 0.07 mmol, 75%); decomposition above 200 °C. 1H NMR (D2O,
400 MHz): d = 0.85 – 1.01 (m, 6H), 1.38 – 1.61 (m, 6H), 1.61 – 1.76 (m, 1H), 2.61 – 2.73 (m,
2H), 3.15 – 3.25 (m, 2H), 3.26 – 3.47 (m, 2H), 3.61 – 3.76 (m, 1H), 5.19 (s, 2H), 7.38 – 7.60 (m,
5H). 13C NMR (D2O, 101 MHz): d = 21.2, 22.2, 24.0, 25.7, 27.6, 38.8, 39.0, 39.7 (d, JCP = 136.4
Hz), 43.3, 54.1, 67.1, 127.8, 128.4, 128.8, 136.4, 158.3, 178.0. 31P NMR (D2O, 162 MHz): d =
17.9. HRMS (ESI): m/z [M + Na]+ calcd for C19H33N4O5PNa: 451.2081; found: 451.2084.
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Compound 25: Compound 11 (44 mg, 0.08 mmol), Pd(PPh3)4 (9 mg, 0.01 mmol), HNEt2 (117
mg, 1.60 mmol), LiOH (8 mg, 0.18 mmol). The product was obtained as a colorless solid (24
mg, 97% purity by qNMR, 0.05 mmol, 66%); decomposition above 200 °C. 1H NMR (D2O, 400
MHz): d = 0.81 – 0.91 (m, 6H), 1.22 – 1.42 (m, 2H), 1.57 – 1.76 (m, 1H), 2.61 – 2.93 (m, 4H),
3.07 – 3.24 (m, 2H), 3.27 – 3.63 (m, 4H), 4.06 – 4.18 (m, 1H), 5.03 – 5.14 (m, 2H), 7.31 – 7.46
(m, 5H). 13C NMR (D2O, 101 MHz): d = 21.2, 22.5, 24.0, 39.7 (d, JCP = 135.2 Hz), 42.6, 43.5,
44.1, 44.5, 46.0, 49.2, 67.1, 127.9, 128.4, 128.8, 136.4, 158.1, 175.4. 31P NMR (D2O, 162 MHz):d = 18.0. HRMS (ESI): m/z [M + Na]+ calcd for C19H31N4O5PNa: 449.1924; found: 449.1922.
Compound 26: Compound 12 (74 mg, 0.15 mmol), Pd(PPh3)4 (17 mg, 0.02 mmol), HNEt2
(219 mg, 3.00 mmol), LiOH (14 mg, 0.33 mmol). The product was obtained as a colorless solid
(39 mg, 97% purity by qNMR, 0.09 mmol, 59%); decomposition above 200 °C. 1H NMR (D2O,
500 MHz): d = 0.91 – 1.04 (m, 6H), 1.63 – 1.75 (m, 3H), 3.35 – 3.46 (m, 2H), 3.51 – 3.63 (m,
2H), 4.26 – 4.35 (m, 1H), 5.17 – 5.28 (m, 2H), 7.44 – 7.58 (m, 5H). 13C NMR (D2O, 101 MHz):d = 20.9, 22.4, 24.6, 38.4, 39.2 (d, JCP = 135.2 Hz), 44.3, 53.7, 67.1, 127.87, 128.4, 128.8, 136.5,
158.2, 174.2, 179.9. 31P NMR (D2O, 202 MHz): d = 20.2. HRMS (ESI): m/z [M + Na]+ calcd for
C17H26N3O7PNa: 483.1401; found: 483.1400.
Compound 27: Compound 13 (76 mg, 0.15 mmol), Pd(PPh3)4 (17 mg, 0.02 mmol), HNEt2
(219 mg, 3.00 mmol), LiOH (14 mg, 0.33 mmol). The product was obtained as a colorless solid
(50 mg, 97% purity by qNMR, 0.11 mmol, 75%); decomposition above 200 °C. 1H NMR (D2O,
500 MHz): d = 0.93 (d, J = 6.2 Hz, 3H), 0.98 (d, J = 6.1 Hz, 3H), 1.33 (d, J = 7.1 Hz, 3H), 1.61 –
1.73 (m, 3H), 3.20 – 3.44 (m, 2H), 3.77 – 3.83 (m, 1H), 4.24 – 4.28 (m, 1H), 5.16 – 5.25 (m, 2H),
7.46 – 7.57 (m, 5H). 13C NMR (D2O, 101 MHz): d = 20.3, 20.9, 22.5, 24.6, 39.4 (d, JCP = 136.1
Hz), 40.8, 50.9, 53.8, 67.1, 127.8, 128.4, 128.8, 136.5, 158.3, 177.1, 179.9. 31P NMR (D2O, 202
MHz): d = 18.9. HRMS (ESI): m/z [M + Na]+ calcd for C18H28N3O7PNa: 452.1557; found:
452.1555.
Compound 28: Compound 14 (81 mg, 0.15 mmol), Pd(PPh3)4 (17 mg, 0.02 mmol), HNEt2
(219 mg, 3.00 mmol), LiOH (14 mg, 0.33 mmol). The product was obtained as a colorless solid
(52 mg, 96% purity by qNMR, 0.11 mmol, 72%); decomposition above 200 °C. 1H NMR (D2O,
400 MHz): d = 0.71 – 0.95 (m, 12H), 1.46 – 1.63 (m, 3H), 1.91 – 2.05 (m, 1H), 3.10 – 3.34 (m,
2H), 3.39 – 3.47 (m, 1H), 4.12 – 4.23 (m, 1H), 5.02 – 5.20 (m, 2H), 7.32 – 7.47 (m, 5H). 13C
NMR (D2O, 101 MHz): d = 16.8, 18.8, 20.9, 22.4, 24.6, 31.5, 39.3 (d, JCP = 136.8 Hz), 40.9, 53.9,
60.8, 67.1, 127.8, 128.4, 128.8, 136.5, 158.3, 176.2, 179.8. 31P NMR (D2O, 162 MHz): d = 18.5.
HRMS (ESI): m/z [M + Na]+ calcd for C20H32N3O7PNa: 480.187; found: 480.1868.
Compound 29: Compound 15 (91 mg, 0.15 mmol), Pd(PPh3)4 (17 mg, 0.02 mmol), HNEt2
(219 mg, 3.00 mmol), LiOH (14 mg, 0.33 mmol). The product was obtained as a colorless solid
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(56 mg, 96% purity by qNMR, 0.12 mmol, 79%); decomposition above 200 °C. 1H NMR (D2O,
500 MHz): d = 0.89 – 1.04 (m, 6H), 1.61 – 1.75 (m, 3H), 2.84 – 3.08 (m, 2H), 3.28 – 3.52 (m,
2H), 3.78 – 3.90 (m, 1H), 4.20 – 4.29 (m, 1H), 5.13 – 5.34 (m, 2H), 7.39 – 7.64 (m, 5H). 13C
NMR (D2O, 101 MHz): d = 20.8, 22.5, 24.7, 39.5 (d, JCP = 134.7 Hz), 40.5, 44.4, 54.1, 56.0, 67.1,
127.8, 128.4, 128.8, 136.5, 158.2, 173.9, 179.8. 31P NMR (D2O, 202 MHz): d = 18.7. HRMS
(ESI): m/z [M + Na]+ calcd for C18H29N4O7PNa: 467.1666; found: 467.1665.
Compound 30: Compound 16 (91 mg, 0.15 mmol), Pd(PPh3)4 (17 mg, 0.02 mmol), HNEt2
(219 mg, 3.00 mmol), LiOH (14 mg, 0.33 mmol). The product was obtained as a colorless solid
(55 mg, 97% purity by qNMR, 0.11 mmol, 77%); decomposition above 200 °C. 1H NMR (D2O,
400 MHz): d = 0.70 – 0.92 (m, 6H), 1.48 – 1.68 (m, 3H), 3.15 – 3.42 (m, 2H), 3.55 – 3.80 (m,
3H), 4.10 – 4.22 (m, 1H), 5.01 – 5.20 (m, 2H), 7.23 – 7.49 (m, 5H). 13C NMR (D2O, 101 MHz):d = 20.9, 22.4, 24.6, 39.5 (d, JCP = 136.7 Hz), 40.7, 54.1, 56.8, 63.8, 67.1, 127.8, 128.4, 128.8, 136.5,
158.2, 174.0, 179.9. 31P NMR (D2O, 162 MHz): d = 18.9. HRMS (ESI): m/z [M + Na]+ calcd for
C18H28N3O8PNa: 468.1506; found: 468.1504.
Compound 31: Compound 17 (77 mg, 0.15 mmol), Pd(PPh3)4 (17 mg, 0.02 mmol), HNEt2
(219 mg, 3.00 mmol), LiOH (14 mg, 0.33 mmol). The product was obtained as a colorless solid
(53 mg, 97% purity by qNMR, 0.12 mmol, 77%); decomposition above 200 °C. 1H NMR (D2O,
400 MHz): d = 0.81 – 0.98 (m, 6H), 1.33 – 1.47 (m, 4H), 1.53 – 1.82 (m, 2H), 3.08 – 3.43 (m,
2H), 3.74 – 3.91 (m, 1H), 4.81 – 4.85 (m, 1H), 5.05 – 5.24 (m, 2H), 7.20 – 7.58 (m, 5H). 13C
NMR (D2O, 101 MHz): d = 16.8, 21.0, 22.4, 23.9, 39.7 (d, JCP = 136.1 Hz), 42.8, 52.8, 67.1, 72.7,
127.8, 128.4, 128.8, 136.4, 158.3, 177.3, 178.6. 31P NMR (D2O, 202 MHz): d = 18.3. HRMS
(ESI): m/z [M + Na]+ calcd for C18H27N2O8PNa: 453.1397; found: 453.1395.
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2.6 Supporting Information
General procedures
General procedure for the synthesis of allyl esters
The N-protected amino acid (1.0 eq) was dissolved in DMF. Cs2CO3 (1.0 eq) and allyl bromide
(1.3 eq) were added and the mixture was stirred at rt overnight. The solvent was removed and
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the resulting residue was taken up in EtOAc. The solution was extracted with 1 M HCl (3 x 10
mL) and sat. NaHCO3 (3 x 10 mL), washed with brine and dried over MgSO4.
General procedure for peptide coupling
The respective Boc-protected amine was dissolved in 2 mL of DCM and HCl (4 M solution in
dioxane, 2.0 eq) was added. The mixture was stirred for 2 h and the solvent was removed under
reduced pressure. A carboxylic acid (1.0 eq), EDC (1.3 eq), HOBt (1.3 eq) and DIPEA (2.5 eq)
were added to the flask. The mixture was dissolved in DCM and the stirred at rt overnight. The
solution was diluted with EtOAc and extracted with 1 M HCl (3 x 15 mL) and sat. NaHCO3 (3
x 15 mL). The combined organic phases were washed with brine and dried over MgSO4. The
crude product was purified by silica gel column chromatography (DCM/MeOH 50:1).
General procedure for the synthesis of protected diamines
The respective Boc-protected diamine and NEt3 (2.0 eq) were dissolved in DCM. Alloc-Cl (1.2
eq) was added dropwise under ice cooling. The reaction mixture was stirred at rt overnight.
After removal of the solvent, the residue was taken up in EtOAc and extracted with 1 M HCl
(3 x 10 mL), sat. NaHCO3 solution (3 x 10 mL) and brine (1 x 10 mL). The organic phase was
dried over MgSO4 and the raw product was purified by silica gel chromatography
(DCM/MeOH 50:1).
Synthesis of peptidic precursors
Synthesis of Peptide S3
Boc-Dab(Alloc)-OH (S1): Boc-Gln-OH (1.72 g, 7.00 mmol, 1.0 eq) and
(Diacetoxyiodo)benzene (2.71 g, 7.40 mmol, 1.20 eq) were dissolved in an ice cold mixture of
EtOAc/MeCN/H2O (2:2:1). The mixture was stirred at 50 °C overnight and afterwards
extracted with EtOAc (3 x 10 mL). K2CO3 (2.42 g, 17.50 mmol, 2.5 eq) was added to the aqueous
phase. A solution of Alloc-Cl (1.01 g, 8.40 mmol, 1.2 eq) in Et2O was added to the flask and the
Scheme S2.1. Synthesis of peptide S3.
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biphasic mixture was stirred at rt overnight. The phases were separated and the aqueous phase
was washed with EtOAc (3 x 10 mL) and the organic phases were discarded. The pH was
adjusted to 1 and the resulting solution was extracted with EtOAc (3 x 15 mL). The combined
organic phases were washed with brine and dried over MgSO4. The product was obtained as a
yellow oil (985 mg, 3.26 mmol, 47%). 1H NMR (400 MHz, CDCl3) Ϣ = 1.45 (s, 9H), 1.77 – 2.13
(m, 2H), 3.03 – 3.58 (m, 2H), 4.30 – 4.47 (m, 1H), 4.52 – 4.68 (m, 2H), 5.21 – 5.43 (m, 3H),
5.46 – 5.58 (m, 1H), 5.83 – 6.03 (m, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 28.4, 42.7, 53.6, 54.6,
66.3, 81.0, 118.1, 132.6, 156.5, 157.5, 173.6. MS (ESI-) m/z calculated for C13H21N2O6 [M-H]-:
301.32; found 301.25.
Boc-Dab(Alloc)-OAll (S2): Synthesized after general procedure 1.1. Boc-Dab(Alloc)-OH (S2,
537 mg, 1.77 mmol, 1.0 eq) was dissolved in MeCN. DIPEA (458 mg, 3.54 mmol, 2.0 eq) and
allyl bromide (645 mg, 5.33 mmol, 3.0 eq) were added and the mixture was stirred at 40 °C
overnight. The solvent was removed and the resulting residue was taken up in EtOAc. The
solution was extracted with 1 M HCl (3 x 10 mL) and sat. NaHCO3 (3 x 10 mL), washed with
brine and dried over MgSO4. The crude product was purified by silica gel chromatography
(cyclohexanes/EtOAc 2:1). The product was obtained as a yellow oil (235 mg, 0.69 mmol, 39%).
1H NMR (500 MHz, CDCl3) Ϣ = 1.44 (s, 9H), 1.64 – 1.72 (m, 1H), 2.05 – 2.14 (m, 1H), 3.01 –
3.11 (m, 1H), 3.47 – 3.54 (m, 1H), 4.36 – 4.42 (m, 1H), 4.52 – 4.61 (m, 2H), 4.63 (d, J = 5.8 Hz,
2H), 5.18 – 5.37 (m, 5H), 5.48 (bs, 1H), 5.85 – 5.98 (m, 2H). 13C NMR (126 MHz, CDCl3) Ϣ =
28.4, 33.8, 37.2, 51.1, 65.7, 66.3, 80.4, 117.7, 119.3, 131.5, 133.1, 156.0, 156.4, 172.4. MS (ESI+)
m/z calculated for C16H30N3O6 [M+NH4]+: 360.21; found 360.19.
Boc-Leu-Dab(Alloc)-OAll (S3): Synthesized after general procedure 1.2. Boc-Dab(Alloc)-OAll
(S4, 685 mg, 2.00 mmol), HCl (4 M solution in dioxane, 1 mL, 4.00 mmol), Boc-Leu-OH (463
mg, 2.00 mmol), EDC (498 mg, 2.60 mmol), HOBt (351 mg, 2.60 mmol) and DIPEA (646 mg,
5.00 mmol). The product was obtained as a yellow oil (874 mg, 1.91 mmol, 96%). 1H NMR (400
MHz, CDCl3) Ϣ = 0.94 (t, J = 6.1 Hz, 6H), 1.43 (s, 9H), 1.58 – 1.76 (m, 4H), 2.10 – 2.21 (m, 1H),
2.91 – 3.03 (m, 1H), 3.45 – 3.56 (m, 1H), 4.03 – 4.13 (m, 1H), 4.50 – 4.72 (m, 5H), 4.87 (d, J =
7.1 Hz, 1H), 5.16 – 5.37 (m, 4H), 5.67 (bs, 1H), 5.82 – 5.99 (m, 2H), 6.77 (d, J = 7.7 Hz, 1H).
13C NMR (101 MHz, CDCl3) Ϣ = 22.1, 23.0, 24.8, 28.3, 33.4, 36.7, 41.1, 49.7, 53.6, 65.6, 66.4,
80.4, 117.6, 119.4, 131.3, 133.1, 155.8, 156.5, 171.9, 173.4. MS (ESI+) m/z calculated for
C22H41N4O7 [M+NH4]+: 473.30; found 473.26.
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Synthesis of Peptides S8–S9
Boc-Orn(Alloc)-OH (S4): Boc-Orn(Cbz)-OH (3.66 g, 10.00 mmol, 1.0 eq) and ammonium
formate (3.15 g, 50.00 mmol, 5.0 eq) were dissolved in MeOH. Palladium on activated charcoal
(10% Pd, 851 mg, 0.80 mmol, 8 mol%) was added and the resulting suspension was stirred for
2 h at rt. The mixture was filtered over Celite, the solvent was removed under reduced pressure.
The residue was taken up in H2O and K2CO3 (3.46 g, 25.00 mmol, 2.5 eq) was added. A solution
of Alloc-Cl (1.45 g, 12.00 mmol, 1.2 eq) in Et2O was added to the flask and the biphasic mixture
was stirred at rt overnight. The phases were separated and the aqueous phase was washed with
EtOAc (3 x 10 mL) and the organic phases were discarded. The pH was adjusted to 1 and the
resulting solution was extracted with EtOAc (3 x 15 mL). The combined organic phases were
washed with brine and dried over MgSO4. The product was obtained as a colorless oil (2.90 g,
9.16 mmol, 92%). 1H NMR (400 MHz, CDCl3) Ϣ = 1.44 (s, 9H), 1.52 – 1.77 (m, 3H), 1.81 – 2.01
(m, 1H), 3.13 – 3.35 (m, 2H), 4.28 – 4.46 (m, 1H), 4.50 – 4.69 (m, 2H), 4.94 – 5.12 (m, 1H),
5.13 – 5.43 (m, 3H), 5.81 – 6.00 (m, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 26.0, 28.4, 29.8, 40.5,
53.1, 65.8, 80.4, 117.9, 132.9, 155.9, 156.8, 175.9. MS (ESI-) m/z calculated for C14H23N2O6 [M-
H]-: 315.35; found 315.25.
Boc-Lys(Alloc)-OH (S5): Boc-Lys(Cbz)-OH (2.66 g, 7.00 mmol, 1.0 eq) and ammonium
formate (2.21 g, 35.00 mmol, 5.0 eq) were dissolved in MeOH. Palladium on activated charcoal
(10% Pd, 745 mg, 0.70 mmol, 10 mol%) was added and the resulting suspension was stirred for
2 h at rt. The mixture was filtered over Celite and the solvent was removed under reduced
pressure. The residue was taken up in H2O and K2CO3 (2.42 g, 17.50 mmol, 2.5 eq) was added.
A solution of Alloc-Cl (1.01 g, 8.40 mmol, 1.2 eq) in Et2O was added to the flask and the
biphasic mixture was stirred at rt overnight. The phases were separated, the aqueous phase was
washed with EtOAc (3 x 10 mL) and the organic phases were discarded. The pH was adjusted
to 1 and the resulting solution was extracted with EtOAc (3 x 15 mL). The combined organic
phases were washed with brine and dried over MgSO4. The product was obtained as a colorless
oil (1.36 g, 4.11 mmol, 59%). 1H NMR (400 MHz, CDCl3) Ϣ = 1.34 – 1.61 (m, 13H), 1.66 – 1.92
Scheme S2.2. Synthesis of peptides S8–S9.
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(m, 2H), 3.18 (s, 2H), 4.30 (s, 1H), 4.51 – 4.65 (m, 2H), 4.90 – 5.14 (m, 1H), 5.15 – 5.36 (m,
2H), 5.83 – 6.01 (m, 1H), 6.31 (bs, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 22.4, 28.5, 29.5, 32.0,
40.6, 53.3, 65.8, 80.3, 117.9, 133.0, 156.0, 156.8, 176.4. MS (ESI+) m/z calculated for C15H30N3O6
[M+NH4]+: 348.21; found 348.26.
Boc-Orn(Alloc)-OAll (S6): Synthesized after general procedure 1.1. Boc-Orn(Alloc)-OH (S7,
2.53 g, 8.00 mmol), Cs2CO3 (2.61 g, 8.00 mmol), allyl bromide (1.26 g, 10.40 mmol). The
product was obtained as a yellow oil (2.18 g, 6.12 mmol, 77%). 1H NMR (400 MHz, CDCl3) Ϣ
= 1.44 (s, 9H), 1.51 – 1.73 (m, 3H), 1.76 – 1.93 (m, 1H), 3.21 (dd, J = 12.7, 6.4 Hz, 2H), 4.26 –
4.40 (m, 1H), 4.50 – 4.69 (m, 4H), 4.81 (s, 1H), 5.07 (d, J = 8.4 Hz, 1H), 5.17 – 5.40 (m, 4H),
5.83 – 6.06 (m, 2H). 13C NMR (101 MHz, CDCl3) Ϣ = 26.1, 28.4, 30.2, 40.6, 53.2, 65.6, 66.1, 80.1,
117.8, 119.1, 131.6, 133.0, 155.5, 156.4, 172.4. MS (ESI+) m/z calculated for C15H30N3O6
[M+NH4]+: 374.23; found 374.23.
Boc-Lys(Alloc)-OAll (S7): Synthesized after general procedure 1.1. Boc-Lys(Alloc)-OH (S8,
1.32 g, 4.00 mmol), Cs2CO3 (1.30 g, 4.00 mmol), allyl bromide (627 g, 5.20 mmol). The product
was obtained as a yellow oil (1.13 g, 3.06 mmol, 76%). 1H NMR (400 MHz, CDCl3) Ϣ = 1.34 –
1.47 (m, 11H), 1.48 – 1.58 (m, 2H), 1.61 – 1.72 (m, 1H), 1.77 – 1.90 (m, 1H), 3.13 – 3.23 (m,
2H), 4.24 – 4.37 (m, 1H), 4.52 – 4.68 (m, 4H), 4.78 (bs, 1H), 5.08 (d, J = 6.9 Hz, 1H), 5.17 – 5.39
(m, 4H), 5.85 – 5.99 (m, 2H). 13C NMR (101 MHz, CDCl3) Ϣ = 22.5, 28.4, 29.5, 32.5, 40.7, 53.4,
65.6, 66.0, 80.1, 117.8, 119.0, 131.7, 133.1, 155.6, 156.5, 172.6. MS (ESI+) m/z calculated for
C18H34N3O6 [M+NH4]+: 388.24; found 388.25.
Boc-Leu-Orn(Alloc)-OAll (S8): Synthesized after general procedure 1.2. Boc-Orn(Alloc)-OAll
(S9, 713 mg, 2.00 mmol), HCl (4 M solution in dioxane, 1 mL, 4.00 mmol), Boc-Leu-OH (463
mg, 2.00 mmol), EDC (498 mg, 2.60 mmol), HOBt (351 mg, 2.60 mmol) and DIPEA (646 mg,
5.00 mmol). The product was obtained as a yellow oil (925 mg, 1.97 mmol, 98%). 1H NMR (400
MHz, CDCl3) Ϣ = 0.91 – 0.97 (m, 6H), 1.43 (s, 9H), 1.46 – 1.59 (m, 2H), 1.61 – 1.79 (m, 4H),
1.87 – 1.98 (m, 1H), 3.16 – 3.25 (m, 2H), 4.07 – 4.16 (m, 1H), 4.51 – 4.67 (m, 5H), 4.81 – 5.02
(m, 2H), 5.16 – 5.38 (m, 4H), 5.82 – 5.97 (m, 2H), 6.75 (d, J = 8.0 Hz, 1H). 13C NMR (101 MHz,
CDCl3) Ϣ = 23.0, 23.2, 24.8, 25.9, 28.4, 29.6, 40.4, 41.1, 52.0, 53.3, 65.7, 66.2, 80.3, 117.8, 119.3,
131.5, 133.1, 155.9, 156.5, 171.7, 172.7. MS (ESI+) m/z calculated for C23H40N3O7 [M+H]+:
470.59; found 470.43.
Boc-Leu-Lys(Alloc)-OAll (S9): Synthesized after general procedure 1.2. Boc-Lys(Alloc)-OAll
(S10, 741 mg, 2.00 mmol), HCl (4 M solution in dioxane, 1 mL, 4.00 mmol), Boc-Leu-OH (463
mg, 2.00 mmol), EDC (498 mg, 2.60 mmol), HOBt (351 mg, 2.60 mmol) and DIPEA (646 mg,
5.00 mmol). The product was obtained as a yellow oil (796 mg, 1.65 mmol, 82%). 1H NMR (400
MHz, CDCl3) Ϣ = 0.90 – 0.98 (m, 6H), 1.30 – 1.40 (m, 2H), 1.43 (s, 9H), 1.46 – 1.58 (m, 2H),
1.61 – 1.76 (m, 4H), 1.82 – 1.93 (m, 1H), 3.09 – 3.24 (m, 2H), 4.10 – 4.20 (m, 1H), 4.53 – 4.69
(m, 5H), 4.98 – 5.15 (m, 2H), 5.18 – 5.38 (m, 4H), 5.83 – 5.98 (m, 2H), 6.69 (d, J = 7.1 Hz, 1H).
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13C NMR (101 MHz, CDCl3) Ϣ = 22.0, 22.4, 23.1, 24.8, 28.4, 29.1, 32.0, 40.5, 41.2, 52.0, 53.1,
65.6, 66.1, 80.2, 117.9, 119.2, 131.6, 133.1, 156.0, 156.5, 171.9, 173.0. MS (ESI+) m/z calculated
for C24H42N3O7 [M+H]+: 484.61; found 484.52.
Synthesis of Peptide S11
Boc-Leu-Gly-NH2 (S10): Synthesized after general procedure 1.2. Boc-Leu-OH (2.31 g, 10.00
mmol, 1.0 eq), glycinamide hydrochloride (1.11 g, 10.00 mmol, 1.0 eq), EDC (2.49 g, 13.00
mmol, 1.3 eq), HOBt (1.76 g, 13.00 mmol, 1.3 eq) and DIPEA (3.23 g, 25.00 mmol, 2.5 eq) were
dissolved in DCM and the mixture was stirred at rt overnight. The solution was diluted with
EtOAc and extracted with 1 M HCl (3x15 mL) and sat. NaHCO3 (3x15 mL). The combined
organic phases were washed with brine and dried over MgSO4. The crude product was purified
by silica gel column chromatography (DCM/MeOH 50:1). The product was obtained as a
colorless foam (2.00 g, 6.94 mmol, 69%). 1H NMR (400 MHz, DMSO-D6) Ϣ = 0.83 – 0.89 (m,
6H), 1.38 (s, 9H), 1.40 – 1.46 (m, 2H), 1.54 – 1.66 (m, 1H), 3.52 – 3.70 (m, 2H), 3.91 (dd, J =
14.7, 7.4 Hz, 1H), 7.01 (d, J = 7.7 Hz, 1H), 7.07 (s, 1H), 7.14 (s, 1H), 7.98 – 8.04 (m, 1H). 13C
NMR (101 MHz, DMSO-D6) Ϣ = 21.6, 23.0, 24.2, 28.2, 40.3, 42.0, 53.0, 78.2, 155.7, 170.9, 172.8.
tert-butyl (S)-(1-(((((allyloxy)carbonyl)amino)methyl)amino)-4-methyl-1-oxopentan-2-
yl)carbamate (S11): Boc-Leu-Gly-NH2 (S13, 287 mg, 1.00 mmol, 1.0 eq) and
(Diacetoxyiodo)benzene (419 mg, 1.30 mmol, 1.3 eq) were dissolved in a mixture of MeCN (5
mL) and allyl alcohol (5 mL) and heated to 50 °C overnight. After removal of the solvent the
crude product was purified by silica gel chromatography (DCM/MeOH 50:1). The product was
obtained as a colorless solid (178 mg, 0.52 mmol, 52%); mp 151–152 °C. 1H NMR (400 MHz,
CDCl3) Ϣ = 0.91 – 0.96 (m, 6H), 1.43 (s, 9H), 1.58 – 1.75 (m, 3H), 4.10 (bs, 1H), 4.53 – 4.61 (m,
4H), 4.89 (d, J = 8.1 Hz, 1H), 5.19 – 5.34 (m, 2H), 5.79 – 5.95 (m, 2H), 7.13 (bs, 1H). 13C NMR
(101 MHz, CDCl3) Ϣ = 22.0, 23.1, 24.8, 28.4, 41.5, 46.4, 53.1, 65.9, 80.2, 118.0, 132.6, 155.7,
156.7, 174.1. MS (ESI+) m/z calculated for C16H33N4O5 [M+NH4]+: 361.25; found: 361.26.
Scheme S2.3. Synthesis of peptide S11.
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Synthesis of Peptides S15–S17
allyl tert-butyl ethane-1,2-diyldicarbamate (S12): Synthesized after general procedure 1.3. tert-
Butyl (2-aminoethyl)carbamate (481 mg, 3.00 mmol), NEt3 (607 mg, 6.00 mmol), Alloc-Cl (434
mg, 3.60 mmol). The product was obtained as a colorless solid (708 mg, 2.90 mmol, 97%); mp
107–108 °C. 1H NMR (400 MHz, CDCl3) Ϣ = 1.43 (s, 9H), 3.16 – 3.38 (m, 4H), 4.55 (d, J = 5.5
Hz, 2H), 4.89 (s, 1H), 5.13 – 5.23 (m, 2H), 5.29 (dd, J = 17.2, 1.4 Hz, 1H), 5.82 – 5.98 (m, 1H).
13C NMR (101 MHz, CDCl3) Ϣ = 28.5, 40.7, 41.6, 65.7, 79.7, 117.8, 132.9, 156.5, 156.8. MS
(ESI+) m/z calculated for C11H24N3O4 [M+H]+: 262.18; found 262.22.
allyl tert-butyl propane-1,3-diyldicarbamate (S13): Synthesized after general procedure 1.3.
tert-Butyl (2-aminopropyl)carbamate (523 mg, 3.00 mmol), NEt3 (607 mg, 6.00 mmol), Alloc-
Cl (434 mg, 3.60 mmol). The product was obtained as a colorless oil (342 mg, 1.32 mmol, 44%).
1H NMR (400 MHz, DMSO-D6) Ϣ = 1.37 (s, 9H), 1.44 – 1.55 (m, 2H), 2.86 – 3.00 (m, 4H), 4.45
(d, J = 5.3 Hz, 2H), 5.12 – 5.19 (m, 1H), 5.22 – 5.31 (m, 1H), 5.84 – 5.98 (m, 1H), 6.74 (bs, 1H),
7.12 (bs, 1H). 13C NMR (101 MHz, DMSO-D6) Ϣ = 28.2, 29.9, 37.5, 38.0, 64.1, 77.4, 116.8, 133.8,
155.6, 155.9. MS (ESI+) m/z calculated for C12H23N2O4 [M+H]+: 259.33; found 259.22.
allyl tert-butyl butane-1,3-diyldicarbamate (S14): Synthesized after general procedure 1.3. tert-
Butyl (2-aminobutyl)carbamate (565 mg, 3.00 mmol), NEt3 (607 mg, 6.00 mmol), Alloc-Cl
(434 mg, 3.60 mmol). The product was obtained as a colorless solid (310 mg, 1.14 mmol, 38%);
mp 100–101 °C. 1H NMR (400 MHz, DMSO-D6) Ϣ = 1.29 – 1.43 (m, 15H), 2.84 – 3.09 (m, 4H),
4.45 (d, J = 5.2 Hz, 2H), 5.16 (dd, J = 10.6, 0.9 Hz, 1H), 5.21 – 5.34 (m, 1H), 5.82 – 6.03 (m,
1H), 6.70 – 6.87 (m, 1H), 7.07 – 7.23 (m, 1H). 13C NMR (101 MHz, DMSO-D6) Ϣ = 26.8, 28.3,
64.1, 77.3, 116.8, 133.9, 155.6, 155.9. MS (ESI+) m/z calculated for C13H25N2O4 [M+H]+: 273.35;
found 273.22.
tert-butyl (S)-(1-((2-(((allyloxy)carbonyl)amino)ethyl)amino)-4-methyl-1-oxopentan-2-
yl)carbamate (S15): Synthesized after general procedure 1.2. S12 (489 mg, 2.00 mmol), HCl (4
M solution in dioxane, 1 mL, 4.00 mmol), Boc-Leu-OH (463 mg, 2.00 mmol), EDC (498 mg,
2.60 mmol, 1.3 eq), HOBt (351 mg, 2.60 mmol) and DIPEA (569 mg, 4.4 mmol). The product
Scheme S2.4. Synthesis of peptides S15–S17.
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was obtained as a yellow oil (681 mg, 1.91 mmol, 95%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.88
– 0.95 (m, 6H), 1.43 (s, 9H), 1.60 – 1.78 (m, 3H), 3.27 – 3.48 (m, 4H), 4.04 (dd, J = 12.9, 8.1 Hz,
1H), 4.55 (d, J = 5.5 Hz, 2H), 4.91 (d, J = 6.7 Hz, 1H), 5.17 – 5.38 (m, 3H), 5.84 – 5.98 (m, 1H),
6.60 (bs, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 22.1, 23.1, 24.9, 28.4, 40.1, 40.9, 41.3, 53.5, 65.8,
80.4, 117.8, 132.9, 156.0, 157.0, 173.6. MS (ESI+) m/z calculated for C17H32N3O5 [M+H]+:
358.46; found 358.23.
tert-butyl (S)-(1-((2-(((allyloxy)carbonyl)amino)propyl)amino)-4-methyl-1-oxopentan-2-
yl)carbamate (S16): Synthesized after general procedure 1.2. S13 (300 mg, 1.16 mmol), HCl (4
M solution in dioxane, 1 mL, 4.00 mmol), Boc-Leu-OH (269 mg, 1.16 mmol), EDC (284 mg,
1.48 mmol), HOBt (200 mg, 1.48 mmol) and DIPEA (442 mg, 3.42 mmol). The product was
obtained as a colorless oil (407 mg, 1.10 mmol, 94%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.80 –
1.06 (m, 6H), 1.31 – 1.52 (m, 9H), 1.55 – 1.73 (m, 4H), 1.82 – 2.02 (m, 1H), 3.11 – 3.42 (m, 4H),
4.05 (bs, 1H), 4.55 (d, J = 5.5 Hz, 2H), 4.92 (s, 1H), 5.10 – 5.50 (m, 3H), 5.78 – 6.00 (m, 1H),
6.64 (bs, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 22.2, 23.1, 24.9, 28.4, 30.1, 36.0, 37.5, 41.4, 53.4,
65.6, 80.3, 117.7, 133.1, 155.9, 156.9, 173.4. MS (ESI+) m/z calculated for C18H34N3O5 [M+H]+:
372.49; found 372.41.
tert-butyl (S)-(1-((2-(((allyloxy)carbonyl)amino)butyl)amino)-4-methyl-1-oxopentan-2-
yl)carbamate (S17): Synthesized after general procedure 1.2. S14 (272 mg, 1.00 mmol), HCl (4
M solution in dioxane, 1 mL, 4.00 mmol), Boc-Leu-OH (231 mg, 1.00 mmol), EDC (249 mg,
1.30 mmol), HOBt (176 mg, 1.30 mmol) and DIPEA (388 mg, 3.00 mmol). The product was
obtained as a colorless solid (364 mg, 0.94 mmol, 94%); mp 80–81 °C. 1H NMR (400 MHz,
CDCl3) Ϣ = 0.85 – 1.01 (m, 6H), 1.42 (s, 9H), 1.49 – 1.56 (m, 4H), 1.58 – 1.70 (m, 2H), 1.83 –
2.01 (m, 1H), 3.10 – 3.38 (m, 4H), 4.06 (bs, 1H), 4.55 (d, J = 5.3 Hz, 2H), 4.96 (bs, 2H), 5.19
(dd, J = 10.4, 1.2 Hz, 1H), 5.25 – 5.34 (m, 1H), 5.84 – 6.05 (m, 1H), 6.42 (bs, 1H). 13C NMR
(101 MHz, CDCl3) Ϣ = 22.1, 23.0, 24.8, 26.7, 27.3, 28.4, 39.1, 40.6, 41.3, 53.2, 65.6, 80.1, 117.7,
133.0, 155.9, 156.5, 172.8. MS (ESI+) m/z calculated for C19H36N3O5 [M+H]+: 386.51; found
386.36.
62  | Chapter 2
Synthesis of Peptide S19
Piperazine S18: Boc-Piperazine (1.12 g, 6.00 mmol, 1.0 eq) and NEt3 (729 mg, 7.20 mmol, 1.2
eq) were dissolved in DCM. The solution was cooled to 0 °C and Alloc-Cl (868 mg, 7.20 mmol,
1.2 eq) was added dropwise. The mixture was allowed to warm to rt overnight and was washed
with 1 M HCl (3 x 10 mL), brine and dried over anhydrous MgSO4. The product was obtained
as a yellow oil (1.38 g, 5.10 mmol, 85%). 1H NMR (400 MHz, CDCl3) Ϣ = 1.46 (s, 9H), 3.15 –
3.64 (m, 8H), 4.46 – 4.75 (m, 2H), 5.17 – 5.33 (m, 2H), 5.73 – 6.10 (m, 1H). 13C NMR (101
MHz, CDCl3) Ϣ = 28.5, 43.5, 66.2, 80.3, 117.8, 133.0, 154.5, 155.2. MS (ESI+) m/z calculated for
C13H26N3O4 [M+NH4]+: 288.37; found 288.20.
Amide S19: Synthesized after general procedure 1.2. S18 (541 mg, 2.00 mmol), HCl (4 M
solution in dioxane, 2 mL, 8.00 mmol), Boc-Leu-OH (463 mg, 2.00 mmol), EDC (498 mg, 2.60
mmol), HOBt (352 mg, 2.60 mmol) and DIPEA (810 mg, 8.00 mmol). The product was
obtained as a yellow oil (415 mg, 1.08 mmol, 54%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.85 – 1.06
(m, 6H), 1.43 (s, 9H), 1.45 – 1.55 (m, 2H), 1.64 – 1.76 (m, 1H), 3.37 – 3.82 (m, 7H), 4.53 – 4.70
(m, 2H), 5.13 – 5.41 (m, 2H), 5.85 – 6.03 (m, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 22.1, 23.5,
24.8, 28.5, 42.0, 43.0, 45.4, 48.5, 49.7, 66.6, 79.9, 118.1, 132.8, 155.1, 155.7, 171.8. MS (ESI+)
m/z calculated for C19H34N3O5 [M+H]+: 384.50; found 384.34.
Scheme S2.5. Synthesis of peptide S19.
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Synthesis of Peptides S21–S26
Boc-Leu-OAll (S20): Synthesized after general procedure 1.1. Boc-Leu-OH (5.00 g, 21.62
mmol, 1.0 eq) and Cs2CO3 (7.04 g, 21.62 mmol, 1.0 eq) were dissolved in DMF. Allyl bromide
(3.39 g, 28.11 mmol, 1.3 eq) was added and the solution was stirred for 5 h at rt. The solvent
was removed under reduced pressure and the residual slurry taken up in EtOAc. The organic
phase was washed with sat. NaHCO3 solution (3 x 15 mL) and brine and dried over MgSO4.
The solvent was removed to give the product as a yellow oil (5.12 g, 18.85 mmol, 87%). 1H
NMR (400 MHz, CDCl3) Ϣ = 0.91 – 0.97 (m, 6H), 1.44 (s, 9H), 1.47 – 1.77 (m, 3H), 4.29 – 4.38
(m, 1H), 4.56 – 4.69 (m, 2H), 4.85 – 4.92 (m, 1H), 5.25 (dd, J = 10.4 Hz, 1.0, 1H), 5.29 – 5.39
(m, 1H), 5.83 – 5.98 (m, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 22.0, 23.0, 24.9, 28.4, 42.0, 52.3,
65.9, 80.05, 118.7, 131.9, 155.6, 173.4. MS (ESI+) m/z calculated for C14H26NO4 [M+H]+:
272.36; found 272.16.
Boc-Gly-Leu-OAll (S21): Synthesized after general procedure 1.2. Boc-Leu-OAll (S20, 407 mg,
1.50 mmol), HCl (4 M solution in dioxane, 1 mL, 4.00 mmol), Boc-Gly-OH (263 mg, 1.50
mmol), EDC (374 mg, 1.95 mmol), HOBt (264 mg, 1.95 mmol) and DIPEA (485 mg, 3.75
mmol). The product was obtained as a colorless oil (431 mg, 1.31 mmol, 87%). 1H NMR (400
MHz, CDCl3) Ϣ = 0.88 – 0.97 (m, 6H), 1.45 (s, 9H), 1.50 – 1.74 (m, 3H), 3.73 – 3.94 (m, 2H),
4.59 – 4.73 (m, 3H), 5.08 – 5.19 (m, 1H), 5.21 – 5.40 (m, 2H), 5.81 – 5.98 (m, 1H), 6.44 – 6.58
(m, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 22.0, 23.0, 24.9, 28.4, 41.6, 44.4, 50.8, 66.1, 80.4,
119.0, 131.7, 156.2, 169.5, 172.7. MS (ESI+) m/z calculated for C16H32N3O5 [M+NH4]+: 346.45;
found 346.28.
Boc-Ala-Leu-OAll (S22): Synthesized after general procedure 1.2. Boc-Leu-OAll (S20, 407 mg,
1.50 mmol), HCl (4 M solution in dioxane, 1 mL, 4.00 mmol), Boc-Ala-OH (284 mg, 1.50
mmol), EDC (374 mg, 1.95 mmol), HOBt (264 mg, 1.95 mmol) and DIPEA (485 mg, 3.75
mmol). The product was obtained as a colorless oil (426 mg, 1.28 mmol, 83%). 1H NMR (400
MHz, CDCl3) Ϣ = 0.88 – 0.97 (m, 6H), 1.35 (d, J = 7.0 Hz, 3H), 1.44 (s, 9H), 1.52 – 1.76 (m,
Scheme S2.6. Synthesis of peptides S21–S26.
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3H), 4.12 – 4.23 (m, 1H), 4.55 – 4.69 (m, 3H), 4.99 (bs, 1H), 5.19 – 5.39 (m, 2H), 5.79 – 6.00
(m, 1H), 6.44 – 6.60 (m, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 18.0, 21.9, 23.0, 24.9, 28.4, 41.6,
50.0, 50.8, 66.0, 80.2, 118.9, 131.7, 155.7, 172.6. MS (ESI+) m/z calculated for C17H34N3O5
[M+NH4]+: 360.47; found 360.34.
Boc-Val-Leu-OAll (S23): Synthesized after general procedure 1.2. Boc-Leu-OAll (S20, 407 mg,
1.50 mmol), HCl (4 M solution in dioxane, 1 mL, 4.00 mmol), Boc-Val-OH (326 mg, 1.50
mmol), EDC (374 mg, 1.95 mmol), HOBt (264 mg, 1.95 mmol) and DIPEA (485 mg, 3.75
mmol). The product was obtained as a colorless solid (444 mg, 1.20 mmol, 80%); mp 93–94 °C.
1H NMR (400 MHz, CDCl3) Ϣ = 0.88 – 1.01 (m, 12H), 1.44 (s, 9H), 1.53 – 1.73 (m, 3H), 2.04 –
2.20 (m, 1H), 3.85 – 3.97 (m, 1H), 4.54 – 4.71 (m, 3H), 4.98 – 5.12 (m, 1H), 5.21 – 5.42 (m, 2H),
5.81 – 5.98 (m, 1H), 6.12 – 6.32 (m, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 18.0, 19.4, 21.9, 23.0,
24.9, 28.4, 31.0, 41.6, 50.8, 60.1, 66.0, 80.0, 119.0, 131.7, 156.0, 171.6, 172.5. MS (ESI+) m/z
calculated for C19H36N3O5 [M+NH4]+: 388.53; found 388.38.
Boc-Dap(Alloc)-Leu-OAll (S24): Synthesized after general procedure 1.2. Boc-Leu-OAll (S20,
407 mg, 1.50 mmol), HCl (4 M solution in dioxane, 1 mL, 4.00 mmol), Boc-Dap(Alloc)-OH
(432 mg, 1.50 mmol), EDC (374 mg, 1.95 mmol), HOBt (264 mg, 1.95 mmol) and DIPEA (485
mg, 3.75 mmol). The product was obtained as a colorless solid (494 mg, 1.12 mmol, 75%); mp
75–76 °C. 1H NMR (400 MHz, CDCl3) Ϣ = 0.84 – 1.00 (m, 6H), 1.44 (s, 9H), 1.54 – 1.67 (m,
3H), 3.49 – 3.66 (m, 2H), 4.24 (bs, 1H), 4.51 – 4.69 (m, 5H), 5.18 – 5.40 (m, 4H), 5.51 (bs, 1H),
5.66 (bs, 1H), 5.83 – 6.01 (m, 2H), 7.04 (s, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 21.8, 23.0,
24.9, 28.4, 41.2, 42.9, 50.9, 51.1, 66.1, 80.7, 118.0, 119.0, 131.7, 132.7, 156.2, 157.5, 170.7, 172.3
MS (ESI+) m/z calculated for C21H39N4O7 [M+NH4]+: 459.56; found 459.40.
Boc-Ser-Leu-OAll (S25): Synthesized after general procedure 1.2. Boc-Leu-OAll (S20, 1.09 g,
4.00 mmol), HCl (4 M solution in dioxane, 2 mL, 8.00 mmol), Boc-Ser-OH (821 mg, 4.00
mmol), EDC (997 mg, 5.20 mmol), HOBt (703 mg, 5.20 mmol) and DIPEA (1.29 g, 10.00
mmol). The product was obtained as a colorless oil (1.14 g, 3.17 mmol, 79%). 1H NMR (400
MHz, CDCl3) Ϣ = 0.87 – 1.01 (m, 6H), 1.45 (s, 9H), 1.53 – 1.74 (m, 3H), 3.63 (dd, J = 11.4, 5.5
Hz, 1H), 4.02 – 4.12 (m, 1H), 4.13 – 4.20 (m, 1H), 4.53 – 4.69 (m, 3H), 5.21 – 5.40 (m, 2H),
5.51 – 5.64 (m, 1H), 5.81 – 6.04 (m, 1H), 6.84 – 6.99 (m, 1H). 13C NMR (101 MHz, CDCl3) Ϣ =
21.7, 23.0, 24.9, 28.4, 41.0, 51.2, 54.7, 63.1, 66.2, 80.6, 119.1, 131.6, 156.2, 171.7, 172.7. MS
(ESI+) m/z calculated for C17H34N3O6 [M+NH4]+: 376.47; found 376.34.
Boc-Ser(OAlloc)-Leu-OAll (S26): Boc-Ser-Leu-OAll (S25, 358 mg, 1.00 mmol, 1.0 eq) was
dissolved in dry DCM under argon and the solution was cooled to -50 °C. Pyridine (197 mg,
2.50 mmol, 2.5 eq) and Alloc-Cl (133 mg, 1.10 mmol, 1.1 eq) were added subsequently. The
mixture was stirred at -50 °C for 2 h and allowed to warm to rt overnight. The solution was
washed with 1 M HCl (3 x 10 mL), sat. NaHCO3 solution (3 x 10 mL), brine and dried over
anhydrous MgSO4. The crude product was purified by silica gel chromatography
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(DCM/MeOH 50:1) to give the pure product as a colorless oil (242 mg, 0.55 mmol, 55%). 1H
NMR (500 MHz, CDCl3) Ϣ = 0.89 – 0.97 (m, 6H), 1.46 (s, 9H), 1.54 – 1.71 (m, 3H), 4.31 (dd, J
= 10.9, 4.8 Hz, 1H), 4.45 (s, 1H), 4.53 (dd, J = 10.9, 5.2 Hz, 1H), 4.59 – 4.71 (m, 5H), 5.20 – 5.42
(m, 4H), 5.83 – 5.99 (m, 2H), 6.68 (d, J = 7.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 25.8,
26.0, 28.4, 29.8, 40.5, 53.1, 54.3, 65.8, 66.1, 66.4, 80.4, 117.9, 118.2, 132.5, 132.9, 155.9, 156.8,
175.8, 175.9. MS (ESI+) m/z calculated for C21H38N3O8 [M+NH4]+: 460.55; found 460.30.
Synthesis of Peptide S28
(S)-2-hydroxypropanoic acid allyl ester (S27): Synthesized after general procedure 1.1. L-lactic
acid (720 mg, 8.00 mmol), Cs2CO3 (2.61 g, 8.00 mmol), allyl bromide (1.26 g, 10.40 mmol).
The product was obtained as a yellow oil (296 mg, 2.27 mmol, 28%). 1H NMR (400 MHz,
CDCl3) Ϣ = 1.44 (d, J = 6.9 Hz, 3H), 4.30 (q, J = 6.9 Hz, 1H), 4.61 – 4.77 (m, 2H), 5.21 – 5.38
(m, 2H), 5.84 – 6.00 (m, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 20.5, 66.2, 66.8, 119.0, 131.5,
175.5.
Ester S28: Synthesized after general procedure 1.2. (S)-2-hydroxypropanoic acid allyl ester
(S27, 260 mg, 2.00 mmol, 1.0 eq), Boc-Leu-OH (462 mg, 2.00 mmol, 1.0 eq), EDC (447 mg,
2.60 mmol, 1.3 eq) and DMAP (24 mg, 0.20 mmol, 0.1 eq) were suspended in DCM. DIPEA
(646 mg, 5.00 mmol, 2.5 eq) was added and the resulting solution was stirred at rt overnight.
The solution was washed with 1 M HCl (3 x 10 mL), sat. NaHCO3 solution (3 x 10 mL), brine
and dried over anhydrous MgSO4. The crude product was purified by silica gel
chromatography (DCM/MeOH 50:1) to give the pure product as a colorless oil (225 mg, 0.66
mmol, 33%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.89 – 1.00 (m, 6H), 1.43 (s, 9H), 1.48 – 1.57 (m,
4H), 1.69 – 1.89 (m, 2H), 4.31 – 4.44 (m, 1H), 4.62 (ddd, J = 5.8, 2.6, 1.2 Hz, 2H), 4.84 (d, J =
8.4 Hz, 1H), 5.15 (q, J = 7.1 Hz, 1H), 5.25 (ddd, J = 10.4, 2.5, 1.2 Hz, 1H), 5.32 (ddd, J = 17.2,
2.9, 1.5 Hz, 1H), 5.82 – 6.00 (m, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 17.0, 21.7, 23.1, 24.8,
28.4, 41.6, 51.9, 66.0, 69.1, 80.0, 119.0, 131.5, 155.6, 170.3, 173.2. MS (ESI+) m/z calculated for
C17H30NO6 [M+H]+: 344.43; found 344.26.
Scheme S2.7. Synthesis of peptide S28.
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Determination of Purity by 1H-qNMR
For the determination of purity by absolute 1H-qNMR, an internal calibration with dimethyl
terephthalate (DMT) was employed. The spectra were recorded in deuterated methanol with
number of scans set to 32 and a relaxation delay of 50–60 s. Purity was calculated as follows
[106]:
ࡼሾ%ሿ ൌ ࢔ࡵ࡯ ∙ ࡵࢇ ∙ ࡹࢇ ∙ ࢓ࡵ࡯ ∙ ࡼࡵ࡯࢔ࢇ ∙ ࡵࡵ࡯ ∙ ࡹࡵ࡯ ∙ ࢓ࢇ
Were n is the number of protons, I is the integral, M is the molecular weight, m is the mass and
P is the purity (in %). Indices IC and a denominate internal calibrant or analyte respectively.
For the determination of analyte integral, the sum of suitable, non-overlapping signals was
used. The OCH3 signal of DMT was not considered for quantitative analysis, since
transesterification with deuterated methanol can result in artificial signal reduction.
Figure S2.1. 1H-qNMR spectrum of 26.
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࢓ࢇ ൌ ૜.૙૙૟࢓ࢍ; ࡹࢇ ൌ ૝૛ૠ.૛૝ ࢍ/࢓࢕࢒; ࡵࢇ ൌ ૚ૢ.૚૙; ࢔ࢇ ൌ ૚ૢ࢓ࡵ࡯ ൌ ૚.૛૙૟࢓ࢍ; ࡹࡵ࡯ ൌ ૚ૢ૝.૚ૡ ࢍ/࢓࢕࢒; ࡵࡵ࡯ ൌ ૜.૟૞; ࢔ࡵ࡯ ൌ ૝ࡼሾ%ሿ ൌ ࢔ࡵ࡯ ∙ ࡵࢇ ∙ ࡹࢇ ∙ ࢓ࡵ࡯ ∙ ࡼࡵ࡯࢔ࢇ ∙ ࡵࡵ࡯ ∙ ࡹࡵ࡯ ∙ ࢓ࢇࡼሾ%ሿ ൌ ૝ ∙ ૚ૢ.૚૙ ∙ ૝૛ૠ.૛૝ ࢍ ∙ ࢓࢕࢒ି૚ ∙ ૚.૛૙૟࢓ࢍ ∙ ૢૢ.ૢૢ%૚ૢ ∙ ૜.૟૞ ∙ ૚ૢ૝.૚ૡ ࢍ ∙ ࢓࢕࢒ି૚ ∙ ૜.૙૙૟࢓ࢍ ൌ ૢૠ.૛૝%
NMR Spectra of 2, 3, 18–31
Figure S2.2. 1H NMR Spectrum of 2.
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Figure S2.3. 13C NMR Spectrum of 2.
Figure S2.4. 31P NMR Spectrum of 2.
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Figure S2.5. 1H NMR Spectrum of 3.
Figure S2.6. 13C NMR Spectrum of 3.
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Figure S2.7. 31P NMR Spectrum of 3.
Figure S2.8. 1H NMR Spectrum of 18.
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Figure S2.9. 13C NMR Spectrum of 18.
Figure S2.10. 31P NMR Spectrum of 18.
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Figure S2.11. 1H NMR Spectrum of 19.
Figure S2.12. 13C NMR Spectrum of 19.
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Figure S2.13. 31P NMR Spectrum of 19.
Figure S2.14. 1H NMR Spectrum of 20.
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Figure S2.15. 13C NMR Spectrum of 20.
Figure S2.16. 31P NMR Spectrum of 20.
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Figure S2.17. 1H NMR Spectrum of 21.
Figure S2.18. 13C NMR Spectrum of 21.
76  | Chapter 2
Figure S2.19. 31P NMR Spectrum of 21.
Figure S2.20. 1H NMR Spectrum of 22.
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Figure S2.21. 13C NMR Spectrum of 22.
Figure S2.22. 31P NMR Spectrum of 22.
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Figure S2.23. 1H NMR Spectrum of 23.
Figure S2.24. 13C NMR Spectrum of 23.
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Figure S2.25. 31P NMR Spectrum of 23.
Figure S2.26. 1H NMR Spectrum of 24.
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Figure S2.27. 13C NMR Spectrum of 24.
Figure S2.28. 31P NMR Spectrum of 24.
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Figure S2.29. 1H NMR Spectrum of 25.
Figure S2.30. 13C NMR Spectrum of 25.
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Figure S2.31. 31P NMR Spectrum of 25.
Figure S2.32. 1H NMR Spectrum of 26.
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Figure S2.33. 13C NMR Spectrum of 26.
Figure S2.34. 31P NMR Spectrum of 26.
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Figure S2.35. 1H NMR Spectrum of 27.
Figure S2.36. 13C NMR Spectrum of 27.
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Figure S2.37. 31P NMR Spectrum of 27.
Figure S2.38. 1H NMR Spectrum of 28.
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Figure S2.39. 13C NMR Spectrum of 28.
Figure S2.40. 31P NMR Spectrum of 28.
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Figure S2.41. 1H NMR Spectrum of 29.
Figure S2.42. 13C NMR Spectrum of 29.
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Figure S2.43. 31P NMR Spectrum of 29.
Figure S2.44. 1H NMR Spectrum of 30.
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Figure S2.45. 13C NMR Spectrum of 30.
Figure S2.46. 31P NMR Spectrum of 30.
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Figure S2.47. 1H NMR Spectrum of 31.
Figure S2.48. 13C NMR Spectrum of 31.
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Figure S2.49. 31P NMR Spectrum of 31.
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3.1 Abstract
A previously studied congeneric series of thermolysin inhibitors addressing the solvent-
accessible S2’ pocket with different hydrophobic substituents showed modulations of the
surface water layers coating the protein-bound inhibitors. Increasing stabilization of water
molecules resulted in enthalpically more favorable binding signature, overall enhancing
affinity. Based on this observation, we optimized the series by designing tailored P2’
substituents to improve and further stabilize the surface water network. MD simulations were
applied to predict the putative water pattern around the bound ligands. Subsequently, the
inhibitors were synthesized and characterized by high-resolution crystallography,
microcalorimetry and surface plasmon resonance. One of the designed inhibitors established
the most pronounced water network of all inhibitors tested so far, composed of several fused
water polygons, and showed 50-fold affinity enhancement with respect to the original
methylated parent ligand. Notably, the inhibitor forming the most perfect water network also
showed significantly prolonged residence time compared to the other tested inhibitors.
Keywords
protein–ligand interactions, thermodynamic optimization, hydrophobic effect, solvent
reorganization, water network prediction, molecular dynamics simulations, X-ray
crystallography, isothermal titration calorimetry, surface plasmon resonance, binding kinetics
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3.2 Introduction
Structure-based drug design (SBDD) seeks to optimize ligand binding with respect to a given
target protein. Thermodynamic parameters such as ∆G, ∆H, –T∆S, ∆Cp and of binding kinetic
properties, such as kinetic association (kon) and dissociation (koff) rate constants, are considered
to rationalize and accelerate affinity optimization by a better characterization of the protein–
ligand binding process [1,2,24,107–110]. Thermodynamic profiling, at its best based on
isothermal titration calorimetry (ITC) [17,111,112], is supposed to provide insights into the
molecular interactions determining the affinity of a ligand to its target. However, past
experience has shown that optimization and prioritization of compounds guided by
thermodynamics is difficult, since the enthalpy–entropy profile reflects the binding event as a
whole. Hence, the high complexity of this event largely impedes factorization into individual
contributions to binding and often only succeeds for congeneric ligand series with minor
structural variations [5,113,114]. The correlation of structural properties with binding kinetic
data is presently poorly understood and reasonable correlations have only been established for
a limited number of cases [115]. Furthermore, we still face an incomplete comprehension of
the fundamental relationships between thermodynamics, kinetics and molecular interactions
[115–117], which can lead to false predictions made under overly simplified assumptions.
Especially, the impact of the versatile and ubiquitously present water molecules is hardly
understood. The involvement of water molecules is a major cause for the inherent complexity,
particularly arising from the ability of water to establish H-bonds and the resultant tendency
to arrange in differently ordered structures [118]. Water molecules can actively mediate H-
bonds across the binding interface between protein and ligand and thereby improve affinity
[119]. The displacement of well-ordered water molecules from apolar surfaces is discussed as
the driving force of the hydrophobic effect (and not the formation of hydrophobic
interactions), a process of utmost importance for molecular recognition and drug action.
According to the so-called “classical” hydrophobic effect [5,92,120–123], the binding of an
apolar ligand portion to a hydrophobic protein cavity correlates with an entropic advantage
due to the displacement of well-ordered water molecules into the bulk water phase. In contrast,
a “non-classical” hydrophobic effect has been defined, which is enthalpy driven. It has been
related to a suboptimal hydration of a protein cavity prior to ligand binding [10,124,125]. In
this case, the enthalpy gain upon binding results from the displacement of orientationally
mobile and thus entropically favored water molecules into the bulk phase where they can
establish better H-bonds than previously observed in the protein cavity.
Despite the popular binary classification of “classical” and “non-classical”, the hydrophobic
effect can range from entirely entropy-driven to entirely enthalpy-driven. This is determined
by the thermodynamic properties of the water molecules that are involved before and after
binding and by the ligand and the binding site (especially by their molecular shape and
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polarity), which affect the formation of adjacent water networks [14]. Of utmost importance
for the thermodynamic signature is the overall inventory of water molecules with respect to
their release into or recruitment from the bulk water phase, and the embedding of water
molecules into H-bonding networks of varying completeness and perfection in the protein-
bound state. In particular, the way water molecules are able to rearrange and establish H-
bonding networks around the newly formed solvent-exposed surface of the protein–ligand
complex seems to have a significant impact on the thermodynamic binding signature
[11,15,93,94,126].
In a previous study [15], we structurally and thermodynamically analyzed a series of
congeneric thermolysin (TLN) inhibitors with a peptidomimetic parent scaffold (Figure 3.1A)
decorated with different hydrophobic P2’ substituents (Figure 3.1B). We selected the zinc
metalloprotease TLN from Bacillus thermoproteolyticus for our studies [34,127,128], as this
enzyme has been frequently used as class representative and exhibits excellent crystallographic
properties [36,129]. In addition, TLN is quite rigid because of its high thermal stability, thus
reducing structural adaptions and facilitating comparative analyses. The active site of TLN is
composed of three subpockets (Figure 3.1A). Firstly, the rather unspecific S1 pocket, a
hydrophobic cavity that recognizes aromatic portions such as Phe. Secondly, the S1’ specificity
pocket, a predominantly hydrophobic, deep and narrow pocket, which preferentially
accommodates hydrophobic amino acids such as Val, Leu, Ile and Phe, and thirdly the S2’
subsite, a hydrophobic, flat, bowl-shaped pocket, which is well-accessible to bulk water
molecules [127]. We selected the S2’ pocket for our studies. Within a previously investigated
series [15], we increased the size of the P2’ substituents addressing the well-solvated S2’ pocket
systematically from a sole methyl to a phenylethyl substituent as displayed in Figure 3.1B. By
detailed ITC analyses (Figure 3.1B), we revealed a difference in binding affinity (Kd:
dissociation constant of the thermodynamic equilibrium) of more than one order of
magnitude [15], or expressed as standard Gibbs free energy, a maximum ∆∆G° of 7.0±0.4
kJ mol–1. Remarkably, ∆∆G° factored in a huge enthalpy–entropy variation, and indicated
pronounced enthalpy–entropy compensation, a phenomenon frequently observed in drug
optimization [4,121,130,131]. We could correlate the observed variations in the
thermodynamic profiles with crystallographically observed structural changes of the P2’
substituents and, triggered thereby, modulations of the adjacent surface water solvation layer
[15]. The ∆H° contributions appeared to be more favorable (and –T∆S° less favorable) where
a better-ordered water network was established next to the surface of the newly formed
protein–ligand complex. In contrast, –T∆S° apparently increased (and ∆H° decreased) where
the first solvation layer next to the bound ligand was unfavorably disrupted. Furthermore, the
increasing contribution to desolvate the gradually growing P2’ substituents seemed to
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Figure 3.1. (A) Schematic binding mode and protonation state of the parent ligand scaffold in
complex with TLN addressing the active site and the S1, S1’ and S2’ subpockets. Structural
components of TLN determinant for the shape of the binding pocket are indicated (GOL = glycerol).
Solvent accessibility of sub-pockets is indicated by a blue contour region. H-bonds of at least
moderate strength (≤3.2 Å) between parent scaffold and TLN are indicated by red dotted lines, all
established to the side-chains of the respective amino acids with the exception of Ala113 (H-bond
to backbone carbonyl O). The carboxyl function of Glu143 is protonated while in complex with the
ligand and thus can form an H-bond to the double-bonded phosphonamidate O of the ligand [93].
(B) Differences in the thermodynamic profiles of the ligands from the previous study [15] were
compared to 1 from the latter study. This ligand was also used as a starting point for the design of
the ligand series of the current study (2–6). A positive term resembles a less favorable parameter of
∆H°, –T∆S° or ∆G° relative to ligand 1, whereas a negative term resembles a more favorable
parameter. The chemical structures of the P2’ groups of the ligands are displayed, and the parent
scaffold of them is displayed in Figure 3.1A. The graph was prepared with the thermodynamic
parameters as analyzed earlier [15]. Mean standard deviations were calculated by the square root of
the sum of variances. (C) P2’ substituents of phosphonamidate-type TLN inhibitors 1–6. The parent
scaffold of the ligands is identical as displayed in Figure 3.1A.
98 | Chapter 3
enhance binding entropy, as expected for the “classical” hydrophobic effect of a well-hydrated,
apolar cavity [132]. Strikingly, the inhibitor with the highest affinity (ligand 1, Figure 3.1B)
showed both, a pronounced burial of its relatively large P2’ group along with a well-established
surface water network wrapping around this substituent in its protein-bound state [15]. This
resulted in a well-balanced thermodynamic profile driven by favorable enthalpic and entropic
contributions, overall resulting in an increase in binding affinity. Consequently, optimization
of the surface water network wrapping around the partly solvent-exposed P2’ substituent
appears an useful approach to enhance ligand binding, since the enthalpic gains seem to overall
improve affinity.
In the present study, we want to validate this working hypothesis by systematically improving
of the surface water network around a newly formed protein–ligand complex to modulate its
thermodynamic binding profile and thus increase affinity of a bound ligand. Starting with the
best and already fairly well-optimized ligand 1 of our previous series (Figure 3.1B), we designed
five additional ligands (2–6, Figure 3.1C) based on the carboxybenzyl-Gly-(PO2)-L-Leu-NH2-
P2’ parent scaffold (Figure 3.1A), and attached distinct apolar P2’ substituents to generate
differently shaped solvent-exposed surfaces in complex with TLN. Prior to ligand synthesis,
we used molecular dynamics (MD) simulations to predict the quality and completeness of the
surface water network established around the newly formed complex [133]. The MD
simulations suggested the highest completeness and quality for the complex with 3 and lowest
for its epimer 6. As the designed ligands seem to be promising candidates to validate our
hypothesis, we synthesized all five to study the established water networks around the formed
complexes by X-ray crystallography and thermodynamically by ITC. Furthermore, as we also
expected an impact on the binding kinetic properties, we studied the association and
dissociation rate constants kon and koff by surface plasmon resonance (SPR).
3.3 Results
Ligand design and solvation pattern prediction using MD simulations
Our design hypothesis to maximize the desolvation of increasingly bulky P2’ substituents along
with an energetically favorable (“optimal”) surface water network to enhance binding affinity
started with the binding pose of 1, which was already characterized in a previous study (PDB
code 4MZN) [15]. This ligand showed a well-established surface water network toward the left
rim of the binding pocket including an energetically favorable five-membered water polygon,
interconnected by H-bonds (Figure 3.2A, left panel). Deficiencies in the network are suggested
on the lower and right-hand side of the S2’ pocket (direction relative to the view of the figure).
Here, the tert-butyl portion of the ligand with the 2,2-dimethylbutanyl P2’ group (Figure 3.2A,
right panel), exhibiting two additional terminal methyl groups relative to 1, stabilized a more
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complete network in this region, and also established the favorable pentagonal polygon to the
left. However, its water network is unfavorably disrupted on top of the tert-butyl portion,
resulting in an entropically highly favored system with an overall lowered affinity (Figure 3.1B).
We therefore envisioned merging the features of both P2’ substituents into size-increased 2
(comprising only one of the two additional methyl groups of the tert-butyl portion) and 3
(exhibiting both additional methyl groups of the tert-butyl portion). As our design involved
Figure 3.2. Ligand design for optimized surface water network stabilization and evaluation of
solvation sites by MD simulations. The inlets of the figures represent the chemical structures of the
P2’ substituents of the displayed ligands, their parent scaffold is shown in Figure 3.1A. In all panels,
the solvent excluded surface of TLN is displayed in white. (A) Crystal structure of 1 (blue) and of the
TLN ligand with the 2,2-dimethylbutanyl P2’ group (green). Water molecules are displayed as
spheres, H-bond distances between them as dotted lines. Water molecules from the first solvation
layer of the P2’ groups are highlighted in red. (B) Comparison between the crystal structure of TLN-
1 and the solvation-site predictions by MD simulations. The crystallographically determined binding
modes of ligand and additive molecules also used in the MD simulations are displayed as blue stick
models with color-coded heteroatoms. Water molecule positions determined in the crystal
structure are displayed as blue spheres, and the Fo–Fc omit electron density is displayed as dark blue
mesh (contour level 3σ) for the water molecules in the first solvation layer of the P2’ group. H-bond
distances are indicated as blue dotted lines. Positions of water molecules, which are discussed in
the main text, are labeled with identifiers according to Figure 3.4. The yellow, semitransparently
contoured regions show computed areas in the first solvation layer of the P2’ groups with an
occupancy probability by a water molecule of at least 48%. (C) Hydration sites of the designed
ligands as predicted by MD simulations. The modeled coordinates for ligand and additive molecules
used in the MD simulations are displayed as yellow stick models (heteroatoms color-coded). The
yellow contoured regions represent areas in the first solvation layer of the P2’ groups with an
occupancy probability by a water molecule of at least 48%.
100 | Chapter 3
the creation of stereogenic centers, we also considered the epimers 5 and 6 of 2 and 3 in our
subsequent MD evaluation.
To predict and analyze the pattern of water solvation sites around the designed P2’ substituents,
we applied our recently introduced MD approach [133] to simulate TLN-1, TLN-2, TLN-3,
TLN-5 and TLN-6. Ligand 4 (the epimer of 1, Figure 3.1C) was not considered for the MD
simulations, as this ligand was only synthesized at a late stage of the study with the purpose to
complete the congeneric series and to further validate the influence of the rearrangement of
water molecules on the thermodynamics of protein–ligand binding. This strategy provided the
opportunity to validate our MD protocol on TLN-1, as we had already determined a high-
resolution crystal structure (1.17 Å) for this complex [15]. MD simulations were run for 20 ns
and the spatial positions of water molecules were recorded every 2 ps along the trajectory, from
which the propensity of water molecules to occupy the indicated solvation sites was calculated.
For the novel complexes, the crystal structure of TLN-1 was used as a template. During the
MD simulations, non-hydrogen atoms and non-water molecules were constrained to their
starting coordinates. Similar protocols were applied to model the designed complexes with 2,
3, 5 and 6 (for further details, see the Experimental Section). For TLN-1, the computed results
are superimposed with the difference electron densities of the water molecules found in the
crystal structure (Figure 3.2B). The displayed solvation sites encompass a probability greater
than 48% to record a water molecule along the trajectory at this site. This contour level was
adjusted by visual inspection of the computed map to qualitatively match with the contouring
of the crystallographically determined Fo–Fc difference electron density at the commonly
applied 3ϯ level. The results matched convincingly well. Only the site W8 is predicted as less
populated compared to the crystal structure and W9 was suggested as being slightly displaced
by the MD approach. Mutually facing the distributions of the computed solvation sites
indicates that TLN-3 displays the most densely packed and complete surface water network in
the series (Figure 3.2C). The simulation of TLN-5 also assigned a rather elaborate surface water
network to this complex, whereas TLN-2 and in particular TLN-6 show a gap in the water
network capping their P2’ substituents.
Stereoselective synthesis of the congeneric phosphonamidate inhibitors 2–
6
Stimulated by the simulation results, we decided to synthesize 2–6. Compound 4, the epimer
of 1, was included for reasons of comparison.
Scheme 3.1 illustrates representatively the synthesis route to prepare 2–6. The stereogenic
center in the P2’ portion of the ligands was synthetically accessible by a strategy employing a
chiral oxazolidinone auxiliary. 4-Benzyl oxazolidinone (7 or 8) was treated with n-BuLi
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the activated phosphonic acid. The final deprotection of the coupling products 40–44 with
aqueous LiOH solution followed by semi-preparative HPLC purification afforded inhibitors
2–6 in high purity.
Structure determination of TLN–2 to TLN–6 by X-ray crystallography
Crystal structures of 2–6 (chemical structures in Figure 3.1C) in complex with TLN were
collected at high resolutions between 1.16–1.38 Å (Table 3.1). As shown in Figure 3.3, the
conformations of the amino acids of their TLN binding sites are highly conserved and
superimpose perfectly well, likewise the binding mode of the parent scaffold of all six ligands
is virtually identical. The binding mode of this conserved part was already described
extensively [33,93,135]. In brief, the scaffold coordinates monodentally the zinc ion with its
negatively charged phosphonamidate oxygen. The carbamate group is disordered over two
conformations with approximately equal occupancy. The iso-butyl portion of the ligand’s
leucine component is buried in the hydrophobic S1’ specificity cavity, a binding motif crucial
for achieving high ligand affinity [33]. The S1 pocket is occupied by a glycerol molecule from
the cryobuffer, on top of which the carboxybenzyl moiety of the ligand is positioned. Also
picked up from the buffer, a DMSO molecule is binding adjacent to the carbamate group of
the ligand. Thus, 1–6 differ solely in their P2’ substituents and in the water networks adjacent
to them. In the following, the positions of fifteen water molecules W1–W15 (referring to water
molecules found at distinct positions in the first solvation layer around the P2’ groups) are
described according to the nomenclature and relative to the view angle chosen in Figure 3.4.
At the right upper rim of the S2’ pocket, a second glycerol molecule is found (Figure 3.4A–F),
which establishes weak H-bonds (distance >3.2 Å) to water molecules W10 and W11 in some
of the crystal structures. We observed the two glycerol molecules in all 19 crystal structures
that we determined in the previous studies [15,93,94,96]. A glycerol molecule is well known to
replace three water molecules as a kind of rigidified surrogate in a crystal structure.
Nonetheless, to validate and exclude whether these glycerol molecules take any artificial
influence on the ligand pose and adjacent water structure, we succeeded to establish alternative
crystallization conditions also yielding well-diffracting crystals using PEG400 and methyl-2,4-
pentanediol (MPD) instead of glycerol as cryoprotectant. We also collected diffraction data of
glycerol-free crystals of TLN in complex with 3, 5 and 6 in order to validate whether the
glycerol molecule exerts any artificial influence on the structural arrangement of the observed
water molecules (Figure S3.2, Supporting Information). In summary, in the crystal structures
with PEG400 and MPD as cryoprotectant, the positions of the glycerol OH groups are occupied
by water molecules, and the established water networks in the S2’ pocket are very similar to the
below described complexes with glycerol as cryoprotectant. The minor differences concern
only highly mobile water molecules (borderline cases with respect to the placement of water
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Figure 3.3. Superimposed crystal structures of the TLN–ligand complexes TLN-1 to TLN-6. From all
six crystal structures, the ligands, glycerol (GOL) and DMSO molecules are displayed with carbon
atoms in light blue (color-coded hetero-atoms), TLN amino acids in beige, and the zinc ion as dark
blue sphere. The S1, S1’ and S2’ subpockets are indicated by semitransparent spheres. Polar
interactions of at least moderate strength (≤3.2 Å) are indicated by black dotted lines. All crystal
structures were superimposed on TLN-1 by the alignment of amino acids within 5 Å of 1 (159 heavy
atoms). The average RMSD is 0.05±0.02 Å as calculated by fconv [136]. As a result of the high rigidity
of TLN, structural components of the binding site superimpose almost perfectly.
molecules in the refinement model) and the differences observed between the crystals exposed
to different cryoprotectants fall into the same range as deviations recognized if diffraction data
collected for different crystals of similar protein structures is compared. In the following, we
compare the crystal structures in terms of observed electron densities in the S2’ pockets (Fo–Fc
omit electron densities in Figure 3.4A–F) and refined B factors of the water molecules (B
factors of all water molecules from the first solvation layer of TLN-1 to TLN-6 displayed as a
heatmap in Figure 3.5) and we avoid to discuss only the presence or absence of a water
molecule in the refinement model.
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Figure 3.4. Crystal structures of TLN–ligand complexes (A) TLN-1, (B) TLN-2, (C) TLN-3, (D) TLN-4,
(E) TLN-5 and (F) TLN-6. In each panel, the solvent excluded surface of the respective crystal
structure is displayed in white and the bound inhibitor is displayed as stick model (C blue,
heteroatoms color-coded). The zinc ion of TLN is indicated as dark blue sphere partly buried by the
surface. Water molecules from the first solvation layer of the ligands’ P2’ groups are displayed as red
spheres and labeled with an identifier (W1–W15) which is referred to in the main text; H-bonding
distances between them are depicted as red dotted lines (maximum depicted distance: 3.4 Å,
without hydrogens). The Fo–Fc omit electron densities of water molecules (green mesh) are
displayed at a contour level of 3σ. For clarity reason, water molecules located outside of the first
solvation layer of the P2’ groups are displayed as blue spheres with H-bonding distances indicated
as blue dotted lines, and their electron densities are omitted. The two conformations of the P2’ group
of 2 in complex with TLN (panel B) are labeled with A and B. Fo–Fc omit electron densities of the TLN-
bound ligands are displayed in Figure S3.1 (Supporting Information).
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Arrangement of water molecules in the S2’ pocket of TLN-1, TLN-2 and TLN-3
The structure of TLN-1 was published previously [15] and served as starting point for the
design of our new congeneric ligand series. Hence, the water networks observed in TLN-2 to
TLN-6 are modifications of that in TLN-1. In TLN-1, the ligand places its 2(S)-methylbutyl P2’
group into the S2’ pocket (Figure 3.4A). The right cleft of the pocket is addressed by the
terminal methyl group of the P2’ portion, whereas the terminal ethyl group is oriented toward
the left. In TLN-1, W5–W9 form a five-membered polygon with H-bond distances between
2.8–3.1 Å exhibiting low B factors (Figure 3.5). In total, twelve water molecules are detected in
the first solvation layer around the P2’ substituent covering its large, solvent-exposed
hydrophobic surface patch (Figure 3.6). Several of the water molecules are anchored to the
protein surface via polar interactions: W1 (Arg203 primary nitrogen, 3.0 Å; His231 carbonyl
oxygen, 2.9 Å), W2 (ligand 1 carboxybenzyl carbonyl O, 2.9 Å; Asn112 amide nitrogen, 3.0 Å),
W6 (Asp226 carboxy oxygen, 2.8 Å), W11 (Asn111 backbone carbonyl oxygen, 2.8 Å) and W13
(Tyr193, 3.1 Å). In contrast, W3, W5, W7, W8, W9, W10 and W12 are only stabilized
Figure 3.5. Heatmap of normalized B factors of water molecules W1–W15 found in complexes TLN-
1 to TLN-6. Chemical structures of 1–6 are displayed in Figure 3.1C, water molecule numbering is
according to Figure 3.4A–F. The normalized B factors are color-coded by a blue-to-red gradient.
Individual B factor values of water molecules are omitted, since only distinct relative differences
between B factors are discussed. A white field indicates no sufficient stabilization of the water
molecule in the crystal structure for placement in the refinement model. W3 in TLN-2 is found in two
conformations A and B. To compensate for differences between the B factor scales of different
crystal structures as a result of varying crystal quality, B factors were normalized on the dataset with
the lowest resolution (TLN-4, Table 3.1) and calculated as Bnormalized = Bobserved ÷ Baverage(Cα) × Baverage(Cα)TLN-
4, where Bobserved is the B factor of a water molecule as observed in the crystal structure, Baverage(Cα) is
the average B factor of the Cα atoms of the respective crystal structure and Baverage(Cα)TLN-4 is the
average B factor of the Cα protein atoms in the crystal structure of TLN-4. No significant non-linearity
is expected for the B factors of the datasets due to the narrow resolution range. Values for
experimentally observed and normalized B factors are listed in Table S3.2 and Table S3.3
(Supporting Information).
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by H-bonds to other water molecules or by van der Waals interactions with the apolar surface
patch of the P2’ substituent of 1.
In TLN-2, the 2(S),3-dimethylbutyl group of 2 orients its P2’ group similarly to 1, and the
additional methyl group is disordered over two positions (Figure 3.4B): conformation A (56%
occupancy) is sticking out into the solvent (no contacts within hydrophobic interaction
distance of ≤4.6 Å), whereas conformation B (44% occupancy) is oriented downward,
alongside the protein surface. The observed disorder of the P2’ substituent is a result of the
shallow, widely open S2’ pocket. Due to the steric requirement of the methyl group in
conformation A, two distinct, mutually excluding sites are observed for W3 (occupancies
constrained to 50/50 in the refinement model). As a consequence of the reduced occupancy
and owing to a strong correlation of B factors with occupancy [141], the refined B factor for
this water molecule (Figure 3.5) has to be regarded with care and will hardly reflect its actual
mobility. Furthermore, the distance between W9 and W10 increases from 3.4 Å in TLN-1 to
4.5 Å in TLN-2, clearly exceeding the maximum distance for an energetically favorable H-bond
[142,143]. The constraint which modifies the water structure between TLN-1 and TLN-2 is
best visualized by use of the solvent accessible surface areas (SASAs; solvent excluded surface
Figure 3.6. Topography of the S2’ pocket of TLN-1. The solvent excluded surface of the TLN–ligand
complex is shown (color-coded, surface indicated for C in white, O in red, N in blue). Water molecules
in the first solvation layer of the P2’ group are displayed as red spheres and labeled with identifiers
according to Figure 3.4. Water molecules further remote than the first solvation layer and the
glycerol molecule are displayed in blue. The position of 1 and TLN amino acids establishing H-bonds
to water molecules of the first solvation layer are indicated by stick models below the surface. H-
bonds between the water molecules of the first solvation layer are depicted as red dotted lines, H-
bonds established to other water molecules, TLN amino acids or 1 are depicted as blue dotted lines
(distances labeled in Å, maximum depicted distance: 3.4 Å).
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area plus radius of a water molecule) as displayed for the P2’ portions in Figure 3.7: W3, W9,
W10, and W12 in TLN-1 would penetrate inside the SASA of TLN-2, thus these water
molecules in TLN-2 must be shifted. Because of the expanded water structure, W12 and W13
become increasingly destabilized (Figure 3.5).
In TLN-3, the ligand exhibits a 2(S)-3,3-trimethylbutyl substituent (Figure 3.4C), representing
the bulkiest P2’ portion in the (S)-configurated series. The binding mode of 3 closely resembles
that of 2 if both conformations A and B of TLN-2 would be merged. Two additional sites for
water molecules (W14 and W15) are refined, resulting in the formation of a six-membered
polygon and well-defined electron density (Figure 3.4C) with strongly decreased B factor
(Figure 3.5) of the incorporated W13. Furthermore, water molecules W8 and W9, both
participating in the five and six-membered polygonal water networks in TLN-3, are here better
stabilized than in TLN-2 (Figure 3.5). In TLN-3, W10 is shifted distal from the P2’ substituent
and is indicated by less electron density along with a higher B factor compared to TLN-2.
Figure 3.7. Differences in shape and size of the solvent accessible surfaces of TLN-1 and TLN-2. In
both images, the crystal structures TLN-1 (blue) and TLN-2 (orange) are superimposed. The
semitransparent solvent accessible surface of the P2’ group of 1 is displayed in the left panel and of
2 in the right panel. In the right panel, shifts of water molecules observed between crystal structures
TLN-1 and TLN-2 are indicated by red arrows. For TLN-2, both conformations A and B of the P2’ group
of 2 are considered for the displayed solvent accessible surface. The solvent excluded surface of TLN
is displayed in white.
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Arrangement of water molecules in the S2’ pocket of TLN-4, TLN-5, and TLN-
6
Ligands 4, 5 and 6 are the epimers of 1, 2 and 3. The overall quality of the crystal structure
TLN-4 is slightly lower compared to that of the other five complexes (resolution, Rwork/Rfree
values, Wilson B factor; see Table 3.1). Nevertheless, only about ten water molecules less are
observed in TLN-4 at a total amount of >400. In TLN-4 (Figure 3.4D), the P2’ portion is flipped
over by 180° compared to TLN-1: The terminal P2’ ethyl group is oriented toward the right
rim, whereas the P2’ methyl group is directed to the left of the S2’ pocket. Only six water
molecules are detected in the crystal structure adjacent to the P2’ group mainly stabilized via
H-bonds to protein residues.
In TLN-5 (Figure 3.4E), in contrast to 4, the P2’ substituent of 5 adopts a conformation
analogous to that of the (S)-configurated P2’ substituents of 1 to 3. One methyl group from the
terminal iso-propyl portion of 5 is not defined in the electron density most likely owing to
enhanced mobility. It was therefore not modelled in the structure. The absence of this methyl
group is also observed in TLN-5 with MPD as cryoprotectant (Figure S3.3B, Supporting
Information). The missing of water molecules W5, W10 and W12 results in an incomplete
water network in TLN-5 (compared to that of the epimeric TLN-bound 2). In the crystal
structure TLN-5 with MPD as cryoprotectant, W5 is highly mobile but sufficient electron
density is detected to allow placement of a water molecule in the refinement model (Figure
S3.2B, Supporting Information). Furthermore, in the structure of TLN-5 with glycerol as
cryoprotectant, some Fo–Fc difference electron density is observed at the positions of W5 and
W10 (Figure 3.4E), which, however, is too weak to justify placement of a fully populated water
molecule in the refinement model of TLN-5. In TLN-6 (Figure 3.4F), W5 and W10 were added
to the refinement model, but they refined as highly mobile (Figure 3.5). Furthermore, W10 is
missing in the crystal structure of TLN-6 with MPD as cryoprotectant (Figure S3.2C,
Supporting Information). Consequently, the water molecules W5 and W10 are highly mobile
in TLN-5 and TLN-6, and the local concentration of their electron density is at the borderline
for water placement in the refinement model. Thus, the water networks of TLN-5 and TLN-6
are highly similar. Overall, in the (R)-series a lower amount of water molecules with increased
residual mobility (especially of W5–W10, Figure 3.5) is observed compared to the (S)-series.
Thermodynamic signatures of TLN-ligand complex formation measured by
ITC
As we recently documented, ITC measurements comparable on the same scale and with
minimal error margins can only be obtained if all ligands are studied with the same optimized
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measurement protocol using the same protein batch [96]. We therefore reevaluated 1 along
with 2–6 in the present study (for further details see Chapter 3.10.4, Supporting Information).
Across the (S)-configurated series (1→2→3), the binding affinity ∆G° improved with growing
number of methyl groups (Figure 3.8). Remarkably, this effect is determined by an increasingly
favorable –T∆S°, which is only partly compensated by a loss in ∆H° (slope of –T∆S° is steeper
than of ∆H°), leaving overall a gain in ∆G°. Interestingly, for the (R)-configurated series
(4→5→6), no affinity enhancement is detected. The mutual compensation of ∆H° and –T∆S°
fully nullifies any affinity improvement as the ∆H° compensation is stronger (slopes of –T∆S°
and ∆H° are equal with opposite sign) compared to the (S)-series. Accordingly, in the (S)-
series, a small but significant advantage in ∆H° is experienced parallel to the growing of the P2’
substituent into the S2’ pocket relative to the (R)-series.
To further validate whether the glycerol molecules found in our cryoprotected crystal
structures have any distorting effect on the thermodynamic signature, we performed ITC
titrations with the addition of different concentrations of glycerol (up to 10%, Figure S3.6 in
the Supporting Information). These titrations revealed a systematical increase of ∆H° with
increasing glycerol concentration paralleled by a compensating decrease of –T∆S°. Most
importantly, the relative difference between ∆H° and –T∆S° remained unchanged, thus no
specific effect and only an overall systematic influence of the added glycerol was observed.
Comparable systematic influences, for example by the type of salt (NaCl or NaSCN) and its
Figure 3.8. Thermodynamic parameters of 1–6 upon binding to TLN measured by ITC. The basic
scaffold of the displayed P2’ groups is displayed in Figure 3.1A. The columns and the error bars
represent the mean values calculated out of three measurements and their standard deviations,
respectively. Trendlines of 1→3 (S) and 4→6 (R) for ∆H° (green), –T∆S° (red) and ∆G° (blue) were
calculated with SigmaPlot. Data values are listed in Table S3.4 (Supporting Information).
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concentration used in the measurement buffer, have been described previously [96]. Similarly,
systematic influences on ∆H° and –T∆S° were also observed for the measurement with the
addition of different concentrations of DMSO (Figure S3.7, Supporting Information). These
findings underscore that ITC data should only be recorded applying highly comparable
measurement conditions and evaluated relative to each other in congeneric compound series
[96].
Binding kinetics of TLN-ligand complex formation measured by SPR
The binding kinetic parameters of 1–3 and 5–6 (Figure 3.9) were determined by single-cycle
SPR measurements preformed in triplicate for each ligand. Kinetic analysis of the SPR
sensorgrams was performed by global analysis of the triplicate data applying a 1:1 binding
model [144,145], which agreed well with individual analysis of the sensorgrams. The relative
standard deviations of the individual analysis results were about 30% for kon and 10% for koff
(Table S3.8, Supporting Information). Ligand 4 was not tested, as this ligand was synthesized
at a later stage of the study. As depicted on the kinetic map (Figure 3.9), 1 showed the fastest
koff within the series, whereas the dissociation rates for 2, 5 and 6 are slower and fall within a
narrow window. Ligand 3 instead shows a significantly prolonged dissociation rate compared
to all other members of the series.
Figure 3.9. Kinetic map (log kon vs. log koff) of 1–3, 5 and 6 as determined by global analysis of the
single-cycle SPR measurements performed in triplicate for each ligand. Measurement results and
SPR sensorgrams are shown in Table S3.7 and Figure S3.8 (Supporting Information). The results and
standard deviations of the kinetic parameters as determined by individual analysis of the SPR
sensorgrams are listed in Table S3.8 (Supporting Information).
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Buried SASAs of the TLN-ligand complexes
Figure 3.10 shows the computed buried solvent accessible surface areas (SASAs) of 1–6 in
complex with TLN. One methyl group of the P2’ portion of 5 remained undetected in the
electron density (Figure 3.4E). Therefore, the missing methyl group was modeled in two
conformations Am and Bm based on the crystal structure (Figure S3.9, Supporting Information)
and the buried SASAs of these two conformations were calculated. The SASA buried within
the (S)-series increases monotonously from 1→2→3 by approximately 15 Å2 per added methyl
group. TLN-4 exhibits the largest buried SASA of all six ligands and the buried SASAs of 5 and
6 are slightly larger than those of their respective epimers 2 and 3.
3.4 Discussion
In the current study, we wanted to validate our hypothesis that ligand binding to an open,
rather flat and solvent-exposed binding pocket can be enhanced by optimizing the surface
water network wrapping around exposed parts of the bound ligand. We started with the
Figure 3.10. Buried solvent accessible surface areas (SASAs) of 1–6 while in complex with TLN. The
P2’ group of 2 adopts two conformations in the crystal structure (A and B, Figure 3.4). One methyl
group of the P2’ portion of 5 is not visible in the electron density and was thus modeled in two
conformations 5Am and 5Bm (Figure S3.9, Supporting Information). Calculated data values are listed
in Table S3.9 (Supporting Information).
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previously characterized peptidomimetic TLN inhibitor 1 [15], and modified its hydrophobic
solvent-exposed P2’ substituent attached to the parent scaffold. We improved binding affinity
by maximizing the desolvation of the increasingly bulky P2’ substituents along with an
enhancement of the water network wetting the surface of the formed complex. Moreover, we
expected that the residence time of the complex could be expanded with increasing quality and
perfection of the formed water network. Prior to synthesis, we predicted the putative water
pattern around the designed ligands by MD simulations.
In our previous purely descriptive studies, we observed that small changes of the solvent-
exposed ligand surface can strongly modulate the stability and complexity of the formed water
network adjacent to the bound ligands [15,93,94]. Since the spatial arrangement of water
molecules across apolar surfaces is governed by a complex architecture and the addition of a
sole methyl group can already lead to the unfavorable disruption of the adjacent water network,
optimal hydration of a partly solvent-exposed apolar P2’ substituent is a challenging design
task.
As starting point we chose 1, which already displayed rather potent inhibition properties but
showed local deficiencies in the solvation pattern next to its P2’ substituent. This was indicated
by a comparison with structures of closely related complexes. By merging features of their P2’
substituents with those of 1, we designed a small series of ligands comprising chiral aliphatic
P2’ substituents. To predict their impact on the quality of the wetting surface water network,
we followed our recently introduced MD approach [133]. To further validate our hypothesis,
we considered both chiral orientations, as the simulations suggested significant differences
between the stereoisomers. Since the designed ligands exhibited a second stereogenic center at
P1’, epimeric pairs of ligands resulted. This leads to the disadvantage that differences in the
desolvation cost to transfer the corresponding ligands of the epimeric pairs from the bulk
solvent phase to the protein pocket cannot be entirely excluded. However, as the two
stereogenic centers are separated by several bonds, we assume quite similar physicochemical
properties for the matching epimeric pairs. Across the series, the MD analysis suggested small
but significant differences in the completeness of the surface water network formed next to the
different P2’ substituents rendering the (S)-configurated 3 as most promising candidate of the
series. Subsequently, we synthesized the ligands stereoselectively and characterized the
complexes formed via crystallography, microcalorimetry and surface plasmon resonance.
Concerning the crystal structure analysis, in all cases we obtained diffraction data with very
high resolution, also falling into a narrow window (mean: 1.22±0.10 Å, ). This is important to
reliably compare details of the water structures between the different crystal structures, as
deviating resolution can affect such details and will complicate the mutual matching of B
factors [146].
114 | Chapter 3
The parent scaffold of all six ligands adopts virtually the same binding pose (Figure 3.3). Thus,
the observed differences between the studied ligands 1–6 most likely originate predominantly
from the desolvation differences of the gradually increasing and partly buried P2’ substituents
and from deviations of the formed surface water networks “wetting” the newly formed
complexes. They show varying degrees of completeness and perfection, which in turn,
influence the thermodynamic and binding kinetic signature of complex formation. Whereas
the fixation of water molecules on the surface of the bound ligand increases binding enthalpy
and reduces entropy, in contrast binding entropy is favored and enthalpy lowered by enhanced
mobility up to the displacement of water molecules into the bulk water phase. The mobility
and occupancy of individual water molecules is indicated by the spatial concentration of the
electron densities (Figure 3.4) and the assigned B factors (Figure 3.5). A strong fixation of a
water molecule results from the embedding into a geometrically rather constrained H-bonding
network, also involving the formation of H-bonds to adjacent functional groups of the
protein’s amino acids.
Although essential in the current series, the arrangement of water molecules is possibly only
one component determining the thermodynamic signature of the binding process. The total
thermodynamic signature is in any case the sum of many contributions and might be
composed of partly compensating or mutually enhancing contributions. Hence, it is even more
important that we attempt to only evaluate relative differences of the studied complexes and
not their absolute values. Furthermore, ligand binding can be accompanied by global
conformational adjustments of the protein partly masking the thermodynamic signature of the
local binding event. However, from our experience with the system, global adjustments of TLN
are unlikely. The enzyme has proven to be highly rigid and the sole differences introduced
between the congeneric ligands are their solvent-exposed P2’ groups. Fenley et al. recently
evaluated a large-scale MD trajectory of BPTI (bovine pancreatic trypsin inhibitor) and
observed remarkable transitions between states of unchanged overall Gibbs free energy but
significantly altered enthalpy/entropy inventory [147]. This entropy–enthalpy transduction
might suggest a physical mechanism underlying entropy–enthalpy compensation in such
systems. However, we propose that in our congeneric ligand series, where binding occurs to a
rigid protein, the ligands always address the same or very similar configurations of TLN.
Prediction of solvation sites by MD simulations and their agreement with
crystallographically determined solvation sites
Based on our earlier study on four TLN ligands [94], we developed an MD simulation protocol
to predict water networks adjacent to solvent-exposed ligand groups [133]. This protocol
correctly reproduced the rupture of a water network between two ligands differing by only one
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single methyl group [94]. The rupture was responded by a dramatic loss in binding enthalpy
(∆∆H°methyl→H = +13.3±0.6 kJ mol–1) and an increase in binding entropy (–T∆∆S°methyl→H = –
7.7±0.4 kJ mol–1), overall resulting in a lowered affinity (∆∆G°methyl→H = +5.7±0.3 kJ mol–1). This
example underlines the pronounced effect of the ligand-capping water network on the
thermodynamic signature.
Importantly, our MD simulation approach does not require any a priori knowledge about
water positions but allows the prediction of hydration sites adjacent to protein–ligand
complexes from scratch in agreement with experiment. In the present study, the tool was
applied to predict TLN-2, TLN-3, TLN-5 and TLN-6. Its predictive power could be further
assessed by simulating TLN-1, as its crystal structure had been determined prior to the present
study [15]. For TLN-1, the computed hydration sites match remarkably well with the difference
electron density assigned to water molecules by crystallography (Figure 3.2B). Only the
population of W8 is underestimated, which is in line with our previous observation that water-
to-methyl interactions are predicted as too weak by the AMBER force field [133].
To estimate whether the designed P2’ substituents exhibit higher or lower hydration
propensities than those of 1, the predicted solvation sites were mutually compared. The
simulations of TLN-1 and TLN-3 suggest some advantages of the latter adjacent to the P2’
substituents (Figure 3.2B,C). This should render 3 superior to 1 with respect to affinity, since
the enthalpic component of stabilizing the water network is larger and can compensate for the
increasing enthalpic cost to (entropical beneficially) desolvate 3 over 1, as its substituent
comprises two additional methyl groups, resulting in a significantly larger buried surface area
(Figure 3.10). For TLN-6, a possible rupture of the water network in the center of the apolar
surface next to the P2’ substituent is suggested. Facing the subsequently determined crystal
structures with our predictions, TLN-3 (Figure 3.11A) exhibits the water molecules capping
the apolar P2’ substituent which are likewise predicted too weak (as W8 in TLN-1). The in the
crystal structure well-stabilized W8 and W9 are weakly indicated by the MD approach, and the
relatively mobile W14 (high B factor and weak electron density) is not predicted by the
computer analysis, at least on the 48% threshold level. W15 is correctly predicted by a tubular
solvation site, which also hosts W13. In TLN-6, W8 and W9 are not predicted by MD, which,
however, agrees with the experimental observation that these water molecules are significantly
less stabilized in TLN-6 than in TLN-1 or TLN-3 (cf. high B factors, Figure 3.5). The shifted
position of W10 was correctly predicted, resulting in a large gap toward W11 beyond H-
bonding distance. Water molecule W12 is not observed in the electron density, whereas the
MD simulation predicts a hydration site at this position. In summary, TLN-1, TLN-3 and TLN-
6 are convincingly predicted on qualitative level and the relative ranking of the epimer
complexes TLN-3 (strong fixation) and TLN-6 (weak fixation) was correctly assigned.
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The predicted solvation sites in TLN-2 and TLN-5 differ more strongly from the
crystallographically observed electron densities. This results from the disorder of the P2’
substituents of 2 and 5 indicated in the crystal structures, which was difficult to predict as the
disorder was not considered in the MD simulations (Figure S3.10, Supporting Information).
Correlation of structural data with thermodynamic signature of complex
formation
Our starting ligand 1 has been established as most potent binder from the previously studied
series (Figure 3.1B) [15]. We related its superior affinity to an entropically beneficial burial of
its surface along with the establishment of an extensive enthalpically favored surface water
network. In TLN-1, a particularly favorable five-membered water polygon is formed (Figure
3.4A, W5–W9), which is well-known for its favorable energetic contribution [148,149].
Compared to TLN-1, the additional methyl group in TLN-2 creates disorder over two
conformational states, perturbing the neighboring water structure (Figure 3.7) and increasing
Figure 3.11. Prediction of water solvation sites as calculated by MD simulations in comparison to
the crystallographically observed electron densities and refined crystal structure models of (A) TLN-
3 and (B) TLN-6. The modeled coordinates of ligand, glycerol and DMSO molecules used in the MD
simulations are displayed as yellow stick models with color-coded heteroatoms. The yellow,
semitransparently contoured regions show computed areas in the first solvation layer of the P2’
substituents with an occupancy probability by a water molecule of at least 48%. The
crystallographically determined binding modes of ligand and additive molecules are superimposed
as blue stick models with color-coded heteroatoms. Water molecule positions determined in the
crystal structures are displayed as blue spheres, and the Fo–Fc omit electron density is displayed as
dark blue mesh at a contour level of 3σ for the water molecules positioned in the first solvation layer
of the P2’ groups. H-bond distances are indicated as blue dotted lines. Positions of water molecules,
which are discussed in the main text, are labeled with identifiers according to Figure 3.4. The solvent
excluded surface of TLN is shown in white.
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the mobility of the adjacent water molecules: W3 is observed in two orientations, and W9,
W10, W12 and W13 show enhanced B factors (Figure 3.5). Consequently, enthalpy decreases
from TLN-1 to TLN-2 (Figure 3.8). This is overcompensated by a more favorable entropy
resulting from the burial of a larger apolar surface area (Figure 3.10) and the enhanced
sidechain mobility, which is entropically beneficial. Altogether, the more favorable entropy
contribution is only partly compensated by enthalpic losses, resulting overall in a slightly
enhanced affinity of 2 over 1 by ∆∆G°1→2 = –1.0±0.1 kJ mol–1.
The thermodynamic signature of 3 is comparable to that of 2, with a slightly elevated entropic
and virtually unchanged enthalpic term leading to an increased affinity of 3 over 2 (Figure 3.8).
The surface water networks of both complexes differ in several regards. In TLN-3 (Figure
3.4C), a complete six-membered water network polygon (W8, W9, W12–W15) is established
adjacent to the five-membered one and is integrated in an eight-membered ring structure
(W3–W5, W9–W12, W14). Such fused polygonal water arrangements can be considered as
optimal solvation shell to coat the surface of a formed protein–ligand complex in terms of H-
bonding and thus inherent enthalpy contributions. Overall, TLN-3 shows the most perfect
water network along with an increased apolar surface burial compared to TLN-2, resulting in
a slightly superior affinity. This leads to an unchanged enthalpic contribution as desolvation
costs are compensated by the formed enthalpically favored water structure. For 3, however, an
entropic benefit remains originating from the burial and desolvation of the additional methyl
group (“classical” hydrophobic effect).
The complexes TLN-5 and TLN-6 formed with (R)-configurated ligands also show elaborate
surface water networks involving the formation of the stabilizing five-membered water
polygon (W5–W9). Detailed analysis suggests that the involved water molecules experience
much higher B factors than in the corresponding complexes with the (S)-configurated epimers
(Figure 3.5). This supposedly less stable arrangement results from the inverted stereochemistry
and increases the steric demand of the (R)-configurated P2’ substituents. Furthermore, one
terminal methyl group of 5 is not detectable in the crystal structure suggesting enhanced
mobility, likely increasing entropy and reducing the stabilization of the adjacent water
network. In contrast to the (S)-series, the (R)-configurated substituents do not enhance affinity
(Figure 3.8). The gradual enhancement in –T∆S° with growing number of methyl groups is
similar within the (S) and (R)-series. However, in the (R)-series the loss in ∆H° completely
nullifies the advantage in –T∆S°. Thus, overall the affinity enhancement across the (S) series
ligands results from an enthalpic advantage of the growing P2’ substituents. They achieve more
elaborated and energetically improved surface water networks.
Ligand 4 shows an unexpected binding mode, as its P2’ group is flipped by 180° compared to
the other five ligands (Figure 3.4D). Remarkably, this ligand shows the largest surface burial
across the series, significantly higher than that of its epimer 1 (Figure 3.10). The flipped
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orientation takes considerable impact on the established water structure, showing a much
lower amount of recruited water molecules compared to the other TLN complexes. This results
in the striking observation that TLN-4, even though exhibiting the largest surface burial, shows
the lowest affinity across all six ligands (Figure 3.8). This underpins our observation that the
sole burial of hydrophobic surface portions of a ligand is clearly not sufficient to explain the
binding features. Due to the considerable conformational change of the P2’ substituent, a direct
comparison of ∆H° and –T∆S° of TLN-4 with the thermodynamic signatures of the other five
ligands is complicated.
Kinetic analysis of the ligands
The overall rather slow association of ligands binding to TLN is likely governed by a large
conformational transition (induced fit) of the protein, rendering influences of individual
ligands on kon rather insignificant. As a matter of fact, the experimental determination of
association rate constants is dependent on the concentration of the studied samples and thus
prone to additional experimental uncertainties (e.g. weighting errors or repeated freeze-thaw
cycles of the inhibitor solution affecting its concentration). For these two reasons, we refrain
from a detailed interpretation of kon. This uncertainty also affects Kd values determined by SPR,
and will also afflict a direct comparison with Kd values from ITC measurements. In any case,
there might be inherent differences from a theoretical point of view between both techniques
involved, making a direct comparison of Kd values taken from both methods difficult. ITC
observes a system under thermodynamic equilibrium conditions based on a particular binding
model, whereas SPR records a steady state situation in a flow cell using immobilized protein,
which does not necessarily relate to the same binding model as different structural states might
determine binding kinetics. This may lead to differences in the determined Kd values [150].
Based on the thermodynamic equilibrium Kd values determined by ITC, 3 clearly shows the
highest affinity of the series (Figure 3.8), whereas in the SPR measurements the second largest
Kd value was determined for this inhibitor (Table S3.7, Supporting Information). Ligand 3
shows, however, a significantly longer residence time compared to all other ligands (Figure
3.9). Since the local interactions of a specific inhibitor conceivably have a higher influence on
the dissociation kinetics, we relate this decreased dissociation rate constant of 3 to the
formation of the pronounced surface water network caging the hydrophobic P2’ substituent to
stabilize the complex and thus prolong residence time of the ligand.
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3.5 Conclusion
Drug optimization aims for the tailored optimization of binding parameters to endow a ligand
with the required potency, selectivity and binding efficacy. We increasingly recognize that the
sole optimization to enhanced binding affinity is not sufficient to render a ligand as most
promising candidate for further development. Consequently, additional parameters such as
thermodynamic and binding kinetic signatures are consulted to obtain a more detailed view
on the binding process. Furthermore, increasing resolution of the crystal structures
determined across narrow series of protein–ligand complexes discloses tiny differences in the
binding poses, and adaptations of the target protein or modulations of the “wetting” surface
water networks. For the medicinal chemist who performs ligand optimization by means of
chemical synthesis, it is essential that these modulations, which finally improve the ligand’s
profile, result from properties of the bound ligand and its partly solvent-exposed substituents.
They allow fine-tuning of affinity, enthalpy, entropy and binding kinetic properties, as they are
accomplished by well-established medicinal chemistry optimization steps. In the present study,
we show that by means of optimizing the composition of a partly exposed, apolar ligand
substituent bound to a flat, solvent-exposed binding pocket of a protein, the relevant binding
parameters can be fine-tuned using rational design principles. We therefore had to analyze,
predict and characterize the substituent’s burial and in parallel the quality and perfection of
the adjacent formed surface water network, which coats the formed complex. The advantage
of this concept is that the chemical adjustments needed to drive the thermodynamic and
kinetic parameters into a desired range are performed using the normal toolbox available to
medicinal chemists. Our strategy requires the following steps along an iterative design cycle:
(i) molecular design of the exposed substituent to optimize the pocket burial and adjacent
surface water layer, (ii) molecular dynamics simulations to validate the proposed surface water
network, (iii) ligand synthesis, followed by (iv) structural, microcalorimetric and binding
kinetic characterization of the formed complexes. The Table of Contents Graphic (Figure 8.3)
shows the stepwise affinity enhancement across our studied series. The most potent complex
TLN-3 (with the 2(S)-3,3-trimethylbutyl P2’ substituent, at the far right of the diagram in the
Table of Contents graphic) is by about 1.5 orders of magnitude more potent in terms of affinity
than the initial purely methylated complex (at the far left of the diagram). As the detailed
thermodynamic characterization shows, this only partly results from enhancements of the
“classical” hydrophobic effect. Moreover, additionally important, mainly more enthalpy-
driven effects result from the optimization of the surface water network that coats TLN-3
almost perfectly and establishes several fused polygonal water arrangements, which are
characterized by a particular stability. Apart from the enhancement of the thermodynamic
profile, TLN-3 shows prolonged residence time that results from a more stable protein–ligand
complex. Obviously, the optimized surface water layer captures and holds the ligand more
tightly to the protein, thus increasing the barrier for its release. It is possible that this is a rather
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general concept to modulate binding kinetics, namely by enhancing the interaction of a bound
ligand with the adjacent surface water network. Exploitation of this property might allow the
medicinal chemist to fine-tune binding kinetic parameters via ligand optimization for many
drug targets.
3.6 Experimental Section
Water Network Prediction by Molecular Dynamics Simulations
The crystal structure of TLN-1 (PDB code 4MZN) was used for modeling of the ligands as well
as for the MD simulations. In order to provide a common environment for modeling and
simulation, the Cartesian coordinates of protein, zinc ion, and cryobuffer molecules (DMSO,
glycerol) were used. The preparation was performed similarly to our protocol described
previously [133]. After protonation, all crystallographically observed water molecules were
removed. All ligands were modeled within the binding site of TLN-1. As template structures
for the modelling of the ligands, 1 was used for the (S)-configurated 2 and 3, and the ligand in
its complex to TLN from the PDB entry 4MTW [15] was used as a template structure for the
(R)-configurated 5 and 6, as they provided suitable exit vectors. Modeling and a subsequent
minimization of the S2’ groups was performed using the molecule builder function and the
AMBER99 force field implemented in MOE [151]. Atomic charges for the ligands were
calculated with the RESP methodology [152] based on quantum mechanical calculations
obtained by Gaussian09 [153] at HF/6-31G* level. The MD simulations were performed with
the AMBER14 package [154], using the ff99SB force field and periodic boundary conditions.
During all simulation steps, all atoms, except hydrogen atoms and water molecules, were
restrained to their coordinates of the crystal structure. In a 20 ns production phase, water
molecule positions were recorded every 2 ps. This trajectory was analyzed to calculate the
solvation sites using the VOLMAP plugin in VMD [155]. The protocol is described in detail in
our earlier contribution [133].
Ligand Synthesis and Purification
1H, 13C and 31P NMR spectra were recorded on a JEOL ECX-400 or JEOL ECA-500 instrument.
All chemical shift values are reported in ppm relative to the non-deuterated solvent signal. An
external standard was used for 31P NMR spectra (referenced to: 85% H3PO4) and 13C NMR
spectra in D2O (referenced to: trimethylsilyl propanoic acid). ESI-MS spectra were recorded
on a Q-Trap 2000 system by Applied Biosystems. For the description of multiplicity the
following abbreviations were used: s = singlet, d = doublet, t = triplet, q = quartet, quint =
quintet, dd = doublet of doublet, m = multiplet, br = broad signal. For high resolution ESI-MS
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a LTQ-FT Ultra mass spectrometer (Thermo Fischer Scientific) was used. EI-MS analysis was
carried out on a Micromass AutoSpec instrument. For HPLC chromatography a Shimadzu LC-
20 system equipped with a diode array detector was used. Analytic separations were carried
out with a MN Nucleodur 100-5 C18 ec 4.6×250 mm column using a water-acetonitrile
gradient. For semi-preparative separations a Water XSelect CSH C18 10×250 mm column
using a water-acetonitrile gradient was used. The purity of all inhibitors used for biophysical
experiments was greater than 95%, as determined by HPLC
General procedure for the synthesis of acyloxazolidinones 9–13: n-BuLi (1.2 eq) was slowly
added to a solution of 7 or 8 (1.0 eq) in THF at -78 °C under argon. The solution was allowed
to warm to room temperature over 30 minutes. The respective acid chloride (1.1 eq) was added
to the yellow solution and the reaction mixture was stirred for 2 h at -78 °C. The reaction was
quenched with saturated NH4Cl solution and extracted with EtOAc (3×20 mL). The combined
organic extracts were washed with brine and dried over MgSO4. The crude product was
purified by silica gel column chromatography (cyclohexane/EtOAc 5:1).
(S)-4-Benzyl-3-(3-methylbutanoyl)oxazolidin-2-one (9): Compound 9 was synthesized
according to the general procedure using n-BuLi (2 M in hexanes, 2.4 mL, 6.00 mmol), (S)-4-
benzyloxazolidin-2-one (7, 886 mg, 5.00 mmol) and 3-methylbutanoyl chloride (663 mg, 5.50
mmol). The product was obtained as a colorless oil (1243 mg, 4.76 mmol, 95%). 1H NMR (400
MHz, CDCl3) Ϣ = 1.02 (t, J = 6.6, 6H), 2.17–2.28 (m, 1H), 2.71–2.76 (m, 1H), 2.79 (dd, J = 10.2,
6.0, 1H), 2.89 (dd, J = 16.2, 6.7, 1H), 3.31 (dd, J = 13.3, 3.3, 1H), 4.12–4.23 (m, 2H), 4.63–4.74
(m, 1H), 7.18–7.39 (m, 5H). 13C NMR (101 MHz, CDCl3) Ϣ = 22.6, 22. 7, 25.1, 38.1, 44.1, 55.3,
66.2, 127.4, 129.1, 129.5, 135. 5, 153.6, 172.8. MS (ESI+) m/z calculated for C15H20NO3 [M+H]+:
262.32; found: 262.09.
(S)-4-Benzyl-3-(3,3-dimethylbutanoyl)oxazolidin-2-one (10): Compound 10 was synthesized
according to the general procedure using n-BuLi (2.5 M in hexanes, 3.4 mL, 8.40 mmol), (S)-
4-benzyloxazolidin-2-one (7, 1240 mg, 7.00 mmol) and 3,3-dimethylbutanoyl chloride (1036
mg, 7.70 mmol). The product was obtained as a colorless oil (1776 mg, 6.45 mmol, 92%). 1H
NMR (400 MHz, CDCl3) Ϣ = 1.09 (s, 9H), 2.71 (dd, J = 13.2, 10.1, 1H), 2.86 (d, J = 14.9, 1H),
2.99 (d, J = 14.9, 1H), 3.35 (dd, J = 13.3, 3.2, 1H), 4.07–4.22 (m, 2H), 4.62–4.78 (m, 1H), 7.16–
7.43 (m, 5H). 13C NMR (101 MHz, CDCl3) Ϣ = 29.7, 31.6, 38.2, 46.3, 55.5, 65.9, 127.4, 129.1,
129.5, 135.6, 153.6, 172.0. MS (ESI+) m/z calculated for C16H22NO3 [M+H]+: 276.35; found:
276.08.
(R)-4-Benzyl-3-butyryloxazolidin-2-one (11): Compound 11 was synthesized according to the
general procedure using n-BuLi (2.5 M in hexanes, 6.6 mL, 16.50 mmol), (R)-4-
benzyloxazolidin-2-one (8, 2660 mg, 15.00 mmol) and butyryl chloride (2238 mg, 21.00
mmol). The product was obtained as a colorless oil (3483 mg, 14.08 mmol, 94%). 1H NMR (400
MHz, CDCl3) Ϣ = 1.01 (t, J = 7.4 Hz, 3H), 1.66–1.80 (m, 2H), 2.77 (dd, J = 13.3, 9.7 Hz, 1H),
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2.83–3.01 (m, 2H), 3.30 (dd, J = 13.3, 3.2 Hz, 1H), 4.14–4.24 (m, 2H), 4.63–4.72 (m, 1H), 7.18–
7.36 (m, 5H). 13C NMR (101 MHz, CDCl3) Ϣ = 13.8, 17.8, 37.5, 38.1, 55.3, 66.3, 127.5, 129.1,
129.6, 135.4, 153.6, 173.4. MS (ESI+) m/z calculated for C14H18NO3 [M+NH4]+: 265.33; found:
265.19.
(R)-4-Benzyl-3-(3-methylbutanoyl)oxazolidin-2-one (12): Compound 12 was synthesized
according to the general procedure using n-BuLi (2.5 M in hexanes, 2.8 mL, 7.00 mmol), (R)-
4-benzyloxazolidin-2-one (8, 1050 mg, 5.90 mmol) and 3-methylbutanoyl chloride (787 mg,
6.50 mmol). The product was obtained as a colorless oil (1368 mg, 5.23 mmol, 88%). 1H NMR
(500 MHz, CDCl3) Ϣ = 1.01 (dd, J = 8.3, 6.7, 2H), 2.15–2.29 (m, 1H), 2.71–2.81 (m, 2H), 2.89
(dd, J = 16.2, 6.7, 1H), 3.31 (dd, J = 13.3, 3.3, 1H), 4.09–4.23 (m, 2H), 4.63–4.73 (m, 1H), 7.18–
7.37 (m, 5H). 13C NMR (126 MHz, CDCl3) Ϣ = 22.5, 22.7, 25.1, 38.1, 44.1, 55.3, 66.2, 127.4,
129.0, 129.5, 135.4, 153.5, 172.8. MS (EI) m/z calculated for C15H19NO3 [M]+: 261.32; found:
261.
(R)-4-Benzyl-3-(3,3-dimethylbutanoyl)oxazolidin-2-one (13): Compound 13 was synthesized
according to the general procedure using n-BuLi (2.5 M in hexanes, 3.4 mL, 8.40 mmol), (R)-
4-benzyloxazolidin-2-one (8, 1240 mg, 7.00 mmol) and 3,3-dimethylbutanoyl chloride (1036
mg, 7.70 mmol). The product was obtained as a colorless oil (1876 mg, 6.81 mmol, 97%). 1H
NMR (500 MHz, CDCl3) Ϣ = 1.09 (s, 9H), 2.71 (dd, J = 13.3, 10.0 Hz, 1H), 2.86 (d, J = 14.9 Hz,
1H), 2.99 (d, J = 14.9, 1H), 3.34 (dd, J = 13.3, 3.3 Hz, 1H), 4.10–4.18 (m, 2H), 4.64–4.73 (m,
1H), 7.21–7.36 (m, 5H). 13C NMR (126 MHz, CDCl3) Ϣ = 29.7, 31.5, 38.1, 46.2, 55.5, 65.9, 127.4,
129.0, 129.5, 135.6, 153.6, 172.0. (MS ESI+) m/z calculated for C17H24NO3 [M+H]+: 290.38;
found: 290.13.
General procedure for the synthesis of acyloxazolidinones 14–18: A solution of
diisopropylamine (1.3 eq) in dry THF under argon was cooled to -78 °C. n-BuLi (1.2 eq) was
slowly added to the solution and the reaction mixture was allowed to warm to room
temperature over 60 minutes. After cooling to -80 °C the respective oxazolidinone 9–13 (1.0
eq) was added dropwise to the mixture. After 60 minutes MeI (4.0 eq) was added to the
solution. The reaction mixture was stirred for 5 h without further cooling. The reaction was
quenched with saturated NH4Cl-solution and extracted with EtOAc (3×20 mL). The combined
organic extracts were washed with brine and dried over MgSO4. The crude reaction product
was purified by silica gel column chromatography (cyclohexane/EtOAc 6:1).
(S)-4-Benzyl-3-((S)-2,3-dimethylbutanoyl)oxazolidin-2-one (14): Compound 14 was
synthesized according to the general procedure using diisopropylamine (591 mg, 5.84 mmol),
n-BuLi (2.5 M in hexanes, 2.2 mL, 5.39 mmol), oxazolidinone 9 (1173 mg, 4.49 mmol) and MeI
(2550 mg, 17.96 mmol). Recrystallization of the chromatographically pure product from
cyclohexane gave the diastereomerically enriched product as a colorless solid (dr 20:1, 892 mg,
3.24 mmol, 68%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.90–0.99 (m, 6H), 1.17 (d, J = 6.4 Hz, 3H),
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1.94–2.06 (m, 1H), 2.76 (dd, J = 13.3, 9.7 Hz, 1H), 3.29 (dd, J = 13.3, 3.1 Hz, 1H), 3.54–3.67 (m,
1H), 4.12–4.23 (m, 2H), 4.63–4.74 (m, 1H), 7.19–7.41 (m, 5H). 13C NMR (101 MHz, CDCl3) Ϣ
= 13.9, 18.7, 21.3, 30.7, 37.9, 43.6, 55.6, 66.0, 127.4, 129.0, 129.5, 135.5, 153.2, 177.2. MS (ESI+)
m/z calculated for C15H20NO3 [M+H]+: 262.32; found: 262.17.
(S)-4-Benzyl-3-((S)-2,3,3-trimethylbutanoyl)oxazolidin-2-one (15): Compound 15 was
synthesized according to the general procedure using diisopropylamine (1383 mg, 13.66
mmol), n-BuLi (2.5 M in hexanes, 5.0 mL, 12.50 mmol), oxazolidinone 10 (2895 mg, 10.51
mmol) and MeI (5967 mg, 42.02 mmol). Recrystallization of the chromatographically pure
product from cyclohexane gave the diastereomerically enriched product as a colorless solid (dr
20:1, 2486 mg, 8.59 mmol, 82%). 1H NMR (400 MHz, CDCl3) Ϣ = 1.00 (s, 9H), 1.19 (d, J = 7.0
Hz, 3H), 2.76 (dd, J = 13.3, 9.7 Hz, 1H), 3.27 (dd, J = 13.3, 3.2 Hz, 1H), 3.89 (q, J = 7.0 Hz, 1H),
4.15 (d, J = 4.8 Hz, 2H), 4.62–4.74 (m, 1H), 7.19–7.42 (m, 5H). 13C NMR (101 MHz, CDCl3) Ϣ
= 13.2, 27.5, 33.7, 37.9, 44.8, 55.7, 65.8, 127.4, 129.0, 129.6, 135.5, 153.5, 176.8. MS (ESI+) m/z
calculated for C17H24NO3 [M+H]+: 290.38; found: 290.07.
(R)-4-Benzyl-3-((R)-2-methylbutanoyl)oxazolidin-2-one (16): Compound 16 was synthesized
according to the general procedure using diisopropylamine (1842 mg, 18.20 mmol), n-BuLi
(2.5 M in hexanes, 6.7 mL, 16.80 mmol), oxazolidinone 11 (3460 mg, 14.00 mmol) and MeI
(7949 mg, 56.00 mmol). The product was obtained as a colorless oil (dr 16:1, 2647 mg, 10.13
mmol, 72%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.94 (t, J = 7.4 Hz, 3H), 1.23 (d, J = 6.9 Hz, 3H),
1.42–1.54 (m, 1H), 1.72–1.85 (m, 1H), 2.78 (dd, J = 13.3, 9.6 Hz, 1H), 3.28 (dd, J = 13.3, 3.3 Hz,
1H), 3.60–3.69 (m, 1H), 4.15–4.24 (m, 2H), 4.65–4.72 (m, 1H), 7.20–7.37 (m, 5H). 13C NMR
(101 MHz, CDCl3) Ϣ = 11.8, 17.0, 26.5, 38.0, 39.3, 55.5, 66.1, 127.5, 129.0, 129.6, 135.5, 153.2,
177.3. MS (ESI+) m/z calculated for C15H23N2O3 [M+H]+: 279.35; found: 279.24.
(R)-4-Benzyl-3-((R)-2,3-dimethylbutanoyl)oxazolidin-2-one (17): Compound 17 was
synthesized according to the general procedure using diisopropylamine (658 mg, 6.50 mmol),
n-BuLi (2.5 M in hexanes, 2.4 mL, 6.00 mmol), oxazolidinone 12 (1307 mg, 5.00 mmol) and
MeI (2839 mg, 20.00 mmol). Recrystallization of the chromatographically pure product from
cyclohexane gave the diastereomerically enriched product as a colorless solid (dr 20:1, 2486
mg, 8.59 mmol, 61%). 1H NMR (500 MHz, CDCl3) Ϣ = 0.93 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.7
Hz, 3H), 1.17 (d, J = 6.9 Hz, 3H), 1.94–2.04 (m, 1H), 2.76 (dd, J = 13.3, 9.7 Hz, 1H), 3.28 (dd, J
= 13.4, 3.3 Hz, 1H), 3.59 (quint, J = 6.9 Hz, 1H), 4.13–4.22 (m, 2H), 4.61–4.72 (m, 1H), 7.20–
7.36 (m, 5H). 13C NMR (126 MHz, CDCl3) Ϣ = 13.9, 18.6, 21.3, 30.7, 37.9, 43.6, 55.5, 66.0, 127.4,
129.0, 129.5, 135.4, 153.2, 177.1. MS (ESI+) m/z calculated for C16H22NO3 [M+H]+: 276.36;
found: 276.12.
(R)-4-Benzyl-3-((R)-2,3,3-trimethylbutanoyl)oxazolidin-2-one (18): Compound 18 was
synthesized according to the general procedure using diisopropylamine (896 mg, 8.85 mmol),
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n-BuLi (2.5 M in hexanes, 3.3 mL, 8.17 mmol), oxazolidinone 13 (1876 mg, 6.81 mmol) and
MeI (3866 mg, 27.24 mmol). Recrystallization of the chromatographically pure product from
cyclohexane gave the diastereomerically enriched product as a colorless solid (dr 20:1, 1379
mg, 4.77 mmol, 70%). 1H NMR (500 MHz, CDCl3) Ϣ = 1.00 (s, 9H), 1.19 (d, J = 7.0 Hz, 3H),
2.75 (dd, J = 13.3, 9.7 Hz, 1H), 3.27 (dd, J = 13.3, 3.2 Hz, 1H), 3.88 (q, J = 7.0 Hz, 1H), 4.11–
4.17 (m, 2H), 4.64–4.72 (m, 1H), 7.19–7.36 (m, 5H). 13C NMR (126 MHz, CDCl3) Ϣ = 13.2,
27.5, 33.6, 37.9, 44.7, 55.6, 65.8, 127.4, 129.0, 129.6, 135.5, 153.5, 176.8. MS (ESI+) m/z
calculated for C12H24NO3 [M+H]+: 290.38; found: 290.13.
General procedure for the synthesis of carboxylic acids 19–23: To a cooled solution of LiOH (2.0
eq) and H2O2 (4.0 eq) in water, a solution of acyloxazolidinone 14–18 (1.0 eq) in THF was
added. The reaction was stirred at room temperature for 16 h. The solution was extracted with
DCM (3×15 mL) and the organic phase was discarded. The aqueous phase was acidified and
extracted with DCM (3×15 mL). The combined organic extracts were washed with brine and
dried over MgSO4. The crude reaction product was purified by silica gel column
chromatography (pentane/Et2O 5:1).
(S)-2,3-Dimethylbutanoic acid (19): Compound 19 was synthesized according to the general
procedure using LiOH (184 mg, 4.38 mmol), H2O2 (30% in H2O, 1000 mg, 8.76 mmol) and
intermediate 14 (573 mg, 2.19 mmol). The product was obtained as a colorless liquid (254 mg,
2.19 mmol, 100%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.93 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 6.8 Hz,
3H), 1.13 (d, J = 7.0 Hz, 3H), 1.88–2.02 (m, 1H), 2.22–2.33 (m, 1H). 13C NMR (101 MHz,
CDCl3) Ϣ = 13.5, 19.1, 20.8, 30.9, 46.0, 182.8. MS (ESI-) m/z calculated for C6H11O2 [M-H]-:
115.15; found: 115.15.
(S)-2,3,3-Trimethylbutanoic acid (20): Compound 20 was synthesized according to the general
procedure using LiOH (203 mg, 4.84 mmol), H2O2 (30% in H2O, 1097 mg, 9.68 mmol) and
intermediate 15 (700 mg, 2.42 mmol). The product was obtained as a colorless liquid (313 mg,
2.40 mmol, 99%). 1H NMR (500 MHz, CDCl3) Ϣ = 0.99 (s, 9H), 1.14 (d, J = 7.1 Hz, 3H). 13C
NMR (126 MHz, CDCl3) Ϣ = 12.7, 27.6, 32.7, 49.6, 182.5. MS (ESI-) m/z calculated for C7H13O2
[M-H]-: 129.18; found: 129.16.
(R)-2-Methylbutanoic acid (21): Compound 21 was synthesized according to the general
procedure using LiOH (722 mg, 17.20 mmol), H2O2 (30% in H2O, 3900 mg, 34.40 mmol) and
intermediate 16 (1998 mg, 7.65 mmol). The product was obtained as a colorless liquid (760
mg, 7.44 mmol, 97%). 1H NMR (500 MHz, CDCl3) Ϣ = 0.95 (t, J = 7.5 Hz, 3H), 1.18 (d, J = 7.0
Hz, 3H), 1.45–1.55 (m, 1H), 1.66–1.76 (m, 1H), 2.36–2.44 (m, 1H). 13C NMR (126 MHz,
CDCl3) Ϣ = 11.7, 16.5, 26.7, 41.0, 183.2. MS (ESI-): m/z calculated for C5H9O2 [M-H]-: 101.13;
found: 101.11.
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(R)-2,3-Dimethylbutanoic acid (22): Compound 22 was synthesized according to the general
procedure using LiOH (258 mg, 6.14 mmol), H2O2 (30% in H2O, 1393 mg, 12.28 mmol) and
intermediate 17 (845 mg, 3.07 mmol). The product was obtained as a colorless liquid (332 mg,
2.86 mmol, 93%). 1H NMR (500 MHz, CDCl3) Ϣ = 0.93 (d, J = 6.8 Hz, 3H), 0.96 (d, J = 6.8 Hz,
3H), 1.13 (d, J = 7.0 Hz, 3H), 1.90–2.01 (m, 1H), 2.21–2.30 (m, 1H). 13C NMR (126 MHz,
CDCl3) Ϣ = 13.5, 19.1, 20.8, 30.8, 46.0, 182.8. MS (ESI-) m/z calculated for C6H11O2 [M-H]-:
115.15; found: 115.15.
(R)-2,3,3-Trimethylbutanoic acid (23): Compound 23 was synthesized according to the general
procedure using LiOH (132 mg, 3.14 mmol), H2O2 (30% in H2O, 713 mg, 6.28 mmol) and
intermediate 18 (455 mg, 1.57 mmol). The crude reaction product was purified by silica gel
column chromatography (pentane/Et2O 5:1). The product was obtained as a colorless liquid
(177 mg, 1.36 mmol, 87%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.99 (s, 9H), 1.14 (d, J = 7.1 Hz,
3H), 2.24–2.34 (m, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 12.7, 27.6, 32.7, 49.5, 182.1. MS (ESI-
) m/z calculated for C7H13O2 [M-H]-: 129.18; found: 129.22.
General procedure for the synthesis of alcohols 24–28: A solution of LiAlH4 in Et2O (2.0 eq) was
added dropwise to a cooled solution of the respective carboxylic acid 19–23 (1.0 eq) in dry
Et2O. After stirring for 1 h the reaction was quenched by the addition of H2O and 1 M HCl.
The crude reaction mixture was filtered over Celite and dried over MgSO4.
(S)-2,3-Dimethylbutan-1-ol (24): Compound 24 was synthesized according to the general
procedure using LiAlH4 (1 M in Et2O, 4.0 mL, 4.02 mmol) and carboxylic acid 19 (233 mg, 2.01
mmol). Careful evaporation of the solvent gave the product as a colorless liquid (161 mg, 1.58
mmol, 78%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.83 (d, J = 6.8Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H),
0.91 (d, J = 6.9 Hz, 3H), 1.44–1.54 (m, 1H), 1.64–1.76 (m, 1H), 3.45 (dd, J = 10.5, 7.0 Hz, 1H),
3.59 (dd, J = 10.6, 5.9 Hz, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 12.6, 18.1, 20.7, 28.9, 41.5, 66.7.
(S)-2,3,3-Trimethylbutan-1-ol (25): Compound 25 was synthesized according to the general
procedure using LiAlH4 (1 M in Et2O, 10.0 mL, 10.00 mmol) and carboxylic acid 20 (1118 mg,
8.59 mmol). Careful evaporation of the solvent gave the product as a colorless liquid (950 mg,
8.17 mmol, 95%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.88 (s, 9H), 0.94 (d, J = 6.8 Hz, 3H), 1.35–
1.45 (m, 1H), 3.28–3.36 (m, 1H), 3.82 (dd, J = 10.3, 3.7 Hz, 1H). 13C NMR (101 MHz, CDCl3)
Ϣ = 12.5, 27.8, 32.2, 45.7, 65.5.
(R)-2-Methylbutan-1-ol (26): Compound 26 was synthesized according to the general
procedure using LiAlH4 (1 M in Et2O, 7.2 mL, 7.20 mmol, 1.2 eq) and carboxylic acid 23 (613
mg, 6.00 mmol). Careful evaporation of the solvent gave the product as a colorless liquid (493
mg, 5.60 mmol, 93%). 1H NMR (500 MHz, CDCl3) Ϣ = 0.89–0.93 (m, 6H), 1.10–1.24 (m, 1H),
1.41–1.49 (m, 1H), 1.51–1.59 (m, 1H), 3.39–3.54 (m, 2H). 13C NMR (126 MHz, CDCl3) Ϣ =
11.5, 16.3, 25.9, 37.5, 68.2.
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(R)-2,3-Dimethylbutan-1-ol (27): Compound 27 was synthesized according to the general
procedure using LiAlH4 (1 M in Et2O, 6.0 mL, 6.00 mmol) and carboxylic acid 22 (326 mg, 2.81
mmol). Careful evaporation of the solvent gave the product as a colorless liquid (176 mg, 1.72
mmol, 61%). 1H NMR (500 MHz, CDCl3) Ϣ = 0.83 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H),
0.91 (d, J = 6.9 Hz, 3H), 1.45–1.54 (m, 1H), 1.65–1.73 (m, 1H), 3.44 (dd, J = 10.6, 7.0 Hz, 2H),
3.59 (dd, J = 10.6, 5.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) Ϣ = 12.6, 18.1, 20.7, 28.9, 41.5, 66.7.
(R)-2,3,3-Trimethylbutan-1-ol (28): Compound 28 was synthesized according to the general
procedure using LiAlH4 (1 M in Et2O, 2.7 mL, 2.70 mmol) and carboxylic acid 23 (177 mg, 1.36
mmol). Careful evaporation of the solvent gave the product as a colorless liquid (106 mg, 0.91
mmol, 67%). 1H NMR (500 MHz, CDCl3) Ϣ = 0.88 (s, 9H), 0.95 (d, J = 6.9 Hz, 3H), 1.37–1.45
(m, 1H), 3.33 (dd, J = 10.4, 8.8 Hz, 1H), 3.82 (dd, J = 10.4, 3.9 Hz, 1H). 13C NMR (126 MHz,
CDCl3) Ϣ = 12.5, 27.8, 32.2, 45.8, 65.5.
General procedure for the synthesis of Intermediates 34–38: PPh3 (3.0 eq) was dissolved in dry
THF and cooled to -15 °C. DEAD (1.4 eq) was added to the solution without the temperature
exceeding -10 °C. After 30 minutes the respective alcohol was added to the reaction mixture
and it was stirred at -15 °C for another 90 minutes. DPPA (1.5 eq) was slowly added to the
solution and the reaction was held at -15 °C for further 4 h and then allowed to warm to RT
overnight. Water (3 mL) was added to the solution and the mixture was stirred for 48 h. The
crude reaction mixture was diluted with EtOAc and extracted with 1 M HCl (3×10 mL). The
aqueous phases were combined and the pH was adjusted to 12. The basic mixture was extracted
with DCM (3×15 mL). The combined organic phases were washed with brine and dried over
K2CO3. Boc-Leu-OH (1.0 eq), EDC (1.3 eq), HOBt (1.3 eq) and DIPEA (3.0 eq) were added to
the DCM phase and the mixture was stirred at rt overnight. The solution was diluted with
EtOAc and extracted with 1 M HCl (3×10 mL) and sat. NaHCO3 (3×10 mL). The combined
organic phases were washed with brine and dried over MgSO4. The crude product was purified
by silica gel column chromatography (cyclohexane/EtOAc 7:1).
tert-Butyl ((S)-1-(((S)-2,3-dimethylbutyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (34):
Intermediate 34 was synthesized according to the general procedure using PPh3 (1141 mg, 4.35
mmol), DEAD (354 mg, 2.03 mmol), alcohol 24 (148 mg, 1.45 mmol), DPPA (600 mg, 2.18
mmol), Boc-Leu-OH (335 mg, 1.45 mmol), EDC (362 mg, 1.89 mmol), HOBt (255 mg, 1.89
mmol), DIPEA (562 mg, 4.35 mmol). The product was obtained as a colorless solid (119 mg,
0.38 mmol, 26%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.80–0.85 (m, 6H), 0.88–0.95 (m, 9H), 1.43
(s, 9H), 1.46–1.79 (m, 5H), 2.99–3.29 (m, 2H), 3.92–4.15 (m, 1H), 4.84 (br, 1H), 6.12 (br, 1H).
13C NMR (101 MHz, CDCl3) Ϣ = 13.6, 17.9, 20.5, 22.2, 22.9, 24.8, 28.4, 30.0, 39.0, 41.1, 43.5,
53.2, 80.1, 155.9, 172.6. MS (ESI+) m/z calculated for C17H35N2O3 [M+H]+: 315.48; found:
315.20.
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tert-Butyl ((S)-1-(((S)-2,3,3-trimethylbutyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate
(35): Intermediate 35 was synthesized according to the general procedure using PPh3 (2361
mg, 9.00 mmol), DEAD (731 mg, 4.20 mmol), alcohol 25 (345 mg, 3.00 mmol), DPPA (1238
mg, 4.50 mmol), Boc-Leu-OH (694 mg, 3.00 mmol), EDC (748 mg, 3.90 mmol), HOBt (527
mg, 3.90 mmol), DIPEA (1163 mg, 9.00 mmol). The product was obtained as a colorless solid
(319 mg, 0.97 mmol, 32%). 1H NMR (500 MHz, CDCl3) Ϣ = 0.85 (d, J = 6.8 Hz, 3H), 0.89 (s,
9H), 0.91–0.95 (m, 6H), 1.34–1.41 (m, 1H), 1.43 (s, 9H), 1.62–1.72 (m, 2H), 2.89–2.98 (m, 1H),
3.37–3.48 (m, 1H), 4.00–4.10 (m, 1H), 4.87 (br, 1H), 6.07–6.18 (m, 1H). 13C NMR (126 MHz,
CDCl3) Ϣ = 13.1, 22.2, 23.0, 24.9, 27.5, 28.4, 32.5, 41.1, 41.9, 43.3, 53.3, 80.1, 155.9, 172.6. MS
(ESI+) m/z calculated for C18H37N2O3 [M+H]+: 329.50; found: 329.19.
tert-Butyl ((S)-4-methyl-1-(((R)-2-methylbutyl)amino)-1-oxopentan-2-yl)carbamate (36):
Intermediate 36 was synthesized according to the general procedure using PPh3 (2361 mg, 9.00
mmol), DEAD (731 mg, 4.20 mmol), alcohol 26 (264 mg, 3.00 mmol), DPPA (1238 mg, 4.50
mmol), Boc-Leu-OH (694 mg, 3.00 mmol), EDC (748 mg, 3.90 mmol), HOBt (527 mg, 3.90
mmol), DIPEA (1163 mg, 9.00 mmol). The product was obtained as a colorless solid (327 mg,
1.09 mmol, 36%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.85–0.96 (m, 12H), 1.08–1.20 (m, 1H),
1.32–1.40 (m, 1H), 1.43 (s, 9H), 1.49–1.61 (m, 2H), 1.61–1.73 (m, 2H), 3.02–3.23 (m, 2H), 3.99–
4.11 (m, 1H), 4.84–4.94 (m, 1H), 6.19 (s, 1H). 13C NMR (101 MHz, CDCl3) Ϣ = 11.4, 17.2, 22.3,
23.0, 24.9, 27.0, 28.4, 35.0, 41.1, 45.1, 53.3, 80.1, 156.0, 172.7. MS (ESI+) m/z calculated for
C16H33N2O3 [M+H]+: 301.45; found: 301.28.
tert-Butyl ((S)-1-(((R)-2,3-dimethylbutyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (37):
Intermediate 37 was synthesized according to the general procedure using PPh3 (1251 mg, 4.77
mmol), DEAD (388 mg, 2.23 mmol), alcohol 27 (162 mg, 1.59 mmol), DPPA (658 mg, 2.39
mmol), Boc-Leu-OH (368 mg, 1.59 mmol), EDC (397 mg, 2.07 mmol), HOBt (280 mg, 2.07
mmol), DIPEA (617 mg, 4.77 mmol). The product was obtained as a colorless solid (136 mg,
0.43 mmol, 22%). 1H NMR (500 MHz, CDCl3) Ϣ = 0.81–0.85 (m, 6H), 0.90 (d, J = 6.8 Hz, 3H),
0.91–0.95 (m, 6H), 1.43 (s, 9H), 1.45–1.54 (m, 1H), 1.55–1.64 (m, 1H), 1.64–1.75 (m, 2H), 3.02–
3.12 (m, 1H), 3.17–3.31 (m, 1H), 3.99–4.08 (m, 1H), 4.87 (br, 1H), 6.16 (br, 1H). 13C NMR (126
MHz, CDCl3) Ϣ = 13.59, 17.98, 20.57, 22.28, 22.98, 24.88, 28.41, 30.07, 38.99, 41.13, 43.53, 53.27,
80.08, 155.95, 172.63. MS (ESI+) m/z calculated for C17H35N2O3 [M+H]+: 315.48; found:
315.05.
tert-Butyl ((S)-1-(((R)-2,3,3-trimethylbutyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate
(38): Intermediate 38 was synthesized according to the general procedure using PPh3 (716 mg,
2.73 mmol), DEAD (222 mg, 1.27 mmol), alcohol 28 (106 mg, 0.91 mmol), DPPA (377 mg,
1.37 mmol), Boc-Leu-OH (210 mg, 0.91 mmol), EDC (227 mg, 1.18 mmol), HOBt (159 mg,
1.18 mmol), DIPEA (353 mg, 2.73 mmol). The product was obtained as a colorless solid (80
mg, 0.24 mmol, 27%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.85 (d, J = 6.9 Hz, 3H), 0.88 (s, 9H),
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0.90–0.96 (m, 6H), 1.32–1.40 (m, 2H), 1.43 (s, 9H), 1.58–1.75 (m, 2H), 2.88–2.97 (m, 1H), 3.38–
3.49 (m, 1H), 3.99–4.14 (m, 1H), 4.86–4.97 (m, 1H), 6.17 (br, 1H). 13C NMR (101 MHz, CDCl3)
Ϣ = 13.1, 22.3, 23.0, 24.9, 27.5, 28.4, 32.6, 41.1, 42.0, 43.3, 53.3, 80.2, 155.9, 172.6. MS (ESI+)
m/z calculated for C18H37N2O3 [M+H]+: 329.50; found: 329.25.
General procedure for phosphonamidate coupling and deprotection: SOCl2 (4.5 eq) was
dissolved in 5 mL dry DCM under argon and cooled to 0 °C. A solution of benzyl
((hydroxy(methoxy)phosphoryl)methyl)carbamate (3 eq) was added to the solution over 30
minutes. The cooling bath was removed and the reaction was stirred at rt for 3-5 h. All volatile
components were removed under reduced pressure. In a second flask, peptidic intermediates
34–38 (1 eq) was treated with HCl (4 M in dioxane,) for 1 h. All volatile components were
removed under reduced pressure. The activated phosphonic acid was dissolved in dry DCM.
DIPEA and the deprotected leucylamide were added to the solution consecutively. The mixture
was heated to 40 °C and stirred overnight. The solution was diluted with EtOAc and extracted
with 5% citric acid (3×10 mL), 1 M HCl (1×10 mL) and 1 M NaOH (3×10 mL). The organic
phase was washed with brine and dried over MgSO4. The crude product was used in the next
step without further purification. The protected phosphonamidate was treated with 3mL of a
0.4 M solution of LiOH in water. If needed, MeCN was added until the solution cleared. The
reaction was stirred for 4-5 h at rt. Under ice cooling the pH was adjusted to 8 using 5% AcOH
and the solvent was removed under reduced pressure. The residue was dissolved in a small
amount of water and purified by semi-preparative HPLC.
Phosphonamidate 2: Ligand 2 was synthesized according to the general procedure using
phosphonic acid monoester 39 (249 mg, 0.96 mmol), SOCl2 (171 mg, 1.44 mmol), intermediate
34 (100 mg, 0.32 mmol), HCl (4 M in dioxane, 1 mL, 4 mmol) and DIPEA (124 mg, 0.96 mmol).
The product was obtained as a colorless solid (45 mg, 0.10 mmol, 31%). 1H NMR (500 MHz,
D2O) Ϣ = 0.84 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 6.7 Hz, 3H), 0.92–0.98 (m, 9H), 1.44–1.52 (m,
1H), 1.52–1.76 (m, 4H), 3.04 (dd, J = 13.2, 8.0 Hz, 1H), 3.20 (dd, J = 13.4, 6.0 Hz, 1H), 3.26–
3.40 (m, 2H), 3.67–3.75 (m, 1H), 5.20 (s, 2H), 7.45–7.56 (m, 5H). 13C NMR (126 MHz, D2O) Ϣ
= 12.7, 17.1, 19.8, 21.5, 22.3, 24.3, 29.5, 38.3, 39.9 (d, J = 136.0), 43.5, 43.7, 43.7, 54.3, 67.3, 127.9,
128.5, 128.9, 136.5, 158.3, 177.8. 31P NMR (202 MHz, D2O) Ϣ = 18.0. HRMS (ESI+) calculated
for C21H35N3O5P [M+H]+: 440.2320; found: 440.2323.
Phosphonamidate 3: Ligand 3 was synthesized according to the general procedure using
phosphonic acid monoester 39 (207 mg, 0.80 mmol), SOCl2 (190 mg, 1.60 mmol), intermediate
35 (131 mg, 0.40 mmol), HCl (4 M in dioxane, 1 mL, 4 mmol) and DIPEA (155 mg, 1.20 mmol).
The product was obtained as a colorless solid (68 mg, 0.15 mmol, 37%). 1H NMR (500 MHz,
D2O) Ϣ = 0.75 (d, J = 6.9 Hz, 3H), 0.81 (s, 9H), 0.82–0.86 (m, 6H), 1.30–1.41 (m, 2H), 1.42–
1.52 (m, 1H), 1.53–1.65 (m, 1H), 2.84 (dd, J = 12.5, 11.0 Hz, 1H), 3.22 (dd, J = 11.8, 5.7 Hz,
2H), 3.27 (dd, J = 13.1, 3.4 Hz, 1H), 3.55–3.64 (m, 1H), 5.09 (s, 2H), 7.33–7.44 (m, 5H). 13C
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NMR (126 MHz, D2O) Ϣ = 12.4, 21.5, 22.3, 24.3, 26.7, 31.8, 40.0 (d, J = 136.3), 42.0, 42.6, 43.7,
43.7, 54.3, 67.2, 127.8, 128.5, 128.9, 136.5, 158.3, 177.8. 31P NMR (202 MHz, D2O) Ϣ = 18.0.
HRMS (ESI+) calculated for C22H37N3O5P: 454.2476 [M+H]+; found: 454.2478.
Phosphonamidate 4: Ligand 4 was synthesized according to the general procedure using
phosphonic acid monoester 39 (117 mg, 0.45 mmol), SOCl2 (81 mg, 0.68 mmol), intermediate
36 (45 mg, 0.15 mmol), HCl (4 M in dioxane, 1 mL, 4 mmol) and DIPEA (58 mg, 0.45 mmol).
The product was obtained as a colorless solid (25 mg, 0.06 mmol, 37%). 1H NMR (500 MHz,
MeOD) Ϣ = 0.85–0.98 (m, 12H), 1.09–1.19 (m, 1H), 1.35–1.48 (m, 2H), 1.52–1.63 (m, 2H),
1.72–1.82 (m, 1H), 2.93–3.04 (m, 1H), 3.09 (dd, J = 13.2, 6.3 Hz, 1H), 3.18–3.29 (m, 2H), 3.67–
3.76 (m, 1H), 5.04–5.14 (m, 2H), 7.25–7.41 (m, 5H). 13C NMR (126 MHz, MeOD) Ϣ = 11.6,
17.5, 22.5, 23.5, 25.7, 28.1, 36.1, 41.2, 42.3, 45.3 (d, J = 5.3), 46.2, 55.5, 67.6, 128.9, 129.0, 129.4,
138.3, 158.8, 178.2. 31P NMR (202 MHz, MeOD) Ϣ = 16.4. HRMS (ESI+) calculated for
C20H33N3O5P: 426.2163 [M+H]+; found: 426.2166.
Phosphonamidate 5: Ligand 5 was synthesized according to the general procedure using
phosphonic acid monoester 39 (249 mg, 0.96 mmol), SOCl2 (171 mg, 1.44 mmol), intermediate
37 (100 mg, 0.32 mmol), HCl (4 M in dioxane, 1 mL, 4 mmol) and DIPEA (124 mg, 0.96 mmol).
The product was obtained as a colorless solid (37 mg, 0.08 mmol, 26%). 1H NMR (500 MHz,
D2O) Ϣ = 0.84 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 6.7 Hz, 3H), 0.92–0.98 (m, 9H), 1.44–1.77 (m,
5H), 3.04 (dd, J = 13.3, 8.0 Hz, 1H), 3.20 (dd, J = 13.3, 6.0 Hz, 1H), 3.27–3.41 (m, 2H), 3.67–
3.74 (m, 1H), 5.20 (s, 2H), 7.45–7.55 (m, 5H). 13C NMR (126 MHz, D2O) Ϣ = 12.7, 17.1, 19.8,
21.5, 22.3, 24.3, 29.5, 38.3, 39.9 (d, J = 135.9), 43.5, 43.7, 43.7, 54.3, 67.3, 127.9, 128.5, 128.9,
136.5, 158.3, 177.8. 31P NMR (202 MHz, D2O) Ϣ = 18.0. HRMS (ESI+) calculated for
C21H35N3O5P [M+H]+: 440.2322; found: 440.2323.
Phosphonamidate 6: Ligand 6 was synthesized according to the general procedure using
phosphonic acid monoester 39 (156 mg, 0.60 mmol), SOCl2 (107 mg, 0.90 mmol), intermediate
38 (65 mg, 0.20 mmol), HCl (4 M in dioxane, 1 mL, 4 mmol) and DIPEA (78 mg, 0.60 mmol).
The product was obtained as a colorless solid (29 mg, 0.06 mmol, 31%). 1H NMR (500 MHz,
D2O) Ϣ = 0.75 (d, J = 6.9 Hz, 3H), 0.82 (s, 9H), 0.83–0.87 (m, 6H), 1.32–1.41 (m, 2H), 1.43–
1.50 (m, 1H), 1.55–1.64 (m, 1H), 2.84 (dd, J = 12.9, 10.7 Hz, 1H), 3.18–3.31 (m, 3H), 3.56–3.63
(m, 1H), 5.09 (s, J = 16.7 Hz, 2H), 7.33–7.44 (m, 5H). 13C NMR (101 MHz, D2O) Ϣ = 12.2, 21.3,
22.1, 24.1, 26.5, 31.6, 39.8 (d, J = 135.7), 41.8, 42.5, 43.6, 54.2, 67.1, 127.7, 128.4, 128.8, 136.2,
152.8, 172.5. 31P NMR (162 MHz, D2O) Ϣ = 17.9. HRMS (ESI+) calculated for C22H37N3O5P:
454.2476 [M+H]+; found: 454.2481.
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Crystal Preparation and Soaking
TLN crystals were prepared similarly to the procedure as previously described [156].
Lyophilized TLN powder was commercially obtained from Calbiochem (EMD Biosciences).
For crystal preparation, 1 mL of demineralized water was pipetted into the reservoir wells of a
24 well sitting drop crystallization plate (Cryschem, Hampton research). An 8 mM protein
suspension was prepared by adding TLN powder to 50 µL of pure DMSO. To the resulting
suspension, 50 µL of an aqueous solution containing 3.8 M CsCl and 100 mM Tris-HCl, pH
7.5 were added. The TLN powder was completely dissolved by mixing with an Eppendorf
pipette, resulting in a clear solution of yellowish color. After centrifugation for 3 min (RCF =
16000 g), 1 µL of clear solution was transferred into each of the protein wells of the crystal
plate. Subsequently, the crystal plate was sealed and TLN crystals stopped growing after five
days at 18 °C. For ligand soaking, crystals with an obelisk shape were transferred into a soaking
solution composed of 100 mM Tris-HCl, pH 7.5, 2 mM CaCl2, 5% DMSO and 1 mM of the
respective ligand followed by incubation for 24 h. Afterwards, crystals were transferred into a
cryo buffer composed of 10 mM Tris/HCl, pH 7.5, 10 mM Ca(CH3COO)2, 5% DMSO, 20%
glycerol and 1 mM of the respective ligand for 5 s and subsequently flash-frozen in liquid
nitrogen. For the glycerol-free crystal structures (Chapter 3.10.2, Supporting Information),
either 30% PEG400 or 20% MPD was used as cryoprotectant instead of glycerol.
Data Collection and Refinement
Data collection of datasets TLN-2GOL, TLN-3GOL, TLN-4GOL, TLN-5GOL,TLN-6GOL, TLN-3PEG400,
and TLN-6MPD was performed with synchrotron radiation at the BESSY II electron storage ring
(Berlin-Adlershof, Germany) operated by the Joint Berlin MX-Laboratory [157] at beamline
14.1 with a wavelength of 0.91841 Å at cryogenic temperature of 100 K on an Dectris Pilatus
6M pixel detector. Dataset TLN-5MPD was collected at Elettra (Trieste, Italy) at beamline XRD1
with a wavelength of 1.0000 Å at cryogenic temperature of 100 K on a Dectris Pilatus 2M pixel
detector. Data collection and refinement statistics for the glycerol-containing crystal structures
are listed in Table 3.1 and for the glycerol-free crystal structures in Table S3.1 (Supporting
Information). Data indexing, integration and scaling was performed with XDS [158].
Molecular replacement was performed with Phaser [159] from the CCP4 software suite version
6.3.0 [137]. A TLN search model from the PDB entry 8TLN was used [160], with flexible side-
chains, additives, water molecules and ions removed. Alternating cycles of model building and
refinement were performed with Coot [161] and phenix.refine version 1.10.1-2155 [162],
respectively, until the models optimally explained the electron densities and their R values
reached convergence. For cross-validation, a randomly chosen 5% of the reflections, which
were not applied for model refinement, were used for the calculation of Rfree. As an initial
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refinement step, Cartesian simulated annealing was performed (start temperature 5000 K, final
temperature 300 K). All macromolecule amino acids were refined with riding hydrogen atoms
which were added to the refinement model coordinates with phenix.refine. In all structures, B
factors of all atoms except for hydrogen atoms were refined anisotropically, since this resulted
in a significant decrease of the Rfree value compared to an isotropically refinement of the B
factors. Ligand molecule building and minimization was performed with MOE version 2014.09
[151], and restraints were prepared with phenix.elbow [163]. Fo–Fc omit electron densities were
created by deletion of parts of the refinement model followed by refinement with phenix.refine.
The graphical representations of the three dimensional structures were prepared with PyMOL
[164].
Isothermal Titration Calorimetry Measurements
ITC titrations were performed based on established protocols introducing some modifications
[15,93,94,96]. For all measurements, the same Microcal ITC200 device (GE Healthcare) was
used. Lyophilized powder of native TLN expressed by Bacillus thermoproteolyticus was bought
from Calbiochem (EMD Biosciences). The protein purity was 60%, additionally containing
Ca(CH3COO)2 and Na(CH3COO). The powder was weighed with a MX5 balance from Mettler
Toledo (readability ± 1 µg) and directly dissolved in measurement buffer without further
processing, as the additional salts did not show any interfering heat effects during the
measurement [15]. All measurements were performed in a buffer composed of 200 mM
NaSCN, 2 mM CaCl2 and 20 mM HEPES, pH 7.5, which was filtered through a 0.22 µm filter
and degassed prior to use. A TLN concentration of 30 µM was used in the titration cell,
resulting in titration curves described by optimal c values in the range of 73 (ligand 4) to 201
(ligand 3). The relatively narrow affinity range of the studied ligands made it possible to keep
the TLN concentration constant during all measurements, which is important to guarantee a
similar activity coefficient of the protein in solution [96]. The ligand solution was prepared by
directly weighing the highly pure, freeze dried ligand powder and dissolving it in measurement
buffer (without the addition of DMSO). For each measurement, new freeze-dried protein and
ligand powder was freshly dissolved in measurement buffer. For highest measurement
precision, a 10 injections scheme with an injection volume of 1.3–1.4 µL and a ligand
concentration in the syringe of 1 mM was applied [165]. This measurement protocol resulted
in injections with strong heat signals exhibiting lower standard deviations compared to a
conventional 25 injection scheme. At the end of the titration, a titrant to titrand ratio of at least
2.2 was achieved. After filling of the syringe with ligand solution and prior to injection of the
syringe into the measurement cell, a manual 1.0 µL injection was performed outside of the
measurement cell in order to adjust the syringe drive mechanism from the a “up” to a “down”
movement in order to increase the precision of the first injection [166]. Furthermore, the
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measurement scheme contained an initial injection of 0.3 µL, which was excluded from data
analysis. The measurement settings were adjusted to an initial spacing of 150–200 s, a spacing
of 150–160 s between the injections, an injection speed of 2.6–2.8 s (depending on the injection
volume), a syringe speed of 1000 rpm, a reference power of 5 µcal s–1 and a measurement
temperature of 298.15 K. Peak extraction and integration was automatically performed with
NITPIC version 1.1.2 [167]. The fitting of a 1:1 binding model curve and binding parameter
extraction was performed with SEDPHAT version 12.1b [168] and plots of the raw data and
binding isotherms were prepared with GUSSI [169] (Figure S3.5, Supporting Information). For
the study of the influence of glycerol on the thermodynamic binding profiles of 2, 3, 5 and 6,
buffers composed of 200 mM NaSCN, 2 mM CaCl2, 20 mM HEPES, pH 7.5 and a glycerol
concentration of 1%, 2.5%, 5% or 10% were used. For the titrations of 3 and 6 with the addition
of DMSO, buffers composed of 200 mM NaSCN, 2 mM CaCl2, 20 mM HEPES, pH 7.5 and a
DMSO concentration of 0.065 M or 0.130 M DMSO were used. All measurements were
performed in triplicate, from which the mean and the standard deviation were calculated.
Surface Plasmon Resonance Measurements
SPR measurements were performed on a Biacore T200 system (GE Healthcare, Sweden) with
analysis and sample compartment temperature set to 25 °C. The binding kinetic assay was
developed as a capture assay of biotinylated TLN utilizing the Biotin CAPture Kit (GE
Healthcare) combined with single cycle kinetics of the inhibitors. For the biotinylation process,
lyophilized powder of native TLN (Calbiochem, see above) was dissolved to approximately 0.5
µg mL–1 in 0.1 M sodium borate buffer pH 8.5 supplemented with 2 mM CaCl2 and
preincubated with excess molar concentration of a high affinity TLN-inhibitor to protect the
binding site from biotinylation. The biotinylation reaction was set up using the EZ-Link Sulfo-
NHS-LC-Biotin reagent (Pierce) with a 0.6 biotin/protein molar ratio. Following incubation
for 1 h at room temperature, the labelled protein was purified from non-reacted biotin reagents
by desalting on a PD-10 column according to the manufacturer’s instructions (GE Healthcare)
to 50 mM Tris pH 8.0, 100 mM NaSCN, 2 mM CaCl2. Concentration of purified TLN-biotin
was determined using the mean value of triplicate absorbance readings at 280 nm on a ND1000
spectrometer (Nanodrop). Aliqous of TLN-biotin were kept at 4 °C for use within the next two
days, alternatively flash frozen in liquid nitrogen for storage at -70 °C. Before use, TLN-biotin
was defrosted on ice if frozen and centrifuged in a bench top centrifuge at high speed for 5 min
at 4 °C.
Sensor Chip CAP was docked in the Biacore and prepared according to the manufacturer’s
instructions. For each day of SPR measurements, new dilutions of inhibitors from 10 mM stock
solutions in 100% DMSO (stored at -20 °C) and TLN-biotin, were made using freshly prepared
buffer. 50 mM Tris pH 8.0, 100 mM NaSCN, 2 mM CaCl2, 2% DMSO was used as sample and
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running buffer. Runs included three start-up cycles and each analysis cycle contained 4 steps:
(1) injection of Biotin CAPture reagent (streptavidin modified with a deoxyriboologonucletide
that hybridizes with the complimentary oligonucleotide present on the Sensor Chip CAP) in
both reference and active flow cells for 300 s and at 2 µl min–1 resulting in response levels of
around 3000 RU, (2) injection of 150–200 Ϫg mL–1 TLN-biotin at 10 ϪL min–1 for 90–180 s in
active flow cell only resulting in capture levels of 800–1200 RU (a capture stabilization time of
300 s was applied for some runs), (3) injection of inhibitor in increasing concentration over
reference and active flow cell using a single cycle kinetics procedure with five 120 s injections
at 30 ϪL min–1 and a 240 s dissociation time after the final injection, and (4) injection of
standard (6 M guanidine-HCl, 0.25 M NaOH) and additional (30% acetonitrile in 0.25 M
NaOH) regeneration solutions to remove the Biotin Cap Reagent, TLN-biotin and any bound
inhibitor from both flow cells. Inhibitor concentrations in the range of 156–2500 nM were used
for 1, 25–2000 nM for 2 and 5 and 156–10000 nM for 3 and 6. Blank cycles defined as analysis
cycles with buffer only in step (3), were performed first, last and between every inhibitor
concentration series. Data were double referenced by first subtraction of reference flow cell
and then subtraction of blank cycles. Fitting of data was performed using Biacore T200
evaluation software 2.0, applying a 1:1 binding model compensating for linear drift.
Calculation of Buried Solvent Accessible Surface Areas
The total and buried SASAs of 1–6 (Figure 3.10) were calculated with the PISA server from the
European Bioinformatics Institute [170]. The buried solvent accessible surface area is defined
as the SASA of the ligand which becomes inaccessible to water molecules (radius 1.4 Å)
through binding of the ligand to the protein cavity. From the disordered ligand’s carbamate
group, only the orientation with the carbonyl oxygen directed to the right (relative to the view
of Figure 3.4) was considered for the calculation of the surface. Furthermore, the zinc ion,
crystallographic additives (glycerol, DMSO) and the crystallographic symmetry mate were
considered for the calculations, whereas hydrogen atoms were excluded from the calculation.
ASSOCIATED CONTENT
3.7 Accession Codes
All described crystal structures were deposited in the PDB [171] and are available upon article
publication under the accession codes 5JT9 (TLN-2GOL), 5JS3 (TLN-3GOL), 5JXN (TLN-4GOL),
5JVI (TLN-5GOL), 5JSS (TLN-6GOL), 5L8P (TLN-3PEG400), 5L41 (TLN-5MPD), and 5L3U (TLN-
6MPD).
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3.10 Supporting Information
Fo–Fc omit electron densities of TLN-bound ligands 1–6
Figure S3.1 (related to Figure 3.4). Crystal structures of TLN bound ligands (A) 1, (B) 2, (C) 3, (D)
4, (E) 5, and (F) 6. Ligands are shown as stick models with carbon atoms in blue and color-coded
heteroatoms. Their Fo–Fc omit electron densities are displayed as gray meshes at a contour level of
3σ. In all six crystal structures, the carbamate group of the bound ligands adopts two conformations.
Moreover, the P2’ group of 2 adopts two conformations and one terminal methyl group of the P2’
group of 5 is not detectable in the electron density. The crystal structure of 1 has been published
previously [15].
136 | Chapter 3
Glycerol-free crystal structures TLN-3PEG400, TLN-5MPD and TLN-6MPD
Figure S3.2. Comparison of the positions of the water molecules in the glycerol-containing and
glycerol-free crystal structures of (A) TLN-3, (B) TLN-5 and (C) TLN-6. Structural elements of the
glycerol-containing crystal structures (blue) are superimposed on structural elements of the
glycerol-free crystal structures (red). Ligand and glycerol molecules are displayed as stick models,
water molecules as spheres. Distances ≤ 3.4 Å between water molecules are displayed as dotted
lines indicating H-bonds. The Fo–Fc omit electron densities are shown as meshes at a contour level
of 3σ in colors corresponding to the structures. For clarity reason, structural elements beyond the
first solvation layer around all ligand P2’ groups and the glycerol molecules are displayed in pale
colors and their electron densities are omitted. The solvent excluded surface of the glycerol-
containing TLN crystal structure is displayed in white. The binding modes of the ligands in the
glycerol-containing and glycerol-free crystal are identical and only minor differences in the adjacent
water structures are observed. In TLN-5MPD (panel B, red), water molecule W5 is observed in the
electron density (highly mobile, non-normalized B factor of 49 Å2), whereas the electron density of
TLN-5GOL (panel B, blue) is too weak for the placement of a water molecule at this position in the
refinement model. Furthermore, in TLN-6MPD (panel C, red), the electron density is too weak for the
placement of water molecules W10 and W13, whereas in TLN-6GOL (panel C, blue) these two water
molecules are sufficiently stabilized for placement in the refinement model (highly mobile, see
Figure 3.5 of the main text). Fo–Fc omit electron densities of the TLN-bound ligands of the glycerol-
free crystal structures are displayed in Figure S3.3.
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Figure S3.3. Crystal structures of the TLN-bound inhibitors (A) TLN-3PEG400, (B) TLN-5MPD and (C) TLN-
6MPD. Ligands are shown as stick models with carbon atoms in blue and color-coded heteroatoms.
The Fo–Fc omit electron densities are displayed as gray meshes at contour levels of 2.5σ for 3 and
3.0σ for 5 and 6. The carboxybenzyl portion of 3 shows a second conformation B (30% occupancy),
occupying the space where a DMSO molecule is found in the other crystal structures (Figure S3.4).
After refinement of the model of TLN-3 against the diffraction data, a positive, featureless Fo–Fc
electron density blob remains in position of the 2Fo–Fc electron density of the phenyl ring of the
carboxybenzyl group in conformation B. Since the electron density reflects the average of all
conformations that a structural element adopts in the protein crystal, the unexplained Fo–Fc electron
density at the position of the phenyl ring most likely originates from a DMSO molecule binding to
this site in case 3 adopts conformation A. The electron density of ligand 5 indicates the missing
terminal P2’ methyl group by a weak Fo–Fc electron density (black arrow), which, however, is not
sufficient for placement of this methyl group in the refinement model.
138 | Chapter 3
Figure S3.4. Superimposition of crystal structures of (A) TLN-3GOL (blue) and TLN-3PEG400 (orange), (B)
TLN-5GOL (blue) and TLN-5MPD (orange), and (C) TLN-6GOL (blue) and TLN-6MPD (orange). Heteroatoms
are color-coded. The three spheres superimposed on the glycerol (GOL) hydroxyl groups represent
water molecules bound to the TLN S1 pocket in the superimposed glycerol-free crystal structure. As
a result of the reduced steric requirement of the three water molecules compared to the glycerol
molecule, the carboxybenzyl portion of the ligands in the glycerol-free crystal structures is buried
more deeply in the S1 pocket of TLN and adopts only a single, fully occupied conformation.
Nevertheless, the binding mode of the leucine and P2’ portions of the ligands in the glycerol-
containing and glycerol-free crystal structures are completely identical and consequently exert
similar influences on the water network establishment in the TLN S2’ pocket.
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Table S3.1. Data collection and refinement statistics for the glycerol-free crystal structures TLN-
2PEG400, TLN-5MPD and TLN-6MPD.a
Complex (PDB code)
TLN-3PEG400
(5L8P)
TLN-5MPD
(5L41)
TLN-6MPD
(5L3U)
(A) Data collection and processing
Space group P6122 P6122 P6122
Unit cell parameters
a, b, c (Å) 92.6, 92.6, 130.4 92.6, 92.6, 130.8 92.8, 92.8, 131.1
Matthews coefficient (Å3/Da)b 2.3 2.3 2.4
Solvent content (%)b 47 48 48
(B) Diffraction data
Resolution range (Å) 50.00–1.29
(1.37–1.29)
50.00–1.25
(1.33–1.25)
50.00–1.23
(1.30–1.23)
Unique reflections 83387 (13109) 91628 (14590) 96812 (15297)
R(I)sym (%) 6.2 (49.4) 8.0 (49.4) 5.5 (47.9)
Wilson B factor (Å2) 9.6 9.3 9.4
Completeness (%) 99.7 (98.5) 100.0 (99.8) 99.8 (99.0)
Redundancy 12.7 (12.5) 12.8 (12.4) 9.6 (9.7)
<I/σ(I)> 27.6 (5.5) 19.8 (4.9) 26.8 (4.7)
(C) Refinement
Resolution range (Å) 40.10–1.29 43.65–1.25  38.42–1.23
Reflections used in refinement (work/free)  79216/4170  87046/4582 91963/4841
Final R value for all reflections (work/free) (%) 10.7/13.3 10.7/13.0 10.4/12.4
Protein residues 316 316 316
Calcium/zinc ions 4/1 4/1 4/1
Inhibitor atoms  31 29 31
Water molecules 423 433 437
RMSD from ideality
     Bond lengths (Å) 0.009 0.011 0.009
     Bond angles (°) 1.2 1.1 1.0
Ramachandran plotc
     Residues in most favored regions (%) 88.1 89.6 88.5
     Residues in additionally allowed regions (%) 10.7 9.3 10.4
     Residues in generously allowed regions (%) 0.7 0.7 0.7
     Residues in disallowed regions (%)d 0.4 0.4 0.4
Mean B factor (Å2)e
     Protein non-hydrogen atoms 10.7 10.6 10.7
     Protein Cα atoms 9.5 9.4 9.4
     Inhibitor 9.9 11.0 11.5
     Water molecules 26.5 26.3 26.5
a Numbers in parentheses represent the values of the highest resolution shells. b Matthews coefficient and
solvent content were calculated with the program Matthews_coef from the CCP4 suite [137]. c Ramachandran
plots were calculated with PROCHECK [138]. dThe Ramachandran outlier is Thr26 as described in literature [139].
e Mean B factors were calculated with MOLEMAN [140].
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Crystallographically determined and normalized B factors
Table S3.2 (related to Figure 3.5). Crystallographically determined (non-normalized) B factors of
W1–W15 of TLN-1 to TLN-6.
B factor (Å2)
Water molecule ID TLN-1 TLN-2 TLN-3 TLN-4 TLN-5 TLN-6
W1 11 10 10 17 10 10
W2 14 13 13 19 12 10
W3 41 25a 45 44 42 25
W4 - - 32 - 49 20
W5 27 27 25 - - 35
W6 13 13 13 23 19 17
W7 14 14 14 - 35 22
W8 31 29 19 - 47 36
W9 34 36 26 - 43 42
W10 32 34 47 49 - 49
W11 21 21 22 32 29 27
W12 38 48 41 - - -
W13 49 46 29 - 39 40
W14 - - 50 - - -
W15 - - 47 - - -
a both conformations A and B of W3 in TLN-2 have similar B factors.
Table S3.3 (related to Figure 3.5). Normalized B factors of W1–W15 of TLN-1 to TLN-6.
normalized B factor (Å2)
Water molecule ID TLN-1 TLN-2 TLN-3 TLN-4 TLN-5 TLN-6
W1 13 14 13 17 13 14
W2 17 17 17 19 16 14
W3 49 34a 59 44 57 35
W4 - - 42 - 68 28
W5 32 37 34 - - 48
W6 15 18 17 23 27 23
W7 17 20 18 - 48 31
W8 37 39 26 - 65 50
W9 41 49 35 - 59 58
W10 39 46 62 49 - 67
W11 26 28 30 32 40 38
W12 45 65 55 - - -
W13 59 62 38 - 53 55
W14 - - 66 - - -
W15 - - 63 - - -
a both conformations A and B of W3 in TLN-2 have similar B factors.
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ITC measurements
Buffer ionization reaction during TLN–ligand complex formation
All ITC measurements were performed in HEPES buffer. Measurements conducted earlier
with ligands exhibiting a similar parent scaffold (Figure 3.1A of the main text) revealed the
uptake of one proton by Glu143 during the protein–ligand complex formation [93,96]. The
proton is transferred from a buffer molecule, resulting in the ionization of the buffer molecule
and a heat of ionization ∆H°ion in addition to the heat signal ∆H°bind from the actual binding
event. Thus, the heat signal observed by the ITC experiment (∆H°obs) is the sum of both, ∆H°ion
and ∆H°bind. Since the magnitude of the heat signal ∆H°ion depends on the applied buffer
molecule [123], it would be unreasonable to discuss the magnitude of ∆H°obs (and thus also the
calculated value of –T∆S°) on an absolute scale without prior correction of ∆H°ion. A correction
of ∆H°ion is possible by measuring the binding reaction in different buffers showing different
heats of ionization [5,96]. However, in a congeneric series, the discussion of relative differences
of ∆H°obs, all with an identical contribution of ∆H°ion, is possible and probably even more
accurate than the comparison of calculated buffer corrected values due to error propagation.
This scenario is given in the current ligand series under investigation [93], as the congeneric
ligands exhibit only small changes in the aliphatic portion sticking into the solvent, and
consequently exert similar heats of ionization ∆H°ion. As only relative differences between the
thermodynamic parameters of 1–6 are discussed and not their absolute values, ITC
measurements were only performed in one buffer and the heat of ionization was not corrected.
Remeasurement of ligand 1 to guarantee high comparability of the thermodynamic
parameters
Ligand 1 was already thermodynamically characterized in the study conducted earlier [15].
However, the protein batch was completely used up for the ITC measurements and therefore
it was necessary to perform the ITC measurements of the current study with TLN from a
different protein batch. Furthermore, the ITC measurement scheme was optimized in order to
improve measurement precision. Moreover, instead of applying Origin7 from OriginLab for
titration curve analysis, we decided to work with the programs NITPIC [167] and SEDPHAT
[168] for a more automated and therefore potentially less user-biased integration and curve
fitting procedure. Since ITC measurements can be very sensitive to changing measurement
conditions and it is highly recommended to keep measurement conditions similar to achieve
high comparability [96], we decided to measure ligand 1 again together with ligands 2–6.
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Table S3.4 (related to Figure 3.8). Thermodynamic parameters measured for ligands 1−6 by ITC.
All measurements were performed in triplicate (a−c) out of which the mean values and the standard
deviations were calculated. All parameters are given as rounded numbers. Measurement curves are
displayed in Figure S3.5 in order to proof the high data quality of the measurements [96,172].
Measurement n Kd (µM) ΔG° (kJ mol−1) ΔH° (kJ mol−1) −TΔS° (kJ mol−1)
TLN-1a 1.015 0.368 -36.7 -23.0 -13.7
TLN-1b 0.988 0.338 -36.9 -22.8 -14.1
TLN-1c 0.952 0.347 -36.9 -23.1 -13.7
0.985±0.032 0.351±0.015 -36.8±0.1 -23.0±0.2 -13.8±0.2
TLN-2a 0.990 0.232 -37.9 -21.6 -16.2
TLN-2b 0.996 0.242 -37.8 -21.1 -16.6
TLN-2c 1.009 0.227 -37.9 -21.1 -16.8
0.998±0.010 0.233±0.008 -37.9±0.1 -21.3±0.3 -16.6±0.3
TLN-3a 0.957 0.149 -39.0 -21.1 -17.9
TLN-3b 1.029 0.218 -38.0 -20.8 -17.2
TLN-3c 0.940 0.189 -38.4 -21.8 -16.6
0.975±0.047 0.185±0.035 -38.5±0.5 -21.2±0.5 -17.2±0.6
TLN-4a 0.987 0.409 -36.5 -18.4 -18.0
TLN-4b 1.058 0.376 -36.7 -18.4 -18.3
TLN-4c 1.021 0.378 -36.7 -18.6 -18.0
1.022±0.036 0.388±0.019 -36.6±0.1 -18.5±0.1 -18.1±0.1
TLN-5a 0.947 0.285 -37.4 -16.6 -20.8
TLN-5b 0.982 0.291 -37.3 -17.0 -20.3
TLN-5c 0.939 0.354 -36.8 -17.0 -19.8
0.956±0.023 0.310±0.038 -37.2±0.3 -16.9±0.3 -20.3±0.5
TLN-6a 0.948 0.368 -36.7 -15.3 -21.4
TLN-6b 1.005 0.314 -37.1 -15.0 -22.1
TLN-6c 0.962 0.380 -36.6 -14.7 -21.9
0.972±0.030 0.354±0.035 -36.8±0.3 -15.0±0.3 -21.8±0.4
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TLN-1a TLN-1b TLN-1c
TLN-2a TLN-2b TLN-2c
TLN-3a TLN-3b TLN-3c
Figure S3.5. ITC measurement data of TLN-1 to TLN-6 each performed in triplicate (a−c). The upper
panel shows the extracted peaks of the titration curve. The lower panel displays the values of the
integrated peaks (black dots) as automatically performed by the NITPIC algorithm, and, fitted to
them, the 1:1 model binding isotherms (red curve) as created with SEDPHAT.
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TLN-4a TLN-4b TLN-4c
TLN-5a TLN-5b TLN-5c
TLN-6a TLN-6b TLN-6c
Figure S3.5. (continued)
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ITC measurements with the addition of glycerol
For all four tested ligands (2, 3, 5, and 6), ∆H° increases and −T∆S° decreases with increasing
concentration of glycerol (Figure S3.6). Almost complete compensation of ∆H° and −T∆S° is
observed, resulting in virtually unchanged ∆G°. The relative differences of the thermodynamic
parameters between the ligands remain constant. For 3 compared to 2, identical values of ∆H°
and more favorable values of −T∆S° and ∆G° are observed for all measured glycerol
concentrations.
Figure S3.6. ITC measurements of 2, 3, 5 and 6 binding to TLN with buffers containing different
glycerol concentrations of 0%, 1%, 2.5%, 5% and 10% (v/v). The symbols indicate the different
ligands, the colors indicate the thermodynamic parameters ∆H° (green), −T∆S° (red) and ∆G°
(blue). For sake of clarity, standard deviation bars are not shown. All measurements were
performed in triplicate. Data values with standard deviations are listen in Table S3.5.
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Table S3.5. ITC measurement results of ligands 2, 3, 5 and 6 measured with the addition of different
concentrations of glycerol. All measurements were performed in triplicate (a−c), from which the mean
values and the standard deviations were calculated. All parameters are given as rounded numbers.
Measurement
(glycerol conc.) n Kd (µM) ΔG° (kJ mol−1) ΔH° (kJ mol−1) −TΔS° (kJ mol−1)
TLN-2a (1.0%) 1.023 0.188 -38.4 -23.8 -14.6
TLN-2b (1.0%) 1.015 0.174 -38.6 -23.6 -15.0
TLN-2c (1.0%) 1.080 0.143 -39.1 -24.0 -15.1
1.039±0.035 0.168±0.023 -38.7±0.3 -23.8±0.2 -14.9±0.3
TLN-2a (2.5%) 1.087 0.188 -38.4 -25.2 -13.2
TLN-2b (2.5%) 1.060 0.281 -37.4 -25.1 -12.3
TLN-2c (2.5%) 1.034 0.186 -38.4 -25.3 -13.2
1.060±0.027 0.218±0.054 -38.1±0.6 -25.2±0.1 -12.9±0.5
TLN-2a (5.0%) 1.037 0.216 -38.0 -28.5 -9.5
TLN-2b (5.0%) 1.014 0.186 -38.4 -28.4 -10.0
TLN-2c (5.0%) 1.025 0.190 -38.4 -27.6 -10.8
1.025±0.012 0.197±0.016 -38.3±0.2 -28.2±0.5 -10.1±0.6
TLN-2a (10.0%) 1.023 0.146 -39.0 -31.1 -7.9
TLN-2b (10.0%) 1.066 0.118 -39.5 -31.4 -8.1
TLN-2c (10.0%) 1.104 0.098 -40.0 -32.5 -7.5
1.064±0.041 0.120±0.024 -39.5±0.5 -31.7±0.7 -7.9±0.3
TLN-3a (1.0%) 1.003 0.154 -38.9 -22.7 -16.2
TLN-3b (1.0%) 0.981 0.158 -38.8 -22.9 -16.0
TLN-3c (1.0%) 0.963 0.175 -38.6 -23.4 -15.1
0.982±0.020 0.162±0.011 -38.8±0.2 -23.0±0.4 -15.8±0.5
TLN-3a (2.5%) 1.012 0.165 -38.7 -24.9 -13.9
TLN-3b (2.5%) 0.990 0.140 -39.1 -25.5 -13.6
TLN-3c (2.5%) 0.991 0.116 -39.6 -25.0 -14.6
0.998±0.012 0.140±0.025 -39.1±0.4 -25.1±0.3 -14.0±0.5
TLN-3a (5.0%) 0.965 0.110 -39.7 -28.8 -10.9
TLN-3b (5.0%) 0.962 0.101 -39.9 -28.4 -11.5
TLN-3c (5.0%) 0.973 0.092 -40.2 -28.3 -11.9
0.967±0.006 0.101±0.009 -39.9±0.2 -28.5±0.2 -11.4±0.5
TLN-3a (10.0%) 0.976 0.106 -39.8 -31.7 -8.2
TLN-3b (10.0%) 0.914 0.085 -40.4 -31.7 -8.7
TLN-3c (10.0%) 0.927 0.081 -40.5 -32.7 -7.8
0.939±0.033 0.091±0.013 -40.2±0.3 -32.0±0.6 -8.2±0.5
TLN-5a (1.0%) 1.058 0.189 -38.4 -17.9 -20.5
TLN-5b (1.0%) 1.015 0.289 -37.3 -17.7 -19.6
TLN-5c (1.0%) 1.053 0.234 -37.8 -18.0 -19.8
1.042±0.024 0.237±0.050 -37.8±0.5 -17.9±0.2 -20.0±0.4
TLN-5a (2.5%) 1.042 0.195 -38.3 -19.6 -18.7
TLN-5b (2.5%) 1.016 0.212 -38.1 -18.9 -19.2
TLN-5c (2.5%) 1.054 0.171 -38.6 -19.8 -18.8
1.037±0.019 0.193±0.021 -38.3±0.3 -19.4±0.5 -18.9±0.3
TLN-5a (5.0%) 0.936 0.288 -37.3 -22.1 -15.3
TLN-5b (5.0%) 0.933 0.210 -38.1 -21.8 -16.3
TLN-5c (5.0%) 0.991 0.241 -37.8 -21.3 -16.5
0.953±0.033 0.246±0.039 -37.7±0.4 -21.7±0.4 -16.0±0.7
TLN-5a (10.0%) 1.067 0.152 -38.9 -24.1 -14.8
TLN-5b (10.0%) 1.063 0.186 -38.4 -24.1 -14.3
TLN-5c (10.0%) 1.042 0.185 -38.4 -23.6 -14.9
1.057±0.013 0.174±0.019 -38.6±0.3 -23.9±0.3 -14.7±0.3
TLN-6a (1.0%) 0.994 0.231 -37.9 -16.2 -21.7
TLN-6b (1.0%) 0.986 0.270 -37.5 -16.0 -21.5
TLN-6c (1.0%) 0.996 0.236 -37.8 -16.1 -21.7
0.992±0.005 0.245±0.021 -37.7±0.2 -16.1±0.1 -21.6±0.2
TLN-6a (2.5%) 1.020 0.212 -38.1 -18.1 -20.0
TLN-6b (2.5%) 0.996 0.260 -37.6 -18.7 -18.8
TLN-6c (2.5%) 0.981 0.198 -38.3 -18.1 -20.2
0.999±0.020 0.223±0.032 -38.0±0.4 -18.3±0.4 -19.7±0.7
TLN-6a (5.0%)  0.955 0.190 -38.4 -20.9 -17.4
TLN-6b (5.0%)  0.939 0.142 -39.1 -21.2 -17.9
TLN-6c (5.0%)  0.953 0.155 -38.9 -20.7 -18.1
0.949±0.009 0.162±0.025 -38.4±0.4 -20.9±0.2 -17.8±0.4
TLN-6a (10.0%) 1.065 0.199 -38.2 -23.5 -14.7
TLN-6b (10.0%)  1.018 0.233 -37.9 -22.2 -15.6
TLN-6c (10.0%)  1.012 0.226 -37.9 -22.8 -15.1
1.032±0.018 0.219±0.018 -38.0±0.2 -22.9±0.6 -15.1±0.5
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ITC measurements with the addition of DMSO
Table S3.6. Thermodynamic parameters measured for ligands 3 and 6 by ITC with the addition of
DMSO. All measurements were performed in duplicate (a+b) out of which the mean values and the
standard deviations were calculated.
Measurement n Kd (µM) ΔG° (kJ mol−1) ΔH° (kJ mol−1) −TΔS° (kJ mol−1)
TLN-3a (0.065 M) 0.907 0.199 -38.2 -24.3 -13.9
TLN-3b (0.065 M) 1.027 0.255 -37.6 -23.2 -14.5
0.967±0.085 0.227±0.040 -37.9±0.4 -23.7±0.8 -14.2±0.4
TLN-3a (0.130 M) 1.014 0.208 -38.1 -24.3 -13.8
TLN-3b (0.130 M) 1.003 0.175 -38.6 -24.4 -14.2
1.009±0.008 0.192±0.024 -38.4±0.3 -24.4±0.1 -14.0±0.2
TLN-6a (0.065 M) 1.007 0.459 -36.2 -17.2 -18.9
TLN-6b (0.065 M) 1.004 0.414 -36.4 -17.4 -19.0
1.006±0.002 0.437±0.032 -36.3±0.2 -17.3±0.1 -19.0±0.0
TLN-6a (0.130 M) 0.992 0.3402518 -36.92 -18.36 -18.56
TLN-6b (0.130 M) 1.005 0.3935458 -36.56 -18.42 -18.14
0.999±0.009 0.367±0.038 -36.7±0.3 -18.4±0.0 -18.4±0.3
Figure S3.7. ITC measurements of 3 and 6 with the addition of DMSO. The measured DMSO
concentrations of 0.065 M and 0.130 M correspond to the molar concentration of glycerol in
the solutions with 5% and 10% glycerol (Figure S3.6). Data values are listed in Table S3.6.
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SPR measurements
Table S3.7 (related to Figure 3.9). SPR measurement results of TLN-ligand complexes TLN-1, TLN-
2, TLN-3, TLN-5 and TLN-6. Kinetic analysis was performed by global analysis of single-cycle
measurements performed in triplicate (Figure S3.8).
TLN complex kon (M−1 s−1) SE (kon)a koff (s−1) SE (koff)a Kd (M) Chi² (RU²)
TLN-1 1.14×105 6.50×102 8.40×10−2 2.70×10−4 7.38×10−7 0.058
TLN-2 7.08×104 4.10×102 5.95×10−2 2.10×10−4 8.41×10−7 0.104
TLN-3 3.10×104 2.10×102 3.78×10−2 1.50×10−4 1.22×10−6 0.257
TLN-5 8.58×104 7.00×102 6.53×10−2 3.20×10−4 7.61×10−7 0.185
TLN-6 4.82×104 3.30×102 6.84×10−2 2.70×10−4 1.42×10−6 0.152
a SE = standard error
Table S3.8 (related to Figure 3.9). Kinetic binding parameters of TLN-ligand complexes TLN-1,
TLN-2, TLN-3, TLN-5 and TLN-6 as determined by individual analysis of the SPR measurements
performed in triplicate, from which the mean values and the standard deviations were calculated.
TLN complex kon (M−1 s−1) SD (kon) koff (s−1) SD (koff) Kd (M) SD (Kd)
TLN-1 1.10×105 8.06×103 7.94×10−2 3.97×10−3 7.24×10−7 8.38×10−8
TLN-2 8.25×104 3.32×104 5.97×10−2 3.07×10−3 8.30×10−7 4.03×10−7
TLN-3 2.69×104 7.08×103 3.87×10−2 5.09×10−3 1.55×10−6 5.95×10−7
TLN-5 9.55×104 3.32×104 6.64×10−2 1.49×10−2 7.55×10−7 2.82×10−7
TLN-6 4.00×104 1.16×104 7.00×10−2 5.98×10−3 1.86×10−6 5.56×10−7
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Figure S3.8 (related to Figure 3.9). SPR sensorgrams showing three separate single cycle kinetics
runs in five concentrations of each (A) TLN-1, (B) TLN-2, (C) TLN-3, (D) TLN-5, and (E) TLN-6. The
analyte concentration ranges spanned (A) 156−2500 nM, (B) 25−2500 nM, (C) 156−10000 nM, (D)
25−2500 nM, (E)156−10000 nM. The colouring of sensorgrams represents the concentrations used
in each cycle (A) 156, 312, 625, 1250, 2500 nM (red, blue, green), (B) and (D) 25−2500 nM (156, 312,
625, 1250, 2500 nM (red), 25, 74, 222, 667, 2000 nM (blue, green)), (C) and (E) 156, 312, 625, 1250, 2500
nM (blue, green), 625, 1250, 2500, 5000, 10000 nM (red). Global analysis of the triplicate data was
performed (black) to account for experimental differences between runs such as variation in capture
level (800–1200 RU), drift and used analyte concentrations. The concentration range used spanned
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from <0.2×Kd to >3.0×Kd for all compounds (Kd values determined by SPR are presented in Table
S3.7).
Calculation of buried SASAs
Figure S3.9. Crystal structure TLN-5 with the missing terminal methyl group of the P2’ portion (panel
A, bound ligand in blue), and the two modeled conformations 5Am (panel B, red) and 5Bm (panel C,
yellow) of the missing methyl group used for the calculations of the SASAs.
Table S3.9 (related to Figure 3.10). Calculated total and buried solvent accessible surface areas
(SASAs) of ligands 1–6 in complex with TLN.
SASA (Å2)
Ligand total buried
1 702 512
2 conformation A 726 536
conformation B 726 535
3 740 548
4 705 566
5 missing P2’ methyl group (Figure S3.9A) 704 520
methyl group modeled in conformation Am (Figure
S3.9B) 729 539
methyl group modeled in conformation Bm (Figure
S3.9C) 729 539
6 748 555
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Comparison MD simulations and crystal structures of TLN-2 and TLN-5
Figure S3.10 (related to Figure 3.11). Prediction of positions of water molecules as calculated by
MD simulations in comparison to the crystallographically observed electron densities and refined
crystal structure models of (A) TLN-2 and (B) TLN-5. The modeled coordinates of ligand, glycerol
and DMSO molecules used in the MD simulations are displayed as yellow stick models with color-
coded heteroatoms. The yellow, semitransparently contoured regions show computed areas in the
first solvation layer of the P2’ groups with an occupancy probability by a water molecule of at least
48%. The crystallographically determined binding modes of ligand and additive molecules are
superimposed as blue stick models with color-coded heteroatoms. Water molecule positions
determined in the crystal structures are displayed as blue spheres, and the Fo–Fc omit electron
density is displayed as dark blue mesh at a contour level of 3σ for the water molecules positioned in
the first solvation layer of the P2’ groups. H-bond distances are indicated as blue dotted lines.
Positions of water molecules, which are discussed in the main text, are labeled with identifiers
according to Figure 3.4. The solvent excluded surface of TLN is shown in white.
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4.1 Abstract
In lead optimization programs in medicinal chemistry, open, solvent-exposed protein pockets
are often disregarded as prospective binding sites. Due the proximity of the bulk solvent, many
researchers are instead enticed to attach charged and polar groups to a respective position of
an inhibitor scaffold in order to improve solubility and pharmacokinetic properties of a lead
candidate. It is rarely considered that solvent effects from the organization of water molecules
in the first hydration shell of a protein–ligand complex can have a significant impact on the
thermodynamics of binding. In this case study, we aimed to investigate the thermodynamic
fingerprint of a series of thermolysin inhibitors featuring a charged ammonium group that is
gradually pulled further into the solvent-exposed S2’ pocket of the protease. It was found that
the cost for the partial desolvation of the polar group at the solvent interface could not easily
be compensated by interactions to the protein or surrounding water molecules. In a direct
comparison to hydrophobic analogues, a significant loss of affinity by a factor of up to 180 in
Kd was recorded.
Keywords
protein–ligand interactions, binding thermodynamics, hydrophobic effect, desolvation, X-ray
crystallography, isothermal titration calorimetry
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4.2 Introduction
During the course of a protein–ligand binding event, the solvation shell of both partners plays
an active role for the recognition process. Water molecules interact with both species in their
solvated state in bulk solution prior to binding. Thus, before a binding event is initiated, the
hydration shell of either molecule has to be partially shed and adapted to allow a direct
interaction between the protein and its ligand. This process is known as desolvation [173,174].
The subsequently formed protein–ligand complex exposes a newly generated surface that again
necessitates an adjustment of the surrounding solvation layer. It is therefore appropriate to
consider water molecules as a third binding partner in biological recognition events. The
thermodynamic signature associated with the reorganization of solvent molecules can be
diverse. Most commonly, the desolvation of hydrophobic ligand portions is believed to result
in an entropically driven free energy gain. This so called “hydrophobic effect” is said to
originate from the displacement of conformationally restricted water molecules from an apolar
interface into the bulk [7,175]. However, it has been shown in multiple studies that this simple
model does not hold true in all cases [9,10,15,16,93,124,176,177]. Depending on the
characteristics of the interface, most notably the shape of the respective surface[14,177], the
partitioning of energy contributions from the displacement of water molecules can be diverse
and driven by enthalpy, as well as entropy. On the other end of the spectrum, polar components
of solutes actively engage in hydrophilic interactions to the water molecules comprising their
hydration shell. The desolvation of a polar moiety is commonly accompanied by an enthalpic
penalty that arises from the loss of a hydrophilic contact, such as hydrogen bonds, to the
solvent molecules in its hydration shell [173]. In order to compensate for that energetic loss,
an equivalent interaction to a binding partner at the protein binding site has to be established
to prevent a free energy deficit [113,120].
In lead optimization programs in medicinal chemistry, charged and polar functional groups
are commonly included in an inhibitor scaffold as means to improve solubility or
pharmacokinetic properties of a prospective drug candidate. If the targeted protein does not
provide a specific interaction for these groups, it is often attempted to place polar components
in open, solvent accessible areas, where they interfere with the solvent interface of the protein–
ligand complex. The underlying assumption of this strategy is that a partial desolvation of the
polar group does not impose a significant penalty to the binding affinity. A systematic study of
the thermodynamics that originate from solvation effects of polar groups at protein–ligand
interfaces, however, has not been realized yet.
In previous studies, we have used the interaction between the metalloprotease thermolysin
(TLN) and carefully tailored phosphonopeptide inhibitors as a model system for the
investigation of solvent effects during protein–ligand binding. These studies focused on the
rearrangement of water molecules around a newly generated hydrophobic surface around the
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solvent accessible, mostly apolar S2’ pocket of the protein. For the research presented in this
contribution, we envisaged an inhibitor system that would be able to introduce a terminal,
increasingly exposed charged and polar functional group into the surface generated by the
formed protein–ligand complex. The hydrophilic moiety was supposed to act as an anchor
point for water molecules in the hydration shell and introduce an augmented ordering of the
solvent network. By an incremental retraction of the polar group deeper into the hydrophobic
pocket, we hoped to be able to study the thermodynamic characteristics of the process of
desolvation and gain insight that may prove useful for the development of new drugs, with a
particular focus on typical protocols to improve pharmacokinetics.
As a suitable inhibitor system for the abovementioned research effort, two series, each
consisting of four compounds, were synthesized. While the basic phosphonopeptide scaffold
of TLN inhibitors was kept constant, a primary amino group, which would be charged under
the assay conditions, was introduced in the P2’ position of the ligands (Figure 4.1). For
inhibitors 1–4, an aminoalkyl chain was included in this position, whereas 5–8 contained an
amino acid scaffold with an equivalent amino function in the side chain. The thermodynamic
profiles of the interaction of inhibitors 1–8 were determined by isothermal titration
calorimetry (ITC) and the binding modes were analyzed by protein X-ray crystallography.
4.3 Results
ITC data collection.
As shown previously, the binding of phosphonamidate type inhibitors to TLN is accompanied
by the release of a proton from the buffer [93]. During the transition from the open to the
closed, ligand-bound state, Glu143 is believed to change its protonation state as it recedes from
the partly exposed binding site into the S1 pocket. The calorimetric experiment records this
protonation linkage in form of a buffer dependent contribution, superimposed on the enthalpy
of binding resulting from the protein–ligand interaction. For an accurate assessment of the net
thermodynamic data of binding, the recorded enthalpy values have to be corrected for this
superimposed enthalpy of ionization.
Therefore, the thermodynamic binding profiles of 1–8 were determined by ITC in three
different buffers of deviating ionization enthalpy. A fit of the recorded enthalpy against the
reported enthalpy of ionization to a linear model gave the buffer corrected enthalpy, as well as
information about the number of protons that are transferred during ligand binding (Figure
4.1 and Figure S4.4) [96]. This value was determined to fall into a range between 0.6 and 0.9
moles of protons for these ligands. Considering the total error across all performed
 Paying the Price of Solvation in Solvent Exposed Protein Pockets | 157
C
h
a
p
te
r 
4
experiments, we conclude that during the binding of 1–8, a roughly equivalent amount of
protons is picked up by the buffer. A statistical test for the equality of the regression lines did
not identify a significant deviation within the sample set [178].
Figure 6.1 gives an overview over the thermodynamic parameters of ligand binding after a
correction for the buffer ionization contribution. Within the aliphatic amine series (1–4), the
free energy of binding shows a steady decline with a reduction of the chain length. From 1–3,
this effect is accompanied by a moderate entropic loss (–TΔΔS°1→2= 2.7 kJ mol−1; –TΔΔS°1→3=
4.1 kJ mol−1) that is only partly compensated by an enthalpic gain (ΔΔH°1→2= –1.5 kJ mol−1;
ΔΔH°1→3= –0.7 kJ mol−1). A further contraction of the aliphatic chain from 3 to 4, however,
reveals a drastic reversal of the thermodynamic contributions. The enthalpy of binding is
reduced significantly (ΔΔH°3→4= 13.0 kJ mol−1), while a pronounced entropic benefit (–
TΔΔS°3→4= –12.1 kJ mol−1) compensates for that loss. Within the amino acid series (5–8), a
slight increase in ΔG° from 5–6 (ΔΔG°5→6= –1.0 kJ mol−1), followed by a steady affinity loss
upon reduction of the chain length is observed (ΔΔG°6→7= 3.7 kJ mol−1; ΔΔG°7→8= 1.9 kJ mol−1).
From 5–7, the change in binding free energy is partitioned into an enthalpic loss (ΔΔH°5→6=
Figure 4.1. Thermodynamic data from ITC experiments. Gibb’s free energy (ΔG°, blue),
enthalpy (ΔH°, green), and entropy of binding (–TΔS°, red).
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0.5 kJ mol−1; ΔΔH°6→7= 5.1 kJ mol−1) and a compensating favorable entropic contribution (–
TΔΔS°5→6= –1.5 kJ mol−1; –TΔΔS°6→7= –1.4 kJ mol−1). For 8, the inhibitor with the shortest chain
length of this series, a significant loss in entropy (–TΔΔS°7→8= 6.6 kJ mol−1) with a
counteracting enthalpic gain (ΔΔH°7→8= 5.1 kJ mol−1) is recorded. In comparison to their polar
analogues, the ligands featuring a hydrophobic substituent in the P2’ position display a
significantly increased affinity, evident by a gain in free energy of binding (ΔΔG°3→9 = 9.9
kJ mol−1, ΔΔG°4→10 = 7.5 kJ mol−1, ΔΔG°7→11 = 10.1 kJ mol−1, ΔΔG°8→12 = 12.1 kJ mol−1). This
effect is mainly driven by a dramatic loss in enthalpy for the polar inhibitors (ΔΔH°3→9 = 11.0
kJ mol−1, ΔΔH°4→10 = 16.0 kJ mol−1, ΔΔH°7→11 = 18.8 kJ mol−1, ΔΔH°8→12 = 16.5 kJ mol−1).
X-ray crystallography
The crystal structures of 1–8 (Figure 4.2) reveal that their overall binding mode to TLN is
highly conserved across the inhibitor series. Significant differences are only observed in the
chemically deviating P2’ moieties and the surrounding hydration pattern. In TLN-1, the
terminal amino group of ligand 1 is hydrogen-bonded to the backbone carbonyl oxygen of
Asn111. No additional water molecules could be confidently assigned to the electron density
within interaction distance to the ligand. Residual electron density peaks in the mFo–DFc map,
however, suggest the presence of weakly populated, transient water sites (Figure S4.5). In the
structure of 2, the truncated alkyl chain still allows the formation of a hydrogen bond to
Asn111. The deviating geometry of this interaction, however, supports the stabilization of two
water molecules in the hydration shell of the terminal ammonium group. A further reduction
of the chain length in TLN-3 prevents the formation of a hydrogen bond to Asn111. Instead, a
water molecule is fixed at a position that was formerly occupied by the amino groups of 1 and
2. The terminal aminoethyl chain of 3 is oriented toward the side, where a conserved water
cluster at the rim of the S2’ pocket is found. It engages in two contacts to water molecules. The
aminomethyl group of 4, the shortest ligand of the series, immerges even further into the
hydrophobic S2’ pocket. In the crystal structure, its side chain is considerably disordered, so
that two conformations had to be considered in the refinement model to explain the observed
electron density. In one conformation (26% occupancy), the amino group is oriented toward
the upper part of the pocket, where it is able to form hydrogen bonds to two conserved water
molecules. In the second conformation (74% occupancy), it is rotated toward the hydrophobic
bottom of the pocket. This allows the charged nitrogen to interact with a conserved water
molecule on the left hand side of the binding pocket. In addition, the water molecule
interacting with Asn111 in 3, is dragged into the hydrophobic crevice, where it acts as a second
interaction partner for one conformer of the aminomethyl group of 4. This arrangement
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extends the distance between the interaction partners from 2.8 Å (in TLN-3) to 3.0 Å, thereby
weakening the interaction to the protein (based on hydrogen bond distance criteria).
Inhibitors 5–8 feature a carboxylic acid group at their P2’ moiety in addition to the aminoalkyl
side chain. In all structures, the carboxy function is fixed in position by a strong interaction to
Asn112. This interaction is believed to increase the affinity of a compound by interfering with
the release mechanism during the dissociation process of the bound ligands [179]. In addition,
the terminal carboxy function of 5–8 engages in strong, charge-assisted hydrogen bonds to
conserved water molecules that form energetically favorable polygonal networks above the
Figure 4.2. Binding modes of TLN inhibitors 1 (A), 2 (B), 3 (C), 4 (D), 5 (E), 6 (F), 7 (G), and 8 (H).
Carbon atoms of the inhibitors are shown in red (1–4) or blue (5–8), protein residues are
displayed in beige. Heteroatoms are color coded by atom type. The white surface represents
the solvent excluded protein surface. Hydrogen bonds are indicated as dashed lines. The 2mFo–
DFc density map for the water molecules is shown as a blue mesh (1.0s).
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pocket. The lysine derivative 5 binds in a position, in which the terminal ammonium group
sticks out into the solvent. Due to its high residual mobility, it is scattered over multiple
positions and thus, not clearly defined in the electron density. The length of the side chain of
this ligand does not allow an interaction with Asn111. Instead, a water molecule donates a
hydrogen bond to this residue. The shorter chain length of the ornithine derivative 6, however,
places the ammonium side chain within an optimal interaction distance to Asn111, while
simultaneously keeping the orientation of the carboxy group unchanged. A water molecule,
placed toward the front of the pocket, provides an additional interaction. The binding mode
of the homolog 7 is very similar to 6. The shorter chain length in 7, however, does not allow an
optimal interaction geometry of the hydrogen bond to Asn111. While the strong interactions
of the carboxy group keep its position fixed, the truncation of the side chain increases the
hydrogen bond distance to Asn111 from 2.8 Å (in TLN-6) to 3.0 Å in TLN-7, thereby
weakening the interaction. Nonetheless, the placement of the terminal ammonium group
allows the recruitment of water molecules that bind toward the lower rim of the S2’ pocket. The
crystal structure of 8 reveals that the distance of the terminal ammonium group of this
compound to Asn111 is too large for a hydrogen bond interaction. As a result, the charged
functionality is disordered over multiple orientations (Figure S4.6), nevertheless interacting
quite extensively with the surrounding hydration shell. In total, six water molecules are trapped
in the close neighborhood of the S2’ pocket and fixed in positions, wrapping around the side
chain of 8. One of these waters takes up the interaction to Asn111.
4.4 Discussion
Thermodynamics–Structure Relationship for 1–4
The thermodynamic binding profile of 2 in comparison to 1 is characterized by an increase inDG° (lower affinity). This can be attributed to an enthalpic gain that is overcompensated by a
less beneficial entropic signal. Both ligands show a strong interaction with Asn111 (hydrogen
bond length 2.8 Å). The more favorable enthalpy of 2 might originate from a stronger fixation
of its aminoalkyl chain. In comparison to 1, 2 seems to provide a better environment for the
stabilization of an additional water molecule in the hydration shell of the ligand, which in turn
reduces the residual flexibility of the aliphatic chain. The stronger fixation of 2 strengthens the
enthalpic interactions while the entropic contribution is reduced. Considering the
experimental error for the determination of enthalpic and entropic contributions, this effect is
not very distinctive. From 2 to 3, the overall decrease in affinity is driven by a slightly less
favorable entropic contribution in combination with an increase in enthalpy. Again, the
change in enthalpy and entropy is not very pronounced and lies within the standard deviation
of the measurement. Due to an increased distance to Asn111, the hydrogen bond to this residue
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is no longer maintained in TLN-3. Instead, the charged ammonium group is fixed in position
by an interaction to two water molecules, which mediate the contact to Asn111. A further
reduction of the chain length introduces a significant shift in the thermodynamics of binding.
For 4, a rather dramatic enthalpic penalty is recorded. This is partly compensated by a gain in
entropy, resulting in a reduced overall affinity. An explanation for this finding might be the
observation that the charged and polar ammonium moiety in 4 is pulled back even further into
the more hydrophobic part of the S2’ pocket. In addition, the terminal ammonium group is
scattered over two orientations, which parallels with an entropic advantage. A water molecule
that engages in the conserved interaction to Asn111 is forced to adopt a position deep within
the hydrophobic pocket in order to maintain a hydrogen bond to both interaction partners.
These manifold changes compared to other complexes of the series result in an unfavorable
situation, which is reflected in the enthalpic penalty of ΔΔH°3→4= 13.0 kJ mol−1. The
compensating entropic benefit of –TΔΔS°3→4= –12.1 kJ mol−1 may originate from an increased
mobility of the water molecules in the surrounding hydration shell, along with the apparent
disorder of the ligand side chain, as evident from the two refined conformations.
Thermodynamics–Structure Relationship for 5–8
As reported for a related series of inhibitors,[94] the addition of a carboxy group in 5–8
imposes a strong ordering of the water structure around the S2’ pocket. For all ligands, the
carboxylic acid group is tightly fixed in position by Asn112 and interacts with a cluster of
structurally conserved water molecules. In comparison to 1–4, this arrangement leads to a gain
in affinity that is dominated by a favorable enthalpic contribution. The side chain of the lysine
derivative 5 sticks out into the solvent and the terminal ammonium moiety is disordered in the
crystal structure. The residual solvation pattern of ordered water molecules toward the lower
rim of the binding pocket appears rather imperfect. A reduction of the chain length to 6 is
accompanied by a slight decrease in the entropy of binding. In TLN-6, the ornithine side chain
is perfectly positioned for an interaction to Asn111 and adopts an orientation very similar to
that observed with the isostructural side chain of 1. A reason for the minor alterations in the
thermodynamic profile from 5 to 6 might be the displacement of a water molecule in TLN-5
with the ammonium side chain of 6. Conceivably, the loss in mobility of the aliphatic chain is
overcompensated by the gain of mobility of the water molecule that is displaced from the
complex. Regarding the enthalpic term, the polar interactions of the terminal ammonium
group of the lysine side chain in 5, which only interacts with the hydrating water molecules in
the bulk phase, are compensated by the hydrogen bond interaction of 6 with Asn111 and an
additional water molecule that is entrapped by the complex. However, this effect is not very
distinctively alternating the overall thermodynamic signature.. In the structure of 7, it becomes
apparent that the strong polar interaction of the carboxy terminus dominates the binding
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mode of the P2’ residue. This group remains fixed at its position in contact with Asn112, while
the truncation of the side chain deteriorates the interaction to Asn111. Due to the shorter chain
length of the diaminobutyric acid in 7, the hydrogen bond distance to this residue is increased
to 3.0 Å, thus weakening the interaction. This correlates with a loss in enthalpy in the
thermodynamic binding profile. A further reduction of the side chain length to the
diaminopropionic acid derivative 8 pulls the polar ammonium moiety further back toward the
hydrophobic part of the binding pocket. In the crystal structure, the aminomethyl side chain
of 8 is disordered over two conformations. The electron density even provides evidence for a
third conformation, which could not be included in the model with sufficient confidence
(Figure S4.6). Similar properties of the side chain are not evident in the crystal structure of the
related complex TLN-3. A total of six water molecules are stabilized in the first hydration layer
around the S2’ pocket. They are engaged in a pronounced network of hydrogen-bond
interactions to the polar side chain of 8, as well as Asn111. In the thermodynamic profile, the
binding event is characterized by an enthalpic advantage of 8 over 7. At the same time, an
unfavorable entropic contribution is recorded. The recorded gain in enthalpy might originate
from the strong polar interactions within the pronounced water network entrapped in the
complex with 8. The stabilization of a similar solvent network above the protein–ligand
complex has been shown to result in an enthalpically favorable contribution to binding.[16]
The fixation of this large amount of solvent molecules is also reflected in the binding profile as
a pronounced entropic disadvantage. However, the multiple conformations of the
aminomethyl side chain parallel an increased residual mobility of the ligand, which likely
counteracts this effect. In total, a trend toward decreasing affinity upon reduction of the chain
length bearing the charged group can be observed in both series, while the partitioning in
enthalpic and entropic contributions vary between the ligands as a result of complex specific
features originating from differences in the complexity of the established hydration pattern,
residual ligand mobility and inventory of formed hydrogen bonds. With respect to the adopted
conformation of the side chain, the isostructural pairs 1/6, 2/7, and 3/8 show similar features.
Discussion of thermodynamic affinity data
Within the two investigated ligand series, the overall affinity shows a steady decrease with a
reduction of the chain length. While this was an expected outcome of the experiment, the effect
of trapping a charged and polar ammonium group increasingly closer to a hydrophobic
environment turned out to be less dramatic than we initially assumed. For 1–4, the difference
in ΔG° between the most and least potent inhibitors (1 and 4) equals 4.2 kJ mol−1, which
corresponds to a factor of 6 in Kd. The potency of the carboxy ligands 5–8 differs by 5.2 kJ mol−1
in ΔG° (6 and 8), which equals a factor of 7 in Kd. In contrast to this, the variation of a purely
hydrophobic chain in the P2’ position of related peptidomimetic TLN inhibitors, which were
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previously studied by us, resulted in a difference in Kd by a factor of 50.[15] In addition to the
burial of hydrophobic surface area, the local ordering of water molecules in
thermodynamically beneficial networks proved to be important for the affinity gain in the
latter cases.[15,16] A comparison of the water structure around the S2’ pocket of TLN-1 – TLN-
8 to the structures of related hydrophobic analogues reveals that hardly any additional water
molecules that are observable in the solid state by crystallography are recruited by the
complexes of the polar compounds. Remarkably, in many cases the apolar and aliphatic
substituents stabilize a more elaborate network of solvent molecules across the newly formed
complex surfaces. Presumably, the polar ligand surface promotes the formation of more
transient interactions with solvating water molecules that cannot be observed with
crystallography. A comparable hydrophobic moiety of equivalent size seems to establish a
more defined and highly directional network of capping water molecules that takes beneficial
impact on the thermodynamic signature of the binding process.
Most importantly, all of the polar inhibitors investigated in this study display a considerably
lower affinity to TLN compared to the more hydrophobic phosphonopeptide analogues
lacking the terminal ammonium group. This is probably owed to the costly partial desolvation
of the charged ammonium group in 1–8. Even when the polar group is able to engage in
hydrogen bond interactions with the protein or succeeds to recruit several surrounding water
molecules, a pronounced disadvantage in the free energy of binding is recorded for the more
hydrophilic inhibitor analogues. This is even true in the case of 5, where the polar terminal
group sticks out into the solvent and is not involved in any direct interactions to the protein or
water molecules of the first solvation layer.
A direct comparison of the binding characteristics of the polar inhibitors 3–4 and their
hydrophobic analogues 9–10 is given in Figure 4.3A. The overall binding mode of the inhibitor
scaffold is virtually conserved for all examples. The deviating orientations of the P2’ side chains,
however, match with the changes of the chemical properties of the respective inhibitors.
Whereas 9 and 10 occupy the hydrophobic cavity below Asn111, the terminal ammonium
groups in 3 and 4 are oriented in a way that the polar head group is integrated into a network
of surrounding water molecules. Even though the P2’ side chains exhibit apolar properties, their
hydration in TLN-9 and TLN-10 results in sophisticated solvation network patterns. In both
cases, more water molecules wrap around the exposed ligand portion than in TLN-3 and TLN-
4 respectively. Similar conclusions can be drawn for the comparison of 7 and 8 to their
respective analogues 11 and 12 (Figure 4.3B).
The apolar derivatives show a gain of affinity by a factor of 20–180 in Kd when compared to
their polar analogs. The observation that this effect seems to originate from a strong enthalpic
advantage is in line with the hypothesis that the rather weak affinity of 3–4 and 7–8 can be
attributed to an unfavorable desolvation penalty of the polar head group. Placing the polar
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group more remotely by using a longer chain as in 1–2 and 5–6, makes the ligand slightly more
potent, the enthalpic cost of desolvation, however, is still to be afforded. In all cases, the purely
hydrophobic group oriented toward the solvent reveals the more potent binding. This is
Figure 4.3. Comparison of binding characteristics of polar inhibitors 3, 4, 7, 8 and aliphatic
compounds 9,10,11,12. (A) Superposition of the crystal structures TLN-3/TLN-9 and TLN-
4/TLN-10 and thermodynamic binding profiles of the respective inhibitors. (B) Superposition
of the crystal structures TLN-7/TLN-11 and TLN-8/TLN-12 and thermodynamic binding profiles
of the respective inhibitors. Carbon atoms, water molecules and hydrogen bonds of TLN-3 and
TLN-4 are colored in red (protein residues in beige), carbon atoms, water molecules and
hydrogen bonds of TLN-7 and TLN-8 are colored in blue (protein residues in beige), carbon
atoms, water molecules and hydrogen bonds of TLN-9, TLN-10, TLN-11, and TLN-12 are shown
in gray. Heteroatoms are color coded according to atom type and the solvent excluded protein
surface is depicted in white.
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emphasized in cases, where the substituent introduces a sophisticated and well-packed
network of water molecules.
Remarkably, no entropic advantage is recorded for the ligands bearing a strictly hydrophobic
alkyl chain. This observation further underlines the fact that simplified models of the entropy
driven “hydrophobic effect”, which are ultimately based on studies of simple hydrophobic
molecules in aqueous solution [6], are not sufficient when complex topologies of protein–
ligand interfaces are considered [14].
4.5 Conclusion
The present study provides a number of important insights. The S2’ pocket of TLN is a flat,
mainly hydrophobic pocket that opens to the solvent environment. Intuitively, such pockets
are not considered as important in the optimization of ligand binding. At best, such pockets,
where ligand portions orient away from the protein binding site, are seen as ideal to attach
polar solubilizing groups to improve pharmacokinetic properties within a ligand class. In a
previous study, we could show that attachment of apolar P2’ substituents, which orient into the
interface between protein and surrounding water bulk phase, can enhance ligand affinity up to
50 fold. The affinity gain is maximized, if the network of water molecules of the first solvation
shell adopts an ideal, energetically favored architecture. The present example underlines,
particularly by facing matching pairs of polar and apolar P2’ substituents, that the attachment
of a terminal ammonium group reduces the affinity of the considered ligands by a factor of up
to 180 in Kd
Even when the polar moiety remains partly solvated or engages in strong interactions to the
protein, an enthalpic penalty, compared to its apolar analogue, is observed. Surprisingly, the
positioning of the charged group close to the solvent interface of the protein–ligand complex
did not induce a pronounced ordering leading to a strong organization of the surrounding
hydration shell. The interactions of solvent molecules with the charged ammonium group
seem to be of a less structured and more transient nature, rendering them difficult to observe
by X-ray crystallography. In terms of ligand potency, the partial desolvation of a hydrophobic
group in conjunction with an optimized structuring of a distinct water network in its hydration
shell, was found to be more beneficial than the introduction of a terminal polar substituent, for
which the costs of partial desolvation have to be accounted for. Within the studied series, the
enthalpic costs that have to be paid for this effect were largely independent of the chain length
to which the charged moiety was attached. We believe that it is reasonable to assume that a
similar energetic inventory will be observed for other systems, where ligand portions bind next
to a solvent interface. The study of such residual hydration effects next to the first solvation
layer will help to improve our understanding of the basic principles of ternary protein–ligand–
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solvent interactions and may prove useful for the developement of more effective drug
molecules.
4.6 Experimental Section
Inhibitor Synthesis
The synthesis of inhibitors 1–12 is detailed elsewhere [15,93,183].
ITC Data Collection
Thermodynamic profiles of all inhibitors were recorded on a Microcal ITC200 (GE
Healthcare) or Microcal ITC200 (Malvern) device. TLN was acquired from Calbiochem (EMD
Biosciences) as a freeze dried powder. Protein samples for ITC measurements were prepared
by dissolving the freeze dried powder in the respective buffer (20 mM HEPES, PIPES or sodium
cacodylate, 2 mM CaCl2, 500 mM NaSCN, pH7.5) directly before the experiment. A protein
concentration of 250 µM was used for the experiments with 1–8. The high protein
concentration was necessary to achieve a c-value > 1 (ܿ ൌ ݊ሾܲሿ଴ܭ௔) for low affinity
compounds. Inhibitor solutions were prepared from the freeze dried solids. A titrand
concentration between 3 mM and 3.5 mM with 10–15 injections of 2.4–3.5 µL was used for the
titrations. For synthetic reasons, ligand 8 could only be obtained in a diastereomeric mixture
with its P2’ epimer. Since the lack of saturation and the binding stoichiometry (n) in initial
titrations indicated that the (S,R)-diastereomer did not bind to TLN, the concentration was
adjusted to 7 mM for this ligand, assuming that the interaction is predominantly determined
by the (S,S)-diastereomer. The purity of all ligands was determined by qNMR and the
concentrations were corrected accordingly. Thermodynamic binding profiles of 9–12 in
HEPES buffer were first published in earlier contributions [15,93]. Due to varying
experimental conditions (buffer composition, protein batch, experimentator), the experiments
were repeated for this study and a buffer correction was performed. For these compounds, a
protein concentration of 48 µM and a ligand concentration of 1 mM with 10–15 injections of
1.6–3.5 µL was used. The raw thermograms were analyzed with NITPIC [167] version 1.1.2 and
SEDPHAT [184] version 12.1b. All titration were performed in duplicate or triplicate.
Crystal Preparation and Soaking
To an 8 mM solution of lyophilized TLN powder (Calbiochem) in 50 µL DMSO, 50 µL of a
solution containing 3.8 M CsCl and 100 mM Tris-HCl (pH 7.5) was added. After
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centrifugation (3 min, 16,000 g), 1 µL of the clear solution was transferred into the wells of a
24 well sitting drop crystallization plate. The reservoir wells were filled with 1 mL of
demineralized water. After sealing the crystallization plates, the crystals finished growing after
5 days at 18 °C. Soaking of the ligands was performed at a concentration of 1 mM for 24 h in a
buffer composed of 100 mM Tris-HCl (pH 7.5), 2 mM CaCl2, 5% DMSO. Subsequently, the
crystals were flash-frozen in liquid nitrogen in a buffer composed of 100 mM Tris-HCl (pH
7.5), 10 mM CaCl2, 5% DMSO, 20% MPD and 1 mM of the respective ligand.
Data Collection, Processing, Structure Determination and Refinement
Data collection for the TLN-1 to TLN-8 crystal structures was performed at BESSY II
(Helmholtz-Zentrum Berlin) MX-beamline 14.1 at a wavelength of 0.91841 Å. This facility is
equipped with a Dectris Pilatus 6M pixel detector. For indexing, integration and scaling of the
datasets, XDS [185] was used. Molecular replacement using Phaser (version 2.5.0) [159] was
applied for phasing with PDB 8TLN as a search model. Cartesian simulated annealing was
performed (default settings) as a first refinement step. Refinement of the initial model (xyz
coordinates, individual B factors, occupancies) was performed with Phenix.refine (version
1.10.1-2155) [162] and Coot (version 0.7) [186] was used for model building into ϯ-weighted
maps (2Fo–Fc and Fo–Fc). Alternating cycles of these processes were performed until R values
reached convergence. For the calculation of Rfree, a randomly chosen subset of 5% of the
reflections was excluded from the refinement. Hydrogen atoms were included to the model
with Phenix.refine. With the exception of hydrogen atoms, an anisotropic refinement strategy
of B factors for all model atoms was applied. An occupancy cutoff of 20% was used for
alternative conformations of protein residues. Ligand molecules were created with MOE [151]
and restraints were calculated with Phenix.elbow [163]. Data collection and refinement
statistics are given in Table 4.1 and Table 4.2.
4.7 Accession Codes
Atomic coordinates and experimental details for all new crystal structures will be released in
the PDB upon publication (TLN-1: 5N2Z; TLN-2: 5N2T; TLN-3: 5N34; TLN-4: 5N3V; TLN-
5: 5N31; TLN-6: 5N2X; TLN-7: 5MNR; TLN-8: 5N3Y). TLN-9 (4MXJ), TLN-10 (3T8F), TLN-
11 (3T8C), and TLN-12 (3T87) were reported earlier [15,93].
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4.9 Supporting Information
Results From Individual ITC Titrations
Table S4.1. Thermodynamic data from individual ITC measurements.
Measurement n Kd (µM) ΔG° (kJ mol−1) ΔH° (kJ mol−1) −TΔS° (kJ mol−1)
Cacodylate-1 a 1.12 5.02 -30.2 -33.3 3.0
Cacodylate-1 b 1.09 5.15 -30.2 -31.8 1.6
Cacodylate-1 c 1.12 4.54 -30.5 -32.1 1.6
 1.11±0.02 4.90±0.32 -30.3±0.2 -32.4±0.8 2.1±0.8
HEPES-1 a 0.98 10.93 -28.3 -14.1 -14.2
HEPES-1 b 1.05 8.33 -29.0 -14.1 -14.9
HEPES-1 c 1.09 9.03 -28.8 -14.0 -14.8
1.04±0.06 9.43±1.35 -28.7±0.3 -14.1±0.1 -14.6±0.4
PIPES-1 a 1.09 5.92 -29.8 -21.1 -8.8
PIPES-1 b 1.00 6.74 -29.5 -18.8 -10.7
PIPES-1 c 1.03 6.12 -29.8 -20.4 -9.3
 1.04±0.05 6.26±0.43 -29.7±0.2 -20.1±1.2 -9.6±1.0
Cacodylate-2 a 1.00 8.64 -28.9 -32.0 3.1
Cacodylate-2 b 0.95 8.58 -28.9 -32.4 3.4
Cacodylate-2 c 0.97 7.99 -29.1 -32.1 3.0
 0.97±0.03 8.40±0.35 -29.0±0.1 -32.2±0.2 3.2±0.2
HEPES-2 a 0.89 12.87 -27.9 -15.1 -12.8
HEPES-2 b 0.88 12.28 -28.0 -15.3 -12.7
HEPES-2 c 0.84 15.01 -27.5 -15.3 -12.2
 0.87±0.03 13.39±1.44 -27.8±0.3 -15.2±0.1 -12.6±0.3
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Table S4.1. Continued.
Measurement n Kd (µM) ΔG° (kJ mol−1) ΔH° (kJ mol−1) −TΔS° (kJ mol−1)
PIPES-2 a 0.91 10.27 -28.5 -24.9 -3.5
PIPES-2 b 0.73 11.33 -28.2 -27.3 -1.0
PIPES-2 c 0.83 11.59 -28.2 -26.5 -1.6
0.82±0.09 11.06±0.70 -28.3±0.2 -26.2±1.2 -2.0±1.3
Cacodylate-3 a 0.80 24.50 -26.3 -32.2 5.9
Cacodylate-3 b 0.73 22.03 -26.6 -33.0 6.4
0.77±0.05 23.27±1.74 -26.5±0.2 -32.6±0.6 6.1±0.4
HEPES-3 a 0.69 30.67 -25.8 -13.2 -12.6
HEPES-3 b 0.65 23.47 -26.4 -14.5 -11.9
HEPES-3 c 0.57 32.03 -25.7 -8.6 -17.1
 0.64±0.06 28.72±4.60 -25.9±0.4 -12.1±3.1 -13.9±2.8
PIPES-3 a 0.78 28.54 -25.7 -8.6 -17.1
PIPES-3 b 0.79 32.82 -25.9 -22.2 -3.8
PIPES-3 c 0.78 19.24 -25.6 -23.0 -2.6
 0.78±0.01 26.87±6.94 -26.1±0.7 -22.0±1.1 -4.2±1.8
Cacodylate-4 a 0.74 41.41 -25.0 -18.6 -6.4
Cacodylate-4 b 0.78 46.40 -24.7 -18.1 -6.6
Cacodylate-4 c 0.84 47.92 -24.7 -18.3 -6.4
 0.79±0.05 45.24±3.41 -24.8±0.2 -18.3±0.3 -6.5±0.2
HEPES-4 a 0.44 22.22 -26.6 -4.2 -22.3
HEPES-4 b 0.44 18.43 -27.0 -3.9 -23.2
HEPES-4 c 0.40 24.29 -26.3 -4.6 -21.7
 0.43±0.02 21.65±2.97 -26.6±0.3 -4.2±0.4 -22.4±0.7
PIPES-4 a 0.64 54.85 -24.3 -12.8 -11.5
PIPES-4 b 0.50 47.33 -24.7 -13.3 -11.3
PIPES-4 c 0.61 47.35 -24.7 -12.4 -12.3
 0.58±0.07 49.84±4.34 -24.6±0.2 -12.9±0.5 -11.7±0.5
Cacodylate-5 a 0.97 1.44 -33.3 -40.8 7.5
Cacodylate-5 b 0.84 1.86 -32.7 -40.5 7.8
Cacodylate-5 c 0.92 1.53 -33.2 -41.1 7.9
0.91±0.07 1.61±0.22 -33.1±0.3 -40.8±0.3 7.7±0.2
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Table S4.1. Continued.
Measurement n Kd (µM) ΔG° (kJ mol−1) ΔH° (kJ mol−1) −TΔS° (kJ mol−1)
HEPES-5 a 0.88 2.44 -32.0 -21.2 -10.8
HEPES-5 b 0.87 2.55 -31.9 -22.0 -9.9
0.88±0.01 2.49±0.08 -32.0±0.1 -21.6±0.6 -10.4±0.7
PIPES-5 a 0.96 1.77 -32.8 -28.4 -4.5
PIPES-5 b 0.82 1.29 -33.6 -29.7 -3.9
PIPES-5 c 0.90 1.54 -33.2 -29.8 -3.3
0.89±0.07 1.53±0.24 -33.2±0.4 -29.3±0.8 -3.9±0.6
Cacodylate-6 a 1.02 0.68 -35.2 -37.0 1.8
Cacodylate-6 b 0.99 0.76 -34.9 -40.0 5.1
Cacodylate-6 c 1.00 1.18 -33.8 -40.8 6.9
 1.00±0.01 0.87±0.27 -34.7±0.7 -39.3±2.0 4.6±2.6
HEPES-6 a 1.00 2.81 -31.7 -22.9 -8.8
HEPES-6 b 1.03 1.96 -32.6 -22.2 -10.4
HEPES-6 c 1.00 1.05 -34.1 -21.1 -13.0
 1.01±0.02 1.94±0.88 -32.8±1.2 -22.1±0.9 -10.7±2.1
PIPES-6 a 0.91 0.71 -35.1 -30.2 -4.9
PIPES-6 b 0.98 1.57 -33.1 -31.4 -1.7
PIPES-6 c 0.97 1.59 -33.1 -33.1 0.0
 0.95±0.03 1.29±0.50 -33.8±1.1 -31.6±1.5 -2.2±2.5
v 0.95 4.33 –30.6 –36.2 5.5
Cacodylate-7 b 0.93 2.55 –31.9 –32.9 1.0
 0.94±0.02 3.44±1.26 –31.3±0.9 –34.5±2.3 3.3±3.2
HEPES-7 a 0.87 11.42 –28.2 –17.4 –10.9
HEPES-7 b 0.88 9.47 –28.7 –17.6 –11.1
HEPES-7 c 0.79 7.69 –29.2 –17.1 –12.1
 0.85±0.05 9.53±1.87 –28.7±0.5 –17.4±0.3 –11.3±0.7
PIPES-7 a 0.80 5.45 –30.0 –25.6 –4.4
PIPES-7 b 0.84 4.50 –30.5 –25.8 –4.7
PIPES-7 c 0.82 5.78 –29.9 –24.7 –5.2
 0.82±0.02 5.24±0.67 –30.2±0.3 –25.4±0.6 –4.8±0.4
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Table S4.1. Continued.
Measurement n Kd (µM) ΔG° (kJ mol−1) ΔH° (kJ mol−1) −TΔS° (kJ mol−1)
Cacodylate-8 a 0.85 9.53 –28.7 –38.4 9.7
Cacodylate-8 b 0.90 9.42 –28.7 –38.4 9.7
Cacodylate-8 c 0.78 9.00 –28.8 –39.5 10.7
 0.84±0.02 9.32±0.28 –28.7±0.1 –38.7±0.6 10.0±0.5
HEPES-8 a 0.82 9.83 –28.6 –18.3 –10.3
HEPES-8 b 0.72 11.40 –28.2 –20.7 –7.5
HEPES-8 c 0.73 11.49 –28.2 –19.8 –8.4
 0.76±0.06 10.91±0.93 –28.3±0.2 –19.6±1.2 –8.7±1.4
PIPES-8 a 0.71 9.97 –28.5 –31.9 3.3
PIPES-8 b 0.75 10.32 –28.5 –33.4 5.0
 0.73±0.03 10.15±0.25 –28.5±0.1 –32.7±1.1 4.2±1.1
Cacodylate-9 a 1.02 0.34 –36.9 –43.7 6.8
Cacodylate-9 b 1.08 0.30 –37.2 –44.1 6.9
 1.05±0.05 0.32±0.03 –37.1±0.2 –43.9±0.3 6.9±0.1
HEPES-9 a 0.98 0.59 –35.6 –19.7 –15.9
HEPES-9 b 0.97 0.67 –35.3 –20.4 –14.8
 0.98±0.01 0.63±0.05 –35.4±0.2 –20.1±0.5 –15.4±0.8
PIPES-9 a 0.99 0.46 –36.2 –31.6 –4.5
PIPES-9 b 1.02 0.53 –35.8 –32.2 –4.4
 1.01±0.02 0.50±0.05 –36.0±0.3 –31.5±0.2 –4.5±0.1
Cacodylate-10 a 1.02 1.36 –33.5 –35.6 2.1
Cacodylate-10 b 0.99 1.19 –33.8 –35.1 1.3
 1.01±0.02 1.27±0.12 –33.7±0.2 –35.3±0.4 1.7±0.6
HEPES-10 a 0.97 2.30 –32.2 –14.1 –18.1
HEPES-10 b 0.94 2.35 –32.1 –14.2 –17.9
 0.95±0.02 2.33±0.04 –32.2±0.1 –14.2±0.1 –18.0±0.1
PIPES-10 a 1.08 2.03 –32.5 –26.3 –6.2
PIPES-10 b 1.03 1.86 –32.7 –25.5 –7.2
 1.06±0.04 1.94±0.11 –32.6±0.2 –25.9±0.6 –6.7±0.7
Cacodylate-11 a 1.12 0.07 –40.8 –53.7 12.9
Cacodylate-11 b 1.18 0.06 –41.4 –55.5 14.1
 1.15±0.05 0.06±0.01 –41.1±0.4 –54.6±1.2 13.5±0.9
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Table S4.1. Continued.
Measurement n Kd (µM) ΔG° (kJ mol−1) ΔH° (kJ mol−1) −TΔS° (kJ mol−1)
HEPES-11 a 1.07 0.13 –39.3 –27.5 11.8
HEPES-11 b 1.09 0.17 –38.6 –28.5 10.2
 1.08±0.01 0.15±0.03 –39.0±0.5 –28.0±0.7 11.0±1.2
PIPES-11 a 1.01 0.09 –40.3 –40.0 –0.3
PIPES-11 b 1.11 0.09 –40.3 –40.0 –0.2
 1.06±0.07 0.09±0.00 –40.3±0.0 –40.0±0.0 –0.3±0.1
Cacodylate-12 a 1.24 0.06 –41.1 –58.5 17,4
Cacodylate-12 b 1.19 0.05 –41.6 –55.7 14.2
 1.21±0.03 0.06±0.01 –41.3±0.3 –57.1±1.9 15.8±2.3
HEPES-12 a 1.18 0.11 –39.7 –33.3 –6.4
HEPES-12 b 1.22 0.13 –39.2 –34.3 –5.0
 1.20±0.03 0.12±0.02 –39.4±0.3 –33.8±0.7 –5.7±1.0
PIPES-12 a 1.16 0.06 –41.0 –42.7 –1.7
PIPES-12 b 1.20 0.07 –40.8 –45.1 –4.3
 1.18±0.03 0.07±0.00 –40.9±0.2 –43.9±1.7 –3.0±1.9
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Representative Thermograms and Binding Isotherms
Figure S4.1. Representative thermograms and extracted binding isotherms from ITC
measurements of 1–4..
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Figure S4.2. Representative thermograms and extracted binding isotherms from ITC
measurements of 5–8..
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Figure S4.3. Representative thermograms and extracted binding isotherms from ITC
measurements of 9–12..
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Buffer correction of the thermodynamic binding profiles
Table S4.2. Buffer corrected thermodynamic data.
Inhibitor Δna ΔG° (kJ mol−1) ΔH° (kJ mol−1) −TΔS° (kJ mol−1)
1 0.77±0.05 –29.6±0.4 –29.4±0.7 –0.15±0.8
2 0.68±0.21 –28.4±0.3 –30.9±2.9 2.6±2.9
3 0.86±0.10 –26.2±0.7 –30.1±1.4 3.9±1.6
4 0.57±0.15 –25.3±0.5 –17.2±2.1 –8.2±2.2
5 0.80±0.01 –32.8±0.5 –38.1±0.2 5.3±0.5
6 0.70±0.14 –33.7±1.8 –37.5±1.9 3.8±2.6
7 0.71±0.07 –30.0±1.1 –32.4±0.9 2.4±1.4
8 0.77±0.27 –28.5±0.2 –37.5±3.7 9.0±3.7
9 0.98±0.11 –36.1±0.8 –41.1±1.5 5.0±1.7
10 0.86±0.17 –32.8±0.7 –33.2±2.3 0.4±2.4
11 1.10±0.08 –40.1±1.0 –51.2±1.1 11.1±1.5
12 0.97±0.05 –40.6±0.9 –54.0±0.7 13.4±1.1
a Number of protons transferred during ligand binding. Inferred from the slope of the
regression line of the plot of DHobs against DHion.
Figure S4.4. Plot of the observed binding enthalpy in three buffers against ionization
enthalpies (taken from [297]).
 Paying the Price of Solvation in Solvent Exposed Protein Pockets | 179
C
h
a
p
te
r 
4
Additional Crystallographic Observations
Figure S4.5. Residual electron density in the crystal structure of 1. The 2mFo–DFc electron
density for the water molecules that were included in the crystallographic models is shown as
a blue mesh (1.0s). The residual electron density (mFo–DFc density map, 3.0s) is shown as
green/red meshes for positive/negative peaks respectively.
Figure S4.6. Indication of a third conformation of the ligand side chain in the crystal structure
of 8. The 2mFo–DFc (1.0s) and the mFo–DFc (3.0s) electron density maps of the ligand are shown
as blue and green meshes, respectively. Water molecules and hydrogen bond interactions are
omitted for reasons of clarity.
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5.1 Introduction
The deep, hydrophobic S1’ pocket of thermolysin (TLN), which is large enough to
accommodate a P1’ substituent up to a benzyl side chain, has previously been reported by us to
be poorly solvated and to contain only disordered water molecules, whose displacement would
give rise to a strong enthalpic benefit [33]. In the current contribution, we try to collect more
evidence for this poor solvation pattern, maximally composed of disordered water molecules
in the S1’ pocket of this metalloprotease, and investigate the origin of the reported enthalpy
gain. In this context, we analyze the protein–ligand complex formation of a series of six
phosphonamidate-type TLN inhibitors (Figure 5.1A) using X-ray crystallography and
isothermal titration calorimetry (ITC). Going from a hydrogen atom to a iso-butyl P1’ group
(Figure 5.1B), an amazingly strong affinity increase of 26.3 kJ mol–1 is observed. For the
explanation of the molecular mechanism behind this considerable affinity increase, exact
knowledge about the solvation state within the S1’ cavity is required. For TLN-1, we determined
an experimentally phased electron density map via a zinc multi-wavelength anomalous
diffraction (MAD) experiment. The experimentally phased electron density map provides the
advantage that no model bias is introduced by phasing of the structure compared to less
elaborate strategies such as molecular replacement. Additionally, we attempt to transform the
sigma-scaled electron density map to an absolute electron number scale (e–/Å3) to enable the
determination of the exact total electron content within the S1’ cavity. This strategy allows the
detection of electron density traces, which can indicate highly mobile, crystallographically
disordered water molecules [187]. To characterize the volume and polarity of the S1’ cavity of
TLN-1 experimentally, we used the noble gases xenon and krypton as probes to fill the pocket.
Considering the complexes of 1 to 4, the residual unoccupied volume of the S1’ cavity is
gradually reduced, thus decreasing the putative residence volume of a potentially bound
mobile water molecule. Inhibitors 5 and 6 even comprise polar functional groups that increase
the polarity within the cavity and provide a potential hydrogen-bonding anchor to fix a
remaining S1’ water occupant. Both strategies, reducing the residence volume and increasing
the polarity within the cavity, should diminish the mobility of a potentially present residual
water molecule and increase the concentration of its electrons within the cavity, thus
facilitating its detection in a crystal structure.
5.2 Results
Isothermal titration calorimetry
ITC measurements of 2–4 were performed by direct titrations (Figure S5.1A–C) and for 1, 5
and 6 by displacement titrations (Figure S5.1D–F). The thermodynamic profiles of 2–4 were
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corrected for proton transfer reactions upon complex formation via measurement in several
buffers showing different ionization enthalpies (Figure S5.2) [123]. Such corrections were not
performed for the displacement titrations of 1, 5 and 6, because this would have resulted in
large experimental uncertainties, rendering the thermodynamic parameters unreliable even for
mutual comparison.
Figure 5.1. Congeneric series of phosphonamidate TLN ligands substituted with different P1’
groups. (A) Schematic binding mode of the parent ligand scaffold in complex with TLN. Protein
residues and the zinc ion forming hydrogen bonds (orange dashed lines) with the parent scaffold
are indicated (GOL = glycerol molecule from the cryo buffer bound to TLN). The S1and S2’ and
pockets of TLN are wide-open and well-accessible to water molecules, whereas the S1’ pocket is
deep and apolar. (B) P1’ substituents of 1–6 and their thermodynamic binding profiles as
determined by ITC. The thermodynamic profiles shown for 2, 3 and 4 were corrected for the heat of
buffer ionization upon complex formation. Error bars represent the 95.4% confidence interval. A
reliable determination of the buffer-corrected enthalpy/entropy partitioning of 1, 5 and 6
(displacement titrations) is impossible and thus in these cases only the standard Gibbs free energy
is discussed. Data values are listed in Table S5.1.
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The thermodynamic profiles of 1–6 are displayed in Figure 5.1B. The affinity strongly increases
with the growing hydrophobic size of the P1’ group (1→2→3→4) over 4.5 orders of magnitude
(expressed in terms of the binding constants as listed in Table S5.1). In particular, the addition
of a single methyl group to 1 yielding 2 (ΔΔG°1→2= –12.3 kJ mol−1) and the addition of two
methyl groups to 2 yielding 3 (ΔΔG°2→3 = –9.2 kJ mol−1) result in substantial affinity boosts.
With respect to the partitioning in ΔH° and –T∆S°, the affinity increase from 2→3→4 is the
result of a sharp increase in ΔH°, which is only partially compensated by a decrease in –T∆S°.
The affinities of 5 and 6 fall between those of 1 and 2. The amino-substituted 6 clearly shows a
higher affinity than the hydroxyl-substituted 5.
Crystal structure analysis
In addition to the already published crystal structures of TLN-2, TLN-3 and TLN-4 [33], we
succeeded in crystallizing TLN-1, TLN-5, and TLN-6 (Table 5.1). Furthermore, we also
obtained TLN-1 in complex with xenon (TLN-1-Xe) and krypton (TLN-1-Kr). Except for the
native structure of TLN-1 that was experimentally phased, all other crystal structures were
phased by the standard molecular replacement technique.
Shape, polarity and solvent content analysis within the S1’ cavity and within
three internal reference cavities of TLN-1
The structure of TLN-1 was experimentally phased using a zinc MAD dataset (Table 5.2). The
experimental phasing of TLN-1 without any further least-squares refinement steps resulted in
a very clear, high-quality electron density (Supporting Information, Figure S5.3) with an
overall figure of merit (FOM) of 0.870. We decided to apply density modification techniques
(solvent flattening and histogram matching) on the experimental phases since this resulted in
a significantly improved quality of the electron density map (overall FOM increased from 0.763
to 0.870). Since the analyzed cavities are completely buried within the core of TLN and exhibit
a narrow shape, the electron density within the cavities is not affected by the applied phase
improvement techniques. The experimentally phased density map was put on an absolute
electron number scale (see Chapter 5.5.8 for further details), and the total electron content
within the S1’ cavity and three internal reference cavities of different solvation state was
calculated. The protein model coordinates displayed in Figure 5.2A–E are taken from the
experimentally phased, fully refined and deposited model of the native TLN-1 (PDB code
5M9W), whereas the superimposed electron density map is the experimentally phased electron
density without any further model-based refinement. In the following, the cavities and electron
density maps are described relative to the view of Figure 5.2B–E.
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Table 5.2. Zinc MAD dataset of TLN-1 used for experimental phasing. a
peak inflection remote
Space group P6122 P6122 P6122
Unit cell parameters: a, b, c
(Å)
92.5, 92.5, 131.0 92.6, 92.6, 131.0 92.6, 92.6, 131.0
Wavelength (Å) 1.281960 1.283060 0.918410
Resolution range (Å) 50.00–1.50
(1.59–1.50)
50.00–1.50
(1.59–1.50)
50.00-1.32
(1.40-1.32)
Unique reflections 91983 (11525) 91926 (11423) 137883 (17564)
Rsym (%) 4.3 (17.2) 3.6 (14.5) 5.4 (46.0)
Completeness (%) 91.4 (71.0) 91.3 (70.3) 93.2 (73.4)
Redundancy 7.8 (7.5) 7.8 (7.5) 7.9 (7.5)
<I/σ(I)> 31.0 (9.8) 37.0 (12.1) 24.2 (4.2)
a Numbers in brackets stand for the highest resolution shells.
The S1’ cavity (Figure 5.2B) comprises a volume of 141 Å3. The top of the cavity is exclusively
formed by apolar amino acid side chains of protein residues in addition to the ligand atoms of
the P1’ group and the leucine P2’ portion of 1. The mid- to lower left part of the cavity is mainly
apolar, except for Asp138, that, however, is inaccessible for hydrogen bonding due to its buried
geometry. The polar side chains of Glu143, Asp170, and Arg203 describe the right-hand
surface portion of the cavity. However, except for the side chain of Glu143, they are all highly
involved in saturating polar contacts and thus not available for hydrogen bonding with
putative occupants of the S1’ pocket. The total electron content integrated over the entire
volume of the S1’ cavity is 6.6 e–.
Reference cavity 1 (Figure 5.2C) is a highly polar cavity comprising a volume of 59 Å3. It
contains three water molecules that establish multiple hydrogen bonds (2.8–3.2 Å) to adjacent
polar functional groups of TLN residues. The observed firm density peaks comprise spherical
shapes and have been refined to fully occupied water molecules with low B factors of 11–12 Å2.
The integrated total electron content within this reference cavity 1 is 19.4 e–.
Reference cavity 2 (Figure 5.2D) opens a volume of 93 Å3. In the lower part of the pocket, a
strong electron density peak originating from a water molecule (refined B factor: 10 Å2) is
detected. This water molecule establishes three hydrogen bonds with Tyr81 (backbone O, 2.9
Å), Arg90 (backbone O, 2.7 Å), and Ser92 (backbone N, 2.8 Å). In contrast, the upper part of
the cavity has a highly apolar character. Apart from the described peak assigned to the
hydrogen-bonded water molecule, a second, far less intense electron density peak is observed
in the center of the large apolar cavity (maximum concentration of 0.62 e–/Å3, Figure 5.2D).
The distance of this peak to that of the already assigned water molecule is 3.2 Å. The integrated
total electron content within reference cavity 2 is 13.4 e–.
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Figure 5.2. Analysis of the experimentally phased electron density map of TLN-1 within selected
cavities. (A) Ribbon model of the refined TLN-1 indicating the solvent excluded surface of the S1’
cavity and of the internal reference cavities 1–3 as dark gray mesh. Water molecules within these
cavities are shown as magenta spheres. The zinc ion is shown as dark blue sphere and the four
calcium ions of TLN are shown as gray spheres. The TLN-bound ligand 1 is indicated as light orange
stick model. (B–E) Depiction of the experimentally phased absolute-scale electron density map
detected within the (B) S1’ cavity (volume 141 Å3; total electron content: 6.6 e–), (C) reference cavity
1 (volume 59 Å3; total electron content: 19.4 e–), (D) reference cavity 2 (volume 93 Å3; total electron
content: 13.4 e–), and (E) reference cavity 3 (volume 16 Å3; total electron content: 0.9 e–). The electron
density map is displayed as blue, cyan or red mesh indicating three different contour levels in e–/Å3.
Selected density peaks are labeled with their concentration maximum. Cavity lining TLN residues
are shown as thin gray stick models. The solvent excluded surfaces of the cavities are indicated in
semi-transparent gray. In panel B, the TLN-bound 1 is shown as light orange stick model, and the
zinc ion is shown as dark blue sphere. In panels C and D, water molecules are shown as magenta
spheres and hydrogen bond interaction distances as orange dashed lines (labeled in Å). The
determined volume and total electron content of the cavities are summarized in Table S5.7
(Supporting Information). The electron density maps of all four cavities are shown at six different
contour levels from –0.2 to 0.3 e–/Å3 in Figure S5.4 to Figure S5.7.
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Reference cavity 3 (Figure 5.2E) is, apart from the S1’ cavity, the largest cavity which remains
non-solvated in the refined structure of TLN-1. Its volume of 16 Å3 is significantly smaller than
that of the S1’ cavity. Its character is primarily apolar, and it is flanked by polar atoms of Asn112
(backbone O), Val121 (backbone O), and Gly123 (backbone N). The integrated total electron
content within reference cavity 3 is 0.9 e–.
Xenon and krypton derivatization of TLN-1
Pressure derivatization of TLN-1 with xenon and krypton was performed at 9 and 5 bar,
respectively. The position of bound xenon and krypton in the crystal structure can be
unambiguously identified in the electron density due to their anomalous scattering properties
[189]. To optimize the anomalous signal of xenon, a wavelength of 1.4 Å (f’’ = 6.3 e–) was
chosen, resulting in a strong anomalous signal without significantly losing scattering power
due to the long wavelength and air absorption of the X-ray beam (Table 5.1). In the case of
krypton, two datasets of the same crystal were collected directly above and below the K
absorption edge of krypton to unambiguously identify bound atoms of the noble gas (Table
5.3). Even though the difference between the wavelengths is only about 0.024 Å, the change of
the anomalous signal of krypton is drastic, whereas its Fo–Fc electron density virtually remains
unaffected (Supporting Information, Figure S5.8). All datasets of the TLN-1 noble gas
derivatives were collected with high redundancy to maximize the accuracy of the anomalous
signal (Table 5.1).
Table 5.3. Datasets of noble gas derivatized TLN-1 used for the determination of the anomalous
signal (Friedels pairs separated).a
TLN-1-Kr
(above K edge)
TLN-1-Kr
(below K edge) TLN-1-Xe
Space group P6122 P6122 P6122
Unit cell parameters: a, b, c (Å) 92.4, 92.4, 130.2 92.5, 92.5, 130.2 92.5, 92.5, 130.0
Wavelength (Å) 0.859400 0.871500 1.40000
Resolution range (Å) 50.00–1.33
(1.41–1.33)
50.00–1.35
(1.43–1.35)
50.00–1.44
(1.53–1.44)
Unique reflections 142833 (23002) 136781 (22091) 111687 (17774)
Rsym (%) 7.8 (48.7) 8.2 (46.6) 9.9 (48.0)
Completeness (%) 99.9 (99.7) 99.9 (99.6) 99.2 (97.6)
Redundancy 11.0 (10.2) 8.6 (8.0) 19.8 (19.3)
<I/σ(I)> 19.2 (4.6) 15.6 (4.0) 20.9 (5.9)
a Numbers in brackets stand for the highest resolution shells.
For both noble gases, binding was observed in the S1’ cavity (refined occupancy of xenon: 17%,
krypton: 8%) as well as in reference cavity 3 (refined occupancy xenon: 68%, krypton: 20%).
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The binding of xenon within the upper, highly apolar part of the deeply buried reference pocket
3 has been previously reported by us (unpublished results, PDB code 3LS7). Both types of noble
gases populate at the same positions in the S1’ cavity as well as in the upper part of reference
cavity 3. In the S1’ cavity, van der Waals interactions (up to 4.6 Å) are established to the side
chains of Val139, His142, Glu143, Ile188, Leu202, Arg203, and the portion of 1 covering the
S1’ pocket (Figure 5.3). No adaptations of cavity-lining residues of the noble gas derivatized
TLN-1 are observed compared to the native structure of TLN-1.
Comparison between the S1’ cavities of TLN-1 to TLN-6
In none of the refined, ϯ-scaled Fo–Fc electron densities of the six crystal structures TLN-1 to
TLN-6, any clearly defined electron density attributable to a bound water molecule could be
detected in the S1’ cavity. Even in the complexes of TLN with the ligands exhibiting the polar
P1’ groups (5 and 6), the unoccupied part of the cavity remains seemingly empty, even though,
as indicated in Figure 5.4, sufficient space to accommodate a water molecule is given.
Figure 5.3. Xenon binding site in the S1’ cavity of TLN-1. The xenon derivatized crystal structure
TLN-1-Xe (dark gray) is superimposed on the native crystal structure of TLN-1 (light gray). The center
of the bound xenon atom is shown as teal sphere, and its van der Waals radius is indicated as teal
mesh. The zinc ion is shown in similar fashion in dark blue. Cavity surface lining TLN residues are
shown as thin sticks, the bound 1 is shown as thick stick model. The solvent excluded surface of the
S1’ cavity is indicated in semi-transparent white. The anomalous map is displayed in gold at a
contour level of 5σ. The crystal structure of TLN-1-Kr is shown in Figure S5.8.
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Figure 5.4 displays the crystal structure models of TLN-1 to TLN-6 and the residual S1’ cavities.
With growing P1’ portion (1→4), the top part of the cavity is gradually occupied, until only the
bottom part of the cavity remains unoccupied (Figure 5.4A–D). Accordingly, the volume of
the S1’ cavity is gradually decreasing from 141 Å3 to 48 Å3 (Figure 5.4). The hydrophobic P1’
groups of TLN-2, TLN-3 and TLN-4 form multiple hydrophobic van der Waals interactions
to the pocket-shape determining amino acid side chains of TLN. Whereas the P1’ OH group of
the serine derivative is found in only one populated conformation forming a hydrogen bond
to the side chain of Glu143 (2.6 Å, Figure 5.4E), three conformations (occupancy a: 42%, b:
27%, and c: 31%) can be assigned to the P1’ amino function of 6 in the refined model (Figure
5.4F). Conformations b and c place the amino group within hydrogen-bonding distance to the
side chain of Asn112 (3.0 Å) and Glu143 (2.5 Å).
Figure 5.4. S1’ cavities of crystal structures TLN-1 to TLN-6. (A) TLN-1, (B) TLN-2, (C) TLN-3, (D) TLN-
4, (E) TLN-5, (F) TLN-6. The solvent excluded surfaces of the S1’ cavities are displayed as dark gray
mesh labeled with their volume in Å3. Cavity lining amino acids are displayed as gray stick models.
Ligands 1–6 are shown as thick stick models in light orange. The zinc ion is displayed as a dark blue
sphere. Hydrogen bonds formed between TLN and the P1’ group of 5 and 6 are indicated as orange
dashed lines (labeled in Å). The three conformations of the P1’ group of 6 are labeled with a–c. All
three conformations of the latter P1’ substituent were considered for the calculation of the residual
cavity volume.
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5.3 Discussion
Analysis of the experimentally phased electron density within the S1’ cavity
of TLN-1
Even with high-resolution data as in the current case, the analysis of the solvation pattern
within a protein cavity by X-ray crystallography is by no means straightforward, since highly
mobile (“disordered”) or partially occupied water molecules are difficult to detect on first
glance. A highly mobile water molecule may be characterized by the lack of a well-defined,
sufficiently deep energy minimum on the free energy landscape, resulting in a widely
distributed, rather blurred electron density lacking a clearly defined center [190]. Model bias
introduced into the electron density via the use of phases transferred from the refined structure
of a related complex can obscure the detection of such weak density signals. In particular, the
use of the commonly applied molecular replacement as phasing technique can result in a
significant impact of model bias [191–193]. Experimentally phased electron densities have the
advantage that no model bias is arbitrarily introduced by the application of predefined model
phases [187,194,195]. Therefore, to reliably detect traces of electron density originating from
highly mobile or partly occupied water molecules, we performed an elaborate experimental
phasing protocol for TLN-1. Even though unbiased phases can be obtained by this procedure,
another obstacle arises from the fact that the total electron number within the crystal unit cell
F000 is impossible to determine experimentally in the case of proteins. In small molecule
crystallography, the content of the diffracting unit cell is usually easy to define and thus the
number of contributing electrons is clear. In the case of proteins showing a large solvent
content particular in the channels passing through the crystal, such an assignment is
impossible and thus can only be estimated. In consequence, electron densities in protein
crystallography are typically ϯ-scaled [196], where zero s corresponds to the average,
numerically unknown electron concentration of the unit cell. Even though this step appears
very reasonable and pragmatic in usual standard refinements of protein structures, it will make
an assignment of an absolute electron number of electrons to a particular integrated volume
virtually impossible. Therefore, we attempted to transform the experimentally phased electron
density to an absolute electron number scale, where the zero value corresponds to vacuum.
Following a similar approach, Liu et al. analyzed a hydrophobic cavity of 134 Å3 in
L99A/M102L T4 lysozyme [195]. In this case, analysis of the experimentally phased electron
density on absolute scale discovered a water cluster of three water molecules with an occupancy
of approximately 50% within this pocket. In another example, the analysis of an experimentally
phased electron density of a central apolar cavity of 40 Å3 observed in interleukin-1ß settled
the debate about the presence of a disordered water molecule in this volume [194,197–199].
From the data analysis, Quillin et al. concluded that the cavity must indeed be empty [194].
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Reference cavity 3 is considered as an internal control for an entirely empty cavity (Figure
5.2E). This small, apolar cavity of 16 Å3 is due to its size and polarity unsuited to host a water
molecule [200–202]. With respect to the calculated volume of 16 Å3 for reference pocket 3 it
must be considered that the calculation of the volume that is really available to host a water
molecule is non-trivial and is actually further reduced adjacent to apolar residues [203,204]. In
other words, the solvent probe radius adjacent to apolar residues is in fact larger than the
commonly applied 1.40 Å. Consequently, the presence of a water molecule in reference cavity
3 can be certainly excluded. The electron concentration peak found within this cavity
comprises a concentration maximum of 0.41 e–/Å3, and the total electron content is 0.9 e–. We
consider this electron content the result of “spillover” of electrons from cavity lining amino
acids into the to some degree fuzzy volume of the empty cavity [194,195], e.g. due to a slight
movement of the protein residues. Reference cavities 1 and 2 (Figure 5.2C and D) serve as an
internal control for clearly solvated cavities. The calculated total electron content within
reference cavity 1 (59 Å3) is 19.4 e–, a number significantly lower than expected for three fully
occupied water molecules (30 e–). Similar as observed by Liu et al. [195], this is possibly the
result of the electron spillover from within the cavity to the outside due to overlapping van der
Waals radii of polar cavity-lining atoms and the tightly hydrogen-bonded water molecules.
Reference cavity 2 (93 Å3) contains a total electron content of 13.4 e–. Apart from the
unambiguous water density in the lower part of the cavity, a significant amount of blurred
electron density with a peak maximum of 0.62 e–/Å3 is detected in the balloon-like shaped
upper, hydrophobic part of the cavity (Figure 5.2D) — which is large enough to host a phenol
molecule without that the water molecule in the lower part of the cavity is displaced [205]. The
electron concentration maximum is within hydrogen bonding distance (3.2 Å) to the modeled
water molecule in the lower part of the cavity and could potentially originate from a second,
very low populated water site. Overall, this results in a higher electron content than expected
for the single fully occupied water molecule, overcompensating the also in this case expected
spillover of electrons of the tightly bound water molecule to the outside of the cavity.
Remarkably, the residual electron distribution within the S1’ cavity shows an electron
concentration of maximally 0.46 e–/Å3, a value close to the one found for the empty reference
cavity 3 (0.41 e–/Å3). The total electron content within the S1’ cavity was determined to be 6.6
e–. If the electron content within the empty reference cavity 3 (0.9 e–) is extrapolated to the
larger volume of the S1’ cavity (141Å3/16 Å3 = 8.8 times larger), this corresponds to 7.9 e– (0.9
e– × 8.8), a number higher than the one for the experimentally determined electron content
within the S1’ cavity (6.6 e–). This can be explained by the fact that relative to their volumes
reference cavity 3 has a significant larger surface than the S1’ cavity, resulting in a
proportionally larger electron “spillover” (vide supra). Taking into account these
considerations we therefore propose that the TLN-1 S1’ cavity is indeed a completely
unsolvated cavity. We also believe that this is not simply a consequence of the binding of 1
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which seals the pocket from the top. Our complex structures of TLN-1 with the noble gases
clearly demonstrate that the pocket is still well accessible in the crystal by particles as large as a
xenon atom, likely due to the residual mobility of the complexes. Thus, smaller water molecules
could easily access the S1’ pocket if their penetration would be favorable.
Analysis of TLN-1 in complex with xenon and krypton and of crystal
structures TLN-1 to TLN-6
The noble gases xenon and krypton are known to preferentially bind to desolvated,
hydrophobic protein cavities through weak van der Waals interactions [206,207]. These atoms
can, therefore, be used as experimental probes to detect such cavities. The S1’ cavity (Figure
5.3) and reference cavity 3 were revealed as noble gas binding sites in TLN-1. The fact that both
noble gases were found binding to the S1’ cavity even though the derivatization pressure was
kept low supports the hypothesis that both cavities do not contain significantly populated
solvent molecules, that need to be displaced upon ligand accommodation. The increased
occupancy of the gaseous probes in reference cavity 3 compared to the S1’ cavity can be
attributed to the deeper burial of this cavity within the apolar interior of TLN. Thus, during
the experimental depressurization phase, that needs to be accomplished to transfer the crystal
specimen from the pressuring cell to the liquid nitrogen, diffusion of the noble gases is slower.
The reduced occupancy of krypton compared to xenon is attributable to the reduced
polarizability of the former [208,209], the lower applied derivatization pressure, and the faster
diffusion kinetics of the smaller krypton atoms. Noble gas binding provides a crude estimate
about the at least available space within a given cavity, and provides information about an at
least detectable electron concentration in a certain volume [208,210]. For instance, in TLN-1-
Kr (Figure S5.8), the krypton atom (36 e–, van der Waals radius 2.0 Å, volume 33.5 Å3) bound
to the S1’ cavity was refined to 8% occupancy. This corresponds to 2.9 electrons (36 e– × 0.08).
Considering the refined temperature factor of 12.5 Å2 of this krypton atom, krypton will occupy
a volume of about 58 Å3 [190,210]. Hence, if we transfer this detection limit to our cavity
analysis, a putative water molecule occupied as low as 29% (corresponding to 2.9 e–) and
distributed over a volume of 58 Å3 should be detectable by conventional refinement. If we apply
this estimation rule to the S1’ cavities of complexes TLN-1 to TLN-6, it is permissible to
conclude that the residual volumes found in TLN-3 to TLN-6 (48–76 Å3, Figure 5.4) must be
virtually empty. This is further supported by the observation that the S1’ cavities of TLN-3,
TLN-4 and TLN-6 are divided by the P1’ groups of the bound ligands into two spatially
separated cavities, reducing the mobility of a putatively present water molecule even further.
Consequently, a potentially present — but nonetheless undetectable — water molecule must
be very low occupied to elude crystallographic detection completely. We believe that this minor
displacement effect would be insignificant for the binding event and would hardly influence
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the overall thermodynamic profile. Thus, for the discussion of the thermodynamic signature,
we refer to the empty state of the cavity.
The polar groups of 5 and 6 were introduced into the S1’ pocket with the aim to provide a local
anchor for hydrogen bonding for a potentially present and disordered water molecule. If such
a water molecule would hypothetically be present in the complexes with the aliphatic ligands,
this hydrogen-bonding decoy should result in the stabilization of a disordered water molecule
— or possibly in the recruitment of a new water molecule from the bulk water phase — and
make it crystallographically detectable [211,212]. However, no clear electron density peak is
observed in the crystal structures of TLN-5 or TLN-6. One reason to be regarded why the polar
groups are not available to establish hydrogen bonds to a putative water molecule might arise
from the fact that they form hydrogen bonds to protein residues. However, conformation a
with the highest population of the amino function of 6 orients toward the void of the cavity
where it could experience hydrogen bonding (Figure 5.4F). Another reason could be that even
though the polarity of the S1’ cavity of TLN-5 and TLN-6 increases, the volume of the cavity is
reduced, which decreases the probability to find a water molecule within a cavity [201].
Thermodynamic binding profiles of 1–6 as determined by ITC
The affinities of the investigated ligand series fall into the range between milli- to nanomolar
binding (Table S5.1). Because of this broad range, it was necessary to apply different
measurement protocols to obtain reliable calorimetric data. Ligands 2, 3 and 4 were measured
by direct titration. Due to their low affinities, 1, 5 and 6 had to be characterized by displacement
titrations. The measurement accuracy of the latter ligands is strongly dependent on how
accurately the thermodynamic data of the applied reference ligand has been recorded. Any
error in the thermodynamic profile of the reference ligand will propagate to the
thermodynamic profile of the analyte. Consequently, such measurements usually result in large
experimental errors, in particular considering the partitioning of enthalpy and entropy [96].
The affinity of 1 is too low to accurately determine the enthalpy/entropy signature via
displacement titration. Furthermore, 5 and 6, comprising polar P1’ groups, show very likely
different changes in their protonation state compared to the ligands with the aliphatic P1’
groups. A superposition of a proton transfer reaction can alter the observed enthalpy of
binding and therefore prevent a direct comparability of measured enthalpy values [213].
Unfortunately, an appropriate enthalpy correction is not reliably feasible in a displacement
titration scenario due to the resulting highly potentiating errors of the buffer-corrected
thermodynamic profiles. Consequently, we decided to refrain from analyzing the
enthalpy/entropy profiles of 1, 5 and 6, and instead solely report their affinities. This value is
independent of buffer effects and allows accurate comparison with the more potent ligands.
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The addition of a single methyl group to the glycine derivative 1 (yielding 2) results in a more
than 100-fold affinity increase (Figure 5.1B and Table S5.1). Adding two further methyl groups
to 2 (yielding 3) results in a further 40-fold affinity increase. Finally, the addition of a further
methyl group from 3 to 4 corresponds to a 7-fold affinity increase. Based on a statistical
evaluation, a 100-fold affinity increase solely achieved by the addition of one single methyl
group has been reported to be a very rare event with a probability of only 0.4% [214]. In the
reported cases, the favorable affinity increase resulted from the placement of a methyl group
into hydrophobic pockets that the authors assumed to be entirely empty, in combination with
an energetically favorable pre-organization of the ligand conformation in solution. This
assumption is supported by MD simulations suggesting that the placement of hydrophobic
groups into supposedly empty, hydrophobic pockets produces an extraordinarily favorable
change of the Gibbs free energy of binding due to the absence of a cavity desolvation step
[215,216]. In the same manner, the extraordinary affinity increase from 1 to 2 (>100-fold) can
be attributed to the insertion of a methyl group into a hydrophobic cavity, that is — as
experiment confirms — virtually empty. This effect is reduced, but nevertheless still
pronounced when further methyl groups are grown into this volume (40-fold affinity increase
between 2 and 3). From 3 to 4, the comparably low 7-fold affinity increase is the result of a
highly favorable enthalpic term, that, however, is partly compensated by unfavorable entropy
(Figure 5.1B). Usually, dispersive (van der Waals) interactions are less significant, because such
interactions established between protein and ligand are largely canceled out by the required
unfavorable disruption of van der Waals interactions between protein and solvent [217].
However, in the case of a vacated pocket that makes a desolvation step obsolete, dispersive
interactions formed between protein and ligand upon complexation become determinant in
terms of affinity [217]. This is the case in the current study — there is no cost to desolvate the
S1’ binding pocket. As a result, the contribution of the established dispersive interactions
between protein and ligand to the enthalpy of binding increases with increasing P1’ chain
length, and overall strongly affects binding affinity. However, with increasing P1’ chain length,
the enthalpic signal is increasingly compensated by a decrease in entropy (Figure 5.1B). This is
potentially the result of a loss of conformational degrees of freedom upon complex formation.
The low affinities of 5 and 6 can be attributed to the large energetic penalty for the desolvation
of their polar functional groups which is not overcompensated by the dispersive interactions
with the cavity-lining residues. The hydrogen-bond interactions formed with Glu143 (and
Asn112 in the case of 6) do not suffice to compensate for this loss. Thus, the free energy gain
resulting from the establishment of dispersive interactions is largely compensated by the high
cost to desolvate 5 and 6, overall lowering their affinity.
Protein cavities can fulfill essential biological functions, e.g. conformational flexibility, and
thus can represent more than “packing defects” [207,218,219]. In the case of TLN (and many
other metalloproteinases), the S1’ pocket is the most important pocket to discriminate
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substrates from non-substrates, and thus defines the selectivity profile of the protease. A
substrate that exhibits shape complementary and thus fills the hydrophobic S1’ pocket
efficiently without requiring a large price for desolvation (e.g. a P1’ leucine, iso-leucine or valine
side chain) will experience strong dispersive interactions with the protease. It thus gets bound
and enzymatically processed. In contrast, if the pre-organized void in the protease is
insufficiently filled by an either small or hydrophilic P1’ substrate portion, a pronounced
affinity reducing enthalpic penalty results. Thus, the unsolvated state of the TLN S1’ pocket is
highly important for the selectivity mechanism of the protease.
An entirely independent proof for the existence of unsolvated protein binding pockets is
provided by a current neutron diffraction study [220]. Neutron scattering can reliably
differentiate between hydrogen and deuterium. We recently determined the joint X-
ray/neutron structures of two trypsin complexes. Crystal growth was performed with the
protein in its hydrogen form and crystals were subsequently exposed to fully deuterated buffer
over 532 days before data collection. Under such conditions polar hydrogen atoms should
exchange by deuterium atoms considering the large excess of deuterons compared to protons.
However, as a precondition the polar groups must be accessible to D2O molecules. In a folded
protein, polar hydrogens usually remain only at sites where they are involved in strong
hydrogen bonds. Nevertheless, in a sterically accessible pocket of our trypsin complexes we
found NH groups where the polar hydrogens are not involved in a hydrogen bond and these
NH groups did hardly exchange to ND over the 1.5 years of incubation in D2O. Only 7%
deuterium could be found at these sites. We therefore hypothesize that they hardly experienced
any contact with D2O molecules in the folded protein indicating that these cavities are
extremely rarely accessed by water molecules. We believe this is another independent
indication that empty and hardly unsolvated pockets exist in folded proteins.
5.4 Conclusion
The discussed experimental data strongly suggest that the S1’ cavity of TLN in complex with
ligands 1–6 is not solvated and contains virtually vacuum prior to ligand binding. We found
no experimental evidence for the occupation with highly mobile water molecules, and the
properties of the cavities (shape, volume, polarity) suggest that the cavity is indeed empty. It
seems energetically more favorable to maintain a vacuum than to host one or several water
molecules within these cavities. It has been discussed that the generation of vacated pockets in
proteins is energetically very costly [221,222]. Nevertheless, it has to be considered that the
costs for producing such a void have to be afforded during protein-folding and not during
ligand or substrate binding.
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In the current case, the fact that the TLN S1’ cavity is empty takes major consequences on the
energetically highly favored accommodation of aliphatic P1’ side chains of either substrate or
inhibitor molecules. The observed enthalpy driven affinity enhancement with increasing size
of the P1’ substituent (1→4) is mainly a result of the binding of aliphatic groups into a void,
where no price for pocket desolvation has to be afforded. The decreasing affinity contribution
of a growing side chain can be attributed to the augmenting desolvation penalty of the larger
P1’ substituents and to a reduction in conformational flexibility. Addition of a polar group
entirely destroys binding affinity due to an uncompensated desolvation penalty. Remarkably,
the derivative with a P1’ benzyl side chain (PDB code 3FV4) that fills the S1’ pocket more
efficiently than the P1’ leucine side chain of 4 is less potent, likely due to the higher desolvation
costs for the aromatic side chain [33]. In the case of TLN, the hydration state of the S1’ cavity
seems to have a pronounced contribution to the selectivity profile of the protease. The
remarkable, about 41,000-fold increase in affinity from the introduction of hydrophobic iso-
butyl group into this pocket also has major implications for medicinal chemistry. The
identification of poorly hydrated cavities can represent a valuable strategy to gain
overwhelmingly in binding affinity of a prospective drug molecule.
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5.5 Experimental section
Ligand synthesis
The synthesis of 1–6 has been reported previously [183].
Crystal preparation and soaking
Crystals were prepared with lyophilized TLN powder commercially obtained from Calbiochem
(EMD Biosciences) identical to the procedure as described earlier [16]. For crystal soaking of
the low-affinity compounds 1, 5 and 6, TLN crystals were transferred into a soaking solution
composed of 100 mM Tris-HCl, pH 7.5, 2 mM CaCl2 and 20% DMSO saturated with the
respective ligand (ligand precipitate visible), followed by incubation for 24 hrs. Afterward,
crystals were flash-frozen in liquid nitrogen after a brief immersion in a cryoprotectant
solution saturated with the respective ligand, composed of 10 mM Tris-HCl, pH 7.5, 10 mM
Ca(CH3COO)2, 20%DMSO, and 20% glycerol.
Derivatization of TLN with xenon and krypton
For the noble gas derivatization of the TLN crystals (TLN-1-Xe and TLN-1-Kr), a pressure cell
from Oxford Cryosystems (Long Hanborough, UK) was used [223]. Before derivatization,
TLN crystals were soaked with 1 in the above-mentioned soaking buffer for 24 hrs. To protect
the crystals from drying out during the pressurization phase, the filter paper of the
pressurization cell was drenched with soaking buffer. Subsequently, xenon derivatization was
performed at 9 bar for 5 minutes, and derivatization with krypton was carried out at 5 bar for
5 minutes. Derivatization was conducted at relatively low pressure because higher pressure
resulted in a strong increase in crystal mosaicity. After the incubation time was up, pressure
was quickly released, and TLN crystals were immediately after flash-frozen in liquid nitrogen.
Data collection
Datasets for crystal structures TLN-1, TLN-5, and TLN-6 (Table 5.1) were collected at BESSY
II (Berlin-Adlershof, Germany) on beamline 14.1 on a Dectris Pilatus 6M pixel detector at 100
K [157,224]. A three-wavelength MAD dataset of TLN-1 (Table 5.2) which was applied for the
determination of the experimental phases was collected from another crystal at BESSY II on
beamline 14.2 on a Rayonix MX-225 pixel detector at 100 K. Datasets for crystal structures
TLN-1-Xe and TLN-1-Kr (Table 5.1) were collected at Elettra (Triest, Italy) on beamline XRD1
at 100 K on a Dectris Pilatus 2M pixel detector. The dataset for TLN-1-Xe was collected at ϩ =
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1.40000 Å. Two datasets were collected for TLN-1-Kr from the same crystal (Table 5.3), the
first at 0.85940 Å above the krypton K absorption edge (that is at 0.86550 Å), against which the
structure was refined, and a second dataset at 0.871500 Å below the krypton K absorption edge.
The second dataset was solely used for analysis of the change of the anomalous signal of
krypton to unambiguously identify the bound atom. The anomalous maps TLN-1-Xe (Figure
5.3) and TLN-1-Kr (Figure S5.8) were created with ANODE [225].
Dataset processing and structure determination
All data sets were indexed, integrated and scaled with XDS [158]. The phases of TLN-1-Xe,
TLN-1-Kr, TLN-5, and TLN-6 were determined by molecular replacement applying Phaser
[159] from the CCP4 suite (version 6.3.0) [137]. The crystal structure of the PDB entry 8TLN
was used as molecular replacement search model [160]. The phases for TLN-1 were
determined experimentally by a MAD dataset (Table 5.2) using the intrinsically bound zinc ion
of TLN as anomalous scatterer. Experimental phasing was performed applying the programs
SHELXC (data preparation), SHELXD (heavy atom substructure determination) [226] and
SHELXE (experimental phasing and density modification) [227] as implemented in
HKL2MAP [228]. The anomalous signal d’’/ϯ of the peak dataset was significant (1.42) to 1.62
Å. Between all datasets the anomalous correlation coefficient was above 30% up to 1.57 Å. The
best solution of the SHELXD substructure search was CCAll=71.3 and CCWeak= 58.9. The
substructure phases calculated by SHELXE from the original hand gave a final contrast of 0.56
and a connectivity of 0.81 (inverted hand: contrast 0.35, connectivity 0.66). The experimentally
determined phases were combined with the amplitudes of a 1.21 Å native dataset of TLN-1
(Table 5.1) followed by density modification with the program DM [229] from the CCP4 suite
applying solvent flattening and histogram matching. A starting model for conventional
refinement was created with ARP/wARP [230], where 314 amino acids in a single polypeptide
chains (99% sequence coverage) were successfully placed into the electron density map with a
resolution of 1.21 Å.
Model building and refinement
Crystal structure model refinement was performed with phenix.refine version 1.10.1-2155
[162]. Simulated annealing with default settings was performed as first refinement step.
Subsequently, all crystal structure models were refined with riding hydrogen atoms added to
protein residues, applying xyz refinement, individual anisotropic B factors for all atoms except
for hydrogens, and occupancy refinement. Refinement cycles were intermittent by model
building with Coot [161]. Ligand building was performed with MOE [151], ligand restraints
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were created with eLBOW [163]. Graphical representations of the crystal structure coordinates
and electron density maps (automatic ccp4 map normalization turned off) were created with
PyMOL [164].
Cavity computation and volume calculation
The cavities as displayed in Figure 5.4 were computed with POVME [231]. Dummy atoms
(DAs) with a radius of 1.40 Å were placed into the cavities (grid spacing 0.2 Å). The radius of
1.40 Å was chosen as it is frequently applied as the radius of a water molecule in the literature
[194,208,210,232,233]. The solvent excluded surfaces of the DA objects representing the
cavities were then displayed with PyMOL. Since POVME can only calculate the solvent
accessible volume, the solvent excluded volumes of the DA objects describing the S1’ cavities
of TLN-1 to TLN-6 (Figure 5.4) were calculated with the program 3V (radius of the DAs set to
1.40 Å) [234]. The volumes of the S1’ cavity and of reference cavities 1–3 as displayed in Figure
5.2 used for the analysis of the electron density map were created with DA comprising a radius
of 1.30 Å. The reduction of the DA radius compared to the DA radius applied for computing
the cavities in Figure 5.4 (1.40 Å) was necessary, otherwise the narrow parts of reference
cavities 1 and 2, where hydrogen-bonded water molecules are closely bound to TLN residues,
would not have been detected.
Placement of the experimentally phased electron density map of TLN-1 on
an absolute electron number scale and determination of the total electron
content within a cavity
Two mathematical operations are required to transform the experimentally phased, ϯ-scaled
map of TLN-1 (ccp4 format) characterized by arbitrarily small map voxel values to an absolute
electron number density map where zero corresponds to vacuum — thus allowing
quantification of the total electron content within a given map volume. First, the values of the
map voxels have to be set to the correct scale by applying a scaling coefficient. Subsequently,
the still ϯ-scaled map — where zero corresponds to the average electron concentration of the
unit cell — has to be shifted in a way that zero corresponds to vacuum. For that, the average
electron concentration (e–/Å3) of the unit cell must be added to every map voxel. To have access
to an absolute electron number density map as a reference, the ϯ-scaled density map of the
fully refined model of TLN-1 was transformed to an absolute electron number density map
applying the END map script developed by Lang et al. [235] running with phenix.refine version
1.8.4-1492. This program computes absolute electron number density (END) maps from
conventionally refined ϯ-scaled maps. However, it is dependent on a refinement program and
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relies on refined model phases for the calculation of the electron density map, thus it is not
possible to directly use it to transform the experimentally phased ϯ-scaled density map to an
absolute electron number scale without the introduction of model phases. The END map script
also provided the structure factor F000 of TLN-1 (256668 e–), which corresponds to the total
electron content within the crystal unit cell under consideration of protein model and bulk
(disordered) solvent. Thereby, the average electron concentration within the unit cell was
accessible by F000/unit cell volume = 256668 e–/967353 Å3 = 0.26533 e–/Å3.
We decided to use the Zn2+ ion (28 e–) that is intrinsically bound to TLN to derive the scale
coefficient. To be independent of the theoretical electron number of the zinc ion and of the
necessity of an integration mask covering the entire zinc ion without any electron spillover
from inside to the outside of the mask (e.g. due to a slightly disordered zinc) or electron
spillover from outside to the inside of the integration mask (e.g. from zinc-complexing
residues), we determined the total electron content of a spherical map fragment describing the
zinc ion of the refined END map. The zinc coordinates of the refined crystal structure TLN-1
were used for the center of the sphere, and 1.39 Å was used as sphere radius. The total electron
content within this map fragment gave 27.3 e– as calculated with an in-house script based on
the program mapman [236]. Subsequently, an identical integration mask was applied to the ϯ-
scaled experimentally phased electron density for scaling of the latter dataset by applying the
program mapmask from the CCP4 suite [137]. The scale coefficient (14.1) was derived in a way
that after applying the scale coefficient followed by addition of the average electron
concentration (0.26533 e–/Å3), integration of the map fragment covering the zinc of the
experimentally phased map resulted in exactly 27.3 e–, just as observed in the map fragment of
the refined END map. Visually, the experimentally phased electron density map was correctly
shifted in a way that zero corresponds to vacuum (Figure S5.4 to Figure S5.7). If an electron
concentration of ³0.0 e–/Å3 is displayed (panels C of Figure S5.4 to Figure S5.7), the entire
cavities are covered with electron density. In contrast, displaying higher (positive) or lower
(negative) electron density concentrations for instance within the empty S1’ pocket (Figure
S5.4) immediately reduces the visible residual electron density.
For the calculation of the total electron content within a given volume, e.g. the volume of the
S1’ cavity and reference cavities 1–3, a map fragment was cut out from the entire electron
density map applying the program Coot via the command “mask map by atom selection”,
followed by integration over all voxels (including negative values) applying the aforementioned
in-house script. For the S1’ cavity and reference cavities 1-3, the DA objects also used for
displaying the contour regions of the cavities as shown in Figure 5.2 were used applying a
radius of 1.3 Å.
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Measurement of the thermodynamic binding profiles
For the ITC measurements, a Microcal ITC200 device from GE Healthcare (Piscataway, New
Jersey) was used. Measurements were performed with freeze-dried TLN powder bought from
Calbiochem (EMD Biosciences), which was dissolved in buffer directly before measurement
without further treatment. Measurement buffers (pH 7.5) were composed of 20 mM ACES,
MOPSO, MES, PIPES or cacodylate buffer substance, 500 mM NaSCN, and 2 mM CaCl2. The
salt NaSCN was selected because it strongly increases the solubility of TLN [237]. The high
concentration of 500 mM was necessary to provide solubility of TLN up to 250 mM that was
necessary to enable a direct measurement of the low-affinity ligand 2. Since different
concentrations of NaSCN are known to influence the measured thermodynamic binding
parameters [96], this salt concentration was applied for all ligands to guarantee relative
comparability of the thermodynamic binding parameters. The thermodynamic profiles of 4
(Table S5.4) and 3 (Table S5.5) were determined by direct titration applying a TLN
concentration of 50 µM, resulting in well analyzable isotherms with clear sigmoidal curvatures
(Figure S5.1C and B). For the low-affinity compound 2 (Table S5.3), the concentration of TLN
was increased to 250 µM, resulting in isotherms described by a c-value of 6 (Figure S5.1A). This
allowed the experimental determination of the inflection point and the determination of
reliable thermodynamic parameters. To determine the heat of ionization associated with the
complex formation of TLN and 2, 3 or 4 (Figure S5.2), measurements were performed in
ACES, MOPSO, HEPES, MES, PIPES and cacodylate buffers. The affinities of the weak binding
compounds 1, 5 and 6 were determined by displacement titrations (Figure S5.2D–F and Table
S5.6) [238]. 50 µM TLN cacodylate buffer solution was preincubated with different
concentrations of weak ligand (1: 5, 8, 20 mM; 5: 5, 10, 15 mM; 6: 1.5, 2, 2 mM), followed by
titration with the reference ligand 4. Different concentrations of the weak ligand (resulting in
titration curves exhibiting different c-values) were applied to improve the accuracy of the
binding parameter determination by global analysis of the ITC isotherms [184]. Measurement
peaks of the raw thermograms were extracted and integrated with NITPIC version 1.1.2
[167,239]. Global analysis of the ITC isotherms was performed with SEDPHAT version 12.1b
[168,240]. The thermodynamic profiles of the ligands measured in individual buffers were
determined by global analysis applying the model “A+B « AB Hetero-Association”.
Correction for the heat of ionization of these thermodynamic profiles was performed using the
model “A+B « AB Hetero-Association Global Buffer Ionization Enthalpy Analysis”. For the
displacement titrations, the model “A+B+C « AB+C « AC+B; competing B and C for A”
was applied. ITC isotherm graphs were prepared with GUSSI [169].
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5.6 Abbreviations
TLN, thermolysin; ITC, isothermal titration calorimetry; FOM, figure of merit; DA, dummy
atom; ACES, N-(2-acetamido)-2-aminoethanesulfonic acid ; MOPSO, 3-morpholino-2-
hydroxypropanesulfonic acid; PIPES, piperazine-N,N-bis(2-ethanesulfonic acid)
5.7 PDB accession codes
Newly reported crystal structures are available in the PDB upon publication of this manuscript
(accession codes in brackets): TLN-1 (5M9W), TLN-5 (5LVD), TLN-6 (5MA7), TLN-1-Xe
(5M69), and TLN-1-Kr (5M5F). The crystal structures of TLN-2 (3FV4), TLN-3 (3FLF), and
TLN-4 (4H57) were previously reported [33].
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5.9 Supporting Information
Isothermal titration calorimetry results
Table S5.1 (related to Figure 5.1). Thermodynamic binding profiles determined for 1–6. The values
in parenthesis describe the boundaries of the 95.4% confidence interval. All values are rounded. The
thermodynamic profiles of 2, 3 and 4 were corrected for the heat signal of buffer ionization upon
complex formation.
ligand Kd (µM) ΔG° (kJ mol−1) ΔH° (kJ mol−1) −TΔS° (kJ mol−1)
1a 5,659 (8,321, 3,762) -12.8 (-11.9, -13.8) - -
2b 40.750 (45.793, 36.299) -25.1 (-24.8, -25.3) -22.7 (-23.6, -21.9) -2.4 (-1.2, -3.4)
3c 0.992 (1.234, 0.792) -34.3 (-33.7, -34.8) -33.7 (-34.8, -32.7) -0.5 (1.1, -2.1)
4c 0.138 (0.201, 0.090) -39.1 (-38.2, -40.2) -45.1 (-46.5, -43.7) 5.9 (8.3, 3.5)
5a 2,407 (3,652, 1,507) -14.9 (-13.9, -16.1) - -
6a 336 (752, 168) -19.8 (-17.8, -21.5) - -
a Determined by displacement titration. b Direct titration with 250 mM TLN. c Direct titration with 50 mM
TLN.
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Figure S5.1. ITC thermograms of the (A) direct titration of 2, (B) direct titration of 3, (C) direct
titration of 4, (D) displacement titration of 1, (E) displacement titration of 5, (F) displacement
titration of 6. The direct titrations shown in panels A–C were performed in different buffers to correctDH° for superimposed buffer ionization reactions and to determine the proton transfer as shown in
Figure S5.2. For the displacement titrations shown in panels D–F, the different isotherm colors
indicate the different concentrations of weak ligand used for pre-incubation of TLN. For clarity
reason always only one thermogram of the measurements performed at least in triplicate is shown.
The thermodynamic binding profiles determined for the individual buffers are listed in Table S5.3
(2), Table S5.4 (3), and Table S5.5 (4). The results of the displacement titrations of 1, 5, and 6 are listed
in Table S5.6.
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Figure S5.2. Determination of the number of protons transferred and the heat of buffer ionization
upon complex formation of TLN-2, TLN-3 and TLN-4. In the left diagram, the observed standard
enthalpies upon ligand binding DH°obs measured in six different buffers are plotted against the
standard heat of ionization DH°ion of the respective buffer [241]. Error bars in gray represent the
95.4% confidence interval of the DH°obs values. Please note that the enthalpic signal of the complex
formation of TLN-2 was not measured in ACES buffer due to a too low exothermic signal. In the right
diagram, the number of protons transferred upon complex formation of the three studied reactions
is displayed as analyzed by global analysis with SEDPHAT. Error bars represent the 95.4% confidence
interval. Data values are listed in Table S5.2.
Table S5.2. Proton transfer between buffer and TLN upon complex formation of TLN with ligands
4, 3 and 2 as analyzed by global analysis with SEDPHAT.
Ligand
TLN proton uptake from buffer molecules
(minimum and maximum of the 95.4% confidence
interval)
4 1.001 (0.940, 1.063)
3 0.904 (0.865, 0.943)
2 0.660 (0.622, 0.692)
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Table S5.3. Thermodynamic parameters obtained for 2. All parameters are listed as rounded values.
buffer
best-fit values global analysis
(95.4% confidence interval) locally fitted
concentration
correction factoraKd (µM) ∆G°(kJ mol-1)
∆H° (kJ mol-
1)
–T∆S° (kJ
mol-1)
buffer
corrected
40.750
(45.793, 36.299)
-25.1
(-24.8, -25.3)
-22.7
(-23.6, -21.9)
-2.4
(-1.2, -3.4)
cacodylate 39.604
(43.013, 36.425)
-25.1
(-24.9, -25.3)
-24.7
(-25.3, -24.1)
-0.5
(0.4, -1.3)
1.014, 0.997, 0.971
PIPES 52.301
(54.676, 50.038)
-24.4
(-24.3, -24.5)
-15.8
(-16.1, -15.5)
-8.6
(-8.2, -9.0)
0.731, 0.754, 0.787
MES 35.817
(41.314, 31.060)
-25.4
(-25.0, -25.7)
-11.9
(-12.5, -11.5)
-13.4
(-12.5, -14.3)
0.927, 0.934, 0.951
HEPES 39.526
(43.301, 36.091)
-25.1
(-24.9, -25.4)
-9.1
(-9.4, -8.8)
-16.0
(-15.5, -16.5)
0.800, 0.797, 0.749,
0.796
MOPSO 16.239
(27.511, 9.335)
-27.3
(-26.0, -28.7)
-5.3
(-6.3, -4.7)
-22.1
(-19.8, -24.0)
0.663, 0.561, 0.543
ACESb - - - - -
a The concentration correction factor is in this case equivalent to the n value. The number of active
sites per molecule was set to 1, and the concentration of the ligand was considered as accurately
known. Therefore, this value corrects for inaccurate protein concentrations, as well as for inactive
protein fractions observed in some of the applied buffers. The number of listed concentration
correction factors reflects the number of performed measurements. b The enthalpic signal in ACES
buffer was too low for a reliable determination of the thermodynamic binding profile
Table S5.4. Thermodynamic parameters determined for 3. All parameters are listed as rounded
values.
buffer
best-fit values global analysis
(95.4% confidence interval; statistics minimum and maximum) locally fitted
concentration
correction factorKd (µM) ∆G°(kJ mol-1)
∆H° (kJ mol-
1) –T∆S° (kJ mol-1)
buffer
corrected
0.992
(1.234, 0.792)
-34.3
(-33.7, -34.8)
-33.7
(-34.8, -32.7)
-0.5
(1.1, -2.1)
cacodylate 0.929
(1.079, 0.798)
-34.4
(-34.1, -34.8)
-35.9
(-36.5, -35.2)
1.4
(2.5, 0.4)
1.131; 1.065; 1.040
PIPES 1.358
(1.599, 1.148)
-33.5
(-33.1, -33.9)
-23.5
(-24.1, -23.0)
-9.9
(-9.0, -10.9)
0.969; 1.005;0.992
MES 0.710
(0.937, 0.530)
-35.1
(-34.4, -35.8)
-20.9
(-21.6, -20.2)
-14.2
(-12.8, -15.6)
0.868; 0.835; 0.855
HEPES 1.191
(1.447, 0.975)
-33.8
(-33.3, -34.3)
-15.7
(-16.1, -15.3)
-18.1
(-17.2, -19.0)
1.005; 0.964; 0.956
MOPSO 1.114
(1.427, 0.850)
-34.0
(-33.4, -34.7)
-11.7
(-12.0, -11.3)
-22.3
(-21.3, -23.4)
0.991; 0.984; 0.940
ACES 2.590
(5.013, 1.303)
-31.9
(-30.3, -33.6)
-6.5
(-7.5, -5.7)
-25.4
(-22.7, -27.9)
0.939; 0.782; 0.742
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Table S5.5. Thermodynamic parameters determined for 4. All parameters are listed as rounded
values.
buffer
best-fit values global analysis
(95.4% confidence interval; statistics minimum and maximum)
locally fitted
concentration
correction factorKd (µM) ∆G°(kJ mol-1) ∆H° (kJ mol-1) –T∆S° (kJ mol-1)
buffer
corrected
0.138
(0.201, 0.090)
-39.1
(-38.2, -40.2)
-45.1
(-46.5, -43.7)
5.9
(8.3, 3.5)
cacodylate 0.105
(0.141, 0.076)
-39.8
(-39.1, -40.6)
-48.2
(-49.0, -47.4)
8.4
(9.9, 6.8)
0.959; 0.939; 0.954;
0.933
PIPES 0.124
(0.168, 0.089)
-39.4
(-38.7, -40.3)
-34.9
(-35.6, -34.3)
-4.5
(-3.0, -6.0)
1.030; 0.954; 1.020;
0.989
MES 0.119
(0.174, 0.077)
-39.5
(-38.6, -40.6)
-29.6
(-30.4, -28.9)
-9.9
(-8.2, -11.7)
0.895; 0.888; 0.871
HEPES 0.182
(0.267, 0.118)
-38.5
(-37.5, -39.5)
-24.9
(-25.6, -24.2)
-13.6
(-11.9, -15.3)
0.962; 0.961; 0.962
MOPSO 0.207
(0.333, 0.122)
-38.1
(-37.0, -39.5)
-21.3
(-22.3, -20.4)
-16.9
(-14.7, -19.1)
0.928, 0.924, 0.882
ACES 0.279
(0.500, 0.132)
-37.4
(-36.0, -39.3)
-14.0
(-14.7, -13.3)
-23.4
(-21.3, -25.9)
0.942; 0.892; 0.892
Table S5.6. Thermodynamic data of 1, 5 and 6 as determined by ITC displacement titrations in
cacodylate buffer. All values are listed as rounded values.
ligand
best-fit values global analysis
(95.4% confidence interval; statistics minimum and
maximum)
locally fitted
concentration
 correction factorKd (mM) ∆G°(kJ mol-1) ∆H° (kJ mol-1) –T∆S° (kJ mol-1)
1a 5.659
(8.321,
3.762)
-12.8
(-11.9, -13.8)
- - 0.907, 0.944, 0.950
5a 2.407
(3.652,
1.507)
-14.9
(-13.9, -16.1) -
- 1.000, 0.998, 0.981
6b 0.336
(0.752,
0.168)
-19.8
(-17.8, -21.5)
-16.9
(-22.7, -13.5)
-2.9
(4.9, -8.0)
0.981, 0.894, 0.916
a Thermodynamic parameters ∆H° and –T∆S° could not be determined accurately due to the extremely
low affinity of 1 and 5, and are thus omitted. b Thermodynamic parameters of 6 were not corrected for
the heats of buffer ionization.
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Analysis of the experimentally phased TLN-1
Figure S5.3. Experimentally phased absolute-scale electron density map of TLN-1 shown as blue
mesh at a contour level of 0.7 e–/Å3. For orientation, the refined model of TLN-1 is superimposed
onto the electron density map. TLN residues are displayed as gray sticks, the bound ligand is
displayed as light orange stick model and water molecules are displayed as magenta spheres.
Table S5.7 (related to Figure 5.2). Solvent excluded volume and electron content of selected
cavities of TLN-1.
cavity volume (Å3)
integrated
electron
content (e–)a
water molecules
in the model
S1’ 141 6.6 0
reference cavity 1  59 19.4 3
reference cavity 2 93 13.4 1
reference cavity 3 16 0.9 0
a All integrated electron contents were scaled on the intrinsically bound zinc atom
of TLN.
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Figure S5.4 (related to Figure 5.2). Absolute-scale electron density map (blue mesh) within the S1’
cavity at different contour levels as labeled in panels A–F.
Figure S5.5 (related to Figure 5.2). Absolute-scale electron density map (blue mesh) within the
reference cavity 1 at different contour levels as labeled in panels A–F.
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Figure S5.6 (related to Figure 5.2). Absolute-scale electron density map (blue mesh) within the
reference cavity 2 at different contour levels as labeled in panels A-F.
Figure S5.7 (related to Figure 5.2). Absolute-scale electron density map (blue mesh) within the
reference cavity 3 at different contour levels as labeled in panels A-F.
212 | Chapter 5
Crystal structure of TLN-1-Kr
Figure S5.8. Krypton binding site in the S1’ cavity of the crystal structure TLN-1-Kr. (A) Dataset
collected below the krypton absorption edge. (B) Dataset collected above the krypton absorption
edge. In both panels, the crystal structure of TLN-1-Kr (dark gray) is superimposed on the crystal
structure of the native TLN-1 (light gray). The anomalous map is shown in gold at a contour level of
5σ, and the detected peaks are labeled with their intensity maximum. The Fo–Fc omit map of the
krypton atom, zinc ion and the ligand is shown in green at a contour level of 3σ
.
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6.1 Abstract
Kinetic parameters of protein–ligand interactions are progressively acknowledged as valuable
information for rational drug discovery. However, a targeted optimization of binding kinetics
is not easy to achieve and further systematic studies are necessary to increase the understanding
about molecular mechanisms involved. We determined association and dissociation rate
constants for 17 inhibitors of the metalloprotease thermolysin by surface plasmon resonance
spectroscopy and correlated kinetic data with high-resolution crystal structures in complex
with the protein. From the structure–kinetics relationship, we conclude that the strength of
interaction with Asn112 correlates with the rate-limiting step of dissociation. This residue is
located at the beginning of a b-strand motif that lines the binding cleft and is commonly
believed to align a substrate for catalysis. A reduced mobility of the Asn112 sidechain owing to
an enhanced engagement in charge-assisted hydrogen bonds prevents the conformational
adjustment associated with ligand release and transformation of the enzyme to its open state.
This hypothesis is supported by kinetic data of ZFPLA, a known pseudopeptidic inhibitor of
thermolysin, which blocks the conformational transition of Asn112. Interference with this
retrograde induced-fit mechanism results in variation of the residence time of thermolysin
inhibitors by a factor of 74,000. The high conservation of this structural motif within the M4
and M13 metalloprotease families underpins the importance of this feature and has significant
implications for drug discovery.
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6.2 Introduction
Ultimately, the goal of a drug design project is the development of a clinical candidate that is
efficacious in vivo. The main surrogate parameter for efficacy in the early stages of
development is the affinity of a prospective lead candidate, assessed in an assay working under
a thermodynamic equilibrium regime. In many cases, however, equilibrium binding affinity
translates poorly to in vivo activity. Thus additional parameters such as the binding kinetics of
protein–ligand interactions can add further insights and are increasingly appreciated as a
valuable indicator for therapeutic efficacy [1,115,242]. Recent studies have shown that an
increased receptor residence time (t = 1/kd) translates into an enhanced pharmacological effect
also in an in vivo setting [24,27]. Furthermore, in a study of adenosine A2A receptor antagonists,
drug response was more strongly correlated to variations in residence time than affinity under
equilibrium conditions (KD) [243]. Yet, the intentional modification of the kinetic parameters
of a given ligand is not easy to achieve, because the underlying molecular determinants are
poorly understood and thus a reliable structure–kinetics relationship is difficult to establish.
Only in rare cases it is possible to rationalize binding kinetic parameters with respect to
variations in the structure of an inhibitor in a mechanistically coherent way [150,244,245].
Generally, high molecular weight, pronounced lipophilicity (clogP >5) and enhanced
molecular flexibility (number of rotatable bonds >5) are accepted to cause slow dissociation
rates [246]. However, since these parameters are likely to correlate with unfavorable
pharmacokinetic properties, they are not necessarily the most preferred ones to be considered
and improved in a targeted drug optimization process. Computational analyses of buried water
clusters in the binding pocket of the adenosine A2A receptor in complex with a series of
antagonists have shown that the number and position of thermodynamically unfavorable water
molecules correlates with decreasing residence time of the inhibitor [247]. Computational
analyses have suggested that desolvation or resolvation of the binding site prior to or after the
binding event determine the rate-limiting steps for association or dissociation, respectively
[174,248]. Especially the hydrophobic shielding of buried polar atoms in the protein binding
site seems to prevent rapid rehydration and thus prolongs dissociation of a bound ligand [249].
Fluctuations in protein conformation can impose a major influence on the binding kinetic
profile of an inhibitor [20,250]. For enoyl-ACP reductase it has been demonstrated that upon
binding of the inhibitor PT70 a loop region that is disordered in the uncomplexed state
transforms into an ordered helical structure. This reduces the association and dissociation rates
of the binding event significantly [251]. The kinetic selectivity of the marketed drug
thiotropium toward the M3 isoform of the muscarinic G protein coupled receptor is believed
to originate from differences in the dynamic behavior of the ECL2 region relative to the M2
isoform [252]. Another common motif is the occlusion of the ligand binding site by a
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hydrophobic lid [253,254]. The ability of a ligand to stabilize this closed conformation is
reflected in its kinetic profile.
In order to further trace putative mechanisms responsible for extended residence times on the
molecular level, we used the metalloprotease thermolysin (TLN) from B. thermoproteolyticus
as a model system. This enzyme has been successfully consulted in the past as a target surrogate
in the development of inhibitors for angiotensin converting enzyme and neutral endopeptidase
[35–37]. Its chemical robustness, excellent crystallographic properties and ready access in large
quantities renders TLN an ideal test system to study details of protein–ligand interactions.
The conformational dynamics of TLN and other zinc proteases upon ligand binding have been
subject of several studies [160,255,256]. It has been hypothesized that TLN, analogous to
several other members of the bacterial neutral protease family, undergoes a kind of “hinge-
bending” motion about its central a-helix and folds upon the bound substrate. However,
experimental evidence for this hypothesis remained elusive for a long time. Approaches that
rely on a static crystallographic model have notoriously been hampered by the fact that a
dipeptide (Val-Lys), cleaved off from the C-terminus of the protease by autoproteolysis, blocks
access to the active site and stabilizes the closed conformation [160]. Exchange of the central
zinc ion against other more heavy metal ions finally revealed an alternate conformation that
was later confirmed as the putative apo form of TLN [255,256]. Although the overall difference
between the two conformers is small (rmsd = 0.62 Å based on 316 Ca atoms) [255], larger
conformational changes were observed for the side chains of Met120, Glu143, and Leu144.
In this study, the kinetic binding parameters of 17 closely related TLN inhibitors are analyzed
with respect to slight chemical modifications in their partly solvent–exposed P2’ substituents
(Figure 6.1A). The ligand series consists of three subsets that can be distinguished according
to their C-terminal functionality. Either a charged carboxy group (subset a, blue), a neutral
carboxamide (subset b, green) or an apolar aliphatic substituent (subset c, red) were
considered. The kinetic profiles are correlated with high-resolution crystal structures of the
compounds in complex with TLN (mean resolution across all 17 structures: 1.30±0.15 Å).
6.3 Results
SPR data collection
The kinetic binding parameters of 1–17 were determined by SPR using an assay based on
capture of biotinylated TLN as outlined in the experimental section. The sensorgrams
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investigated series (Supporting Information Figure S6.1).
Kinetic data analysis
Figure 6.1B shows a map of the binding kinetic parameters (log ka vs. log kd) of ligands 1–17.
The diagonal lines indicate lines of equal affinity (equilibrium dissociation constant KD = kd/ka).
Overall, the affinity varies within the ligand series from 40 nM to 3.3 µM. The association rate
constants across all subsets scatter within one order of magnitude about a mean value of 104
M-1s-1. In contrast, the dissociation rate constants display a larger variance between 6.15×10-1
s-1 and 2.77×10-3 s-1. It is apparent that ligands bearing a C-terminal carboxy group (1–5) show
a slower dissociation rate than ligands with only an aliphatic substituent at the P2’ position
lacking the acid group (7–17). Compound 6 with a terminal carboxamide falls in-between both
series with a kd of 4.46×10-2 s-1. Within subset a, 5 shows a significantly faster dissociation from
the TLN binding pocket, with kd increased by a factor of ten relative to the other ligands of the
subset. In subset c, 13 and 14 depart toward slower dissociation and 7 displays the fastest
Figure 6.1. Binding kinetic data. (A) Schematic representation of the relevant interactions between
phosphonopeptide ligands 1–17 and TLN. The ligands are categorized in three groups according to
the chemical composition of their P2’ groups. Subset a (blue): P2’-carboxy (1–5), subset b (green): P2’-
carboxamide (6), subset c (red): P2’-aliphatic (7–17). (B) Kinetic map (log ka vs. log kd) of 1–17. Subset
a: blue triangles, subset b: green circle, subset c: red diamonds. The diagonal lines indicate regions
of equal affinity.
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association and dissociation rates compared to the other compounds. The rapid approach to
steady state for 7, resulting in a squared shaped pulse (Supporting Information Figure S6.1), is
governed mostly by its fast dissociation rate (kd = 6.15×10-1 s-1). A small subset of the inhibitors
(14–17) was already analyzed previously in a detailed study including structural,
thermodynamic and kinetic properties [16]. While differences in ka were observed, we mainly
focused on an interpretation of dissociation kinetics for this study.
In order to assess the dependence of the binding kinetic data of the phosphonamidates on
electrostatic properties, the rate constants of a representative member of each subset were
determined at three different ionic strength conditions (Supporting Information Table S6.2).
In addition to the standard buffer conditions, NaCl was added in a concentration of 100 mM
or 500 mM, respectively. A significant deviation could not be detected in the investigated range
of ionic strength.
X-ray crystallography
The high-resolution crystal structures of several ligands in complex with TLN have been
reported by us in previous studies [15,93,94]. The structures of 5 and 6 were additionally
determined in the context of this study (crystallographic information in Supporting
Information Table S6.3). In Figure 6.2A, 1 is depicted as a representative example for the
binding mode topology of 1–17 within the binding cleft of TLN. The carbamate nitrogen
interacts with Tyr157 and a glycerol (GOL) molecule that is picked up from the buffer and
bound to the S2 pocket. One oxygen atom of the phosphonamidate moiety binds to the catalytic
zinc ion in a monodentate fashion and is further positioned within hydrogen-bond distance of
His231. The other oxygen atom interacts with the GOL molecule. The phosphonamidate
nitrogen is likely protonated under the applied experimental conditions [135] and interacts
with Glu143, Ala113 and Asn112. The hydrophobic leucine side chain of the inhibitors is
deeply buried in the S1’ pocket. Additionally, a hydrogen-bonding interaction of Arg203 to the
leucine carbonyl oxygen is established. The polar groups of the C-terminal ligand portion are
in contact with the side chain carboxamide of Asn112 (vide infra). The variable hydrophobic
P2’ moieties are positioned in the shallow, solvent exposed S2’ pocket. Figure 6.2B shows a
superposition of the binding mode of all investigated ligands. Apart from the chemically
deviating P2’ substituents, the structures show virtually perfect overlap of the parent inhibitor
scaffold.
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6.4 Discussion
Interactions of inhibitors 1–17 with Asn112
Since all interactions that do not involve the P2’ substituent are geometrically highly conserved
between 1–17, the explanation for their deviating kd values must originate from the
interactions of their deviating C-terminal portion. A comparison of the interactions across the
three subsets shows that the ligands engage in a deviating hydrogen-bonding pattern with
respect to the side chain of Asn112. As shown in Figure 6.3, all inhibitors involve the
carboxamide group of this residue into multiple hydrogen bonds. In all cases, the
phosphonamidate nitrogen, which is likely protonated under the applied conditions,
Figure 6.2. General binding mode of phosphonopeptide ligands to TLN. (A) 1 is shown in blue,
protein residues adjacent to the inhibitor are shown in orange. The dashed lines indicate hydrogen
bonds between ligand and protein with the distance between the respective heavy atoms
annotated in Å. The gray-blue sphere represents the catalytic zinc ion. The solvent-excluded surface
of TLN is shown in white. (B) Superposition of the binding mode of inhibitors 1–17.
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interacts with the side chain carbonyl oxygen of Asn112. The secondary amide nitrogen of the
P2’ group also forms a hydrogen bond to Asn112. Inhibitors with an aliphatic P2’ group do not
show any further interactions with Asn112 (Figure 6.3C). The addition of a C-terminal carboxy
group allows further fixation of Asn112 due to a chelating charged-assisted hydrogen bond to
the side chain carboxamide nitrogen (Figure 6.3A). The binding mode of 6, which features a
C-terminal primary carboxamide, resembles that of the analogous carboxy compounds (Figure
6.3B). In this case, however, the hydrogen bond between the terminal carboxamide and Asn112
is weakened due to the loss of a formal charge, which potentially induces an electrostatic
enhancement in case of 1–5.
The conformational dynamics of Asn112 and their implications for the
kinetics of TLN
Previous discussions concerning the dynamic properties of TLN mainly focused on
conformational transformations of Met120, Glu143 and Leu144 [255,256]. So far, a
contribution of Asn112 has not been taken into consideration. Our structural and kinetic
results, however, suggest major involvement of this residue in the dissociation step. We
Figure 6.3. Interaction pattern of a representative ligand of each group with Asn112. Residues of
the active site are shown in orange. For reasons of clarity, only hydrogen bonds formed by Asn112
are shown. (A) The C-terminal amino acid moiety of P2’-carboxy inhibitor 1 (blue) engages in a
bidentate charge-assisted hydrogen bond to Asn112. (B) The general binding mode of P2’-amide
inhibitor 6 (green) resembles that of P2’-carboxy compounds. (C) P2’-aliphatic inhibitor 7 (red) solely
interacts with the carbonyl oxygen of Asn112. Bidentate coordination of the C-terminal residue is
lost.
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therefore propose the following release mechanism: The rotation of Asn112 is necessary to
enable the “hinge-bending” motion, which is required to expel a tightly bound substrate or
ligand from the binding pocket. In Figure 6.4A, the structure of TLN in complex with the
peptidic inhibitor IMPI (insect metalloprotease inhibitor) from Galleria mellonella is shown.
IMPI is cleaved by the protease, yet, the hydrolysis product is not released but forms an
inhibitory complex with the enzyme [257]. Therefore, its binding mode supposedly resembles
a geometry adopted by the substrate after peptide-bond cleavage. The C-terminal
Figure 6.4. Binding mode of the cleaved peptidic product fragments of IMPI (pdb entry: 3ssb). (A)
Only the four central residues of the “reactive-site” loop are shown in orange. Asn112 in the closed
conformation is shown in cyan. (B) Superposition of IMPI residues 57–58 with the open
conformation of TLN. Asn112 is shown in red.
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fragment of IMPI engages in a contact to Asn112 resembling the hydrogen-bonding pattern
also observed for our P2’-carboxy ligands. Obviously, this interaction stabilizes Asn112 in a
position, in which its carboxamide side chain forms a lid over the S1’ pocket, augmenting the
barrier for the release of the bound substrate product. If the latter complex is superimposed
with the open conformation of TLN (Figure 6.4B), it becomes apparent that the outward
rotation of Asn112 is involved in an opening of the S1’ specificity pocket, which subsequently
allows the release of the cleaved peptide fragment. Our hypothesis supports the assumption
that the dissociation of a cleaved substrate follows a sequential process. As a first step, the
weakly bound N-terminal peptide (occupying the less specific binding pockets on the
unprimed side) has to dissociate from the binding pocket. Once the S1 pocket is abandoned
(and conceivably rehydrated), Asn112 is able to rotate toward this pocket, thus giving access
to the well-defined S1’ pocket. This retrograde induced-fit mechanism allows the dissociation
of the deeply buried C-terminal product fragment from the hydrophobic cavity. In contrast to
this sequential process, a transition-state mimetic inhibitor would have to dissociate from the
binding pockets in a concerted way. A pronounced fixation of Asn112 through a strong
interaction to the P2’ substituent imposes an additional energetic barrier for the induced-fit
step along the escape trajectory [20].
A structural alignment of proteases from the M4 family (TLN-like zinc metalloproteases)
reveals that Asn112 is highly conserved across the members of this group (97% consensus in
Pfam-A family) [258]. Within the less related M13 family (Neprilysin family), multiple
proteases featuring this structural motif are found (79% consensus in Pfam-A family). Figure
6.5 shows the crucial part of the secondary structure alignment of TLN with other members of
the M4 and M13 family. Important representatives such as the human endothelin-converting-
enzyme (ECE-1) or the human neutral endopeptidase (Neprilysin), associated
Figure 6.5. A section of the secondary structure alignment of TLN and representative members of
the M4 and M13 protease families (alignment of the full sequence in SI). Partially or functionally
conserved residues are indicated by red letters, full conservation is highlighted with white letters on
red background. Lower case letters indicate the source organism of the respective protein (bt = B.
thermoproteolyticus, pa = P. aeruginosa, bc = B. cereus, sa = S. aureus, pp = P. polymyxa, mt = M.
tuberculosis, h = human). For the secondary structure alignment the protein structure comparison
service PDBeFold at European Bioinformatics Institute (http://www.ebi.ac.uk/msd-srv/ssm) was
used [298]. The results were displayed using the ESPript server (http://espript.ibcp.fr) [299].
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with diseases like breast cancer, Alzheimer’s disease and heart failure belong to these families
[259–261]. Furthermore, it has been shown that N112X mutants (X = A, H, K, R) of TLN lose
their catalytic activity [262]. Only the variants N112D and N112E partly retain their proteolytic
activity (64% and 19% respectively) [263]. This underpins the crucial role of Asn112 for the
substrate turnover of TLN-like proteases.
Structure-Kinetics relationship
Based on these considerations, it becomes obvious that the strength of the ligand-to-Asn112
interaction is reflected by the kinetic binding profile. Especially the dissociation rate constant
correlates with this property. Members of subset a engage in strong, charged-assisted hydrogen
bonds between the ligand carboxy and Asn112 carboxamide group. Consequently, these
inhibitors show the longest residence times across the series. For 6, the chelating hydrogen
bond is attenuated due to the loss of one formal negative charge. As a result, its kd corresponds
to a three-fold faster release (compared to the mean of 1–5). Total abandonment of this
interaction, as given for ligands from subset c, results in a thirteen-fold accelerated dissociation
(factor between the mean kd value of 1–5 and 7–17).
In a study by Bartlett and Marlowe [264], the binding kinetics of a related inhibitor exhibiting
a benzyl group in the P1 position (ZFPLA, 18, Figure 6.6) was determined in a photometric
inhibition assay. The latter ligand is the most potent TLN inhibitor described in literature, with
an affinity of KD = 68 pM. This high potency originates from a considerably lower dissociation
rate resulting in the remarkable residence time of 168 days (kd = 6.8×10-8 s-1). Although
inherent differences between the applied photometric method and our SPR analysis to record
the kinetic constants hampers a straightforward quantitative comparison, the data of 1,
examined in both studies, suggests that the deviations between both approaches fall maximally
into the range of one order of magnitude (for a detailed comparison see Supporting
Information Figure S6.2). The exchange of the substitution pattern at P1 from hydrogen to (R)-
benzyl resulted in a 74,000-fold deceleration of the dissociation rate constant, based on the
photometric inhibition assay (Figure 6.6). This finding is in full agreement with our proposed
release mechanism and explains the remarkable kinetic properties of 18. The binding mode
shows some significant deviations from 1–17 that all contain a GlyP-motif in the P1 position.
In the crystal structure of 18, the PheP substituent is positioned in van der Waals distance to
Phe114 (Figure 6.7A). The mutual positioning of the two aromatic portions blocks the outward
rotation of Asn112. However, as described, this movement is an important prerequisite for the
simultaneous release of the bound ligand, while translocating TLN to its open conformation.
This hypothesis is substantiated by a structural superposition of the open conformation of the
apo-protein and the inhibited complex of 18 (Figure 6.7B).
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Figure 6.6. Influence of a P1 substitution from hydrogen to (R)-benzyl on residence time (residence
time for 18 was calculated from kd determined by Bartlett and Marlowe) [264].
Figure 6.7. Binding mode of ZFPLA (18; PDB entry 4TMN). (A) The PheP substituent is within van der
Waals distance to Phe114 and shields the top of the binding cleft. (B) Superposition of Asn112 from
TLN in the open conformation (red). In the closed conformation, the polar side chain of Asn112 is in
close contact to the apolar PheP portion of ligand 18.
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Within each subset, binding kinetic parameters are fine-modulated and a more complex
picture determines the correlation. As discussed in our previous contribution, the quality and
completeness of the surface water network wrapping around ligand-exposed parts of the newly
formed protein–ligand complex can take impact on kd in the range of one order of magnitude
[16]. Within subset a, 5 is clearly separated from 1–4 in the direction of faster dissociation.
Since 5 exhibits the largest molecular weight within the series, this result opposes the generally
accepted correlation of increasing molecular mass with slower dissociation rate [246]. A closer
inspection of the binding modes of 1–5 reveals differences in the surface water network
adjacent to the partly exposed P2’ side chain of the ligands, which provide an explanation
(Figure 6.8). Due to the large size of the hydrophobic cyclohexyl substituent of 5, the formation
of the surface water network remains incomplete and is more strongly perturbed compared to
those formed with 1–4. This destabilization of the surface water network supposedly facilitates
Figure 6.8. Water arrangement around the P2’-portion of ligands. (A) 1, (B) 2, (C) 3, (D) 4 and (E) 5
in complex with TLN. (F) Representation of the solvent-excluded surface generated from the
complex of 5 with TLN. The surface is color-coded according to atom types (red = oxygen, blue =
nitrogen, white = carbon). Water molecules are shown as red spheres with red dashes indicating
hydrogen bond interactions.
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dissociation of the bound ligand due to the loss of solvent–solvent interactions that have to be
disrupted upon ligand dissociation.
It has been demonstrated for several protein–ligand systems that electrostatic attraction or
repulsion can play an important role in binding kinetics [265–268]. While electrostatic factors
are generally believed to predominantly influence association through enhanced probability
for diffusional collisions or conformational preorganization of the binding partners, minor
impact on the dissociation process cannot be neglected. In order to elucidate possible long-
range electrostatic effects between the differently charged molecules, we repeated our kinetic
experiments in buffers of varying ionic strength. In our experiments, none of the kinetic
constants for the TLN-phosphonamidate interactions showed a significant dependence on the
ionic strength, regardless of the presence or absence of any nominal charge on the ligand’s C-
terminus (Supporting Information Table S6.2). We are therefore confident that long-range
electrostatic effects do not matter significantly in the current example and the differences in
binding kinetics can be traced back to the interaction with Asn112.
6.5 Conclusion
The kinetic characterization of 17 congeneric inhibitors of the metalloprotease TLN by SPR
and their correlation with structural data reveals insights into the molecular mechanism of
binding. We suggest that the involvement of the Asn112 side chain in hydrogen bonds with
the bound ligand provokes a prolonged residence time of the respective inhibitor. Asn112 is
crucially involved in the motion transforming the protease from its opened to closed state. We
therefore propose that a reinforced interaction to Asn112 by the bound ligand restricts the
conformational flexibility of this residue. This deteriorates ligand release from the bound state
as the Asn112 side chain has to move out of space to allow access to the S1’ pocket. The
activation of this retrograde induced-fit step can be further impeded by augmenting the steric
hindrance of the Asn112 movement, as observed in the complex of the highly potent TLN
inhibitor ZFPLA (18). This ligand exhibits a drastic decrease in the dissociation rate constant
by a factor of 74,000 compared to its analog 1 [264]. Additionally, a fine-tuning of the binding
kinetic properties results from modulations of the P2’ portion of the ligands that are linked to
variations in the structure of the surface water network which wraps around the S2’ pocket.
Perturbance of these networks of hydrogen-bonded water molecules may lead to an enhanced
dissociation rate.
These results highlight the determining role of changes in protein conformation on the binding
kinetics of bound ligands. Therefore, a profound understanding of protein flexibility,
experienced during the ligand binding event, is of vital importance for a rational design and
optimization of ligand binding kinetic parameters.
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6.6 Methods
Surface Plasmon Resonance Measurements
SPR measurements were performed on a Biacore T200 system (GE Healthcare) with analysis
and sample compartment temperature set to 25 °C. The binding kinetic assay was developed
as a capture assay of biotinylated TLN utilizing the Biotin CAPture Kit (GE Healthcare)
combined with single cycle kinetics of the inhibitors as previously described [16]. Briefly,
sensor Chip CAP was docked in the Biacore and prepared according to the manufacturer’s
instructions. For each day of SPR measurements, new dilutions of inhibitors from 10 mM stock
solutions in DMSO (stored at –20 °C) and biotinylated TLN, were made using freshly prepared
buffer. 50 mM Tris pH 8.0, 100 mM NaSCN, 2 mM CaCl2, 2% DMSO was used as sample and
running buffer. Runs included three start-up cycles and each analysis cycle contained 4 steps:
(1) injection of Biotin CAPture reagent (streptavidin modified with a deoxyriboologonucletide
that hybridizes with the complimentary oligonucleotide present on the Sensor Chip CAP) in
both reference and active flow cells for 300 s and at 2 µl/min resulting in response levels of
around 3000 RU, (2) injection of 150–200 Ϫg mL-1 TLN-biotin at 10 ϪL/min for 90–180 s in
active flow cell only resulting in capture levels of 800–1200 RU (a capture stabilization time of
300 s was applied for some runs), (3) injection of inhibitor in increasing concentration over
reference and active flow cell using a single cycle kinetics procedure with five 120 s injections
at 30 ϪL min-1 and a 240 s dissociation time after the final injection, and (4) injection of
standard (6 M guanidine-HCl, 0.25 M NaOH) and additional (30% acetonitrile in 0.25 M
NaOH) regeneration solutions to remove the Biotin Cap Reagent, TLN-biotin and any bound
inhibitor from both flow cells. Inhibitors were analyzed in duplicate or triplicate measurements
using concentrations in the range of 25–2000 nM for 2, 4; 25–2500 nM for 16, 17; 156–2500
nM for 1, 3, 6, 11; 156–10000 nM for 8, 9, 14, 15, 625–10000 nM for 5, 10, 12, 13 and 1250–
20000 nM for 7. Analysis of 2, 6 and 8 at higher ionic strength was performed in duplicate
measurements at concentrations between 156–2500 nM using the above running buffer
supplemented with 100 mM and 500 mM NaCl, respectively. Blank cycles defined as analysis
cycles with buffer only in step (3), were performed first, last and between every inhibitor
concentration series. Data were double referenced by first subtraction of reference flow cell
and then subtraction of blank cycles. Fitting of data was performed using Biacore T200
evaluation software 3.0, applying a 1:1 binding model compensating for linear drift.
Crystal Preparation and Soaking
Lyophilized TLN powder (Calbiochem) was dissolved in 50 µL DMSO to yield a solution with
a concentration of 8 mM, followed by the addition of 50 µL of a solution containing 3.8 M CsCl
and 100 mM Tris-HCl (pH 7.5). After centrifugation (3 min, 16,000 g), 1 µL of the clear
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solution was pipetted into the wells of a 24 well sitting drop crystallization plate (reservoir wells
filled with 1 mL demineralized water). The crystal plate was sealed and crystals finished
growing after 5 days at 18 °C. Ligands were soaked into the crystals at a concentration of 1 mM
for 24 hrs in a buffer composed of 100 mM Tris-HCl (pH 7.5), 2 mM CaCl2, 5% DMSO and
subsequently flash-frozen in liquid nitrogen in a buffer composed of 10 mM Tris-HCl (pH 7.5),
10 mM Ca(CH3COO)2, 5% DMSO, 20% glycerol and 1 mM of the respective ligand.
Data Collection, Processing, Structure Determination and Refinement
Data collection of the crystal structures TLN-5 and TLN-6 (Supporting Information Table
S6.3) was performed at BESSY II (Helmholtz-Zentrum Berlin) at the MX-beamline 14.1.
Datasets were collected on a Dectris Pilatus 6M pixel detector at a wavelength of 0.91841 Å.
XDS [158] was used for indexing, integration and scaling of the datasets. The structures were
determined by molecular replacement using Phaser (version 2.5.0) [159] applying the structure
with the PDB code 8TLN [160] as a search model. Subsequently, model refinement (xyz
coordinates, individual B factors, occupancies) with Phenix.refine (version 1.10.1-2155) [162]
and model building into ϯA-weighted maps (2Fo–Fc and Fo–Fc) with Coot (version 0.7) [186]
were performed in alternating cycles until R values reached convergence. A randomly chosen
subset of 5% of the reflections was excluded from the refinement and used for the calculation
of Rfree. As a first refinement step, Cartesian simulated annealing was performed (default
settings). B factors for all model atoms (except for hydrogen atoms) were refined
anisotropically. Hydrogen atoms (riding model) were added to the amino acids with
Phenix.refine. Alternative conformations of amino acid side chains and ligand moieties were
assigned to the electron density if an occupancy of at least 20% was obtained after refinement.
Ligand molecules were modeled with MOE [269] and restraints were created with Phenix.elbow
[163] (5) or with the Grade web server [270] (6).
Accession Codes
Atomic coordinates and experimental details for the crystal structures of 5 and 6 (PDB codes
5LIF and 5LWD) will be released upon publication.
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6.8 Supporting Information
Experimental data from SPR measurements
Table S6.1. SPR derived kinetic data of thermolysin inhibitors 1–17.
Compound ka [M-1s-1] SD ka [M-1s-1] log ka kd [s-1] SD kd [s-1] log kd Kd [µM]
1 2.38 × 104 3.54 × 103 4.38 5.06 × 10-3 1.63 × 10-4 -2.30 0.21
2 6.88 × 104 6.46 × 102 4.84 2.77 × 10-3 8.49 × 10-5 -2.56 0.04
3 3.53 × 104 2.40 × 103 4.55 2.87 × 10-3 3.04 × 10-4 -2.54 0.08
4 4.94 × 104 6.93 × 103 4.69 7.86 × 10-3 4.31 × 10-4 -2.10 0.16
5 3.47 × 104 6.01 × 103 4.54 4.63 × 10-2 1.02 × 10-3 -1.33 1.34
6 7.88 × 104 7.07 × 103 4.91 4.46 × 10-2 3.25 × 10-3 -1.35 0.57
7 1.88 × 105 1.34 × 104 5.27 6.15 × 10-1 4.95 × 10-3 -0.21 3.28
8 1.44 × 105 9.19 × 103 5.16 1.71 × 10-1 7.07 × 10-4 -0.77 1.19
9 8.96 × 104 1.41 × 103 4.95 2.34 × 10-1 5.66 × 10-3 -0.63 2.61
10 1.01 × 105 1.41 × 103 5.00 2.08 × 10-1 7.78 × 10-3 -0.68 2.05
11 1.10 × 105 8.06 × 103 5.04 7.94 × 10-2 3.97 × 10-3 -1.10 0.72
12 1.01 × 105 1.27 × 104 5.00 1.82 × 10-1 5.66 × 10-3 -0.74 1.80
13 8.65 × 104 4.95 × 102 4.94 1.40 × 10-1 1.27 × 10-2 -0.85 1.62
14 2.69 × 104 7.08 × 103 4.43 3.87 × 10-2 5.09 × 10-3 -1.41 1.44
15 4.00 × 104 1.16 × 104 4.60 7.00 × 10-2 5.98 × 10-3 -1.15 1.75
16 8.25 × 104 3.32 × 102 4.92 5.97 × 10-2 3.07 × 10-3 -1.22 0.72
17 9.55 × 104 3.32 × 104 4.98 6.64 × 10-2 1.49 × 10-2 -1.18 0.70
Experimental data from SPR measurements at varying ionic strength
conditions
Table S6.2. SPR derived kinetic data of selected inhibitors at varying ionic strength conditions.
Compound
Ionic
strengtha
[mM] ka [M-1s-1] SD ka [M-1s-1] log ka kd [s-1] SD kd [s-1] log kd
Kd
[µM]
2 134 6.88 × 104 3.46 × 103 4.84 2.77 × 10-3 8.49 × 10-5 -2.56 0.04
2 234 5.73 × 104 6.06 × 103 4.76 3.29 × 10-3 2.45 × 10-4 -2.48 0.06
2 634 4.24 × 104 1.91 × 103 4.63 2.85 × 10-3 7.25 × 10-4 -2.55 0.07
6 134 7.88 × 104 7.07 × 103 4.90 4.46 × 10-2 3.25 × 10-3 -1.35 0.57
6 234 4.78 × 104 1.19 × 104 4.89 3.38 × 10-2 3.13 × 10-3 -1.47 0.43
6 634 5.15 × 104 1.30 × 104 4.71 4.80 × 10-2 1.85 × 10-3 -1.32 0.93
8 134 1.44 × 105 9.19 × 103 5.16 1.71 × 10-1 7.07 × 10-4 -0.77 1.19
8 234 2.75 × 105 3.00 × 104 5.44 1.93 × 10-1 3.75 × 10-3 -0.71 0.70
8 634 2.49 × 105 2.40 × 103 5.40 1.89 × 10-1 7.64 × 10-3 -0.72 0.76
a Ionic strength was calculated from all ionized buffer components at pH 8.0 as ܫ ൌ ∑ ܿ௜ ∙ ݖ௜ଶ௜
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Sensograms from SPR measurements
1 2
3 4
5 6
7 8
9 10
Figure S6.1. SPR sensorgrams showing one representative single cycle kinetics run (green or red)
of ligand 1-17, respectively, fitted to a 1:1 kinetic binding model (black). The five concentrations
used in the shown sensorgrams were 0.025, 0.074, 0.22, 0.67, 2.0 µM for ligand 2, 4, 16, 17; 0.16,
0.31, 0.63, 1.25, 2.5 µM for ligand 1, 3, 6, 8, 11; 0.63, 1.25, 2.5, 5.0, 10.0 µM for ligand 5, 9, 10, 12, 13,
14, 15 and 1.25, 2.5, 5.0, 10.0, 20.0 µM for ligand 7.
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Figure S6.1. (continued)
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Comparison of kinetic data from SPR and photometric inhibition assay
Figure S6.2. Kinetic Map containing binding kinetic data of 1b and 18 taken from Bartlett and
Marlowe (orange blocks) [264]. From the kinetic rate constants of 1a and 1b the variation between
the inherently different experimental methods (SPR vs. photometric inhibition assay) can be
estimated to fall within one order of magnitude.
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Crystallographic tables
Table S6.3. Data collection and refinement statistics for crystal structures 5LIF and 5LWD.
 Complex (PDB code)
TLN-5 (5LIF) TLN-6 (5LWD)
Data collection and processing
Space group P6122 P6122
Unit cell parameters: a, b, c (Å) 91.8, 91.8, 130.0 92.8, 92.8, 130.6
Matthews  coefficient (Å3/Da)a 2.3 2.4
Solvent content (%)a 46.3 47.7
Resolution range (Å) 50.00-1.31 (1.31–1.39) 50.00-1.23 (1.30–1.23)
Wilson B factor (Å2) 10.1 9.1
Unique reflections 77996 (12256) 96448 (15229)
Rsym (%) 5.7 (49.0) 6.4 (47.3)
Completeness (%) 99.8 (99.0) 99.7 (98.8)
Redundancy 10.6 (10.3) 24.9 (24.6)
<I/σ(I)> 27.3 (5.2) 36.3 (7.3)
Refinement
Resolution range (Å) 19.66–1.31 31.75–1.23
Reflections used in refinement (work/free)  74096/3900 91621/4822
Rcryst (%) 11.3 10.4
Rfree (%) 13.6 12.3
Protein residues 316 316
Calcium/zinc ions 4/1 4/1
Inhibitor atoms  35 32
Water molecules 407 401
RMSD from ideality:
     Bond lengths (Å) 0.008 0.010
     Bond angles (°) 1.0 1.2
Ramachandran plot (%):b
     Residues in most favored regions 87.8 88.5
     Residues in additionally allowed regions 11.1 10.4
     Residues in generously allowed regions 0.7 0.7
     Residues in disallowed regionsc 0.4 0.4
Mean B factor (Å2):d
     Protein 10.5 10.7
     Inhibitor 12.5 10.7
     Water molecules 26.0 26.6
The highest resolution shell is described by values in parentheses. aMatthews coefficient and solvent
content were calculated with the program Matthews_coef from the CCP4 suite (version 6.3.0) [180].
bRamachandran plots were calculated with PROCHECK [138]. cThe Ramachandran outlier (Thr26) occurs
in every structure of TLN and is described in literature [181]. dMean B factors were calculated with
MOLEMAN [188].
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Ligand synthesis and purification
Experimental details. 1H, 13C and 31P NMR spectra were recorded on a JEOL ECX-400 or JEOL
ECA-500 instrument. All chemical shift values are reported in ppm relative to the non-
deuterated solvent signal. An external standard was used for 31P NMR spectra (referenced to:
85% H3PO4) and 13C NMR spectra in D2O (referenced to: trimethylsilyl propanoic acid). For
the description of multiplicity the following abbreviations were used: s = singlet, m = multiplet.
ESI-MS spectra were recorded on a Q-Trap 2000 system by Applied Biosystems. For high
resolution ESI-MS a LTQ-FT Ultra mass spectrometer (Thermo Fischer Scientific) was used.
For HPLC chromatography a Shimadzu LC-20 system equipped with a diode array detector
was used. Analytic separations were carried out with a MN Nucleodur 100-5 C18 ec 4.6×250
mm column using a water-acetonitrile gradient. For semi-preparative separations a Water
XSelect CSH C18 10×250 mm column employing a water-acetonitrile gradient was used.
Scheme S6.1. Synthesis of compound 6 from Boc-Leu-OH.
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Boc-Leu-Leu-OMe (S1). To a suspension of Boc-Leu-OH (347 mg, 1.50 mmol, 1.0 eq), EDC
(374 mg, 1.95 mmol, 1.3 eq), HOBt (264 mg, 1.95 mmol, 1.3 eq), and H-Leu-OMe HCl(272
mg, 1.50 mmol, 1.0 eq) in DCM, DIPEA (485 mg, 3.75 mmol, 2.5 eq) was added and the
reaction mixture was stirred at rt overnight. The solvent was removed under reduced pressure
and the resulting residue was taken up in EtOAc and extracted with 1 M HCl (3 × 10 mL) and
sat. NaHCO3 (3 × 10 mL). The organic phase was washed with brine and dried over anhydrous
MgSO4. The crude product was purified by silica gel chromatography (DCM/MeOH 50:1) to
give Boc-Leu-Leu-OMe as a colorless solid (410 mg, 1.14 mmol, 76%). 1H NMR (400 MHz,
CDCl3) Ϣ = 0.78 – 1.00 (m, 12H), 1.43 (s, J=9.8, 9H), 1.58 – 1.75 (m, 6H), 3.72 (s, 3H), 4.03 –
4.15 (m, 1H), 4.61 (td, J=8.7, 4.7, 1H), 4.86 (d, J=7.7, 1H), 6.43 (d, J=8.2, 1H). 13C NMR (101
MHz, CDCl3) Ϣ = 21.9, 22.2, 22.9, 24.7, 28.3, 40.9, 41.6, 50.7, 52.4, 53.0, 80.2, 155.8, 172.4, 173.3.
MS (ESI+) m/z calculated for C18H35N2O5 [M+H]+: 349.49; found: 359.24.
Boc-Leu-Leu-NH2 (S2). To 7 mL of a 7 M solution of NH3 in MeOH, Boc-Leu-Leu-OMe (427
mg, 1.19 mmol) was added. The mixture was stirred at rt for 48 h, the solvent was removed
under reduced pressure and the crude product was purified by silica gel chromatography
(cyclohexane/EtOAc 1:1). The product was isolated as a colorless solid (239 mg, 0.70 mmol,
59%). 1H NMR (400 MHz, CDCl3) Ϣ = 0.85 – 0.99 (m, 12H), 1.43 (s, 9H), 1.45 – 1.83 (m, 6H),
4.06 (bs, 1H), 4.41 – 4.53 (m, 1H), 4.93 (s, 1H), 5.54 (s, 1H), 6.47 – 6.64 (m, 2H). 13C NMR (101
MHz, CDCl3) Ϣ = 21.8, 22.0, 23.0, 23.2, 24.8, 28.4, 40.7, 40.9, 51.3, 53.6, 80.5, 156.1, 175.0, 191.2.
MS (ESI+) m/z calculated for C17H34N3O4 [M+H]+: 344.48; found: 344.21.
Phosphonamidate S3. SOCl2 (238 mg, 2.00 mmol, 4.0 eq) was dissolved in 5 mL dry DCM
under argon and cooled to 0 °C. A solution of benzyl ((hydroxy(methoxy)phosphoryl)
methyl)carbamate (233 mg, 0.90 mmol, 1.8 eq) was added to the solution over 30 minutes. The
cooling bath was removed and the reaction was stirred at rt for 3–5 h. All volatile components
were removed under reduced pressure. In a second flask, Boc-Leu-Leu-NH2 (172 mg, 0.50
mmol, 1.0 eq) was treated with HCl (4 M in dioxane, 0.5 mL, 2 mmol, 4.0 eq) for 1 h. All volatile
components were removed under reduced pressure. The activated phosphonic acid was
dissolved in dry DCM. DIPEA and the deprotected dipeptide were added to the solution
consecutively. The mixture was heated to 40 °C and stirred overnight. The solution was diluted
with EtOAc and extracted with 5% citric acid (3×10 mL), 1 M HCl (1×10 mL) and 1 M NaOH
(3×10 mL). The organic phase was washed with brine and dried over MgSO4. The product was
obtained as a mixture of diastereomers in form of a brown solid (145 mg, 0.30 mmol, 60%). 1H
NMR (400 MHz, CDCl3) Ϣ = 0.71 – 1.06 (m, 12H), 1.16 – 2.27 (m, 6H), 3.40 – 3.82 (m, 5H),
3.81 – 4.00 (m, 1H), 4.50 (s, 1H), 5.00 – 5.23 (m, 2H), 7.25 – 7.49 (m, 5H). 13C NMR (101 MHz,
CDCl3) Ϣ = 21.7, 21.85, 21.90, 22.1, 23.0, 24.5, 24.6, 24.85, 24.94, 37.4, 37.8, 38.7, 39.3, 41.0,
41.1, 43.7, 43.9, 51.3, 51.4, 52.0, 53.4, 53.5, 67.15, 67.24, 128.1, 128.3, 128.6, 136.28, 136.36,
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156.8, 157.0, 174.2, 174.3, 175.7, 175.9. 31P NMR (162 MHz, CDCl3) Ϣ = 28.6, 29.7. MS (ESI+)
calculated for C22H37N4NaO6P: 507.52 [M+Na]+; found: 507.42.
Inhibitor 6: The protected phosphonamidate was treated with 3 mL of a 0.4 M solution of LiOH
in water. MeCN was added until the solution cleared. The reaction was stirred for 4 h at rt.
Under ice cooling the pH was adjusted to 8 using 5% AcOH and the solvent was removed
under reduced pressure. The residue was dissolved in 1 mL of water and purified by semi-
preparative HPLC. Lyophilization of fractions containing the pure product afforded a colorless
solid (36 mg, 0.08 mmol, 50%). 1H NMR (500 MHz, D2O) Ϣ = 0.89 – 1.01 (m, 12H), 1.46 – 1.59
(m, 2H), 1.63 – 1.84 (m, 4H), 3.19 – 3.58 (m, 2H), 3.65 – 3.85 (m, 1H), 4.29 – 4.44 (m, 1H),
5.09 – 5.28 (m, 2H), 7.38 – 7.66 (m, 5H). 13C NMR (101 MHz, D2O) Ϣ = 20.1, 21.0, 22.3, 22.4,
24.2, 24.4, 39.1 (d, JCP = 134.1 Hz), 39.3, 42.9, 51.8, 54.5, 67.2, 127.8, 128.4, 128.8, 136.4, 158.2,
178.1, 178.9. 31P NMR (202 MHz, D2O) Ϣ = 19.1. HRMS (ESI+) calculated for C21H35N4O6PNa:
493.2186 [M+Na]+; found: 493.2184.
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Sequence alignment of representative M4 and M13 proteases
Figure S6.3. Secondary structure alignment of thermolysin and proteases from the M4 and M13
family. Only the main chain of thermolysin (Uniprot P00800) was used for the alignment. The
sequences of the signal- and propeptide were omitted to conserve canonical numbering
throughout the main text. The protein structure comparison service PDBeFold at European
Bioinformatics Institute (http://www.ebi.ac.uk/msd-srv/ssm) was used for secondary structure
alignment [298]. The results were displayed using the ESPript server (http://espript.ibcp.fr) [299].
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Figure S6.3. Continued.
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7.1 Abstract
With the rising popularity of fragment-based approaches in drug development, more and more
attention has to be devoted to the detection of false-positive screening results. In particular, the
small size and low affinity of fragments drives screening techniques to their limit. The pursuit
of a false-positive hit can cause significant loss of time and resources. Here, we present an
instructive and intriguing example about the origin of misleading assay results for a fragment
that emerged as most potent binder for the aspartic protease endothiapepsin (EP) across
multiple screening assays. This molecule shows its biological effect mainly after conversion to
another entity through a reaction cascade that involves major rearrangements of its
heterocyclic scaffold. The formed ligand binds EP through an induced-fit mechanism
involving remarkable electrostatic interactions. Structural information in the initial screening
proved to be crucial for the identification of this false-positive hit.
Keywords
drug discovery • fragment-based lead discovery • PAINS • reactivity • medicinal chemistry
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7.2 Main Text
Fragment-based approaches are very efficient in the generation of new lead molecules required
for the design of drug candidates. However, the screening methods that are commonly applied
to identify promising hits for subsequent X-ray crystallographic experiments can give
misleading results. The identification of false-positives, often caused by so called Pan Assay
Interference Scaffolds (PAINS) [271], is a major challenge in any library screening program. It
has been shown that the molecular mechanisms for the generation of false-positive signals
include unspecific binding, colloidal aggregation, inherent reactivity and interference with the
assay detection method [81,272–274]. Additionally, the presence of impurities from synthesis
or degradation of the compound can give misleading results [68,76,275]. The pursuit of a false-
positive binder can lead to a significant loss of time and resources. Therefore, the identification
of such “red herrings” has become a major concern in library design.
Recently we performed an extensive screening of a fragment library containing 361
compounds against the aspartic protease endothiapepsin (EP) [64,65]. In this context we
compared the outcome of various state-of-the-art screening methods. Additionally, the entire
library was subjected to a crystallographic screen with a subsequent characterization of the hits
by isothermal titration calorimetry (ITC). Compound 1 (fragment number 177) emerged as
one of the most potent binders across multiple screening methods. It was found among the top
ten ranking fragments in four out of six and as hit in five out of six screening techniques,
showing virtually complete inhibition of the enzyme in two different biochemical assays, the
highest thermal shift of 3.4 ± 0.3 °C and a Kd of 115 ± 8 µM by ITC [64,65]. Importantly, during
the selection of molecules for the STD-NMR experiments, the fragment passed a filter process
based on purity, aggregation behavior and solubility criteria typically applied in
pharmaceutical companies [65]. Moreover, 1 is not predicted as PAINS using the approach of
Baell and Holloway [81]. Therefore 1 seemed to be an attractive starting point for a fragment-
based lead optimization campaign.
With our established crystallographic protocol, we were able to collect a dataset of 1 in complex
with EP to a resolution of 1.25 Å. To our surprise the ligand, which was bound near the active
site of the enzyme, showed little resemblance to 1 in four independent crystallization
experiments. The electron density clearly indicated the presence of a much larger molecule
accommodated in the binding cleft (Figure 7.1A). This molecule featured a tricyclic core that
was substituted with a bicyclic and a monocyclic moiety. The characteristic methyl substitution
pattern and the unambiguous presence of a chlorine atom, as indicated by its anomalous
scattering, suggested a chemical relation to 1. Fortunately, the high resolution of the
crystallographic model, referred to as EP-2 in the following, allowed us to determine the atomic
connectivity of the unknown binder 2.
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Supplier specifications as well as our own HPLC and NMR experiments excluded the
possibility of an impurity in the sample that could account for the crystallographic results.
Therefore, we proposed that 2 has to be generated from 1 under the applied assay conditions.
To verify this hypothesis, we monitored a solution of 1 in the assay buffer by HPLC, which
clearly showed the time-dependent formation of multiple species in the reaction mixture. Since
some material precipitated from aqueous solution, we repeated the experiment in methanol at
50 °C, which gave equivalent results (Figure S7.1A). Mass spectrometric analysis revealed
molecules with m/z values of 192.3, 196.1, 337.3, 355.3 and 533.1 as the main components of
the mixture. Subsequently, these compounds were isolated by preparative HPLC and subjected
to HR-MS, MS/MS, NMR and protein X-ray crystallography, leading to the assignment of
putative structures (Scheme 7.1).
m/z 192.3: MS analysis indicated the absence of a chlorine substituent and thus allowed the
identification of 3, the alcoholysis product of 1. This finding suggests that the chloropyridazine
heterocycle in 1 is prone to react in a nucleophilic substitution reaction. Remarkably, the
methoxy derivative 3 was found to bind to EP. Four copies of the molecule, two of which had
sufficient occupancy to assign them to the electron density in the crystal structure, bind upon
Phe291, which is known to be a binding hotspot in EP [67], in a 5-fold stacking arrangement
(Figure S7.2A, structure referred to as EP-3).
m/z 196.1: HR-MS and NMR results confirmed that this molecule corresponds to the parent
compound 1. Furthermore, we could reproduce the above-mentioned HPLC reaction pattern
by a repeated exposition of the isolate to methanol at 50 °C. This observation verifies the
reactive nature of 1 in solution. Soaking experiments with this isolate resulted in a structure
containing 2 with some density for additionally bound 1, now visible in comparison to EP-2,
presumably due to the higher concentration or resolution (Figure 7.1B, structure referred to as
EP-1-2). It could therefore be excluded that trace impurities from the synthesis of 1 accumulate
in the binding pocket of EP or that such impurities are required for the formation of 2.
m/z 337.3: From the mass spectrum it was obvious that no chlorine atoms were present in this
molecule. In agreement with our HR-MS and NMR experiments, we assigned structure 4 to
this compound. Importantly, this structure closely resembles the central scaffold of 2, the
putative molecule initially found in the binding pocket of EP.
m/z 355.5: The isotopic distribution of this molecule suggested the presence of a single
chlorine atom, leading to the assignment of structure 5. NMR, HR-MS and MS/MS analyses
supported this proposal (Scheme S7.1). Crystallographic experiments did not reveal electron
density in the EP active site that might correspond to 5. Instead, density for parts of 4 could be
detected (Figure S7.2B, structure referred to as EP-4), which might be explained by the finding
that the better water-soluble 5 is readily converted into 4.
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m/z 533.1: The associated NMR spectrum indicated the presence of a trimeric form of 1.
However, the absence of a CH2-group excluded a composition that could explain the electron
density observed in the crystal structure. Instead, in agreement with HR-MS and MS/MS
experiments (Scheme S7.1), structure 6 could be assigned to this molecule. Consistently, 6,
which we could provide for interaction studies after HPLC isolation, did not bind to EP in
crystallographic experiments.
From the chemical composition of the isolated compounds, we deduced a mechanism for the
reaction of 1 in methanolic solution, which is depicted in Scheme 7.1. The reaction pathway is
initiated by a nucleophilic attack of an imino nitrogen of 1 on the 3-chloropyridazine ring of a
second molecule. This dimerization results in the formation of the charged intermediate 5. In
a competitive reaction, the halogen atom is exchanged against a methoxy group upon
nucleophilic attack of a solvent molecule, which forms 3. After its generation, 5 is transformed
into 4 by an intramolecular substitution reaction. This reaction is proposed to proceed via the
hypothetical intermediate 7 that is formed by a hydrolytic cleavage of the iminium moiety in
5. A similar reaction cascade has been described for unsubstituted 6H-pyrrolo[3,4-d]
Scheme 7.1. Proposed reaction mechanism of 1 in methanolic solution. Experimentally observed
HR-MS data are compared to calculated m/z values of the postulated reaction intermediates.
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pyridazines [276]. The suggested reaction pathway could be supported by the treatment of 5
with an aqueous ammonia solution. In this experiment, HR-MS analysis showed a quantitative
transformation of 5 to 4. Under low-pH conditions, however, a transformation of 5 to 4 is
severely decelerated. Compound 4 finally reacts with an additional molecule of 1 to the trimeric
form 6, a charged hemi-aminal species.
To explain the inherent reactivity of 1, we calculated Nucleus Independent Chemical Shifts
(NICS), natural atomic charges, Wiberg bond indices and electrophilicity indices for this
molecule and several derivatives thereof using QM methods at a high level of theory (Table
S7.2).  The aromatic nature of the compound's pyridazine ring has been investigated by a
comparison with related isoindole, [2’,3’]-pyrrolo annelated indole-like and monocyclic
analogs (Table S7.2). The NICS(1) calculations (Table S7.11) revealed a loss in aromaticity on
the six-membered ring of 1 and other isoindoles compared to indole analogs. At the same time,
an increased bond ordering for the C=N bond in 1 compared to pyridazine and its [2’,3’]-
pyrrolo annelated indole-like analogs is indicative for an imine-like C=N bond, facilitating the
Figure 7.1. Crystal structures of EP in complex with different reaction products of 1 (see also Figure
S7.3). The mFo-DFc electron density for bound ligands are depicted as gray meshes at the 3σ level
(2.8σ for 1 in panel B) prior to the inclusion of each respective ligand into the model. (A) Structure
of an unknown contaminant in complex with EP from the crystallographic screening campaign (EP-
2). The observed electron density clearly cannot be explained by the chemical formula of 1 but
instead reveals the presence of a larger molecule that is characterized by the connectivity defined
via gray sticks and contains a chlorine atom as indicated by the anomalous signal shown in red (5σ
level). (B) Structure generated by soaking of an EP crystal with the HPLC isolate m/z = 196.1 (EP-1-
2). The specific interaction of 1 with its environment is highlighted in orange while the methoxy
analog of 1 (molecule 3) is shown with its primary binding mode from a superimposition of the EP-
3 onto the EP-1-2 structure in transparent cyan (see also Figure S7.3A).
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initial reaction. The high global electrophilicity index of 1 (Table S7.16) and the positive atomic
charge of the carbon atom attached to the chlorine (Table S7.3) further indicate that this
position is prone to nucleophilic attacks. A putative positive charge, as proposed for
compound 2, should lead to an additional gain in reactivity, as indicated by increased
electrophilicity and decreased HOMO-LUMO gap (P-4 in Table S7.15, Table S7.16). This
might explain why 2 is only formed in minute quantities, resulting in a partial binding-site
occupancy (67%).
To further investigate which of the molecules from the reaction mixture bind to EP, we
performed different NMR experiments in the presence of EP. In a time-resolved series of
standard 1D 1H-NMR experiments, we were able to corroborate the reactivity of 1 in an EP-
containing sample (Figure S7.1B). A 2D 1H-1H-NOESY NMR experiment confirmed the
correct structure assignment to 4 and demonstrated that this molecule binds to EP not only in
the crystal but also in solution as indicated by positive NOE cross-peaks (Figure 7.2 and Figure
S7.2B), which were negative in the absence of EP. An additional 1H-13C-HSQC experiment
underlined that this molecule in fact contains an aldehyde function (Figure S7.5). Furthermore,
the NOESY spectra confirmed that also 1 can interact with EP (Figure 7.1B and Figure 7.2).
Overall, our NMR experiments could identify 1 and 4, but not 2, as EP binders. Presumably,
Figure 7.2. NMR analysis of the reaction mixture in the presence of EP. 1H-1H-NOESY NMR spectrum
collected from an EP sample incubated with 1 for 12 hours. Positive peaks are shown in blue,
negative peaks in cyan. The cross-peaks annotated in black correspond to intramolecular NOE
contacts of 4. Additional intermolecular contacts (green) between 4 and 1 indicate a spatial
proximity of both weak binders in the binding pocket of EP. Observed NOE peak intensities match
the interatomic distances of the three-dimensional model of 4 (highlighted in red). High-intensity
peaks in both spectrum excerpts are signals of the excess 1.
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Figure 7.3. Crystallographic elucidation of the unknown structure of 2. (A) Selected geometric
parameters and estimated standard deviations underlining the presence of an aldehyde function
and methylene bridge in 2. The depicted values and 2mFo-Fc map (1σ level) were derived using the
SHELXL-based refinement strategy described in the Supporting Information and compared to CSD
queries (Figure S7.4 and Figure S7.5). (B) Non-planarity of the chloropyridazinium ring. Our SHELXL
refinement revealed that one of the pyridazinium carbons is significantly shifted out of the ring
plane (4.3 σ). To further highlight the positional accuracy achieved by the refinement of this high-
resolution structure, the 2mFo-Fc electron density is shown at 1.7 σ for this out-of-plane atom in red
as well as for two other pyridazinium carbon atoms in blue. A slightly higher σ-cutoff was chosen for
the residual atoms of this positively charged heterocycle (2.3 σ, gray meshes) in order to better
visualize the location of each atom as indicated by the density maxima. How the partial positive
charge on the slightly pyramidalized carbon atom and attached nitrogen might be compensated
by the protein environment is indicated in orange. Based on distance criteria, Thr223 likely points
with its hydroxyl hydrogen toward one of the Asp15 carbonyl oxygen lone pairs so that one of the
Thr223 lone pairs is directed toward the pyramidalized carbon of 2. The second Asp15 CO lone pair,
in contrast, can compensate the partial positive charge on the nearby pyridazinium nitrogen.
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the strong interactions of 2 in the EP binding site, its low level of formation or high reactivity
in solution prevented a spectroscopic detection. The binding affinity of 2 can be estimated to
be better than 10 µM, as judged by the crystallographic observation of this ligand despite its
presence at only µM or even lower concentrations in the soaking solution. The determination
of an exact binding constant, however, seems to be hardly possible because 2 is formed in only
minute quantities and is very reactive as shown by our QM-calculations, both yet indicating
that the ligand might bind even more tightly to EP.
While the finding that 1 and 4 both can weakly interact with EP supported our hypothesis that
the unknown EP-binder 2 is composed of these two compounds as suggested by its electron
density (Figure 7.1A), it was crucial to show that these two molecular parts are actually
covalently linked in the crystal structure. Indeed, the electron density observed in the initial
crystal structure could not be explained by the presence of either 1 or 4 in partial occupancy
but only by the presence of both parts at the same time in a distance too close to represent
separated molecules. Fortunately, the EP-1-2 structure, subsequently obtained from a crystal
treated with the HPLC isolate 1, was of such high resolution (1.03 Å, Figure 7.1B) that it
enabled a least-squares refinement using SHELXL and thereby the determination of geometric
parameters of the bound molecule 2 along with estimated standard deviations [277]. In
particular, we analyzed the geometry of the methylene bridge that must have formed upon
connection of 1 and 4 and compared it to values derived from small-molecule crystal
structures, clearly indicating that a covalent linkage is chemically consistent and thus very
likely (Figure 7.3A and Figure S7.4). Based on our EP-1-2 structure, the presence of an
aldehyde in 2 could also be confirmed by its derived geometric characteristics, such as a typical
CO bond length of 1.24 Å ± 0.03 Å (Figure 7.3A and Figure S7.5). In summary, this made us
confident to assign structure 2 to the initially unknown EP inhibitor. Importantly, an LC/HR-
MS experiment indicated the presence of a compound with the proposed molecular
composition of 2 in the crude reaction mixture. An MS/MS fragmentation of this isolate,
moreover, supported this assignment (Scheme S7.1).
For a hypothetical reaction of 1 and 4 to 2, the activation of an aliphatic CH3 group and the
subsequent substitution of a hydrogen atom would be a mechanistic requirement. Since 2-
methylpyrroles and related 2-methylindoles are known to react at their respective CH3 groups
after irradiation with visible light, anodic or catalytic oxidation [278–281], a radical mechanism
was assumed to be involved in the formation of 2. To investigate the photochemical reactivity
of the methyl groups, a sample of the parent compound 1 was irradiated in a photochemical
reactor. Compounds 8 and 9 were identified as main products that had been formed under
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photochemical activation of 1 in methanol (Scheme 7.1). While this indicated a certain
photochemical reactivity, the formation of 2 was also observed in the absence of light. Since 2
was traceable in solution in minute quantities, EP might selectively trap and thereby stabilize
this highly reactive molecule. Alternatively, it seems possible that the juxtaposition of 1 and 4
Figure 7.4. Recognition of 2 by EP. (A) Interactions between 2 (yellow) and EP (gray), assessed via
intermolecular distances (orange). For more details concerning the proposed electrostatic
interactions between Asp15, Thr223 and 2 please see Figure 7.3 and Figure S7.6. (B) Induced-fit
binding of 2. Compared to the EP apo form (cyan, PDB-code 4Y5L), the ligand-bound protein
underwent significant conformational changes as indicated by black arrows (RMSD of depicted
protein atoms = 0.44 Å). Since the binding site of 2 is not fully populated in the EP-1-2 structure
(occupancy of 63%), some of the depicted residues are found in the apo (violet) as well as in the
ligand-bound (gray) conformation (e.g. Asp33). Red arrows indicate clashes that would occur
between the apo state and the ligand without conformational adaption of the protein.
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in the EP binding pocket may directly facilitate the final reaction between these two species
upon activation of 4.
EP specifically recognizes the final reaction product 2 via three hydrogen bonds, one of which
is mediated by water (Figure 7.4A). In particular, the aldehyde oxygen of 2 accepts an H-bond
from Thr222 although this residue usually acts as an acceptor [66]. This phenomenon is part
of several structural adaptations that take place upon binding of the ligand. 2 would sterically
interfere with the apo protein, which therefore experiences an induced fit as shown in Figure
4B and simultaneously takes up a glycerol molecule from the soaking buffer at the position of
the catalytic water. Finally, the question arises how the positive charge of 2 is stabilized within
the EP binding pocket. This charge will be partially located within the pyrrole heterocycle that
can electrostatically interact with the negatively charged Asp15 stacking on top of the ring
(Figure 7.4A). In addition, the least-squares refinement of the EP-1-2 structure revealed a very
interesting chemical phenomenon that further clarifies the charge stabilization. The carbon
atom attached to the formally positively charged pyridazinium nitrogen is significantly shifted
out of the ring plane (4.3 ϯ, Figure 7.3B). A partial transfer of the negative charge from Thr223
to this imine carbon and the accompanying hybridization change might explain the local
breakdown of ring planarity. Since the presence of a positive charge in the ring system of the
pyridazine moiety in 2 leads to its destabilization according to our quantum chemical
calculations, these electrostatic interactions seem to be key for its stabilization within the
binding pocket. In small-molecule crystal structures analogous pyridazinium and pyridinium
rings are generally found to be fully planar (Figure S7.6A-B). Two host-guest complexes,
however, are exceptions from this trend and bear astonishing similarities to the EP-1-2
protein-ligand complex (Figure S7.6C-E). All of these complexes exhibit two partially
negatively charged oxygen atoms in the host next to the positively charged guest molecule. A
partial electron transfer from the host to the guest might explain the observed local deviation
from planarity.
In summary, we conclude that the presumably weak affinity of 1 to EP alone cannot fully
explain the astonishing biological activity observed in multiple assays. Instead, a number of
other molecules, which are generated from 1 in a reaction cascade leading to a profound
rearrangement of its heterocyclic core structure, contribute to EP inhibition. The
unequivocally non-fragment like molecule 2 seems to exhibit the strongest interaction of all
reaction products, with an estimated affinity of at least 10 µM if not decidedly much better. It
contacts EP via multiple H-bonds and electrostatic interactions that are enabled by the unique
chemistry of the inherently cationic compound. This study shows that in addition to a
thorough investigation of chemical stability of fragment library members, structural
information is essential for the identification of false-positive binders, which is of utmost
importance in the early stages of a fragment-based drug discovery project to avoid investments
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made to follow up futile leads. Driven by crystallographic data, we were able to identify the 1-
chloropyrrolopyridazine core of 1 as a moiety representing an intriguing case of a self-reacting
fragment that may be generally prone to react under conditions commonly employed in
biological assays.
7.3 Experimental Section
The reaction cascade emanating from 1 was simply initiated by dissolving the compound.
Purchased 1 as well as all HPLC isolates have been soaked into EP crystals prepared as
described previously before collection of diffraction data and structure determination [64,67].
Additional details about these and all further experiments are provided in the Supporting
Information.
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7.5 Supporting Information
Supporting Figures
Figure S7.1. Monitoring the reaction of 1 by HPLC and NMR spectroscopy. (A) HPLC chromatogram
of a sample of 1 after incubation for 0, 24, 72, and 96 h at 50 °C in methanol. (B) Time-resolved 1H-
NMR spectrum of 1 in the presence of EP. Over the course of 12 h, spectra were recorded at 1 h
intervals. For clarity, the figure only displays spectra every 3 hours, namely after 0 (blue), 3 (red), 6
(green), and 9 hours of incubation (violet). The major peaks are derived from 1, whereas additional
peaks come up over time.
254 | Chapter 7
Figure S7.2. EP in complex with reaction products of 1. The mFo-DFc electron density maps for bound
ligands are depicted as gray meshes at the 3σ level prior to the inclusion of each respective ligand into
the model. (A) Interaction between EP and molecule 3. The depicted structure EP-3 is the result from
a diffraction experiment with a crystal soaked with the HPLC isolate m/z = 192.3. Electron density has
been observed for four copies of compound 3 stacking on top of Phe291 in a regular arrangement.
The density was sufficient to model the two molecules closest to Phe291 (the second molecule has
only been partially modeled). The TFA molecule shown in two alternative conformations in orange
stems from the HPLC purification and binds in a small pocket on the surface of EP. (B) Electron density
for molecule 4 in the EP binding pocket after soaking of 5, the precursor of 4. While the isolated
molecule 4 itself did not bind with sufficient occupancy to the enzyme to make it visible in the electron
density, the presence of 4 was indicated by soaking experiments with the better water-soluble
compound 5 that is easily converted into 4 (Scheme 7.1 in the main manuscript). For better
orientation, the picture contains molecule 2 as a stick model in gray, derived from a superimposition
of the EP-1-2 onto the EP-4 structure (gray surface representation). The bicyclic component of 2 that
differentiates it from molecule 4 is depicted in transparent colors. Presumably due to its poor aqueous
solubility, 4 does not sufficiently occupy the EP binding site to allow modelling it in the EP-4 structure.
However, for several reasons, we are very confident that 4 binds to EP in a similar manner as the
corresponding part of 2. In particular, the mFo-DFc (gray mesh) electron density map indicates the
presence of the substituted pyrrole ring of 4, which is further supported by the observation of the
alternative conformations of several residues arising from the induced-fit binding discussed in Figure
7.4B. Presumably, the simultaneous presence of apo and 4-bound EP molecules in the crystal also
results in electron density next to the aldehyde group of 4 originating from a water molecule of the
apo protein, which is represented by the red sphere derived from a superimposition of the apo
structure (PDB-code 4Y5L) onto the EP-4 structure. For clarity, the mFo-DFc map is only shown around
the pyrrole ring. Moreover, an isomorphous difference map (depicted in green) between the EP-4 and
a ligand-free EP structure of an isomorphous crystal (PDB-code 5P71) provides some evidence for the
presence of the tricyclic core of 4 (gray sticks). In contrast, no density could be identified for the atoms
of the bicyclus additionally present in 2 (transparent gray sticks).
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Figure S7.3. 1H-13C-HSQC NMR spectrum collected from an EP sample incubated with 1 after an
incubation time of three weeks at 7 °C. Cross-peaks corresponding to 1 and 4 are annotated in the
spectrum. Additionally observed signals originate from an unknown molecule, presumably
generated from hydrolysis of the 3-chloropyridazine moiety in 1. An aldehyde function is clearly
present in 4 as indicated by a 1H chemical shift of 9.53 ppm and a 13C chemical shift of 186.6 ppm.
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Figure S7.4. Comparison of geometric parameters for the proposed methylene bridge of molecule
2 derived from the crystallographic experiment (EP-1-2 structure) with results from CSD searches
for comparable compounds. (A) Definition of the CSD query and investigated geometric
parameters. In order to investigate whether molecule 4 and 1 are fused to compound 2 via a
methylene bridge, the geometric parameters highlighted in blue, green, orange, magenta and red
derived from the crystallographic experiment have been compared with the distributions of the
same parameters resulting from a CSD query on comparable molecules as defined in the gray box.
In the following panels, the mean values and standard deviations of the individual histogram peaks
are given on top of each plot and compared to the crystallographically identified value for 2
including estimated standard deviation (purple, according to the SHELXL refinement performed as
described in the experimental section). These analyses reveal that 2 likely harbors an intact
methylene bridge. (B) Distribution of the distances between atoms 2 and 3 as defined in panel A. (C)
Histogram for the distance between atoms 3 and 4. (D) Distribution of the methylene bridge angles
between atoms 2,3 and 4. (E) Histogram for the torsion angle between atoms 4, 3, 2 and 1. If less
than 180° rotation of the bond between atoms 4 and 3 in a clockwise fashion (indicated by the
magenta arrow in panel A) is required in order to create the eclipsed conformation with the bond
between atoms 2 and 1, the torsion angle is considered positive (else negative) according to IUPAC.
(F) Histogram for the torsion angle between atoms 2, 3, 4 and 5. If less than 180° rotation of the bond
between atoms 2 and 3 in a clockwise fashion (indicated by the red arrow in panel A) is required in
order to create the eclipsed conformation with the bond between atoms 4 and 5, the torsion angle
is considered positive (else negative). All histograms have been generated using the statistical
framework R.
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Figure S7.5. Comparison of geometric parameters for the proposed aldehyde group of molecule 2
derived from the crystallographic experiment (EP-1-2 structure) with results from CSD queries for
comparable compounds. (A) Definition of the CSD queries and investigated geometric parameters.
To decide whether 2 contains an aldehyde (blue boxes in panel A and transparent blue bars in
panels B-D) or alcohol (red) functionality, CSD queries were performed with pyrrole-3-
carboxaldehydes and pyrrol-3-ylmethanols (left). Since the number of structures containing these
motifs in the CSD was rather limited (N = 30 and 4, respectively), similar queries have been
performed on much more abundant benzaldehydes and benzylalcohols (N = 1204 and 475,
respectively). The three investigated parameters are defined in green, orange and magenta. For
instance, the distance between the aldehyde/alcohol carbon and oxygen is highlighted in green. (B)
Distribution of aldehyde (blue) vs. alcohol (red) bond lengths (between atoms 3 and 4). The mean
values and standard deviations of the individual histogram peaks are given on top of each plot and
compared to the crystallographically identified value for 2 including estimated standard deviation
(purple, according to the SHELXL refinement performed as described in the experimental section).
This comparison clearly indicates that compound 2 contains an aldehyde as supported by similar
analyses of the associated angle and dihedral (panels C and D). (C) Histogram for the angle between
atoms 2, 3 and 4 (for the definition of these numbers see panel A). (D) Distribution of torsion angle
values between atoms 1, 2, 3 and 4. If less than 180° rotation of the bond between atoms 1 and 2 in
a clockwise fashion (indicated by the magenta arrow in panel A) is required in order to create the
eclipsed conformation with the bond between atoms 3 and 4, the torsion angle is considered
positive (else negative) according to IUPAC. These figures have been prepared using the statistical
program R.
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Figure S7.6. Non-planar pyridazinium and pyridinium cations. (A) Comparison of the non-planarity
of the pyridazinium heterocycle of molecule 2 as derived from the crystallographic experiment (EP-
1-2 structure) with usual geometric features of pyridazinium ions. A CSD query was set up as defined
in the gray box. The below histogram reports the distribution of distances between the carbon atom
highlighted in red from the plane that is made up by the residual atoms of the heterocycle (out-of-
plane deviation). The mean values and standard deviation of the single histogram peak is given on
top of the plot and compared to the crystallographically identified value including estimated
standard deviation (purple, according to the SHELXL refinement performed as described in the
experimental section). (B) Comparison of the non-planarity of the pyridazinium heterocycle of
molecule 2 with usual geometric features of pyridinium ions. Since only seven pyridazinium
moieties are currently present in the CSD fulfilling our search criteria (for details see also the
experimental section), we additionally searched for much more frequent pyridinium ions (N = 3107)
and plotted the results in the same way as described for panel A. Both analyses underline that these
heterocyclic cations are usually planar. However, some exceptions with significantly shifted carbon
positions out of the ring plane do exist. We visually analyzed all small molecule crystal structures
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with d > 0.08 Å including their packing and found that this deviation can frequently be attributed
to unusually twisted and strained molecular structures as found e.g. in helicenes. Two outliers,
however, are very interesting with respect to the observed phenomenon (panels C and D). Both are
host-guest complexes that bear similarities to the EP-1-2 protein-ligand complex (panel E). All
complexes have two partially negatively charged oxygen atoms in close vicinity to the positively
charged pyridinium/pyridazinium nitrogen and attached slightly pyramidalized carbon atom. The
latter atom is highlighted in red along with the distance from the plane while important
intermolecular distances are shown in orange. (C) A host-guest complex containing a significantly
non-planar pyridinium ion (CSD-code XUBDAA) [300]. (D) A rotaxane containing a slightly distorted
pyridinium ion (CSD-code XUXGAZ) [301]. (E) The high-resolution EP-1-2 crystal structure
containing a non-planar pyridazinium moiety. The environment of the pyridazinium cation is
highlighted. All histograms have been generated using the statistical framework R while structural
figures have been prepared using Pymol.a clockwise fashion (indicated by the magenta arrow in
panel A) is required in order to create the eclipsed conformation with the bond between atoms 3
and 4, the torsion angle is considered positive (else negative) according to IUPAC. These figures
have been prepared using the statistical program R.
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Supporting Tables
Table S7.1. X-ray diffraction data collection and refinement statistics.
Complex (PDB code)
EP-2
(5LWR)
EP-1-2
(5LWS)
EP-3
(5LWT)
EP-4
(5LWU)
(A) Data collection and
processing
Wavelength (Å) 0.91841 0.91841 0.91841 0.91841
Beamline BESSY BL14.2 BESSY BL14.1 BESSY BL14.1 BESSY BL14.1
Detector MARMOSAIC 225 PILATUS 6M PILATUS 6M PILATUS 6M
Space group P21 P21 P21 P21
Unit cell parameters
a, b, c (Å) 45.2, 72.8, 52.6 45.3, 73.1, 53.0 45.4, 73.1, 52.7 45.3, 73.3, 53.1
Ⱥ, Ȼ, ȼ (°) 90.0, 109.2, 90.0 90.0, 109.8, 90.0 90.0, 109.6, 90.0 90.0, 109.9, 90.0
(B) Diffraction data
Resolution range (Å) 42.7-1.25
(1.32-1.25)
41.2-1.03
(1.09-1.03)
42.7-1.07
(1.13-1.07)
42.6-1.11
(1.18-1.11)
Unique reflections 87290 (12864) 151655 (23423) 142071 (22805) 128260 (20551)
R(I)sym (%) 3.8 (31.8) 5.5 (51.5) 5.1 (48.5) 4.7 (48.6)
Wilson B factor (Å2) 10.5 9.3 9.0 10.3
Completeness (%) 98.1 (89.7) 94.6 (90.6) 99.5 (98.9) 99.6 (99.0)
Redundancy 4.0 (3.0) 3.9 (3.8) 3.7 (3.6) 3.7 (3.6)
<I/σ(I)> 20.7 (3.5) 11.8 (2.3) 13.1 (2.3) 13.5 (2.3)
(C) Refinement
Resolution range (Å) 28.1 - 1.25 36.5 - 1.03 29.4 - 1.07 39.8 - 1.11
Reflections used in refinement
(work/free)
82903 / 4363 144059 / 7581 134943 / 7103 121835 / 6413
Final R value for all reflections
(work/free) (%)
11.3 / 13.1 11.6 / 13.2 12.8 / 14.8 12.3 / 14.3
Protein residues 330 330 330 330
Ligand atoms  38 49 26
Other ligand atoms  44 47 43 42
Water molecules 329 350 312 326
RMSD from ideality
     Bond lengths (Å) 0.006 0.007 0.007 0.006
     Bond angles (°) 0.9 1.0 1.0 1.0
Ramachandran plotc
     Most favored regions (%) 93.9 93.5 94.2 94.2
     Additionally allowed regions
(%)
6.1 6.5 5.8 5.8
     Generously allowed regions
(%)
0 0 0 0
     Disallowed regions (%)d 0 0 0 0
Mean B factor (Å2)
     Protein non-hydrogen
atoms
12.0 11.5 11.6 12.6
     Main Chain 11.0 10.5 10.7 11.7
     Side Chain 12.8 12.5 12.5 13.4
     Ligand 11.7 17.1 30.7
    Other ligand atoms 21.6 23.2 25.3 25.8
     Water molecules 29.1 26.1 24.8 27.7
a Values in parenthesis refer to the highest resolution shell  b Other ligands are glycerol, ethylene glycol, DMSO,
acetate and TFA c Calculated using PROCHECK [138] d Calculated using MOLEMAN [182].
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Experimental Section
General Experimental Information
1-Chloro-5,6,7-trimethyl-6H-pyrrolo[3,4-d]pyridazine (1) was purchased as a hydrochloride
salt from Enamine (UKR). 1H and 13C spectra were recorded on a JEOL ECX-400 or Bruker
AV II 300 instrument. All chemical shift values are reported in ppm relative to the non-
deuterated solvent signal. Trimethylsilyl propanoic acid was used as an external standard for
13C NMR spectra in D2O. To describe the multiplicity of the signal, the following abbreviations
were used: s = singlet, q = quartet, m = multiplet. ESI-MS spectra were recorded on a Q-Trap
2000 system by Applied Biosystems. For high resolution ESI-MS, MS/MS and LC/MS a LTQ-
FT Ultra (Thermo Fischer Scientific) or Orbitrap Velos Pro (Thermo Fisher Scientific) mass
spectrometer were used. For HPLC chromatography a Shimadzu LC-20 system equipped with
a diode array detector was used. Analytic separations were carried out with a MN Nucleodur
100-5 C18ec 4.6 × 250 mm column using a water-acetonitrile gradient with the addition of
0.1% TFA. For semi-preparative separations a Waters XSelect CSH C18 10 × 250 mm column
using a water-acetonitrile gradient was used. Preparative separations were carried out on a
Varian PrepStar 218 instrument equipped with a MNagel Nucleodur 100-5 C18ec 32 x 250 mm
column, employing a water-acetonitrile gradient with the addition of 0.1% TFA.
Ageing of Compound 1
To initiate the reaction cascade, a sample of 1 was placed in a clear glass flask or GC-vial,
dissolved in methanol (Fisher, HPLC grade) and stirred at rt or 50 °C. Preliminary experiments
were carried out in EP protein buffer (100 mM NaOAc pH 4.6), in the presence and absence
of EP, respectively, as well as in water at various conditions. Since these experiments did not
give any additional insight and are comparable to the results in methanol, the details are not
reported here. For analytical HPLC and MS experiments, 1–5 mg of 1 were dissolved and the
resulting solution was used as is. The experiment was also carried out with exclusion of sunlight
(brown glass vial, rt, 24 h) and under protective gas (Argon, rt, 24 h).
For a semi-preparative separation 20 mg of 1 (HCl salt, 0.09 mmol) were used, the solvent
methanol was removed after the reaction (24 hours, 50 °C) under reduced pressure and the
resulting residue was taken up in 1 mL MeOH/H2O 1:9. The crude product was purified on a
semi-preparative HPLC system equipped with a Waters XSelect CSH C18 (10 x 250 mm)
column using a water/acetonitrile gradient. After lyophilization, compound 4 (4 mg, 0.01
mmol, 13%) was isolated as a light brown solid as the main product of the reaction. 12 mg (0.05
mmol, 57 %) of the starting material could be recovered.
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The preparative separation was carried out with 100 mg of 1 (HCl salt, 0.43 mmol). The solvent
methanol was removed after the reaction (24 hours, 50 °C) under reduced pressure and the
resulting residue was taken up in 2 mL MeOH/H2O 1:9. The crude product was purified on a
preparative HPLC system using a water/acetonitrile gradient with the addition of 0.1% TFA.
Fractions that contained a reaction product were collected and lyophilized. Compound 3 (TFA
salt, < 1 mg, < 3.29 µmol, < 0.76%) was isolated as a light brown solid. Compound 5 (TFA salt,
31 mg, 0.07 mmol, 15%) was isolated as a red oil as the main product of the reaction.
Compound 6 (TFA salt, < 1 mg, < 1.55 mmol, < 0.4%) was isolated as a red oil. 38 mg (0.12
mmol, 29 %) of the starting material could be recovered.
Photochemical Activation of 1
A sample of 1 (HCl salt, 108 mg, 0.47 mmol) was dissolved in 200 mL of methanol and placed
in an immersion-type photochemical reaction apparatus equipped with a 150 W medium
pressure Hg lamp (Hanau TQ 150). The solution was irradiated for 150 min and the solvent
was subsequently removed under reduced pressure. The crude product was taken up in 2 mL
MeOH/H2O 1:9 and subjected to a preparative HPLC separation. After lyophilization, the TFA
salt of compound 9 (26 mg, 0.07 mmol, 15%) was isolated as a dark oil as the main product of
the reaction.
Conversion of Compound 5 to Compound 4
A sample of 5 was placed in a screw cap vial and treated with 10% ammonia solution. After 24
h the sample was analyzed by HR-ESI-MS.
Tandem MS analysis of Compounds 2, 5, 4 and 6
MS/MS experiments of compounds 2, 5, 4 and 6 were conducted on an Orbitrap Velos Pro
(Thermo Fischer Scientific) mass spectrometer using an unpurified reaction mixture (24
hours, 50 °C). Because of a superimposed signal, compound 2 could not be isolated in the ion
trap. Instead it was analyzed by LC/MS/MS on a LTQ-FT Ultra (Thermo Fischer Scientific)
instrument. Due to the low concentration of 2, an ITMS2 configuration had to be used, which
resulted in a reduced resolution of the spectra.
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Scheme S7.1. Tandem MS fragmentation patterns observed for 2, 5, 4 and 6. Experimentally
observed HRMS data is compared to calculated m/z values of the postulated fragments.
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Quantum Chemical Calculations
Table S7.2. Overview of compounds investigated by quantum chemical calculations. Compounds
I-X and P-X refer to bicyclic structures (left) while compounds B-X and Pyr-X refer to monocyclic
structures (right).
Compound Scaffold Y1 Y2 R1 R2
I-1 isoindole C C H H
I-2 isoindole C C H CH3
I-3 isoindole C C Cl CH3
I-4 isoindole C-CH3 C Cl CH3
P-1 isoindole N N H H
P-2 isoindole N N H CH3
P-3 (1) isoindole N N Cl CH3
P-4 isoindole N+-CH3 N Cl CH3
P-5 indole N N H CH3
P-6 indole N N Cl CH3
B-1 monocyclic C C H -
B-2 monocyclic C C Cl -
Pyr-1 monocyclic N N H -
Pyr-2 monocyclic N N Cl -
Structures were initially build with MOE [151] and optimized at the B3LYP/6-31+G(d) level
using Gaussian09 [282]. No imaginary frequencies were found at the stationary points,
indicating that the optimization converged to a true energy minimum. The optimized
geometries were used as input structures for single point SCF calculations using different basis
sets (6-31G(d), 6-31+G(d) and 6-311+G(d)). The data trends discussed in the main text refer
to calculations on the 6-311G(d) level of theory. The detailed results are described in Tables
S5.3 to S5.16.
NICS calculation: Absolute NMR-shielding tensors were calculated using the GIAO method
[283]. The in-plane ring centers (NICS(0)) and out-of-plane ring centers (NICS(1.0)) were
calculated based on the positions of carbon and nitrogen atoms only.
NBO Analysis: Wiberg bond indices (WBI) and natural atomic charges were calculated using
NBO 3.1[284] as implemented in Gaussian09.
Y1
Y2
N
R2
H3C
R2
R1
AB
1
2
34
5
67
8
910
11
12
13
Y1
Y2N
R2
H3C
R2
R1
AB
1
2
34
5
67
8
910
11
12
13
Y1
Y2
R1
A
1
2
34
5
6
13
indole ([2',3']-pyrrolo)isoindole ([3',4']-pyrrolo) monocyclic
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Electrophilicity index w: The electrophilicity index w was calculated according to Parr et al.
[285] as w = m2/(2h). The chemical potential m is defined as µ = 0.5 ∙ (ELUMO + EHOMO) and the
chemical hardness h is defined as h = 0.5 ∙ (ELUMO - EHOMO).
Example Gaussian input file:
%chk=I-1_6-311+Gd
 %nproc=2
 #B3LYP/6-311+G* SCF=tight Test freq nmr pop=nboread IOp(10/46=1) gfprint
remark line goes here
<<Coordinates>>
$NBO RESONANCE NPA NBO NBOSUM BNDIDX E2PERT NLMO DIPOLE NRT PLOT
$END
NOESY and HSQC Experiments in the Presence of Endothiapepsin
NMR measurements were carried out with 300 Ϫl of protein/ligand solution (148 ϪM EP, 13
mM compound 1) in a 50 mM CD3CO2Na buffer at a pD of 5.1 in a Shigemi tube. The time-
resolved 1H- and the [1H-1H]-NOESY spectra (ϰm=2 s) were measured on a Bruker 800 MHz
1H frequency spectrometer, equipped with a triple-resonance cryoprobe, at 298K. 12
consecutive 1H- and 5 consecutive [1H-1H]-NOESY spectra were recorded every hour, starting
from mixing the protein and the ligand. The [1H-1H]-NOESY spectra were recorded with
96152(t2)*272(t1) complex points, t1max=14.2 ms, t2max=3.0 s, 4 scans, interscan delay 0.3 s. The
HSQC spectra were measured three weeks after mixing the protein and the ligand, at a Bruker
600 MHz 1H frequency spectrometer, equipped with a triple-resonance cryoprobe, at 298K.
The HSQC experiment was recorded as two separate experiments, focusing on the aliphatic
and on the aromatic and carbonyl 13C chemical shift range, respectively, each with 120 ppm
spectral width in the indirect dimension, to ensure complete excitation of all 13C nuclei. The
phase-sensitive, echo/anti-echo-edited HSQC spectra were recorded with 1024(t2)*128(t1)
complex points, t1max=3.5 ms, t2max=53.2 ms, 192 scans, and interscan delay of 2 s.
Crystallization, Soaking and X-ray Diffraction Data Collection
EP was extracted from Suparen samples, kindly supplied by DSM Food Specialties, as described
previously [286]. Subsequently, the protein was crystallized in its apo-form upon streak-
seeding using the vapor diffusion method with a mother liquor composed of 100 mM
NH4OAc, 100 mM NaOAc pH 4.6, 24-30% (w/v) PEG 4000 at 17 °C [64,67] The originally
purchased compound 1 has been soaked into EP crystals once at a concentration of 45 mM
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and thrice at 90 mM resulting in the structures EP-1-2 and EP-2, respectively. Following a
similar approach, all soaking experiments with the compounds isolated via HPLC (1, 3, 4, 5
and 6) have been performed at two different concentrations of 90 and 250 mM. At 45 and 90
mM, soaking was performed for 48 h at 17 °C in 70 mM NH4OAc, 70 mM NaOAc pH 4.6, 16-
20% PEG 4000, 23% glycerol, 9% DMSO and 45 or 90 mM of the ligand, respectively. At the
higher 90 mM ligand concentration, EP crystals have been transferred to this solution via a 1:1
mixture of this solution with the crystallization mother liquor. The same procedure was also
applied at 250 mM where the soaking solution consisted of 65 mM NH4OAc, 65 mM NaOAc
pH 4.6, 14-18% PEG 4000, 10% glycerol, 25% DMSO and 250 mM ligand. In contrast to the 90
mM soaks, the duration of the experiment had been reduced to 24 h under the more harsh
conditions at 250 mM. Finally, all crystals were directly flash-frozen in liquid nitrogen prior to
data collection at the BESSY MX beamlines BL14.1 and BL14.2 [224]. Subsequently diffraction
data have been processed using XDS [185].
Structure Determination
To be able to evaluate and compare the outcome of all diffraction experiments thoroughly, we
used our automated refinement pipeline [68] to determine structural models for all collected
data sets via molecular replacement using Phaser [159] and several Phenix-based refinement
steps [162]. Following this approach, the data set with the highest quality and clearest ligand
electron density has been chosen for each ligand-bound structure (EP-2: 45 mM, EP-1-2: 90
mM, EP-4: 90 mM, EP-3: 250 mM). Subsequently, the associated models were manually
further refined against structure factor amplitudes until convergence. Library files for all non-
standard ligands were generated using the Grade web server application [287]. For ligand 2,
the obtained restraints have been modified in a way to allow the pyridazinium bridge head
nitrogen and attached carbon to deviate from the ring plane as observed in the unrestrained
SHELXL refinement described below. In order to obtain a reliable estimate of the real binding-
site occupancy of 2, we first refined the occupancy of the system Asp33-H2O-Gly221-Thr222
that appeared in two alternative conformations, one of which represents the apo-form and one
the ligand-bound conformation (Figure 7.4B). After validation of the refined value via visual
inspection of the anisotropic displacement parameters, the resulting occupancy for the latter
conformational state was assigned also to ligand 2 (67% for EP-2 structure and 63% for EP-1-
2). Finally, all resulting structures and structure factor amplitudes have been deposited in the
PDB. Data collection and refinement statistics are given in Table S7.1. Figures displaying
structural information have been prepared using Pymol [164].
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Estimation of Standard Deviations for Different Geometric Parameters
To enable an estimation of standard deviations for geometric parameters, a least-squares
BLOC refinement was performed against intensities using SHELXL [277]. As a starting point,
the final Phenix-refined EP-1-2 structure has been chosen and adapted in several modeling
and refinement steps. For the subsequent determination of distances and angles within ligand
2, all of its atoms were refined in an unrestrained manner except for planarity restraints for the
three ring systems excluding the carbon atom next to the pyridazinium nitrogen which was
observed to be significantly out-of-plane (Figure 7.3B). This observation was made via a similar
refinement in which the planarity restraint for the bicyclic component of 2 was additionally
omitted and the deviation of each atom of the pyridazinium ring from a least-squares plane
made up by the residual five atoms of the ring was calculated along with estimated standard
deviations. While the bridge head pyridazinium nitrogen was found to be located significantly
below the plane (-0.20 ± 0.05 Å, corresponding to -4.1 ϯ) and the attached carbon atom
accordingly above the plane (0.23 ± 0.05 Å, corresponding to 4.3 ϯ), all other atoms did not
deviate as significantly from their respective planes (-0.11 to 0.06 Å, -2.1 to 1.1 ϯ). In order to
ensure that these results had not been biased by the ligand restraints used in the previous
Phenix-based refinement steps, we repeated both analyses with starting structures that
contained an alcohol CO bond length of 1.41 Å instead of the aldehyde bond length of 1.22 Å
and an approximately planar pyridazinium ring, respectively. Importantly, the results did not
deviate significantly from those obtained before.
Queries in the Cambridge Structural Database (CSD)
CSD searches have been performed using Conquest [288] vs. 1.18 based on CSD vs. 5.37 as of
November 2015 (with 2 updates) while the results were analyzed with Mercury [289] vs. 3.8
and plotted via the statistical program R [290]. The following adjustments have been used for
all searches: 3D coordinates determined, only organics, R ≤ 0.075, not disordered, no errors
and not polymeric. The investigated chemical structures and geometric parameters are defined
in Figure S7.4, Figure S7.5 and Figure S7.6.
Experimental Data
Compound 1. 1H NMR (400 MHz, D2O) Ϣ = 2.78 (s, 3H), 2.85 (s, 3H), 3.97 (s, 3H), 9.53 (s, 1H).
13C NMR (101 MHz, D2O) Ϣ = 10.3, 10.7, 32.8, 110.4, 113.5, 129.6, 136.5, 142.4, 150.9. HRMS
(ESI+) calculated for C9H11ClN3: 196.0636 [M+H]+; found: 196.0636.
Compound 2. HRMS (ESI+) calculated for C27H29ClN9O: 530.2178 [M]+; found: 530.2176.
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Compound 3 (TFA salt). 1H NMR (400 MHz, D2O) Ϣ = 2.63 (s, 3H), 2.65 (s, 3H), 3.81 (s, 3H),
4.11 (s, 3H), 9.15 (s, 1H). HRMS (ESI+) calculated for C10H14N3O: 192.1131 [M+H]+; found:
192.1128.
Compound 4.a 1H NMR (400 MHz, MeOH-d4) Ϣ = 2.26 (s, 3H), 2.62 (s, 3H), 2.63 (s, 3H), 2.80
(s, 3H), 3.63 (s, 3H), 3.81 (s, 3H), 8.52 (s, 1H), 9.70 (s, 1H). 13C NMR (101 MHz, MeOH-d4) Ϣ
= 10.4, 10.8, 11.0, 11.8, 30.9, 31.7, 111.8, 125.3, 133.6, 143.8, 170.3. HRMS (ESI+) calculated
for C18H21N6O: 337.1771 [M+H]+; found: 337.1767.
Compound 5 (TFA salt). 1H NMR (400 MHz, D2O) Ϣ = 2.45 (s, 3H), 2.80 (s, 3H), 2.83 (s, 3H),
2.87 (s, 2H), 3.95 (s, 3H), 3.97 (s, 2H), 9.70 (s, 1H). 13C NMR (101 MHz, D2O) Ϣ = 10.6, 10.8,
10.9, 12.3, 33.4, 105.6, 109.4, 115.6, 116.2 (q, 1JCF = 288.7), 116.4, 128.5, 132.1, 138.4, 142.9,
144.0, 144.9, 150.4, 151.4, 162.9 (q, 2JCF = 35.2). HRMS (ESI+) calculated for C18H20ClN6:
355.1438 [M]+; found: 355.1433.
Compound 6 (TFA salt). 1H NMR (400 MHz, D2O) Ϣ = 2.32 (s, 3H), 2.54 (s, 3H), 2.75 (s, 3H),
2.79 (s, 3H), 2.87 (s, 3H), 2.93 (s, 3H), 3.89 (s, 3H), 3.95 (s, 3H), 4.04 (s, 3H), 9.74 (s, 1H), 10.15
(s, 1H), 10.44 (s, 1H). HRMS (ESI+) calculated for C27H31ClN9O: 532.2335 [M]+; found:
532.2334.
Compound 8. HRMS (ESI+) calculated for C10H13ClN3O: 226.0742 [M+H]+; found: 226.0730.
Compound 9 (TFA salt). 1H NMR (400 MHz, D2O) Ϣ = 3.44 – 3.49 (m, 6H), 4.14 (s, 3H), 5.07
(s, 2H), 5.18 (s, 2H), 9.84 (s, 1H). 13C NMR (101 MHz, D2O) Ϣ = 33.8, 57.6, 58.2, 61.5, 63.2,
114.2, 115.6, 116.2 (q, 1JCF = 291.7), 128.0, 135.1, 143.1, 150.9, 162.8 (q, 2JCF = 43.1). HRMS
(ESI+) calculated for C11H15ClN3O2: 256.0847 [M+H]+; found: 256.0833.
a Due to its poor solubility, compound 4 was dissolved in a mixture of MeOH-d4 and acetone-
d6. The low concentration prohibited the observation of several signals of quaternary carbon
atoms in the 13C spectrum.
Data from Quantum Chemical Calculations
Table S7.3. Natural atomic charges at atom position 4.
Compound 6-31G(d) 6-31+G(d) 6-311+G(d)
I-1 -0.21638 -0.21759 -0.18359
I-2 -0.21592 -0.21616 -0.18410
I-3 -0.01476 -0.01326 -0.00804
I-4 -0.00645 -0.00394 0.01021
P-1 0.03557 0.03206 0.06757
P-2 0.03546 0.03085 0.08457
P-3 (1) 0.22077 0.20894 0.22538
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Table S7.3. continued.
Compound 6-31G(d) 6-31+G(d) 6-311+G(d)
P-4 0.23685 0.22813 0.24438
P-5 -0.03548 -0.03769 -0.00296
P-6 0.15427 0.14564 0.16039
B-1 -0.23527 -0.24218 -0.20333
B-2 -0.23848 -0.24463 -0.20632
Pyr-1 -0.01251 -0.02041 0.02052
Pyr-2 -0.01417 -0.02107 0.01868
Table S7.4. Natural atomic charges at atom position 1.
Compound 6-31G(d) 6-31+G(d) 6-311+G(d)
I-1 -0.21638 -0.21759 -0.18359
I-2 -0.21594 -0.21959 -0.17120
I-3 -0.21468 -0.21542 -0.17048
I-4 -0.21542 -0.21410 -0.18760
P-1 0.03439 0.03198 0.06752
P-2 0.03546 0.03378 0.06459
P-3 (1) 0.03818 0.03664 0.07056
P-4 0.12658 0.13490 0.16506
P-5 0.01105 0.00766 0.04347
P-6 0.01253 0.00908 0.04383
B-1 -0.23527 -0.24218 -0.20333
B-2 -0.04358 -0.05584 -0.04102
Pyr-1 -0.01251 -0.02041 0.02052
Pyr-2 0.15588 0.14349 0.16034
Table S7.5. WBI for atomic bond at position 2-3.
Compound 6-31G(d) 6-31+G(d) 6-311+G(d)
I-1 1.2657 1.2663 1.2669
I-2 1.2604 1.2603 1.2167
I-3 1.2556 1.2542 1.2535
I-4 1.2204 1.2198 1.2167
P-1 1.2191 1.2227 1.2239
P-2 1.2107 1.2129 1.2147
P-3 (1) 1.1936 1.1945 1.1935
P-4 1.1269 1.1302 1.1264
P-5 1.335 1.3374 1.3397
P-6 1.3086 1.3095 1.3097
B-1 1.4368 1.4371 1.439
B-2 1.432 1.4324 1.4327
Pyr-1 1.3976 1.4027 1.4047
Pyr-2 1.3736 1.3765 1.3763
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Table S7.6. WBI for atomic bond at position 3-4.
Compound 6-31G(d) 6-31+G(d) 6-311+G(d)
I-1 1.5988 1.5980 1.6005
I-2 1.6013 1.6004 1.5679
I-3 1.5624 1.5598 1.5623
I-4 1.5758 1.5735 1.5679
P-1 1.6445 1.6473 1.6468
P-2 1.6492 1.6504 1.6436
P-3 (1) 1.6370 1.6387 1.6356
P-4 1.5705 1.5672 1.5648
P-5 1.5291 1.531 1.5299
P-6 1.5408 1.5451 1.5437
B-1 1.4368 1.4371 1.439
B-2 1.4037 1.4027 1.4025
Pyr-1 1.4824 1.4866 1.4856
Pyr-2 1.4748 1.4782 1.4745
Table S7.7. NICS(0) values at ring A.
Compound 6-31G(d) [ppm] 6-31+G(d) [ppm] 6-311+G(d) [ppm]
I-1 -8.3573 -6.7175 -6.5780
I-2 -7.8801 -6.3974 -6.1650
I-3 -8.1807 -7.3796 -7.4937
I-4 -8.6765 -7.3959 -7.0781
P-1 -5.0951 -4.4809 -4.5637
P-2 -4.6257 -4.1097 -4.1701
P-3 (1) -5.6378 -4.9806 -4.9024
P-4 -6.2992 -5.5065 -5.2127
P-5 -8.9700 -8.3265 -8.3780
P-6 -8.9700 -8.3265 -8.3780
B-1 -9.6482 -8.0216 -7.9345
B-2 -10.2524 -8.9027 -9.9924
Pyr-1 -5.7556 -5.0531 -5.2485
Pyr-2 -6.4445 -5.8008 -5.8481
Table S7.8. NICS(0) values at ring B.
Compound 6-31G(d) [ppm] 6-31+G(d) [ppm] 6-311+G(d) [ppm]
I-1 -17.4253 -15.6495 -15.3332
I-2 -16.8376 -15.3714 -15.2396
I-3 -17.2753 -16.0619 -15.8239
I-4 -16.9905 -15.5229 -15.2236
P-1 -17.9539 -16.4588 -16.0083
P-2 -17.3109 -15.8880 -15.6712
P-3 (1) -17.4879 -16.4384 -16.1498
P-4 -16.6222 -15.4282 -15.1428
P-5 -13.5300 -12.7020 -12.3425
P-6 -13.9308 -13.1218 -12.6420
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Table S7.9. NICSzz(0) values at ring A.
Compound 6-31G(d) [ppm] 6-31+G(d) [ppm] 6-311+G(d) [ppm]
I-1 -5.6777 -5.4037 -6.0251
I-2 -3.1337 -2.8154 -3.4881
I-3 -29.4937 -29.6613 -30.4412
I-4 -2.5119 -1.9326 -2.4267
P-1 -2.4149 -2.4149 -3.5926
P-2 0.1742 0.1742 -0.9561
P-3 (1) 0.0075 0.0075 -0.7008
P-4 4.2965 4.6270 4.4654
P-5 -11.4265 -11.9404 -12.6243
P-6 -10.2845 -10.4693 -11.0410
B-1 -13.7989 -13.1765 -14.0643
B-2 -13.3587 -12.6903 -13.3565
Pyr-1 -10.4678 -10.7302 -11.5122
Pyr-2 -9.8905 -9.8762 -10.4523
Table S7.10. NICSzz(0) values at ring B.
Compound 6-31G(d) [ppm] 6-31+G(d) [ppm] 6-311+G(d) [ppm]
I-1 -16.6309 -16.1241 -16.6410
I-2 -13.8302 -13.8624 -14.5943
I-3 -13.8886 -13.9385 -14.6399
I-4 -12.6404 -12.2745 -12.9272
P-1 -16.7125 -16.7125 -16.8537
P-2 -13.7984 -13.7984 -14.5550
P-3 (1) -13.5122 -13.5122 -14.1549
P-4 -12.9942 -12.6259 -13.3833
P-5 -28.3137 -28.2621 -28.3954
P-6 -25.8995 -25.6857 -25.7820
Table S7.11. NICS(1.0) values at ring A.
Compound 6-31G(d) [ppm] 6-31+G(d) [ppm] 6-311+G(d) [ppm]
I-1 -9.4985 -8.2738 -8.4818
I-2 -9.0535 -7.9922 -8.1357
I-3 -9.1508 -8.0746 -8.0797
I-4 -8.9200 -7.8523 -7.8267
P-1 -9.2444 -8.3725 -8.5583
P-2 -8.5047 -7.7288 -7.9358
P-3 (1) -8.2936 -7.4413 -7.6149
P-4 -7.2098 -6.4063 -6.4560
P-5 -11.7000 -10.8731 -11.0804
P-6 -11.1418 -10.3154 -10.5151
B-1 -11.1929 -10.1364 -10.1345
B-2 -11.0419 -9.9924 -10.0023
Pyr-1 -11.0397 -10.2596 -10.4739
Pyr-2 -10.6968 -9.9392 -10.0860
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Table S7.12. NICS(1.0) values at ring B.
Compound 6-31G(d) [ppm] 6-31+G(d) [ppm] 6-311+G(d) [ppm]
I-1 -13.8887 -12.2812 -12.3669
I-2 -13.6878 -12.2126 -12.4800
I-3 -13.7288 -12.3437 -12.3577
I-4 -13.4765 -12.0651 -12.1919
P-1 -14.1433 -12.7693 -12.8363
P-2 -13.8699 -12.5762 -12.9047
P-3 (1) -13.7434 -12.5977 -12.6247
P-4 -14.0630 -12.8504 -12.9812
P-5 -11.3494 -10.4291 -10.5042
P-6 -11.4074 -10.4793 -10.4817
Table S7.13. HOMO Energies
Compound 6-31G(d) [eV] 6-31+G(d) [eV] 6-311+G(d) [eV]
I-1 -4.72988 -5.05424 -5.09887
I-2 -4.37777 -4.65396 -4.69968
I-3 -4.64471 -4.8942 -4.93941
I-4 -4.58593 -4.82294 -4.86839
P-1 -5.78840 -6.11440 -6.15957
P-2 -5.33942 -5.61997 -5.66514
P-3 (1) -5.62486 -5.88065 -5.92555
P-4 -9.84780 -9.98250 -10.02440
P-5 -5.7751 -6.1315 -6.1645
P-6 -6.1476 -6.3922 -6.4390
B-1 -6.6940 -6.9939 -7.0385
B-2 -6.7016 -6.9457 -6.9822
Pyr-1 -6.3465 -6.6997 -6.7332
Pyr-2 -6.8390 -7.1514 -7.1835
Table S7.14. LUMO Energies
Compound 6-31G(d) [eV] 6-31+G(d) [eV] 6-311+G(d) [eV]
I-1 -0.38612 -0.78994 -0.78994
I-2 -0.27946 -0.63456 -0.63456
I-3 -0.59592 -0.91375 -0.91375
I-4 -0.51211 -0.81253 -0.81253
P-1 -1.1428 -1.50479 -1.50479
P-2 -0.97117 -1.28764 -1.28764
P-3 (1) -1.25417 -1.53227 -1.53227
P-4 -5.92909 -6.07902 -6.07902
P-5 -0.6664 -1.0275 -1.0917
P-6 -0.9285 -1.2251 -1.2912
B-1 0.0841 -0.3951 -0.4620
B-2 -0.3499 -0.7761 -0.8444
Pyr-1 -1.3910 -1.7979 -1.8618
Pyr-2 -1.8153 -2.1742 -2.2376
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Table S7.15. HOMO-LUMO Energy Gaps.
Compound 6-31G(d) [eV] 6-31+G(d) [eV] 6-311+G(d) [eV]
I-1 -4.34375 -4.26429 -4.30892
I-2 -4.09830 -4.01939 -4.06511
I-3 -4.04878 -3.98048 -4.02565
I-4 -4.07381 -4.01041 -4.05585
P-1 -4.64553 -4.60961 -4.65478
P-2 -4.36824 -4.33232 -4.37749
P-3 (1) -4.37069 -4.34838 -4.39328
P-4 -3.91871 -3.90347 -3.94538
P-5 -5.1087 -5.1040 -5.0727
P-6 -5.2191 -5.1672 -5.1479
B-1 -6.7781 -6.5988 -6.5765
B-2 -6.3517 -6.1696 -6.1378
Pyr-1 -4.9555 -4.9019 -4.8714
Pyr-2 -5.0238 -4.9772 -4.9459
Table S7.16. Electrophilicity Indexw.
Compound 6-31G(d) [eV] 6-31+G(d) [eV] 6-311+G(d) [eV]
I-1 1.5064 2.0023 2.0120
I-2 1.3231 1.7396 1.7499
I-3 1.6958 2.1186 2.1276
I-4 1.5949 1.9798 1.9893
P-1 2.5853 3.1484 3.1550
P-2 2.2791 2.7534 2.7608
P-3 (1) 2.7067 3.1593 3.1650
P-4 15.8796 16.5220 16.4319
P-5 2.0305 2.5104 2.5949
P-6 2.3984 2.8073 2.9020
B-1 1.6115 2.0685 2.1386
B-2 1.9571 2.4161 2.4950
Pyr-1 3.0204 3.6827 3.7912
Pyr-2 3.7271 4.3682 4.4864
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Data from NMR, MS and HPLC Experiments
1H (400 MHz, D2O) and 13C NMR (101 MHz, D2O) of compound 1
Figure S7.7. 1H NMR Spectrum of 1.
Figure S7.8. 13C NMR Spectrum of 1.
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1H (400 MHz, D2O) NMR spectrum of compound 3
1H (400 MHz, MeOH-d4) and 13C NMR (101 MHz, MeOH-d4) spectra of compound 4
Figure S7.9. 1H NMR Spectrum of 3.
Figure S7.10. 1H NMR Spectrum of 4.
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1H (400 MHz, D2O) and 13C NMR (101 MHz, D2O) spectra of compound 5
Figure S7.11. 13C NMR Spectrum of 4.
Figure S7.12. 1H NMR Spectrum of 5.
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1H (400 MHz, D2O) NMR spectrum of compound 6
Figure S7.13. 13C NMR Spectrum of 5.
Figure S7.14. 1H NMR Spectrum of 6.
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1H (400 MHz, D2O) NMR spectrum of compound 9
ESI-MS and HR-MS spectra of compound 1
Figure S7.15. 1H NMR Spectrum of 9.
Figure S7.16. ESI-MS Spectrum of 1.
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ESI-MS and HR-MS spectra of compound 2
Figure S7.17. ESI-HRMS Spectrum of 1.
Figure S7.18. ESI-MS Spectrum of 2.
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ESI-MS and HR-MS spectra of compound 3
Figure S7.19. ESI-HRMS Spectrum of 2.
Figure S7.20. ESI-MS Spectrum of 3.
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ESI-MS and HR-MS spectra of compound 4
Figure S7.21. ESI-HRMS Spectrum of 3.
Figure S7.22. ESI-MS Spectrum of 3.
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ESI-MS and HR-MS spectra of compound 5
Figure S7.23. ESI-HRMS Spectrum of 3.
Figure S7.24. ESI-MS Spectrum of 5.
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ESI-MS and HR-MS spectra of compound 6
Figure S7.25. ESI-HRMS Spectrum of 5.
Figure S7.26. ESI-MS Spectrum of 6.
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ESI-MS and HR-MS spectra of compounds 8 and 9
Figure S7.27. ESI-MS Spectrum of 6.
Figure S7.28. ESI-MS Spectrum of 8 and 9.
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Figure S7.29. ESI-HRMS Spectrum of 8.
Figure S7.30. ESI-HRMS Spectrum of 9.
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MS/MS Spectra of compound 2
Figure S7.31. MS/MS Spectrum of 2.
Figure S7.32. MS/MS Spectrum of 2.
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MS/MS Spectra of compound 4
Figure S7.33. MS/MS Spectrum of 4.
Figure S7.34. MS/MS Spectrum of 4.
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Figure S7.35. MS/MS Spectrum of 4.
Figure S7.36. MS/MS Spectrum of 4.
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MS/MS Spectrum of compound 5
MS/MS Spectra of compound 6
Figure S7.37. MS/MS Spectrum of 5.
Figure S7.38. MS/MS Spectrum of 6.
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Figure S7.39. MS/MS Spectrum of 6.
Figure S7.40. MS/MS Spectrum of 6.
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Figure S7.41. MS/MS Spectrum of 6.
Figure S7.42. MS/MS Spectrum of 6.
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ESI-MS and HR-MS spectra of the crude reaction mixture from the conversion of 5
to 4
Figure S7.43. ESI-MS Spectrum of the crude reaction mixture from the conversion of 5 to 4.
Figure S7.44. ESI-HRMS Spectrum of the crude reaction mixture from the conversion of 5 to 4.
Chapter 8
Discussion
294 | Chapter 8
8.1 Introductory Remark
The previous chapters were taken from self-contained articles in scientific journals. Due to the
independent nature of the publications, the compound numbering is ambiguous when the
articles are combined to a coherent thesis. In the summarizing discussion in Chapter 8, the
compound numbering is expanded to enable a unique identification of each compound. For
this, the chapter number is added as a prefix in front of the compound number used in the
publication. Thus, the identifier 1.1 refers to compound 1 from the first chapter of this thesis.
For a better overview, a summary of relevant compounds is given in each section.
8.2 Synthesis of Phosphonamidate Peptides as Inhibitors of TLN
The application of phosphonamidates in biomedical research has been restricted by their
synthetic inaccessibility and their inherent instability under certain experimental conditions.
In contrast to the formation of carboxamide peptide bonds, the P–N coupling reaction
represents a significant synthetic challenge. The most commonly applied reagents for the
activation of the phosphonic acid coupling partner are the phosphonium reagent PyBOP, as
well as thionyl chloride and oxalyl chloride (Scheme 1.1). While the use of PyBOP routinely
gives good results for the coupling reaction, the method has a significant drawback that is often
not considered during the planning phase of a synthesis. During the course of the reaction,
equimolar amounts of the byproduct tris(N,N-tetramethylene)phosphoric acid triamide are
formed. After the reaction is complete, this compound has to be separated from the
phosphonamidate ester product. Usually this task is easily accomplished by a chromatographic
purification step. However, for many of the phosphonamidate peptides that were synthesized
in the context of this thesis, a chromatographic purification using silica gel lead to a complete
decomposition of the product. This finding was attributed to the acidity of the stationary phase
and persisted even with the use of basic modifiers like NEt3 in the mobile phase. Therefore,
thionyl chloride was chosen as the activation reagent for phosphonamidate coupling. The side
products of thionyl chloride activation, SO2 and HCl, can easily be removed by distillation.
After a simple aqueous workup, which removes residual starting material and amine bases used
for the coupling, the protected phosphonamidate peptide can be obtained in sufficiently pure
form.
For this reaction, the stoichiometry, order, and rate, in which the reagents are added to the
reaction mixture, was found to be crucial. During the preactivation step of the phosphonic
acid, it is important to maintain an excess of the activation reagent over the phosphonic acid
in order to suppress the formation of inactive pyrophosphonate intermediates. Therefore, a
dilute solution of the phosphonic acid was slowly added to a highly concentrated solution of
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two equivalents of SOCl2. With this method, the desired phosphonamidates could routinely be
obtained in a high yield.
The most commonly employed protection strategy for phosphonamidate peptides utilizes
methyl or ethyl esters for the central phosphonic acid and the C-terminal carboxylic acid
functions. Saponification using aqueous alkali hydroxide solutions then gives the deprotected
inhibitors as lithium or sodium salts. These highly polar compounds are then purified by
preparative reversed-phase HPLC. During the course of this process, we routinely struggled
with very low recovery rates of the desired inhibitors, which could be attributed to an evident
hydrolysis of the P–N bond during the HPLC purification. Even though the pH of the mobile
phase was kept neutral, the deprotected phosphonamidate peptides were found to decompose
during the chromatographic separation. The hydrolytic instability of the deprotected
inhibitors necessitated an adaptation of the synthetic strategy. The hydrolytically labile methyl
ester protecting groups were replaced with allyl esters, which can be cleaved via a palladium
catalyzed deallylation reaction, using diethylamine as a nucleophilic scavenger. The side
products of this reaction can be easily removed by distillation and a subsequent aqueous
workup procedure, which gives the deprotected inhibitors as diethylammonium salts. Since
the resulting peptides proved to be highly hygroscopic, they were transformed into their
respective lithium salts by the addition of LiOH during the aqueous workup step. Alternative
purification methods were evaluated in order to avoid the HPLC separation procedure that
was previously found to decompose a significant amount of the product. For this task, SPE
(solid phase extraction) seemed to be a suitable substitute. While this technique still relies on
a chromatographic separation principle, the exposure of the analyte to mobile and stationary
Figure 8.1.  Graphical abstract: An allyl protection and improved purification strategy enables the
synthesis of functionalized phosphonamidate peptides. Reproduced from [183].
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phases is reduced to a minimum. With polymeric DPA-6S resin and cyano or amino modified
silica gel phases, no retention of the products or contaminants was observed. The use of
zwitterionic ammonium sulfonic acid phases in hydrophilic-lipophilic interaction
chromatography (HILIC) proved to be efficient, yet, hydrolysis of the surface modification and
the necessity for buffered mobile phases prevent an effective use of this technique. The most
success can be achieved with a C18 modified silica gel phase. SPE cartridges with this surface
modification show little retention of the desired inhibitors, but hydrophobic contaminants are
efficiently retained, so that the phosphonopeptides can be obtained in excellent purity.
The developed allyl ester/alloc protection strategy in combination with a SPE purification
method represents an operationally simple protocol for the synthesis of phosphonamidate
peptides. Using the procedure reported in Chapter 2, 17 inhibitors were successfully
synthesized with high purity. Most notably, this procedure allows the incorporation of polar
and nucleophilic functional groups, such as alcohols and amines. In addition, an inhibitor
containing a hydrolytically labile ester group can be synthesized, which has been proven to be
a challenging task with the commonly applied strategy [105]. The excellent purity of the
products allows their use in biophysical experiments, such as ITC, that rely heavily on an
accurate knowledge of ligand concentrations.
8.3 Understanding Solvation Effects in the Binding of TLN Inhibitors
Rational Design of Water Networks
Upon formation of a protein–ligand complex, the newly generated surface necessitates a
rearrangement of the surrounding water molecules in the hydration shell. The shape of this
surface has a major impact on the shape of the resulting water structure, which in turn
contributes to the binding affinity of the ligand. Solvent effects like this have generally been
neglected in the design process of a new drug.
In the study presented in Chapter 3, an attempt is made to include a consideration of this
contribution in the design of a ligand for the metalloprotease TLN. Based on a fairly well
optimized ligand from a previous study (3.1), a series of inhibitors is designed that optimize
the resulting water network in the first layer of hydration around their hydrophobic P2’
substituents, which address the shallow and solvent exposed S2’ pocket of TLN (3.2, 3.3). As a
control, a set of the respective diastereomers is included in the series (3.4, 3.5). The reversal of
the P2’ stereocenter is believed to sufficiently disrupt the water networks, so that its
contribution to the thermodynamic binding profile can be evaluated.
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An MD simulation, using an explicit solvent approach with a significant damping of the
protein movement turns out to be suitable to predict water network formation. This method
reveals the most beneficial water organization for ligand 3.3 (Figure 3.11).
The synthetic challenge in the preparation of the envisioned inhibitor series is the introduction
of the additional stereocenter of the aliphatic amine in the P2’ position. Not many synthetic
methodologies are available for the direct generation of aliphatic b-chiral amines.
Figure 8.2.  Overview of relevant compounds from Chapter 3.
Figure 8.3.  Graphical abstract: Rational Design of Thermodynamic and Kinetic Binding Profiles by
Optimizing Surface Water Networks Coating Protein-Bound Ligands. Reproduced from [16].
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While the desired amino building blocks have been synthesized previously by utilizing an
enantioselective hydroboration procedure, the reported enantiomeric purities are not
sufficient for the intended purpose [291–293]. The copper catalyzed enantioselective
hydroamination protocol, reported by Zhu and Buchwald, which generates the desired amines
with a much better enantioselectivity [294], was not available at the time of this work.
Additionally, neither a crystallographic resolution of the racemic mixture, nor a
chromatographic separation of a leucine adduct of the desired molecules proved to be
successful. Therefore, the stereogenic center is formally shifted to the a-position of the
compounds by a change of the oxidation state of the terminal carbon center. The
correspondinga-chiral carboxylic acids are accessible by a diastereoselective enolate alkylation
utilizing Evan’s chiral oxazolidinone auxiliary. This procedure enables the synthesis of the
desired inhibitors starting from the commercially available carboxylic acid derivatives (Scheme
8.1, Scheme 3.1).
From the crystal structures of TLN in complex with the inhibitors it is evident that the MD
prediction of the solvation patterns around the P2’ substituents has been very accurate,
demonstrating that this approach can be used for the evaluation of hydration propensities of a
ligand series without any a priori knowledge about the details of binding (Figure 3.11). The
crystallographic analysis of the water structure (Figure 3.4) shows that the favorable hydration
pattern of the original ligand 3.1 is retained for its iso-propyl homolog 3.2 and can even be
improved for the tert-butyl derivative 3.3. In contrast to that, the (R)-configured epimers 3.4,
3.5 and 3.6 display a much reduced stabilization of the surrounding water shell. This is
especially indicative for 3.4, which loses the ability to support the favorable five-membered
ring water arrangement that is present in the other structures, due to a flip of the orientation
of the P2’ chain. Furthermore, an evaluation of the crystallographic B-factors reveals a more
pronounced stabilization of the water molecules in the first solvation layer for the (S,S)-
configured inhibitors in comparison to their (S,R)-configured analogues (Figure 3.5).
The thermodynamic binding profiles of the inhibitors were subsequently analyzed by ITC
(Figure 3.8) and observed differences in the thermodynamics of binding correlated to changes
in the respective crystal structures (Figure 3.4). In comparison to ligand 3.1, its homolog 3.2
Scheme 8.1. Retrosynthetic analysis of chiral alkylamines used in the preparation of TLN
inhibitors 3.2–3.6.
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shows a slightly increased entropic benefit, which can be attributed to a more favorable
desolvation entropy, owing to the larger hydrophobic surface that is buried upon binding.
Additionally, the observation of two distinct conformations in the crystal structure implies an
intrinsic disorder of the aliphatic P2’ chain, which might give an entropic benefit. This effect is
superimposed by an enthalpic loss that might originate from a disorder in the water structure,
weakening solvent–solvent interactions.
In the structure of 3.3, additional water molecules are recruited to the complex (Figure 3.4C).
An extensive network of multiple fused water polygons is observed. This inhibitor also shows
the highest affinity of the series. However, the free energy gain determined for this compound
originates from a beneficial entropic term compared to its iso-propyl analog 3.2. This
observation was credited to an increase of the buried hydrophobic surface area for the tert-
butyl group. While the enlargement of the hydrophobic portion results in a destabilization of
the water network with a concomitant loss in enthalpy in the case of 3.2, the shape of the
hydrophobic surface generated by the tert-butyl in 3.3 group allows an optimal stabilization of
the solvation layer. This compensates for the desolvation cost of the larger hydrophobic
residue, resulting in a more beneficial free energy of binding.
The crystal structures of the (R)-configured ligands (Figure 3.4E/F) reveal a significant increase
of the B-factors of the water molecules in the network surrounding the P2’ moiety. The
inversion of the stereogenic center results in an increased steric demand of the (R)-configured
side chains that is sufficient to disrupt the solvation pattern of the hydration shell. As a result,
the expected entropic gain upon burial of an increased patch of hydrophobic surface is entirely
compensated by an enthalpic loss, nullifying the free energy balance. Thus, the gain in affinity,
which was observed in the (S)-configured series, represents an enthalpic advantage from a
beneficial stabilization of favorable water structures in the first solvation layer.
The Price of Solvation for Ligands Binding to Protein–Solvent Interfaces
Charged and polar functional groups are often included into a ligand scaffold to improve its
solubility or pharmacokinetic properties. When the target protein does not offer a suitable
interaction for the newly introduced function, it is commonly placed into a position, from
which the polar substituent sticks out into the solvent and remains partially hydrated. The
study in Chapter 4 is aimed to investigate the phenomenon of partial desolvation of a charged
and polar functional group and evaluate the binding thermodynamics in comparison to an
inhibitor featuring a purely hydrophobic group in this position. The crystal structures of TLN
in complex with ligands 4.1–4.8, which feature a protonated ammonium group at the terminus
of an aliphatic chain of variable length in the P2’ position, reveal that the terminal functional
group tends to interact with Asn111 (Figure 4.2). Whenever the length of the aliphatic chain
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permits, the backbone carbonyl group of this residue accepts a hydrogen bond from the
charged moiety. For the ligands with a shorter aminoethyl or aminomethyl group, the
interaction distance becomes too large and the hydrogen bond to Asn111 is taken up by a water
molecule instead. In these cases, the ammonium groups interact with solvent molecules that
are recruited into the complex. The thermodynamic binding profiles are characterized by a
steady decrease of affinity upon reduction of the linker length (Figure 4.1). The free energy of
binding is split up into enthalpic and entropic contributions that, apart from minor
compensations, do not dramatically deviate between the ligands. Only for the shortest ligand
(4.4), a striking loss in the enthalpic term is recorded. This contribution might originate from
an increased cost for the partial desolvation of the charged group, as it is pulled further into
the hydrophobic environment of the S2’ pocket. The unfavorable enthalpic term, however, is
partially compensated by an entropic benefit. The necessity to assign multiple conformations
to the ligand side chain in the refinement model indicates a disorder in the system that might
explain the recorded entropic gain. The ligands, comprising a lysine homolog in the P2’
position (4.5–4.8), adopt similar binding modes when compared to their isostructural analogs.
Depending on the linker length, an interaction to either Asn111, or water molecules in the
hydration shell is observed. Only for the longest ligand (4.5), the terminal ammonium group
sticks out into the solvent and is disordered in the crystal structure. The thermodynamic
binding profiles within this series also reveal a slight decrease in affinity when the linker length
is gradually reduced. This is driven by an enthalpic loss that is partially compensated by an
entropically beneficial contribution. For the shortest ligand of this series (4.8), a pronounced
gain in enthalpy, which is compensated by an entropic loss, can be observed. The enthalpic
benefit of this inhibitor might originate from the stabilization of six additional water molecules
in the solvation shell around the terminal ammonium group. Consequently, this loss of
mobility is also recorded as a penalty in the entropic term. Even though the ligand side chain
Figure 8.4.  Overview of relevant compounds from Chapter 4.
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dominates the thermodynamics of binding.
Binding kinetic data recorded by SPR measurements of four compounds (Figure 8.5) reveal a
steady decrease in the rate constant of association, while the dissociation rate is mostly constant
within the series. Only for the ornithine derivative (4.6), a slightly slower off-rate is observed.
The association mechanism of inhibitors of TLN is likely governed by a conformational
adaption of the protein. During this process, Glu143 is protonated and recedes deeper into the
Figure 8.5.  Binding kinetic data of 4.5–4.8 from SPR measurements.
Figure 8.6.  Graphical abstract: Paying the Price of Solvation in Solvent-Exposed Protein Pockets:
Impact of Solubilizing Polar Groups on Affinity and Binding Thermodynamics in a Series of
Thermolysin Inhibitors.
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S1 pocket. In addition, the catalytic water molecule that is bound to the central zinc ion has to
be displaced into the bulk. Since the inhibitor scaffold of the investigated ligands is kept
constant, it is conceivable that a significant variation in this part of the process can be ruled
out. Most likely, the decrease in ka with a reduction of the chain length can be attributed to an
increasing kinetic penalty for the desolvation of the terminal ammonium functionality.
A comparison of the characteristics of binding with structural analogs that feature a purely
hydrophobic substituent in the P2’ position (4.9–4.12) yields valuable insight. In either case,
the apolar compounds are significantly more potent than their hydrophilic analogs. This gain
in free energy by a factor of 20–180 in Kd is the result of a dramatic enthalpic penalty that
accompanies the inclusion of a charged moiety in the inhibitor scaffold. Probably as a result of
the partial desolvation of the polar ammonium group, the respective inhibitors lose potency.
An inspection of the crystal structures reveals that the organization of residual solvent
molecules around the P2’ groups of the ligands does not favor the polar compounds (Figure
4.3). In all cases, an equivalent or even superior network of water molecules is established if a
strictly aliphatic residue is included in this position. This highlights the fact that contributions
of the solvent as a third interaction partner in protein–ligand binding have to be considered in
the design of a prospective drug molecule. In the case of the inhibitor series investigated here,
the partial desolvation of a polar group dominates the interaction, even when it is bound to a
mostly solvent-exposed binding pocket.
Exploiting Poorly Solvated Binding Pockets in Drug Design
It has been postulated in literature that the accommodation of water molecules in hydrophobic
cavities depends on the shape of the surface, and that insufficiently solvated protein pockets
exist in nature [11,14,295]. In the study presented in Chapter 5, the S1’ pocket of TLN is
identified as such a poorly hydrated cavity. The ligand that was used in the initial experiments
features a glycine residue in its P1’ position (5.1). This configuration covers the S1’ pocket, while
the lack of a bulky substituent hypothetically allows the accommodation of several water
molecules in the residual cavity of > 140 Å³. In order to obtain a reliable estimation of the
content of the enclosed crevice, it is necessary to utilize experimentally determined phase
information for the calculation of an electron density map. In comparison to the most
commonly applied phasing technique,  molecular replacement, experimental phasing does not
only avoid bias, but also allows the computation of absolute electron content instead of the
usually applied sigma scaled electron density calculation. For this study, a MAD experiment
using the anomalous scattering properties of the catalytic zinc ion in TLN was utilized. The
resulting electron density map revealed that no water molecules are bound in the S1’ cavity
below the inhibitor (Figure 5.2).
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In comparison to three reference pockets in various states of hydration, no electron density
that might correspond to a disordered water molecule can be detected in the crystal structure.
In a second experiment, crystals of TLN were treated with gaseous krypton and xenon. The
noble gasses are found to bind to the hydrophobic S1’ cavity in the presence of the inhibitor
(Figure 5.3). From the electron configuration and the crystallographic temperature factors of
the xenon and krypton atoms, it can be estimated that, considering the size of the pocket,
disordered water molecules with an occupancy as low as 14% should be observable with
crystallographic techniques. The results of these experiments suggest that the S1’ pocket of TLN
is indeed unsolvated, and thus empty, when no ligand is bound to the protease. This
observation raises the question how the accommodation of a ligand portion in the empty space
translates into the thermodynamics of binding. To analyze this, a series of ligands was
synthesized that feature a hydrophobic substituent, gradually increasing in size, in the P1’
position (Figure 8.7). The introduction of a methyl group alone (5.2) results in an affinity gain
by a factor of 100 in Kd (Figure 5.1). A further growth of the hydrophobic substituent up to a
leucine residue (5.4) then yields a further 40-fold increase of potency. The decrease in free
energy of binding is mainly driven by a favorable enthalpic contribution, which originates from
the reduction of the vacuum inside the S1’ cavity (Figure 5.4).
The results of this study highlight the potential that poorly hydrated protein pockets provide
for drug design. When such a cavity can be identified and properly addressed by a ligand, a
significant gain in potency can be expected.
8.4 The Origin of Long Residence Time Binding in TLN
The pursuit of long residence time binders has become a prominent objective in drug discovery
projects. Molecules with this feature are believed to show a better correlation of preclinical data
Figure 8.7.  Overview of relevant compounds from Chapter 5.
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to in vivo efficacy and display an increased selectivity against their target in the complex
environment of a cell [1,21,23,115]. However, medicinal chemists currently lack the tools for a
targeted alteration of the kinetic binding parameters of a ligand, because the underlying
mechanisms are not well understood. The metalloprotease TLN has proven to be a valuable
model system for the study of protein–ligand interactions. In order to improve our
understanding of the molecular determinants of long residence time binding, binding kinetic
data of a series of TLN inhibitors was determined by SPR and correlated to crystallographic
data of the corresponding protein–inhibitor complex. The investigated compound series
contained phosphonopeptides with differing functional groups in their respective P2’ portion.
In this position, a charged and polar carboxylic acid, a polar but uncharged carboxamide or an
apolar aliphatic residue was accommodated. Representative members of the series are given in
Figure 8.8. SPR results revealed that compounds containing a terminal carboxylic acid
displayed the highest dissociation rates throughout the series. This value was reduced for the
carboxamide compound, which showed an intermediate residence time. For the aliphatic
compounds, the fastest dissociation kinetics within the investigated compound series was
found (Figure 6.1).
Since the binding mode of the inhibitors is conserved for all members of the series (Figure 6.2),
the differences in the dissociation rates could be linked to the interaction of the compounds
with the side chain of Asn112. This residue is accommodated above the S1’ pocket of TLN and
usually assists in the positioning of a substrate during peptide bond cleavage. Inhibitors
featuring a carboxylic acid in the P2’ position are able to engage in a strong, charge assisted
hydrogen bond to this residue. This results in a residence time around several minutes. For the
carboxamide compound, this interaction pattern is conserved, although the negative charge
Figure 8.8.  Overview of relevant compounds from Chapter 6.
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assisting the interaction is lost, therefore weakening the resulting hydrogen bond. The loss of
a polar interaction partner for Asn112 finally results in a significant decrease in residence time
to the order of several seconds for the aliphatic compounds (Figure 6.3).
The strong correlation of the residence time to the ability of an inhibitor to interact with the
Asn112 side chain gave rise to the hypothesis that this residue might be involved in the rate
limiting step of dissociation. During the turnover of a substrate, TLN and related M4
metalloproteases are believed to undergo a hinge-bending motion around their central a-helix
[160,255,256]. From the crystal structure of the apo form of TLN, it is evident that this
conformational adaption includes a rotation of the Asn112 side chain toward the active site of
the protein. Supposedly, this rotation is imperative for the release of a bound inhibitor or
substrate, since the side chain carboxamide of Asn112 is located directly above the S1’
specificity pocket that usually accommodates a large, apolar residue. This hydrophobic
substituent is thoroughly fixed in its position until Asn112 gives way and allows the cleavage
product to dissociate from the well-defined and deeply buried binding pocket (Figure 6.4). The
experimental evidence suggests that this retro induced fit mechanism is the rate limiting step
for the release of a bound substrate or inhibitor, and thus, the dissociation kinetics of TLN.
The paramount function of Asn112 is further underlined by the finding that this residue is
highly conserved within the M4 protease family (Figure 6.5). The related family of M13
proteases, which contains several key enzymes involved in the pathophysiology of heart failure,
Figure 8.9.  Graphical abstract: Elucidating the Origin of Long Residence Time Binding for the
Inhibitors of the Metalloprotease Thermolysin. Reproduced from [179].
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Alzheimer’s disease and certain types of cancer, shows a close structural analogy [259–261].
Furthermore, a mutagenesis study revealed that TLN mutants, in which Asn112 was exchanged
against other amino acids, lost their catalytic activity. Only N112D and N112E mutants partly
retained their proteolytic capabilities, supposedly due to the close chemical relation of the
newly introduced residues to asparagine [262,263].
In 1983, Bartlett and Marlowe reported binding kinetic data of the TLN inhibitor ZFPLA (6.18)
[264]. This compound is chemically related to the phosphonopeptides studied for this work,
but features a (R)-benzyl substituent in the P1 position. ZFPLA is the most potent known
inhibitor of TLN (Kd = 68 pM) with a remarkable residence time of 168 days. From the crystal
structure of this molecule in complex with TLN it is apparent that the binding mode of the
PheP compound ZFPLA shows a significant difference to that of the less potent GlyP inhibitors
(Figure 6.7). The P1 benzyl moiety is oriented toward the solvent above the S1 pocket and placed
within van der Waals distance of Phe114. Most importantly, this arrangement blocks the
outward movement of Asn112, as evident from a superposition of the open-state structure.
Since the conformational adaption of Asn112 was found to be a prerequisite for the
dissociation of a bound inhibitor, this steric restriction results in a functionally irreversible
inhibition of the enzyme. This example demonstrates the effect that an inhibition of the retro
induced fit mechanism in TLN can represent. The conservation of this structural motif
throughout the M4 and M13 protease family implies that this mechanism might be exploited
for the development of inhibitors against other pharmaceutically relevant targets.
8.5 A False Positive in a Fragment Screening Campaign
From an elaborate fragment screening campaign of a library of 361 entries, 7.1 emerged as one
of the most potent endothiapepsin binders in multiple orthogonal assays. It is quite surprising
that the molecule found to bind to the active site of EP by X-ray crystallography, does not
resemble this compound, but instead indicates that a much larger species is accommodated
within the binding cleft. The purity of the substance used for the crystallographic experiments
was verified by NMR and MS, so it seems apparent that the unknown molecule is generated
under the conditions of the experiment.
Monitoring a sample of the fragment in solution by HPLC reveals that a number of different
species are formed simply by exposing the compound to a protic solvent (Figure S7.1A). The
intermediates from this reaction were isolated by preparative HPLC and their chemical
composition was analyzed by NMR and MS. Based on the structure of the intermediates, a
reaction mechanism for the observed degradation of the sample is proposed (Scheme 7.1). A
substitution of the halogen substituent in the chloropyridazine moiety of 7.1 by an imine
nitrogen of a second molecule, initiates the reaction cascade. The charged dimer 7.5 is the
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product of that reaction. In an alternate pathway, a solvolysis of 7.1 to its methoxy derivative
7.3 is observed when methanol is used as a solvent. In the presence of hydroxide ions, the
central iminium function in the charged dimeric intermediate 7.5 is hydrolyzed to give
aldehyde 7.7 as a hypothetical intermediate. Under formation of a central 1,2,4-triazole
heterocycle, this species reacts in an intramolecular substitution reaction to 7.4. A trimeric
compound, which originates from an addition of 7.1 to the aldehyde function of 7.4, is also
observed. While none of the isolated compounds corresponds to the unknown binder observed
in the crystal structure, it seems likely that it is formed from 7.4, whose heterocyclic core
structure shows a close resemblance to the connectivity inferred from the original electron
density. Based on this finding, structure 7.2 could be assigned to the compound found in the
binding site of EP. In addition, a molecule with the corresponding molecular mass was found
in minute concentration in the raw reaction mixture by LC-MS.
Fortunately, one of the crystal structures of EP in complex with 7.2 could be refined to a
resolution of 1.05 Å. This allows an unrestrained least-squares refinement of the geometric
parameters of the ligand. The bond lengths, torsion, and dihedral angles are in line with the
proposed structure of the molecule (Figure S7.4, Figure S7.5). The observed electron density
Figure 8.10. Graphical abstract: Watch Out for the Red Herring: Surprising Reactivity of a Fragment
Results in Biological Activity. Reproduced from [302].
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cannot be explained by the presence of two separate molecules, which precluded the
simultaneous or subsequent binding of 7.1 and 7.4 with reduced occupancy.
For a hypothetical synthesis of the target compound from 7.1 and the 7.4, a C-H activation of
one of the methyl groups would be a mechanistic requirement. Since the methyl centers in
related 2-methyl pyrroles and 2-methyl indoles are known to react under catalytic or anodic
oxidation, as well as under photochemical activation [278,280,281,296], it is reasonable to
assume that a single electron transfer reaction is involved in the formation of 7.2. An exposure
of the original fragment to the irradiation of a medium pressure mercury lamp in a
photochemical reactor gives a nearly quantitative transformation to the methoxylated
derivatives 7.8 and 7.9 (Scheme 7.1). This finding might indicate that the methyl positions in
chemically related compounds, such as 7.4, are susceptible to a photochemical activation. The
reaction product 7.2, however, can also be detected by LC-MS when a sample
Figure 8.11. Overview of relevant compounds from Chapter 7.
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of the starting fragment is incubated in methanol in the absence of light, suggesting that a
different mechanism of activation might be involved.
The reactivity of 7.1 proved to be a lot higher than expected from its structure. It was not
flagged as a PAINS compound, nor did a rigorous filter applied before an STD-NMR screening
exclude the fragment from the experiment. Therefore, quantum chemical calculations were
applied to understand the reactive nature of the compound. Nucleus-independent chemical
shift (NICS) calculations indicate a reduced aromaticity for the 3-chloropyridazine ring. The
more imine-like nature of the C=N bond is further supported by the observation of an
increased bond order. The defining structural feature for these properties is the [3’,4’]-pyrrolo
annelation of the pyridazine. This isoindol-like configuration prevents a continuous
delocalization of the p-electron system throughout the molecule, resulting in a less aromatic,
and thus, more reactive heterocycle (Figure 8.12). Overall, the high electrophilicity index that
is calculated for the molecule, indicates a high reactivity in nucleophilic reactions, which might
facilitate the initial step of the reaction cascade. For 7.2, the postulated product of the reaction
cascade, an even higher electrophilicity index is found. This observation might explain why the
molecule could not be isolated. Its high reactivity likely results in a quick degradation in
solution. Presumably the molecule is only sufficiently stabilized in the environment of the
protein pocket.
The potentially very potent inhibitor 7.2 is bound to EP by multiple strong interactions (Figure
7.4). With its aldehyde moiety, the triazole heterocycle form hydrogen bonds to Thr222.
Another hydrogen bond to Tyr226 is mediated by a water molecule. These interactions require
a significant rearrangement of the surrounding protein residues. Perhaps of even greater
importance are the electrostatic interactions evident from the crystal structure. The negatively
charged Asp15 side chain is stacked directly above the permanently positively charged
pyrrolopyridazine moiety. In addition to that, the least-squares refinement of the crystal
structure reveals a curious detail of the interaction. The carbon atom of the formally charged
Figure 8.12.  The [3’,4’]-pyrrolo annelation reduces the aromaticity of 7.1 compared to the [2’,3’]
annelated analog 7.10.
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pyridazinium ion is significantly shifted out of the ring plane. This finding is in line with the
hypothesis that a change of the hybridization state, along with a partial charge transfer from
the hydroxy group of Thr223, mitigate the positive charge in the heterocycle and lead to a
stabilization of the highly reactive molecule.
The biological activity that was detected for 7.1 in multiple assays does not originate from the
interactions of the parent molecule alone. This compound was found to react in solution,
forming a number of different species that all contribute to the binding affinity of the analyzed
mixtures. The most significant contribution to the binding affinity probably emanates from a
highly instable trimeric form of the original molecule (7.2), which was found to engage EP in
strong electrostatic interactions.
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